<table>
<thead>
<tr>
<th>Introducing PHARMAC</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Part I</strong></td>
<td><strong>General Rules</strong></td>
</tr>
<tr>
<td><strong>Part II</strong></td>
<td><strong>Alimentary Tract and Metabolism</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Blood and Blood Forming Organs</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Cardiovascular System</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Dermatologicals</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Genito-Urinary System</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Hormone Preparations</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Infections</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Musculoskeletal System</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Nervous System</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Oncology Agents and Immunosuppressants</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Respiratory System and Allergies</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Sensory Organs</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Various</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Extemporaneous Compounds (ECPs)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Special Foods</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Vaccines</strong></td>
</tr>
<tr>
<td><strong>Part III</strong></td>
<td><strong>Optional Pharmaceuticals</strong></td>
</tr>
<tr>
<td><strong>Index</strong></td>
<td></td>
</tr>
</tbody>
</table>
Introducing PHARMAC
The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

PHARMAC’s role:

“Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided.”

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at http://www.pharmac.health.nz/about.

Glossary

Units of Measure
gram ................................................ g
kilogram ........................................... kg
international unit ............................ iu
microgram ................................. mcg
milligram ................................ mg
millilitre ........................................ ml
millimole ................................ mmol
unit ................................................ u

Abbreviations
application ............................... app
capsule ..................................... cap
cream ........................................... CRM
dispersible ................................. disp
effervescent ............................... eff
eulsion .......................................... emul
enteric coated .............................. EC
granules ...................................... grans
injection ....................................... inj
liquid .......................................... liq
lotion .......................................... lotn
ointment ...................................... oint
solution ...................................... soln
suppository ................................. suppos
tablet ........................................... tab	
tincture ....................................... tinc

HSS Hospital Supply Status
<table>
<thead>
<tr>
<th>ANATOMICAL HEADING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price (ex man. Excl. GST) $</td>
</tr>
<tr>
<td>--------------------------</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THERAPEUTIC HEADING</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHEMICAL A - Restricted see terms below</td>
</tr>
<tr>
<td>Presentation A ................................................. 10.00</td>
</tr>
<tr>
<td>- Restricted</td>
</tr>
<tr>
<td>Only for use in children under 12 years of age</td>
</tr>
<tr>
<td>CHEMICAL B - Some items restricted see terms below</td>
</tr>
<tr>
<td>Presentation B1 ................................................. 1,589.00</td>
</tr>
<tr>
<td>Presentation B2</td>
</tr>
<tr>
<td>- Restricted</td>
</tr>
<tr>
<td>Oncologist or haematologist</td>
</tr>
<tr>
<td>CHEMICAL C - Restricted see terms below</td>
</tr>
<tr>
<td>Presentation C 1% DV Limit Jan-12 to 2014 ................................................. 15.00</td>
</tr>
<tr>
<td>- Restricted</td>
</tr>
<tr>
<td>Limited to five weeks' treatment</td>
</tr>
<tr>
<td>Either:</td>
</tr>
<tr>
<td>1 For the prophylaxis of venous thromboembolism following a total hip replacement; or</td>
</tr>
<tr>
<td>2 For the prophylaxis of venous thromboembolism following a total knee replacement.</td>
</tr>
<tr>
<td>CHEMICAL D - Restricted see terms below</td>
</tr>
<tr>
<td>Presentation D -1% DV Limit Mar-13 to 2014 ................................................. 38.65</td>
</tr>
<tr>
<td>- Reserved</td>
</tr>
<tr>
<td>Standard national price excluding GST</td>
</tr>
<tr>
<td>CHEMICAL E - Restricted see terms below</td>
</tr>
<tr>
<td>Presentation E</td>
</tr>
<tr>
<td>- Reserved</td>
</tr>
</tbody>
</table>

- Item restricted (see above); - Item restricted (see below)

Products with Hospital Supply Status (HSS) are in **bold**

---

*Guide to Section H listings*

**Example**
PART I: GENERAL RULES

General Rules for Section H of the Pharmaceutical Schedule are included in Section A General Rules and are located on the PHARMAC website.
### Antacids and Antiflatulents

#### Antacids and Reflux Barrier Agents

**ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETICONE**
- Tab 200 mg with magnesium hydroxide 200 mg and simeticone 20 mg
- Oral liq 400 mg with magnesium hydroxide 400 mg and simeticone 30 mg per 5 ml
  - e.g. Mylanta
  - e.g. Mylanta Double Strength

**SIMETICONE**
- Oral drops 100 mg per ml
- Oral drops 20 mg per 0.3 ml
- Oral drops 40 mg per ml

**SODIUM ALGINATE WITH MAGNESIUM ALGINATE**
- Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet
  - e.g. Gaviscon Infant

**SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE**
- Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg
  - e.g. Gaviscon Double Strength
- Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml
  - 4.95 500 ml Acidex

**SODIUM CITRATE**
- Oral liq 8.8% (300 mmol/l)

#### Phosphate Binding Agents

**ALUMINIUM HYDROXIDE**
- Tab 600 mg

**CALCIUM CARBONATE** — Restricted see terms below
- Oral liq 250 mg per ml (100 mg elemental per ml)
  - 39.00 500 ml Roxane
  - Restricted (RS1698) Initiation
  - Only when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate.

#### Antidiarrhoicals and Intestinal Anti-Inflammatory Agents

### Antipropulsives

**DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE**
- Tab 2.5 mg with atropine sulphate 25 mcg

**LOPERAMIDE HYDROCHLORIDE**
- Tab 2 mg
  - 10.75 400 Nodia
- Cap 2 mg — 1% DV Oct-19 to 2022
  - 6.25 400 Diamide Relief

### Rectal and Colonic Anti-Inflammatories

**BUDESONIDE** — Restricted see terms on the next page
- Cap 3 mg
Restricted (RS1723)

Initiation – Crohn’s disease
Both:

1. Mild to moderate ileal, ileocaecal or proximal Crohn’s disease; and
2. Any of the following:
   2.1 Diabetes; or
   2.2 Cushingoid habitus; or
   2.3 Osteoporosis where there is significant risk of fracture; or
   2.4 Severe acne following treatment with conventional corticosteroid therapy; or
   2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
   2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
   2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initiation – Collagenous and lymphocytic colitis (microscopic colitis)
Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initiation – Gut Graft versus Host disease
Patient has gut Graft versus Host disease following allogenic bone marrow transplantation.

Initiation – non-cirrhotic autoimmune hepatitis
Re-assessment required after 6 months
All of the following:

1. Patient has autoimmune hepatitis*; and
2. Patient does not have cirrhosis; and
3. Any of the following:
   3.1 Diabetes; or
   3.2 Cushingoid habitus; or
   3.3 Osteoporosis where there is significant risk of fracture; or
   3.4 Severe acne following treatment with conventional corticosteroid therapy; or
   3.5 History of severe psychiatric problems associated with corticosteroid treatment; or
   3.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
   3.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated); or
   3.8 Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth).

Note: Indications marked with * are unapproved indications.

Continuation – non-cirrhotic autoimmune hepatitis
Re-assessment required after 6 months
Treatment remains appropriate and the patient is benefiting from the treatment.

HYDROCORTISONE ACETATE
Rectal foam 10%, CFC free (14 applications) ................................................. 26.55 21.1 g Colifoam

HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE
Topical Aerosol foam, 1% with pramoxine hydrochloride 1%

MESALAZINE
Tab EC 400 mg ................................................................. 49.50 100 Asacol
Tab EC 500 mg ................................................................. 49.50 100 Asamax
Tab long-acting 500 mg .................................................. 59.05 100 Pentasa
Tab 800 mg ................................................................. 85.50 90 Asacol
Modified release granules 1 g ........................................ 141.72 120 g Pentasa
Suppos 500 mg ................................................................. 22.80 20 Asacol
Suppos 1 g ................................................................. 54.60 30 Pentasa
Enema 1 g per 100 ml .................................................. 41.30 7 Pentasa
## ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OLSALAZINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td>$93.37</td>
<td>Dipentum</td>
</tr>
<tr>
<td>Cap 250 mg</td>
<td>$53.00</td>
<td>Dipentum</td>
</tr>
<tr>
<td><strong>SODIUM CROMOGLICATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SULFASALAZINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td>$14.00</td>
<td>Salazopyrin</td>
</tr>
<tr>
<td>Tab EC 500 mg – 1% DV Dec-19 to 2022</td>
<td>$15.53</td>
<td>Salazopyrin EN</td>
</tr>
</tbody>
</table>

### Local Preparations for Anal and Rectal Disorders

#### Antihaemorrhoidal Preparations

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CINCHOCaine HYDROCHLORIDE WITH HYDROCORTISONE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint 5 mg with hydrocortisone 5 mg per g</td>
<td>$15.00</td>
<td>Proctosedyl</td>
</tr>
<tr>
<td>Suppos 5 mg with hydrocortisone 5 mg per g</td>
<td>$9.90</td>
<td>Proctosedyl</td>
</tr>
<tr>
<td>FLUCORTOLONE CAPROATE WITH FLUCORTOLONE PIVALATE AND CINCHOCaine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine</td>
<td>$6.35</td>
<td>Ultraproct</td>
</tr>
<tr>
<td>Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine</td>
<td>$2.66</td>
<td>Ultraproct</td>
</tr>
</tbody>
</table>

#### Management of Anal Fissures

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLYCERYL TRINITRATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint 0.2%</td>
<td>$22.00</td>
<td>Rectogesic</td>
</tr>
</tbody>
</table>

#### Rectal Sclerosants

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>OILY PHENOL [PHENOL OILY]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5%, 5 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Antispasmodics and Other Agents Altering Gut Motility

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLYCOPYRRONIUM BROMIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 200 mcg per ml, 1 ml ampoule</td>
<td>$17.14</td>
<td>Max Health</td>
</tr>
<tr>
<td>HYOSCINE BUTYLBROMIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Dec-17 to 2020</td>
<td>$8.75</td>
<td>Buscopan</td>
</tr>
<tr>
<td>Inj 20 mg, 1 ml ampoule</td>
<td>$9.57</td>
<td>Buscopan</td>
</tr>
<tr>
<td>MEBEVERINE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 135 mg</td>
<td>$18.00</td>
<td>Colofac</td>
</tr>
</tbody>
</table>

### Antiulcerants

#### Antisecretory and Cytoprotective

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MISOPROSTOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mcg</td>
<td>$41.50</td>
<td>Cytotec</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per ........................</td>
<td>.................................</td>
</tr>
</tbody>
</table>

### H2 Antagonists

#### CIMETIDINE
- Tab 200 mg
- Tab 400 mg

#### FAMOTIDINE
- Tab 20 mg
- Tab 40 mg
- Inj 10 mg per ml, 2 ml vial
- Inj 10 mg per ml, 4 ml vial

#### RANITIDINE – Restricted see terms below
- Tab 150 mg – 1% DV Oct-17 to 2020 ................................................................. 12.91 500 Ranitidine Relief
- Tab 300 mg – 1% DV Oct-17 to 2020 ................................................................. 18.21 500 Ranitidine Relief
- Oral liq 150 mg per 10 ml – 1% DV Oct-17 to 2020 ........................................ 5.14 300 ml Peptisoothe
- Inj 25 mg per ml, 2 ml ampoule ................................................................. 13.40 5 Zantac

**Initiation**

Either:
1. For continuation use; or
2. Routine prevention of allergic reactions.

### Proton Pump Inhibitors

#### LANSOPRAZOLE
- Cap 15 mg – 1% DV Sep-18 to 2021 ................................................................. 4.58 100 Lanzol Relief
- Cap 30 mg – 1% DV Sep-18 to 2021 ................................................................. 5.41 100 Lanzol Relief

#### OMEPRAZOLE
- Tab dispersible 20 mg

**Restricted (RS1027)**

**Initiation**

Only for use in tube-fed patients.

- Cap 10 mg – 1% DV Mar-18 to 2020 ................................................................. 1.98 90 Omeprazole actavis 10
- Cap 20 mg – 1% DV Mar-18 to 2020 ................................................................. 1.96 90 Omeprazole actavis 20
- Cap 40 mg – 1% DV Mar-18 to 2020 ................................................................. 3.12 90 Omeprazole actavis 40
- Powder for oral liq. ......................................................................................... 42.50 5 g Midwest
- Inj 40 mg ampoule with diluent – 1% DV Oct-19 to 2022 .......................... 33.98 5 Dr Reddy's Omeprazole
- Inj 40 mg vial – 1% DV Oct-19 to 2022 ............................................................. 11.46 5 Omezol IV

#### PANTOPRAZOLE
- Tab EC 20 mg – 1% DV Oct-19 to 2022 ........................................................... 2.02 100 Panzop Relief
- Tab EC 40 mg – 1% DV Oct-19 to 2022 ........................................................... 2.85 100 Panzop Relief
- Inj 40 mg vial

### Site Protective Agents

#### COLLOIDAL BISMUTH SUBCITRATE
- Tab 120 mg ................................................................. 14.51 50 Gastrodenol

#### SUCRALFATE
- Tab 1 g
### Bile and Liver Therapy

**L-ORNITHINE L-ASPARTATE** – Restricted see terms below

- Grans for oral liquid 3 g
- **Restricted (RS1261)**

**Initiation**
For patients with chronic hepatic encephalopathy who have not responded to treatment with, or are intolerant to lactulose, or where lactulose is contraindicated.

**RIFAXIMIN** – Restricted see terms below

- Tab 550 mg – 1% DV Sep-17 to 2020................................. 625.00  56  Xifaxan
- **Restricted (RS1416)**

**Initiation**
For patients with hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

### Diabetes

#### Alpha Glucosidase Inhibitors

**ACARBOSE**

- Tab 50 mg – 1% DV Sep-18 to 2021................................. 3.50  90  Glucobay
- Tab 100 mg – 1% DV Sep-18 to 2021................................. 6.40  90  Glucobay

#### Hyperglycaemic Agents

**DIAZOXIDE** – Restricted see terms below

- Cap 25 mg......................................................................... 110.00  100  Proglicem
- Cap 100 mg...................................................................... 280.00  100  Proglicem
- Oral liq 50 mg per ml....................................................... 620.00  30 ml  Proglycem
- **Restricted (RS1028)**

**Initiation**
For patients with confirmed hypoglycaemia caused by hyperinsulinism.

**GLUCAGON HYDROCHLORIDE**

- Inj 1 mg syringe kit......................................................... 32.00  1  Glucagen Hypokit

**GLUCOSE [DEXTROSE]**

- Tab 1.5 g
- Tab 3.1 g
- Tab 4 g
- Gel 40%

**GLUCOSE WITH SUCROSE AND FRUCTOSE**

- Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet

### Insulin - Intermediate-Acting Preparations

**INSULIN ASPART WITH INSULIN ASPART PROTAMINE**

- Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen .................................................... 52.15  5  NovoMix 30 FlexPen

**INSULIN ISOPHANE**

- Inj insulin human 100 u per ml, 10 ml vial
- Inj insulin human 100 u per ml, 3 ml cartridge
<table>
<thead>
<tr>
<th>Item Code</th>
<th>Description</th>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE</td>
<td>Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge</td>
<td>$42.66</td>
<td>5 Humalog Mix 25</td>
</tr>
<tr>
<td></td>
<td>Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge</td>
<td>$42.66</td>
<td>5 Humalog Mix 50</td>
</tr>
<tr>
<td>INSULIN NEUTRAL WITH INSULIN ISOPHANE</td>
<td>Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin - Long-Acting Preparations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSULIN GLARGINE</td>
<td>Inj 100 u per ml, 3 ml disposable pen</td>
<td>$94.50</td>
<td>5 Lantus SoloStar</td>
</tr>
<tr>
<td></td>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td>$94.50</td>
<td>5 Lantus</td>
</tr>
<tr>
<td></td>
<td>Inj 100 u per ml, 10 ml vial</td>
<td>$63.00</td>
<td>1 Lantus</td>
</tr>
<tr>
<td>Insulin - Rapid-Acting Preparations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSULIN ASPART</td>
<td>Inj 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 100 u per ml, 3 ml syringe</td>
<td>$51.19</td>
<td>5 NovoRapid FlexPen</td>
</tr>
<tr>
<td>INSULIN GLULISINE</td>
<td>Inj 100 u per ml, 10 ml vial</td>
<td>$27.03</td>
<td>1 Apidra</td>
</tr>
<tr>
<td></td>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td>$46.07</td>
<td>5 Apidra</td>
</tr>
<tr>
<td></td>
<td>Inj 100 u per ml, 3 ml disposable pen</td>
<td>$46.07</td>
<td>5 Apidra Solostar</td>
</tr>
<tr>
<td>INSULIN LISPRO</td>
<td>Inj 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin - Short-Acting Preparations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSULIN NEUTRAL</td>
<td>Inj human 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj human 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Hypoglycaemic Agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLIBENCLAMIDE</td>
<td>Tab 5 mg – 1% DV Oct-18 to 2021</td>
<td>$6.00</td>
<td>100 Daonil</td>
</tr>
<tr>
<td>GLICLAZIDE</td>
<td>Tab 80 mg – 1% DV Sep-17 to 2020</td>
<td>$10.29</td>
<td>500 Glizide</td>
</tr>
<tr>
<td>GLIPIZIDE</td>
<td>Tab 5 mg – 1% DV Dec-18 to 2021</td>
<td>$3.27</td>
<td>100 Minidiab</td>
</tr>
</tbody>
</table>
# Metformin Hydrochloride

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per 1,000</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab immediate-release 500 mg</td>
<td>$8.63</td>
<td>Apotex</td>
</tr>
<tr>
<td>Tab immediate-release 850 mg</td>
<td>$7.04</td>
<td>Apotex</td>
</tr>
</tbody>
</table>

# Pioglitazone

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per 90</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 15 mg</td>
<td>$3.47</td>
<td>Vexazone</td>
</tr>
<tr>
<td>Tab 30 mg</td>
<td>$5.06</td>
<td>Vexazone</td>
</tr>
<tr>
<td>Tab 45 mg</td>
<td>$7.10</td>
<td>Vexazone</td>
</tr>
</tbody>
</table>

# Vildagliptin

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per 60</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg</td>
<td>$40.00</td>
<td>Galvus</td>
</tr>
</tbody>
</table>

## Vildagliptin with Metformin Hydrochloride

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per 60</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg with 1,000 mg metformin hydrochloride</td>
<td>$40.00</td>
<td>Galvumet</td>
</tr>
<tr>
<td>Tab 50 mg with 850 mg metformin hydrochloride</td>
<td>$40.00</td>
<td>Galvumet</td>
</tr>
</tbody>
</table>

## Digestives Including Enzymes

### Pancreatic Enzyme

- **Cap pancreatin** (175 mg (25,000 U lipase, 22,500 U amylase, 1,250 U protease))
- **Cap pancreatin** 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) – 1% DV Sep-18 to 2021 $34.93 100 Creon 10000
- **Cap pancreatin** 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U) – 1% DV Sep-18 to 2021 $94.38 100 Creon 25000

### Ursodeoxycholic Acid

**Cap 250 mg** – 1% DV Sep-17 to 2020 $37.95 100 Ursosan

#### Restricted (RS1647)

- **Initiation – Alagille syndrome or progressive familial intrahepatic cholestasis**
  - Either:
    1. Patient has been diagnosed with Alagille syndrome; or
    2. Patient has progressive familial intrahepatic cholestasis.

- **Initiation – Chronic severe drug induced cholestatic liver injury**
  - All of the following:
    1. Patient has chronic severe drug induced cholestatic liver injury; and
    2. Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
    3. Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

- **Initiation – Primary biliary cholangitis**
  - Both:
    1. Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
    2. Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis.

- **Initiation – Pregnancy**
  - Patient diagnosed with cholestasis of pregnancy.

- **Initiation – Haematological transplant**
  - Both:
    1. Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
    2. Treatment for up to 13 weeks.
continued…

Initiation – Total parenteral nutrition induced cholestasis
Both:
1. Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
2. Liver function has not improved with modifying the TPN composition.

### Laxatives

#### Bowel-Cleansing Preparations

**CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE**
- Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet
  - e.g. PicoPrep

**MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE**
- Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet
  - e.g. Glycogrep-C

**MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE**
- Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet – 1% DV Aug-19 to 2022
  - 14.31

#### Bulk-Forming Agents

**ISPAGHULA (PSYLLIUM) HUSK**
- Powder for oral soln – 1% DV Oct-17 to 2020
  - 6.05

**STERCULIA WITH FRANGULA – Restricted:** For continuation only
  - Powder for oral soln

#### Faecal Softeners

**DOCUSATE SODIUM**
- Tab 50 mg – 1% DV Sep-17 to 2020
  - 2.31

**DOCUSATE SODIUM WITH SENNOSIDES**
- Tab 50 mg with sennosides 8 mg – 1% DV Jun-18 to 2021
  - 3.10

**PARAFFIN**
- Oral liquid 1 mg per ml
- Enema 133 ml

**POLOXAMER**
- Oral drops 10% – 1% DV Sep-17 to 2020
  - 3.78

#### Opioid Receptor Antagonists - Peripheral

**METHYLNALTREXONE BROMIDE – Restricted** see terms on the next page

- Inj 12 mg per 0.6 ml vial
  - 36.00

- 246.00
### Restricted (RS1601)

**Initiation – Opioid induced constipation**

Both:

1. The patient is receiving palliative care; and
2. Either:
   2.1 Oral and rectal treatments for opioid induced constipation are ineffective; or
   2.2 Oral and rectal treatments for opioid induced constipation are unable to be tolerated.

#### Osmotic Laxatives

**GLYCEROL**

- Suppos 1.27 g
- Suppos 2.55 g
- Suppos 3.6 g – 1% DV Oct-18 to 2021

**LACTULOSE**

- Oral liq 10 g per 15 ml – 1% DV Nov-19 to 2022

**MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE**

- Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg
- Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – 1% DV Feb-18 to 2020

**SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE**

- Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – 1% DV Nov-19 to 2022

**SODIUM PHOSPHATE WITH PHOSPHORIC ACID**

- Oral liq 16.4% with phosphoric acid 25.14%
- Enema 10% with phosphoric acid 6.58%

#### Stimulant Laxatives

**BISACODYL**

- Tab 5 mg – 1% DV Sep-18 to 2021
- Suppos 10 mg – 1% DV Sep-18 to 2021

**SENNOSIDES**

- Tab 7.5 mg

#### Metabolic Disorder Agents

**ALGLUCOSIDASE ALFA – Restricted** see terms below

- Inj 50 mg vial

**Restricted (RS1545)**

**Initiation**

Metabolic physician

*Re-assessment required after 12 months*

All of the following:

1. The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and

*continued…*
continued...

2 Any of the following:
   2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
   2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
   2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
   2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and

3 Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and

4 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and

5 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

Continuation
Metabolic physician
Re-assessment required after 12 months
All of the following:
   1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
   2 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
   3 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
   4 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
   5 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
   6 There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
   7 There is no evidence of new or progressive cardiomyopathy.

ARGININE
Powder
Inj 600 mg per ml, 25 ml vial

ARGinine
Powder
Inj 600 mg per ml, 25 ml vial

BETaine – Restricted see terms below
Powder for oral soln.................................................................575.00 180 g Cystadane

Initiation
Metabolic physician
Re-assessment required after 12 months
All of the following:
   1 The patient has a confirmed diagnosis of homocystinuria; and
   2 Any of the following:
      2.1 A cystathionine beta-synthase (CBS) deficiency; or
      2.2 A 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency; or
      2.3 A disorder of intracellular cobalamin metabolism; and
   3 An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation.

Continuation
Metabolic physician
Re-assessment required after 12 months
The treatment remains appropriate and the patient is benefiting from treatment.
### BIOTIN – Restricted see terms below

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 50 mg</td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Cap 100 mg</td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml vial</td>
<td>$</td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1330)</strong></td>
<td>$</td>
<td></td>
</tr>
</tbody>
</table>

Metabolic physician or metabolic disorders dietitian

### GALSULFASE – Restricted see terms below

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg per ml, 5 ml vial</td>
<td>$2,234.00</td>
<td>Naglazyme</td>
</tr>
<tr>
<td><strong>Restricted (RS1523)</strong></td>
<td>$2,234.00</td>
<td></td>
</tr>
</tbody>
</table>

**Initiation**
Metabolic physician

**Re-assessment required after 12 months**

Both:
1. The patient has been diagnosed with mucopolysaccharidosis VI; and
2. Either:
   1.1 Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency confirmed by either enzyme activity assay in leukocytes or skin fibroblasts; or
   1.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.

**Continuation**
Metabolic physician

**Re-assessment required after 12 months**

All of the following:
1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
3. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
4. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

### HAEM ARGINATE

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 25 mg per ml, 10 ml ampoule</td>
<td>$</td>
<td></td>
</tr>
</tbody>
</table>

### IDURSULFASE – Restricted see terms below

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 3 ml vial</td>
<td>$4,608.30</td>
<td>Elaprase</td>
</tr>
<tr>
<td><strong>Restricted (RS1546)</strong></td>
<td>$4,608.30</td>
<td></td>
</tr>
</tbody>
</table>

**Initiation**
Metabolic physician

**Limited to 24 weeks treatment**

All of the following:
1. The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II); and
2. Either:
   1.1 Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
   1.2 Detection of a disease causing mutation in the iduronate 2-sulfatase gene; and
3. Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant; and
4. Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
5. Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.
ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LARONIDASE – Restricted</strong> see terms below</td>
</tr>
<tr>
<td>Inj 100 U per ml, 5 ml vial ...................................................... 1,335.16 1 Aldurazyme</td>
</tr>
<tr>
<td>→ Restricted (RS1607)</td>
</tr>
</tbody>
</table>

**Initiation**
Metabolic physician

*Limited to 24 weeks treatment*

All of the following:

1. The patient has been diagnosed with Hurler Syndrome (mucopolysaccharidosis I-H); and
2. Either:
   1. Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
   2. Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome; and
3. Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be bridging treatment to transplant; and
4. Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
5. Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every week.

**LEVOCARNITINE – Restricted** see terms below

1. Cap 500 mg
2. Oral soln 1,000 mg per 10 ml
3. Inj 200 mg per ml, 5 ml vial
→ Restricted (RS1035)

Neurologist, metabolic physician or metabolic disorders dietitian

**PYRIDOXAL-5-PHOSPHATE – Restricted** see terms below

1. Tab 50 mg
→ Restricted (RS1331)

Neurologist, metabolic physician or metabolic disorders dietitian

**SAPROPTERIN DIHYDROCHLORIDE – Restricted** see terms below

1. Tab soluble 100 mg ............................................................... 1,452.70 30 Kuvan
→ Restricted (RS1656)

**Initiation**
Metabolic physician

*Re-assessment required after 1 month*

All of the following:

1. Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant; and
2. Treatment with sapropterin is required to support management of PKU during pregnancy; and
3. Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
4. Sapropterin to be used alone or in combination with PKU dietary management; and
5. Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

**Continuation**
Metabolic physician or any relevant practitioner on the recommendation of a metabolic physician

*Re-assessment required after 12 months*

All of the following:

1. Either:

...continued...
continued…

1. Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or

2. On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and

Any of the following:

1. Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or

2. Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or

3. Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and

Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and

Sapropterin to be used alone or in combination with PKU dietary management; and

Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

SODIUM BENZOATE

Cap 500 mg
Powder
Soln 100 mg per ml
Inj 20%, 10 ml ampoule

SODIUM PHENYLBUTYRATE – Some items restricted see terms below

Tab 500 mg
Grans 483 mg per g…………………………………………………………………..1,920.00 174 g Pheburane
Oral liq 250 mg per ml
Inj 200 mg per ml, 10 ml ampoule

➡️ Restricted (RS1526)

Initiation
Metabolic physician
Re-assessment required after 12 months
For the chronic management of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.

Continuation
Metabolic physician
Re-assessment required after 12 months
The treatment remains appropriate and the patient is benefiting from treatment.

TALIGLUCERASE ALFA – Restricted see terms below

Inj 200 unit vial…………………………………………………………………..1,072.00 1 Eleyso

➡️ Restricted (RS1034)

Initiation
Only for use in patients with approval by the Gaucher Treatment Panel.

TRIENTINE DIHYDROCHLORIDE

Cap 300 mg

Minerals

Calcium

CALCIUM CARBONATE

Tab 1.25 g (500 mg elemental) – 1% DV Mar-18 to 2020 ……………………..7.52 250 Arrow-Calcium
Tab eff 1.75 g (1 g elemental)
## ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Drug Category</th>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fluoride</strong></td>
<td>SODIUM FLUORIDE</td>
<td>Tab 1.1 mg (0.5 mg elemental)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Iodine</strong></td>
<td>POTASSIUM IODATE</td>
<td>Tab 253 mcg (150 mcg elemental iodine) – 1% DV Mar-19 to 2020</td>
<td>4.69 90</td>
<td>NeuroTabs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>POTASSIUM IODATE WITH IODINE</td>
<td>Oral liq 10% with iodine 5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Iron</strong></td>
<td>FERRIC CARBOXYMALTOSE – Restricted see terms below</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FERRIC CARBOXYMALTOSE – Restricted (RS1417) Initiation</td>
<td>Treatment with oral iron has proven ineffective or is clinically inappropriate.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FERROUS FUMARATE</td>
<td>Tab 200 mg (65 mg elemental) – 1% DV Jan-19 to 2021</td>
<td>3.09 100</td>
<td>Ferro-tab</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FERROUS FUMARATE WITH FOLIC ACID</td>
<td>Tab 310 mg (100 mg elemental) with folic acid 350 mcg – 1% DV Jun-18 to 2021</td>
<td>4.68 60</td>
<td>Ferro-F-Tabs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FERROUS GLUCONATE WITH ASCORBIC ACID</td>
<td>Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FERROUS SULFATE</td>
<td>Oral liq 30 mg (6 mg elemental) per ml – 1% DV Nov-19 to 2022</td>
<td>12.08 500 ml</td>
<td>Ferodan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FERROUS SULPHATE</td>
<td>Tab long-acting 325 mg (105 mg elemental) – 1% DV Jun-18 to 2021</td>
<td>2.06 30</td>
<td>Ferrograd</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FERROUS SULPHATE WITH ASCORBIC ACID</td>
<td>Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IRON POLYMALTOSE</td>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
<td>34.50 5</td>
<td>Ferrosig</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IRON SUCCROSE</td>
<td>Inj 20 mg per ml, 5 ml ampoule</td>
<td>100.00 5</td>
<td>Venofer</td>
<td></td>
</tr>
<tr>
<td><strong>Magnesium</strong></td>
<td>MAGNESIUM AMINO ACID CHELATE</td>
<td>Cap 750 mg (150 mg elemental)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MAGNESIUM CHLORIDE</td>
<td>Inj 1 mmol per 1 ml, 100 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MAGNESIUM HYDROXIDE</td>
<td>Tab 311 mg (130 mg elemental)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MAGNESIUM OXIDE</td>
<td>Cap 663 mg (400 mg elemental)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cap 696 mg (420 mg elemental)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*
MAGNESIUM OXIDE WITH MAGNESIUM ASPARTATE, MAGNESIUM AMINO ACID CHELATE AND MAGNESIUM CITRATE

Cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium)

MAGNESIUM SULPHATE

Inj 0.4 mmol per ml, 250 ml bag
Inj 2 mmol per ml, 5 ml ampoule – 1% DV Sep-17 to 2020 ......................... 10.21 10 DBL
Inj 100 mg per ml, 50 ml bag

Zinc

ZINC
Oral liq 5 mg per 5 drops

ZINC CHLORIDE
Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule

ZINC SULPHATE
Cap 137.4 mg (50 mg elemental) – 1% DV Dec-19 to 2022 ......................... 11.00 100 Zincaps

Mouth and Throat

Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE
Soln 0.15%
Spray 0.15%
Spray 0.3%

BENZYDAMINE HYDROCHLORIDE WITH CETYLPYRIDINIUM CHLORIDE
Lozenge 3 mg with cetylpyridinium chloride

CARBOXYMETHYLCELLULOSE
Oral spray

CARMELLOSE SODIUM WITH PECTIN AND GELATINE
Paste
Powder

CHLORHEXIDINE GLUCONATE
Mouthwash 0.2% ................................................................. 2.57 200 ml healthE

CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE
Adhesive gel 8.7% with cetalkonium chloride 0.01%

DICHLOROBENZYL ALCOHOL WITH AMYLMETACRESOL
Lozenge 1.2 mg with amylmetacresol 0.6 mg

TRIAMCINOLONE ACETONIDE
Paste 0.1% – 1% DV Sep-17 to 2020 ............................................. 5.33 5 g Kenalog in Orabase

Oropharyngeal Anti-Infectives

AMPHOTERICIN B
Lozenge 10 mg ................................................................. 5.86 20 Fungilin

MICONAZOLE
Oral gel 20 mg per g – 1% DV Sep-18 to 2021 ................................. 4.74 40 g Decozol

NYSTATIN
Oral liquid 100,000 u per ml – 1% DV Oct-17 to 2020 ..................... 1.95 24 ml Nilstat

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Other Oral Agents

HYALURONIC ACID WITH LIDOCAINE [LIGNOCAIN] 
Inj 20 mg per ml

SODIUM HYALURONATE [HYALURONIC ACID] – Restricted see terms below
\[\text{Inj 20 mg per ml, 1 ml syringe}\]
\[\text{Restricted (RS1175)}\]
Otolaryngologist

THYMOL GLYCERIN 
Compound, BPC.........................................................................................................9.15 500 ml PSM

Vitamins

Multivitamin Preparations

MULTIVITAMIN AND MINERAL SUPPLEMENT – Restricted see terms below
\[\text{Cap}..................................................................................................................23.35 180 \text{ Clinicians Multivit \\& Mineral Boost}\]
\[\text{Restricted (RS1498)}\]
Initiation
Limited to 3 months treatment
Both:
1 Patient was admitted to hospital with burns; and
2 Any of the following:
   2.1 Burn size is greater than 15% of total body surface area (BSA) for all types of burns; or
   2.2 Burn size is greater than 10% of BSA for mid-dermal or deep dermal burns; or
   2.3 Nutritional status prior to admission or dietary intake is poor.

MULTIVITAMIN RENAL – Restricted see terms below
\[\text{Cap}....................................................................................................................6.49 30 \text{ Clinicians Renal Vit}\]
\[\text{Restricted (RS1499)}\]
Initiation
Either:
1 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or
2 The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73m² body surface area (BSA).
MULTIVITAMINS

Tab (BPC cap strength) – 1% DV Mar-20 to 2022........................................11.45 1,000 Mvite

▼ Restricted (RS1620)
Initiation
Any of the following:
1. Patient has cystic fibrosis with pancreatic insufficiency; or
2. Patient is an infant or child with liver disease or short gut syndrome; or
3. Patient has severe malabsorption syndrome.

Powder vitamin A 4200 mcg with vitamin D 155.5 mcg, vitamin E 21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg, thiamine 3.2 mg, riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid 303 mcg, vitamin B12 8.6 mcg, biotin 214 mcg, pantothenic acid 17 mg, choline 350 mg and inositol 700 mg
e.g. Paediatric Seravit

▼ Restricted (RS1178)
Initiation
Patient has inborn errors of metabolism.
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1)
e.g. Pabrinex IV
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1)
e.g. Pabrinex IM
Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1)
e.g. Pabrinex IV

VITAMIN A WITH VITAMINS D AND C
Note: that funding of vitamin A oral liquid can be applied for through the Exceptional Circumstances process; the application form can be found on the PHARMAC website https://pharmac.govt.nz/assets/form-alphacopherylacetate-and-vitaminA.pdf
Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops e.g. Vitadol C
(e.g. Vitadol C Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops to be delisted 1 July 2020)

Vitamin A

RETINOL
Tab 10,000 iu
Cap 25,000 iu
Oral liq 150,000 iu per ml
Oral liq 666.7 mcg per 2 drops, 10 ml
Oral liq 5,000 iu per drop, 30 ml

Vitamin B

HYDROXOCOBALAMIN
Inj 1 mg per ml, 1 ml ampoule – 1% DV Sep-18 to 2021..............................1.89 3 Neo-B12
## ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PYRIDOXINE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Jan-18 to 2020</td>
<td>2.70</td>
<td>90 Vitamin B6 25</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Oct-17 to 2020</td>
<td>13.63</td>
<td>500 Apo-Pyridoxine</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 2 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 30 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>THIAMINE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Nov-18 to 2020</td>
<td>4.89</td>
<td>100 Max Health</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 2 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VITAMIN B COMPLEX</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab strong, BPC</td>
<td>7.15</td>
<td>500 Bplex</td>
</tr>
</tbody>
</table>

### Vitamin C

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASCORBIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Mar-20 to 2022</td>
<td>9.90</td>
<td>500 Cvite</td>
</tr>
<tr>
<td>Tab chewable 250 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Vitamin D

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALFACALCIDOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 0.25 mcg – 1% DV Aug-17 to 2020</td>
<td>26.32</td>
<td>100 One-Alpha</td>
</tr>
<tr>
<td>Cap 1 mcg – 1% DV Aug-17 to 2020</td>
<td>87.98</td>
<td>100 One-Alpha</td>
</tr>
<tr>
<td>Oral drops 2 mcg per ml – 1% DV Aug-17 to 2020</td>
<td>60.68</td>
<td>20 ml One-Alpha</td>
</tr>
<tr>
<td>CALCITRIOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 0.25 mcg – 1% DV Oct-19 to 2022</td>
<td>7.95</td>
<td>100 Calcitriol-AFT</td>
</tr>
<tr>
<td>Cap 0.5 mcg – 1% DV Oct-19 to 2022</td>
<td>13.75</td>
<td>100 Calcitriol-AFT</td>
</tr>
<tr>
<td>Oral liq 1 mcg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mcg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COLECALCIFEROL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 1.25 mg (50,000 iu) – 1% DV Oct-17 to 2020</td>
<td>2.50</td>
<td>12 Vit.D3</td>
</tr>
<tr>
<td>Oral liq 188 mcg per ml (7,500 iu per ml)</td>
<td>9.00</td>
<td>4.8 ml Puria</td>
</tr>
</tbody>
</table>

### Vitamin E

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALPHA TOCOPHERYL – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 156 u per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>→ Restricted (RS1632)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Initiation – Cystic fibrosis**
Both:

1. Cystic fibrosis patient; and
2. Either:
   2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
   2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

**Initiation – Osteoradionecrosis**
For the treatment of osteoradionecrosis.

---

*Item restricted (see ➔ above); Item restricted (see ➔ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
continued...

**Initiation – Other indications**

All of the following:

1. Infant or child with liver disease or short gut syndrome; and
2. Requires vitamin supplementation; and
3. Either:
   3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
   3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

**ALPHA TOCOPHERYL ACETATE** – Restricted see terms below

- Cap 100 u
- Cap 500 u
- Oral liq 156 u per ml

**Initiation – Cystic fibrosis**

Both:

1. Cystic fibrosis patient; and
2. Either:
   2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
   2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

**Initiation – Osteoradionecrosis**

For the treatment of osteoradionecrosis.

**Initiation – Other indications**

All of the following:

1. Infant or child with liver disease or short gut syndrome; and
2. Requires vitamin supplementation; and
3. Either:
   3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
   3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.
## Antinaemtics

### Hypoplastic and Haemolytic

<table>
<thead>
<tr>
<th>EPOETIN ALFA – Restricted see terms below</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1,000 iu in 0.5 ml syringe – 1% DV Apr-19 to 2022</td>
</tr>
<tr>
<td>Inj 2,000 iu in 1 ml syringe – 1% DV Apr-19 to 2022</td>
</tr>
<tr>
<td>Inj 3,000 iu in 0.3 ml syringe – 1% DV Apr-19 to 2022</td>
</tr>
<tr>
<td>Inj 4,000 iu in 0.4 ml syringe – 1% DV Apr-19 to 2022</td>
</tr>
<tr>
<td>Inj 5,000 iu in 0.5 ml syringe – 1% DV Apr-19 to 2022</td>
</tr>
<tr>
<td>Inj 6,000 iu in 0.6 ml syringe – 1% DV Apr-19 to 2022</td>
</tr>
<tr>
<td>Inj 8,000 iu in 0.8 ml syringe – 1% DV Apr-19 to 2022</td>
</tr>
<tr>
<td>Inj 10,000 iu in 1 ml syringe – 1% DV Apr-19 to 2022</td>
</tr>
<tr>
<td>Inj 40,000 iu in 1 ml syringe – 1% DV Apr-19 to 2022</td>
</tr>
</tbody>
</table>

### Initiation – chronic renal failure

All of the following:

1. Patient in chronic renal failure; and
2. Haemoglobin is less than or equal to 100g/L; and
3. Either:
   3.1 Both:
      3.1.1 Patient does not have diabetes mellitus; and
      3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
   3.2 Both:
      3.2.1 Patient has diabetes mellitus; and
      3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
4. Patient is on haemodialysis or peritoneal dialysis.

### Initiation – myelodysplasia*

*Re-assessment required after 2 months*

All of the following:

1. Patient has a confirmed diagnosis of myelodysplasia (MDS); and
2. Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
3. Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
4. Other causes of anaemia such as B12 and folate deficiency have been excluded; and
5. Patient has a serum epoetin level of < 500 IU/L; and
6. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

### Continuation – myelodysplasia*

*Re-assessment required after 12 months*

All of the following:

1. The patient’s transfusion requirement continues to be reduced with epoetin treatment; and
2. Transformation to acute myeloid leukaemia has not occurred; and
3. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

### Initiation – all other indications

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative.

Note: Indications marked with * are unapproved indications.
EPOETIN BETA – Restricted see terms below
Note: Epoetin beta is considered a Discretionary Variance Pharmaceutical for epoetin alfa.

- Inj 2,000 iu in 0.3 ml syringe
- Inj 3,000 iu in 0.3 ml syringe
- Inj 4,000 iu in 0.3 ml syringe
- Inj 5,000 iu in 0.3 ml syringe
- Inj 6,000 iu in 0.3 ml syringe
- Inj 10,000 iu in 0.6 ml syringe

Initiation – chronic renal failure
All of the following:
1. Patient in chronic renal failure; and
2. Haemoglobin is less than or equal to 100g/L; and
3. Either:
   - 3.1 Both:
     - 3.1.1 Patient does not have diabetes mellitus; and
     - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
   - 3.2 Both:
     - 3.2.1 Patient has diabetes mellitus; and
     - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
4. Patient is on haemodialysis or peritoneal dialysis.

Initiation – myelodysplasia*
Re-assessment required after 12 months
All of the following:
1. Patient has a confirmed diagnosis of myelodysplasia (MDS); and
2. Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
3. Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
4. Other causes of anaemia such as B12 and folate deficiency have been excluded; and
5. Patient has a serum epoetin level of < 500 IU/L; and
6. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Continuation – myelodysplasia*
Re-assessment required after 2 months
All of the following:
1. The patient's transfusion requirement continues to be reduced with epoetin treatment; and
2. Transformation to acute myeloid leukaemia has not occurred; and
3. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Initiation – all other indications
Haematologist.
For use in patients where blood transfusion is not a viable treatment alternative.
*Note: Indications marked with * are unapproved indications.

Megaloblastic

FOLIC ACID

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 0.8 mg</td>
<td>$21.84 1,000</td>
<td>Apo-Folic Acid</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>$12.12 500</td>
<td>Apo-Folic Acid</td>
</tr>
<tr>
<td>Oral liq 50 mcg per ml</td>
<td>$26.00 25 ml Biomed</td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Antifibrinolytics, Haemostatics and Local Sclerosants

ALUMINIUM CHLORIDE – Restricted see terms below
↓ Topical soln 20% w/v
— Restricted (RS1500)
Initiation
For use as a haemostatis agent.

APROTININ – Restricted see terms below
↓ Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial
— Restricted (RS1332)
Initiation
Cardiac anaesthetist
Either:
1 Paediatric patient undergoing cardiopulmonary bypass procedure; or
2 Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug.

ELTROMBOPAG – Restricted see terms below
↓ Tab 25 mg .................................................................1,550.00 28 Revolade
↓ Tab 50 mg .................................................................3,100.00 28 Revolade
— Restricted (RS1648)
Initiation – idiopathic thrombocytopenic purpura - post-splenectomy
Haematologist
Re-assessment required after 6 weeks
All of the following:
1 Patient has had a splenectomy; and
2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
3 Any of the following:
   3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
   3.2 Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or
   3.3 Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

Initiation – idiopathic thrombocytopenic purpura - preparation for splenectomy
Haematologist
Limited to 6 weeks treatment
The patient requires eltrombopag treatment as preparation for splenectomy.

Continuation – idiopathic thrombocytopenic purpura - post-splenectomy
Haematologist
Re-assessment required after 12 months
The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre

Initiation – idiopathic thrombocytopenic purpura contraindicated to splenectomy
Haematologist
Re-assessment required after 3 months
All of the following:
1 Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and

continued…
Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and

Either:

1. Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
2. Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Continuation – idiopathic thrombocytopenic purpura contraindicated to splenectomy

Re-assessment required after 12 months

All of the following:
1. The patient’s significant contraindication to splenectomy remains; and
2. The patient has obtained a response from treatment during the initial approval period; and
3. Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
4. Further treatment with eltrombopag is required to maintain response.

Initiation – severe aplastic anaemia

Re-assessment required after 3 months

Both:
1. Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
2. Either:
   1. Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
   2. Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Continuation – severe aplastic anaemia

Re-assessment required after 12 months

Both:
1. The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
2. Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

FERRIC SUBSULFATE
Gel 25.9%
Soln 500 ml

POLIDOCANOL
Inj 0.5%, 30 ml vial

SODIUM TETRADECYL SULPHATE
Inj 3%, 2 ml ampoule

THROMBIN
Powder

TRANEXAMIC ACID
Tab 500 mg – 1% DV May-20 to 2022.................................................................20.67 100 Cyklokapron

Inj 100 mg per ml, 5 ml ampoule – 1% DV Sep-18 to 2021..................................6.95 5 Mercury Pharma

Inj 100 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021............................10.95 5 Tranexamic-AFT

(Cyklokapron Tab 500 mg to be delisted 1 May 2020)
# BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Anticoagulant Reversal Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IDARUCIZUMAB</strong> – <strong>Restricted</strong> see terms below</td>
</tr>
<tr>
<td>▪ <strong>Inj 50 mg per ml, 50 ml vial</strong>..........................4,250.00 2 Praxbind</td>
</tr>
<tr>
<td>▪ <strong>Restricted (RS1535)</strong></td>
</tr>
</tbody>
</table>

**Initiation**
For the reversal of the anticoagulant effects of dabigatran when required in situations of life-threatening or uncontrolled bleeding, or for emergency surgery or urgent procedures.

<table>
<thead>
<tr>
<th>Blood Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EFTRENONACOG ALFA [RECOMBINANT FACTOR IX]</strong> – <strong>Restricted</strong> see terms below</td>
</tr>
<tr>
<td>▪ <strong>Inj 250 iu vial</strong>.............................................612.50 1 Alprolix</td>
</tr>
<tr>
<td>▪ <strong>Inj 500 iu vial</strong>.............................................1,225.00 1 Alprolix</td>
</tr>
<tr>
<td>▪ <strong>Inj 1,000 iu vial</strong>...........................................2,450.00 1 Alprolix</td>
</tr>
<tr>
<td>▪ <strong>Inj 2,000 iu vial</strong>...........................................4,900.00 1 Alprolix</td>
</tr>
<tr>
<td>▪ <strong>Inj 3,000 iu vial</strong>...........................................7,350.00 1 Alprolix</td>
</tr>
<tr>
<td>▪ <strong>Restricted (RS1684)</strong></td>
</tr>
</tbody>
</table>

**Initiation**
For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

| **EPTACOG ALFA [RECOMBINANT FACTOR VIIA]** – **Restricted** see terms below |
| ▪ **Inj 1 mg syringe**.................................1,178.30 1 NovoSeven RT |
| ▪ **Inj 2 mg syringe**.................................2,356.60 1 NovoSeven RT |
| ▪ **Inj 5 mg syringe**.................................5,891.50 1 NovoSeven RT |
| ▪ **Inj 8 mg syringe**.................................9,426.40 1 NovoSeven RT |
| ▪ **Restricted (RS1704)** |

**Initiation**
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group. Rare Clinical Circumstances Brand of bypassing agent for > 14 days predicted use. Access to funded treatment for > 14 days predicted use is by named patient application to the Haemophilia Treaters Group, subject to access criteria.

| **FACTOR EIGHT INHIBITOR BYPASSING FRACTION** – **Restricted** see terms below |
| ▪ **Inj 500 U**.........................................................1,315.00 1 FEIBA NF |
| ▪ **Inj 1,000 U**.......................................................2,630.00 1 FEIBA NF |
| ▪ **Inj 2,500 U**.......................................................6,575.00 1 FEIBA NF |
| ▪ **Restricted (RS1705)** |

**Initiation**
For patients with haemophilia. Preferred Brand of bypassing agent for > 14 days predicted use. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

| **MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII]** – **Restricted** see terms below |
| ▪ **Inj 250 iu prefilled syringe**.............................287.50 1 Xyntha |
| ▪ **Inj 500 iu prefilled syringe**.............................575.00 1 Xyntha |
| ▪ **Inj 1,000 iu prefilled syringe**...........................1,150.00 1 Xyntha |
| ▪ **Inj 2,000 iu prefilled syringe**............................2,300.00 1 Xyntha |
| ▪ **Inj 3,000 iu prefilled syringe**............................3,450.00 1 Xyntha |
| ▪ **Restricted (RS1706)** |

**Initiation**
For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.
NONACOG GAMMA, [RECOMBINANT FACTOR IX] – Restricted see terms below

- Inj 500 iu vial.................................................................435.00 1 RIXUBIS
- Inj 1,000 iu vial.............................................................870.00 1 RIXUBIS
- Inj 2,000 iu vial............................................................1,740.00 1 RIXUBIS
- Inj 3,000 iu vial............................................................2,610.00 1 RIXUBIS

→ Restricted (RS1679)

Initiation
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – Restricted see terms below

- Inj 250 iu vial.................................................................210.00 1 Advate
- Inj 500 iu vial.................................................................420.00 1 Advate
- Inj 1,000 iu vial.............................................................840.00 1 Advate
- Inj 1,500 iu vial.............................................................1,260.00 1 Advate
- Inj 2,000 iu vial............................................................1,680.00 1 Advate
- Inj 3,000 iu vial............................................................2,520.00 1 Advate

→ Restricted (RS1707)

Initiation
For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) – Restricted see terms below

- Inj 250 iu vial.................................................................237.50 1 Kogenate FS
- Inj 500 iu vial.................................................................475.00 1 Kogenate FS
- Inj 1,000 iu vial.............................................................950.00 1 Kogenate FS
- Inj 2,000 iu vial............................................................1,900.00 1 Kogenate FS
- Inj 3,000 iu vial............................................................2,850.00 1 Kogenate FS

→ Restricted (RS1708)

Initiation
For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria

RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] – Restricted see terms below

- Inj 250 iu vial.................................................................300.00 1 Adynovate
- Inj 500 iu vial.................................................................600.00 1 Adynovate
- Inj 1,000 iu vial.............................................................1,200.00 1 Adynovate
- Inj 2,000 iu vial............................................................2,400.00 1 Adynovate

→ Restricted (RS1682)

Initiation
For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group

Vitamin K

<table>
<thead>
<tr>
<th>PHOTOMENADIONE</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg in 0.2 ml ampoule .................................................................8.00 5 Konakion MM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule ..............................................................9.21 5 Konakion MM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## Antithrombotics

### Anticoagulants

**BIVALIRUDIN** – **Restricted** see terms below

- Inj 250 mg vial

**Initiation**

Either:

1. For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance; or
2. For use in patients undergoing endovascular procedures.

**CITRATE SODIUM**

- Inj 4% (200 mg per 5 ml), 5 ml ampoule
- Inj 46.7% (1.4 g per 3 ml), 3 ml syringe
- Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule

**DABIGATRAN**

- Cap 75 mg
- Cap 110 mg
- Cap 150 mg

**DALTEPARIN**

- Inj 2,500 iu in 0.2 ml syringe
- Inj 5,000 iu in 0.2 ml syringe
- Inj 7,500 iu in 0.75 ml syringe
- Inj 10,000 iu in 1 ml syringe

*(Fragmin Inj 2,500 iu in 0.2 ml syringe to be delisted 1 April 2020)*
*(Fragmin Inj 5,000 iu in 0.2 ml syringe to be delisted 1 April 2020)*
*(Fragmin Inj 7,500 iu in 0.75 ml syringe to be delisted 1 April 2020)*
*(Fragmin Inj 10,000 iu in 1 ml syringe to be delisted 1 April 2020)*

**DANAPAROID** – **Restricted** see terms below

- Inj 750 u in 0.6 ml ampoule

**DEFIBROTIDE** – **Restricted** see terms below

- Inj 80 mg per ml, 2.5 ml ampoule

**DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]**

- Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml,
  100 ml bag
### Enoxaparin Sodium

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 20 mg in 0.2 ml syringe</td>
<td>27.93</td>
<td>Clexane</td>
</tr>
<tr>
<td>Inj 40 mg in 0.4 ml syringe</td>
<td>37.27</td>
<td>Clexane</td>
</tr>
<tr>
<td>Inj 60 mg in 0.6 ml syringe</td>
<td>56.18</td>
<td>Clexane</td>
</tr>
<tr>
<td>Inj 80 mg in 0.8 ml syringe</td>
<td>74.90</td>
<td>Clexane</td>
</tr>
<tr>
<td>Inj 100 mg in 1 ml syringe</td>
<td>93.80</td>
<td>Clexane</td>
</tr>
<tr>
<td>Inj 120 mg in 0.8 ml syringe</td>
<td>116.55</td>
<td>Clexane</td>
</tr>
<tr>
<td>Inj 150 mg in 1 ml syringe</td>
<td>133.20</td>
<td>Clexane</td>
</tr>
</tbody>
</table>

### Fondaparinux Sodium

- **Restricted** see terms below
  - Inj 2.5 mg in 0.5 ml syringe
  - Inj 7.5 mg in 0.6 ml syringe
  - **Restricted** (RS1184)

**Initiation**

For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance.

### Heparin Sodium

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 iu per ml, 250 ml bag</td>
<td>98.53</td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 1,000 iu per ml, 1 ml ampoule</td>
<td>58.57</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 1,000 iu per ml, 5 ml ampoule</td>
<td>28.40</td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 5,000 iu in 0.2 ml ampoule</td>
<td>203.68</td>
<td>Pfizer</td>
</tr>
</tbody>
</table>

### Heparinised Saline

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 iu per ml, 5 ml ampoule</td>
<td>56.94</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 100 iu per ml, 2 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 iu per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Phenindione

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Protamine Sulphate

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Rivaroxaban

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td>83.10</td>
<td>Xarelto</td>
</tr>
<tr>
<td>Tab 15 mg</td>
<td>77.56</td>
<td>Xarelto</td>
</tr>
<tr>
<td>Tab 20 mg</td>
<td>77.56</td>
<td>Xarelto</td>
</tr>
</tbody>
</table>

### Sodium Citrate with Sodium Chloride and Potassium Chloride

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74.6 mcg per ml, 5,000 ml bag</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Warfarin Sodium

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg</td>
<td>7.60</td>
<td>Marevan</td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>11.80</td>
<td>Marevan</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>13.50</td>
<td>Marevan</td>
</tr>
</tbody>
</table>

### Antiplatelets

#### Aspirin

- **10% DV Nov-19 to 2022**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>1.95</td>
<td>Ethics Aspirin EC</td>
</tr>
<tr>
<td>Suppos 300 mg</td>
<td>10.80</td>
<td>Ethics Aspirin EC</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
CLOPIDOGREL

Tab 75 mg – 1% DV May-20 to 2022.................................5.44 84 Arrow - Clopid
4.60 Clopidogrel Multichem

(Arrow - Clopid Tab 75 mg to be delisted 1 May 2020)

DIPYRIDAMOLE

Tab 25 mg
Tab long-acting 150 mg – 1% DV Oct-19 to 2022.............10.90 60 Pytazen SR

Inj 5 mg per ml, 2 ml ampoule

EPTIFIBATIDE – Restricted see terms below

‖ Inj 2 mg per ml, 10 ml vial – 1% DV Nov-18 to 2021.............138.75 1 Integrilin
‖ Inj 750 mcg per ml, 100 ml vial – 1% DV Nov-18 to 2021........405.00 1 Integrilin

Restricted (RS1362)

Initiation
Either:
1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
2 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography.

LYSINE ACETYLSALICYLATE [LYSINE ASPRIN] – Restricted see terms below

‖ Inj 500 mg

Restricted (RS1689)

Initiation
Both:
1 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and
2 Administration of oral aspirin would delay the procedure.

PRASUGREL – Restricted see terms below

‖ Tab 5 mg .................................................................108.00 28 Effient
‖ Tab 10 mg .............................................................120.00 28 Effient

Restricted (RS1187)

Initiation – Bare metal stents
Limited to 6 months treatment
Patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic.

Initiation – Drug-eluting stents
Limited to 12 months treatment
Patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic.

Initiation – Stent thrombosis
Patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Initiation – Myocardial infarction
Limited to 1 week treatment
For short term use while in hospital following ST-elevated myocardial infarction.
Note: Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment

TICAGRELOR – Restricted see terms below

‖ Tab 90 mg .............................................................90.00 56 Brilinta

Restricted (RS1724)

Initiation
Restricted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been

continued…
given in the last 24 hours and is not planned.

**Initiation – thrombosis prevention post neurological stenting**

*Re-assessment required after 12 months*

Both:

1. Patient has had a neurological stenting procedure* in the last 60 days; and
2. Either:
   1. Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay and requires antiplatelet treatment with ticagrelor; or
   2. Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event.

**Continuation – thrombosis prevention post neurological stenting**

*Re-assessment required after 12 months*

Both:

1. Patient is continuing to benefit from treatment; and
2. Treatment continues to be clinically appropriate.

Note: Indications marked with * are unapproved indications.

**TICLOPIDINE**

Tab 250 mg

**Fibrinolytic Agents**

**ALTEPLASE**

- Inj 2 mg vial
- Inj 10 mg vial
- Inj 50 mg vial

**TENECTEPLASE**

- Inj 50 mg vial

**UROKINASE**

- Inj 5,000 iu vial
- Inj 10,000 iu vial
- Inj 50,000 iu vial
- Inj 100,000 iu vial
- Inj 500,000 iu vial

**Colony-Stimulating Factors**

**Drugs Used to Mobilise Stem Cells**

**PLERIXAFOR – Restricted** see terms below

- Inj 20 mg per ml, 1.2 ml vial ............................................................... 8,740.00 1 Mozobil

*Restricted (RS1536)*

**Initiation – Autologous stem cell transplant**

Haematologist

*Limited to 3 days treatment*

All of the following:

1. Patient is to undergo stem cell transplantation; and
2. Patient has not had a previous unsuccessful mobilisation attempt with plerixafor; and
3. Any of the following:

continued...
continued...

3.1 Both:
   3.1.1 Patient is undergoing G-CSF mobilisation; and
   3.1.2 Either:
      3.1.2.1 Has a suboptimal peripheral blood CD34 count of less than or equal to \(10 \times 10^6\)/L on day 5 after 4 days of G-CSF treatment; or
      3.1.2.2 Efforts to collect > \(1 \times 10^6\) CD34 cells/kg have failed after one apheresis procedure; or

3.2 Both:
   3.2.1 Patient is undergoing chemotherapy and G-CSF mobilisation; and
   3.2.2 Any of the following:
      3.2.2.1 Both:
         3.2.2.1.1 Has rising white blood cell counts of > \(5 \times 10^9\)/L; and
         3.2.2.1.2 Has a suboptimal peripheral blood CD34 count of less than or equal to \(10 \times 10^6\)/L; or
      3.2.2.2 Efforts to collect > \(1 \times 10^6\) CD34 cells/kg have failed after one apheresis procedure; or
      3.2.2.3 The peripheral blood CD34 cell counts are decreasing before the target has been received; or

3.3 A previous mobilisation attempt with G-CSF or G-CSF plus chemotherapy has failed.

### Granulocyte Colony-Stimulating Factors

**FILGRASTIM** – Restricted see terms below

- Inj 300 mcg in 0.5 ml prefilled syringe – 1% DV May-19 to 2021 ..................96.22 10 Nivestim
- Inj 300 mcg in 1 ml vial ..................................................................................520.00 4 Neupogen
- Inj 480 mcg in 0.5 ml prefilled syringe – 1% DV Mar-19 to 2021 .................161.50 10 Nivestim

- Restricted (RS1188)

- Haematologist or oncologist

**PEGFILGRASTIM** – Restricted see terms below

- Inj 6 mg per 0.6 ml syringe ........................................................................1,080.00 1 Neulastim

- Restricted (RS1262)

- Initiation

For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%*).

Note: *Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines

### Fluids and Electrolytes

### Intravenous Administration

**CALCIUM CHLORIDE**

- Inj 100 mg per ml, 10 ml vial
- Inj 100 mg per ml, 50 ml syringe  
  e.g. Baxter

**CALCIUM GLUCONATE**

- Inj 10%, 10 ml ampoule  
  e.g. Max Health

**COMPOUND ELECTROLYTES**

- Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 500 ml bag – 1% DV Jun-18 to 2021 .................................................................44.10 18 Plasma-Lyte 148
- Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 1,000 ml bag – 1% DV Jun-18 to 2021..........................................................27.24 12 Plasma-Lyte 148
### BLOOD AND BLOOD FORMING ORGANS

**Price (ex man. excl. GST) $ Per**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Products with Hospital Supply Status (HSS) are in <strong>bold</strong></th>
<th>Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.</th>
</tr>
</thead>
</table>

#### COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]

- **Inj sodium 140 mmol/l, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, glucose 23 mmol/l (5%), 1,000 ml bag — 1% DV Jun-18 to 2021**
  - **Plasma-Lyte 148 & 5% Glucose**
  - **$211.92 12**

#### COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION]

- **Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml bag — 1% DV Jun-18 to 2021**
  - **Baxter**
  - **$23.40 18**

#### GLUCOSE [DEXTROSE]

- **Inj 5%, 1,000 ml bag — 1% DV Aug-18 to 2021**
  - **Fresenius Kabi**
  - **$16.80 10**

- **Inj 5%, 100 ml bag — 1% DV Aug-18 to 2021**
  - **Fresenius Kabi**
  - **$77.50 50**

- **Inj 5%, 250 ml bag — 1% DV Aug-18 to 2021**
  - **Fresenius Kabi**
  - **$52.50 30**

- **Inj 5%, 50 ml bag — 1% DV Jun-18 to 2021**
  - **Baxter Glucose 5%**
  - **$143.40 60**

- **Inj 5%, 500 ml bag — 1% DV Aug-18 to 2021**
  - **Fresenius Kabi**
  - **$24.00 20**

- **Inj 10%, 1,000 ml bag — 1% DV Jun-18 to 2021**
  - **Baxter Glucose 10%**
  - **$111.96 12**

- **Inj 10%, 500 ml bag — 1% DV Jun-18 to 2021**
  - **Baxter Glucose 10%**
  - **$109.98 18**

- **Inj 5%, 10 ml ampoule — 1% DV Oct-17 to 2020**
  - **Biomed**
  - **$29.50 5**

- **Inj 50%, 500 ml bag — 1% DV Jun-18 to 2021**
  - **Baxter Glucose 50%**
  - **$337.32 12**

- **Inj 50%, 90 ml bottle — 1% DV Oct-17 to 2020**
  - **Biomed**
  - **$14.50 1**

#### GLUCOSE WITH POTASSIUM CHLORIDE

- **Inj 10% glucose with 20 mmol/l potassium chloride, 500 ml bag**

#### GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE

- **Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 3,000 ml bag**

- **Inj 10% glucose with potassium chloride 10 mmol/l and sodium chloride 15 mmol/l, 500 ml bag**

- **Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, 1,000 ml bag — 1% DV Jun-18 to 2021**
  - **Baxter**
  - **$203.40 12**

- **Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 1,000 ml bag — 1% DV Jun-18 to 2021**
  - **Baxter**
  - **$159.96 12**

- **Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.9%, 1,000 ml bag — 1% DV Jun-18 to 2021**
  - **Baxter**
  - **$282.72 12**

#### GLUCOSE WITH SODIUM CHLORIDE

- **Inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag**

- **Inj 4% glucose and sodium chloride 0.18%, 1,000 ml bag — 1% DV Jun-18 to 2021**
  - **Baxter**
  - **$163.32 12**

- **Inj 5% glucose and sodium chloride 0.45%, 1,000 ml bag — 1% DV Jun-18 to 2021**
  - **Baxter**
  - **$163.20 12**

- **Inj 5% glucose and sodium chloride 0.9%, 1,000 ml bag — 1% DV Jun-18 to 2021**
  - **Baxter**
  - **$173.40 12**

#### POTASSIUM CHLORIDE

- **Inj 75 mg (1 mmol) per ml, 10 ml ampoule**

- **Inj 225 mg (3 mmol) per ml, 20 ml ampoule**
### POTASSIUM CHLORIDE WITH SODIUM CHLORIDE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag</td>
<td>$476.64</td>
<td>Baxter</td>
</tr>
<tr>
<td>– 1% DV Jun-18 to 2021</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Inj 20 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag</td>
<td>$163.08</td>
<td>Baxter</td>
</tr>
<tr>
<td>– 1% DV Jun-18 to 2021</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Inj 40 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag</td>
<td>$253.32</td>
<td>Baxter</td>
</tr>
<tr>
<td>– 1% DV Jun-18 to 2021</td>
<td>12</td>
<td></td>
</tr>
</tbody>
</table>

### POTASSIUM DIHYDROGEN PHOSPHATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mmol per ml, 10 ml ampoule</td>
<td>$151.80</td>
<td>Hospira</td>
</tr>
</tbody>
</table>

### RINGER'S SOLUTION

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, 1,000 ml bag</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SODIUM ACETATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 4 mmol per ml, 20 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SODIUM BICARBONATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 8.4%, 10 ml vial</td>
<td>$19.95</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 8.4%, 50 ml vial</td>
<td>$20.50</td>
<td>Biomed</td>
</tr>
</tbody>
</table>

### SODIUM CHLORIDE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.9%, 5 ml ampoule – 1% DV Dec-19 to 2022</td>
<td>$2.80</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 0.9%, 10 ml ampoule – 1% DV Dec-19 to 2022</td>
<td>$5.40</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>† Inj 0.9%, 3 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021</td>
<td>$160.90</td>
<td>BD PosiFlush</td>
</tr>
<tr>
<td>† Restricted (RS1297) Initiation For use in flushing of in-situ vascular access devices only.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Inj 0.9%, 5 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021</td>
<td>$162.91</td>
<td>BD PosiFlush</td>
</tr>
<tr>
<td>† Restricted (RS1297) Initiation For use in flushing of in-situ vascular access devices only.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Inj 0.9%, 10 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021</td>
<td>$170.35</td>
<td>BD PosiFlush</td>
</tr>
<tr>
<td>† Restricted (RS1297) Initiation For use in flushing of in-situ vascular access devices only.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.9%, 20 ml ampoule – 1% DV Dec-19 to 2022</td>
<td>$5.00</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 23.4% (4 mmol/ml), 20 ml ampoule</td>
<td>$33.00</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 0.45%, 500 ml bag</td>
<td>$71.28</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 3%, 1,000 ml bag</td>
<td>$91.20</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 50 ml bag</td>
<td>$109.80</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 100 ml bag</td>
<td>$109.80</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 250 ml bag</td>
<td>$44.64</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 500 ml bag</td>
<td>$22.14</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 1,000 ml bag</td>
<td>$15.12</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 1.8%, 500 ml bottle</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mmol per ml, 20 ml ampoule – 1% DV Oct-18 to 2021</td>
<td>$48.70</td>
<td>Biomed</td>
</tr>
</tbody>
</table>
# BLOOD AND BLOOD FORMING ORGANS

### Price (ex man. excl. GST) Per Brand or Generic Manufacturer

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Quantity</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>WATER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 ml ampoule</td>
<td>7.00</td>
<td>50</td>
<td>InterPharma</td>
</tr>
<tr>
<td>Inj 10 ml ampoule</td>
<td>6.63</td>
<td>50</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 20 ml ampoule</td>
<td>5.00</td>
<td>20</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td></td>
<td>7.50</td>
<td>30</td>
<td>InterPharma</td>
</tr>
<tr>
<td></td>
<td>5.00</td>
<td>20</td>
<td>Multichem</td>
</tr>
<tr>
<td>Inj 250 ml bag</td>
<td>7.50</td>
<td>30</td>
<td>InterPharma</td>
</tr>
<tr>
<td>Inj 500 ml bag</td>
<td>5.00</td>
<td>20</td>
<td>Multichem</td>
</tr>
<tr>
<td>Inj 1,000 ml bag</td>
<td>19.08</td>
<td>12</td>
<td>Baxter</td>
</tr>
</tbody>
</table>

### Oral Administration

**CALCIUM POLYSTYRENE SULPHONATE**
- Powder .......................................................... 169.85 300 g Calcium Resonium

**COMPOUND ELECTROLYTES**
- Powder for oral soln – 1% DV Apr-20 to 2022 ...................... 9.77 50 Electral
  - 2.30 10 Enerlyte

*(Enerlyte Powder for oral soln to be delisted 1 April 2020)*

**COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]**
- Soln with electrolytes (2 x 500 ml) – 1% DV Nov-18 to 2021 ........ 6.55 1,000 ml Pedialyte - Bubblegum

**PHOSPHORUS**
- Tab eff 500 mg (16 mmol)

**POTASSIUM CHLORIDE**
- Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)
- Tab long-acting 600 mg (8 mmol) – 1% DV Oct-18 to 2021 .............. 8.90 200 Span-K
- Oral liq 2 mmol per ml

**SODIUM BICARBONATE**
- Cap 840 mg ......................................................... 8.52 100 Sodibic

**SODIUM CHLORIDE**
- Tab 600 mg
- Oral liq 2 mmol/ml

**SODIUM POLYSTYRENE SULPHONATE**
- Powder – 1% DV Sep-18 to 2021 ........................................ 84.65 454 g Resonium A

### Plasma Volume Expanders

**GELATINE, SUCCINYLATED**
- Inj 4%, 500 ml bag – 1% DV Jun-18 to 2021 ...................... 120.00 10 Gelofusine
## Agents Affecting the Renin-Angiotensin System

### ACE Inhibitors

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CAPTOPRIL</strong></td>
<td></td>
</tr>
<tr>
<td>Oral liq 5 mg per ml</td>
<td>94.99 95 ml Capoten</td>
</tr>
</tbody>
</table>

- **Restricted (RS1263)**

**Initiation**

Any of the following:

1. For use in children under 12 years of age; or
2. For use in tube-fed patients; or
3. For management of rebound transient hypertension following cardiac surgery.

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CILAZAPRIL</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 0.5 mg – 1% DV Sep-19 to 2022</td>
<td>2.09 90 Zapril</td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Feb-20 to 2022</td>
<td>4.80 90 Zapril</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Feb-20 to 2022</td>
<td>8.35 90 Zapril</td>
</tr>
</tbody>
</table>

**ENALAPRIL MALEATE**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg – 1% DV Jun-20 to 2022</td>
<td>1.82 100 Acetec</td>
</tr>
<tr>
<td></td>
<td>3.84</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Jun-20 to 2022</td>
<td>2.02 100 Acetec</td>
</tr>
<tr>
<td></td>
<td>4.96</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Jun-20 to 2022</td>
<td>2.42 100 Acetec</td>
</tr>
<tr>
<td></td>
<td>7.12</td>
</tr>
</tbody>
</table>

**LISINOPRIL**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg – 1% DV Dec-18 to 2021</td>
<td>2.07 90 Ethics Lisinopril</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Dec-18 to 2021</td>
<td>2.36 90 Ethics Lisinopril</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Dec-18 to 2021</td>
<td>3.17 90 Ethics Lisinopril</td>
</tr>
</tbody>
</table>

**PERINDOPRIL**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2 mg – 1% DV Sep-17 to 2020</td>
<td>3.75 30 Apo-Perindopril</td>
</tr>
<tr>
<td>Tab 4 mg – 1% DV Sep-17 to 2020</td>
<td>4.80 30 Apo-Perindopril</td>
</tr>
</tbody>
</table>

**QUINAPRIL**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg – 1% DV Nov-18 to 2021</td>
<td>6.01 90 Arrow-Quinapril 5</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Nov-18 to 2021</td>
<td>3.16 90 Arrow-Quinapril 10</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Nov-18 to 2021</td>
<td>4.89 90 Arrow-Quinapril 20</td>
</tr>
</tbody>
</table>

### ACE Inhibitors with Diuretics

**CILAZAPRIL WITH HYDROCHLOROTHIAZIDE** – **Restricted:** For continuation only

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg with hydrochlorothiazide 12.5 mg</td>
<td>10.18 100 Apo-Cilazapril/ Hydrochlorothiazide</td>
</tr>
</tbody>
</table>

(Apo-Cilazapril/ Hydrochlorothiazide Tab 5 mg with hydrochlorothiazide 12.5 mg to be delisted 1 December 2020)

**QUINAPRIL WITH HYDROCHLOROTHIAZIDE**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Dec-18 to 2021</td>
<td>3.83 30 Accuretic 10</td>
</tr>
<tr>
<td>Tab 20 mg with hydrochlorothiazide 12.5 mg – 1% DV Dec-18 to 2021</td>
<td>4.92 30 Accuretic 20</td>
</tr>
</tbody>
</table>

*Item restricted (see ➥ above); ➥ Item restricted (see ➥ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*
Angiotensin II Antagonists

Candesartan Cilexetil
- Tab 4 mg – 1% DV Sep-18 to 2021 ................................................................. 1.90 90 Candestar
- Tab 8 mg – 1% DV Sep-18 to 2021 ................................................................. 2.28 90 Candestar
- Tab 16 mg – 1% DV Sep-18 to 2021 ................................................................. 3.67 90 Candestar
- Tab 32 mg – 1% DV Sep-18 to 2021 ................................................................. 6.39 90 Candestar

Losartan Potassium
- Tab 12.5 mg – 1% DV Nov-17 to 2020 ............................................................ 1.39 84 Losartan Actavis
- Tab 25 mg – 1% DV Nov-17 to 2020 ............................................................... 1.63 84 Losartan Actavis
- Tab 50 mg – 1% DV Nov-17 to 2020 ............................................................... 2.00 84 Losartan Actavis
- Tab 100 mg – 1% DV Nov-17 to 2020 ............................................................. 2.31 84 Losartan Actavis

Angiotensin II Antagonists with Diuretics

Losartan Potassium with Hydrochlorothiazide
- Tab 50 mg with hydrochlorothiazide 12.5 mg – 1% DV Jan-19 to 2021 .......... 1.88 30 Arrow-Losartan & Hydrochlorothiazide

Angiotensin II Antagonists with Neprilysin Inhibitors

Sacubitril with Valsartan
- Tab 24.3 mg with valsartan 25.7 mg ............................................................... 190.00 56 Entresto 24/26
- Tab 48.6 mg with valsartan 51.4 mg ............................................................... 190.00 56 Entresto 49/51
- Tab 97.2 mg with valsartan 102.8 mg ............................................................. 190.00 56 Entresto 97/103

Initiation
Re-assessment required after 12 months
All of the following:
1 Patient has heart failure; and
2 Any of the following:
   2.1 Patient is in NYHA/WHO functional class II; or
   2.2 Patient is in NYHA/WHO functional class III; or
   2.3 Patient is in NYHA/WHO functional class IV; and
3 Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; and
4 Patient is receiving concomitant optimal standard chronic heart failure treatments.

Continuation
Re-assessment required after 12 months
The treatment remains appropriate and the patient is benefiting from treatment.
Note: Due to the angiotensin II receptor blocking activity of sacubitril with valsartan it should not be co-administered with an ACE inhibitor or another ARB.

Alpha-Adrenoceptor Blockers

Doxazosin
- Tab 2 mg – 1% DV Sep-17 to 2020 ................................................................. 6.75 500 Apo-Doxazosin
- Tab 4 mg – 1% DV Sep-17 to 2020 ................................................................. 9.09 500 Apo-Doxazosin

Phenoxybenzamine Hydrochloride
- Cap 10 mg
- Inj 50 mg per ml, 1 ml ampoule
- Inj 50 mg per ml, 2 ml ampoule

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## Cardiovascular System

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### PHENTOLAMINE MESYLATE
- Inj 5 mg per ml, 1 ml ampoule
- Inj 10 mg per ml, 1 ml ampoule

### PRAZOSIN
- Tab 1 mg
- Tab 2 mg
- Tab 5 mg

### TERAZOSIN
- Tab 1 mg
- Tab 2 mg
- Tab 5 mg

### Antiarrhythmics

#### ADENOSINE
- Inj 3 mg per ml, 2 ml vial – 1% DV Feb-20 to 2022

#### AJMALINE
- Inj 5 mg per ml, 10 ml ampoule – Restricted (RS1266)

#### AMIODARONE HYDROCHLORIDE
- Tab 100 mg
- Tab 200 mg
- Inj 50 mg per ml, 3 ml ampoule – 1% DV Feb-20 to 2022

#### ATROPINE SULPHATE
- Inj 600 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021

#### DIGOXIN
- Tab 62.5 mcg
- Tab 250 mcg
- Oral liq 50 mcg per ml
- Inj 250 mcg per ml, 2 ml vial

#### DISOPYRAMIDE PHOSPHATE
- Cap 100 mg

#### FLECAINIDE ACETATE
- Tab 50 mg
- Cap long-acting 100 mg
- Cap long-acting 200 mg
- Inj 10 mg per ml, 15 ml ampoule

#### IVABRADINE
- Tab 5 mg – Restricted (RS1566)

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)

* *e.g. Brand indicates brand example only. It is not a contracted product.*
continued...

1. Patient is indicated for computed tomography coronary angiography; and
2. Either:
   2.1 Patient has a heart rate of greater than 70 beats per minute while taking a maximally tolerated dose of beta blocker; or
   2.2 Patient is unable to tolerate beta blockers.

**MEXILETINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mexiletine Hydrochloride USP</td>
<td>$162.00</td>
</tr>
<tr>
<td>Mexiletine Hydrochloride USP</td>
<td>$202.00</td>
</tr>
</tbody>
</table>

**PROPAFENONE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$162.00</td>
</tr>
<tr>
<td></td>
<td>$202.00</td>
</tr>
</tbody>
</table>

**Antihypotensives**

**MIDODRINE** – *Restricted* see terms below
- Tab 2.5 mg
- Tab 5 mg
- *Restricted (RS1427)*

**Initiation**
Patient has disabling orthostatic hypotension not due to drugs.

**Beta-Adrenoceptor Blockers**

**ATENOLOL**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mylan Atenolol</td>
<td>$4.26</td>
</tr>
<tr>
<td>Mylan Atenolol</td>
<td>$7.30</td>
</tr>
<tr>
<td>Atenolol-AFT</td>
<td>$21.25</td>
</tr>
</tbody>
</table>

**BISOPROLOL FUMARATE**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bosvate</td>
<td>$3.53</td>
</tr>
<tr>
<td>Bosvate</td>
<td>$5.15</td>
</tr>
<tr>
<td>Bosvate</td>
<td>$9.40</td>
</tr>
</tbody>
</table>

**CARVEDILOL**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carvedilol Sandoz</td>
<td>$2.24</td>
</tr>
<tr>
<td>Carvedilol Sandoz</td>
<td>$2.30</td>
</tr>
<tr>
<td>Carvedilol Sandoz</td>
<td>$2.95</td>
</tr>
</tbody>
</table>

**CELIPROLOL**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celol</td>
<td>$21.40</td>
</tr>
</tbody>
</table>

**ESMOLOL HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presolol</td>
<td>$11.36</td>
</tr>
<tr>
<td>Presolol</td>
<td>$29.74</td>
</tr>
</tbody>
</table>

**LABETALOL**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presolol</td>
<td>$11.36</td>
</tr>
<tr>
<td>Presolol</td>
<td>$29.74</td>
</tr>
</tbody>
</table>

**METOPROLOL SUCCINATE**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betaloc CR</td>
<td>$1.03</td>
</tr>
<tr>
<td>Betaloc CR</td>
<td>$1.25</td>
</tr>
<tr>
<td>Betaloc CR</td>
<td>$1.99</td>
</tr>
<tr>
<td>Betaloc CR</td>
<td>$3.00</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

METOPROLOL TARTRATE
Tab 50 mg – 1% DV Oct-18 to 2021……………………………………….5.66 100 Apo-Metoprolol
Tab 100 mg – 1% DV Oct-18 to 2021……………………………………….7.55 60 Apo-Metoprolol
Tab long-acting 200 mg………………………………………………………23.40 28 Slow-Lopresor
Inj 1 mg per ml, 5 ml vial – 1% DV Feb-19 to 31 Jan 2022……………..29.50 5 Metoprolol IV Mylan

NADOLOL
Tab 40 mg – 1% DV Oct-18 to 2021………………………………………..16.69 100 Apo-Nadolol
Tab 80 mg – 1% DV Oct-18 to 2021………………………………………..26.43 100 Apo-Nadolol

PINDOLOL
Tab 5 mg – 1% DV Oct-18 to 2021……………………………………….13.22 100 Apo-Pindolol
Tab 10 mg – 1% DV Oct-18 to 2021……………………………………….23.12 100 Apo-Pindolol
Tab 15 mg – 1% DV Oct-18 to 2021……………………………………….33.31 100 Apo-Pindolol

PROPRANOLOL
Tab 10 mg – 1% DV Oct-18 to 2021……………………………………….4.64 100 Apo-Propranolol
Tab 40 mg – 1% DV Oct-18 to 2021……………………………………….5.72 100 Apo-Propranolol
Cap long-acting 160 mg……………………………………………………18.17 100 Cardinol LA
Oral liq 4 mg per ml
Inj 1 mg per ml, 1 ml ampoule

SOTALOL
Tab 80 mg – 1% DV Oct-19 to 2022………………………………………..32.58 500 Mylan
Tab 160 mg – 1% DV Oct-19 to 2022………………………………………..10.98 100 Mylan

TIMOLOL MALEATE
Tab 10 mg

**Calcium Channel Blockers**

**Dihydropyridine Calcium Channel Blockers**

AMLODIPINE
Tab 2.5 mg – 1% DV Sep-17 to 2020……………………………………….1.72 100 Apo-Amlodipine
Tab 5 mg – 1% DV Sep-17 to 2020……………………………………….3.33 250 Apo-Amlodipine
Tab 10 mg – 1% DV Sep-17 to 2020……………………………………….4.40 250 Apo-Amlodipine

FELODIPINE
Tab long-acting 2.5 mg – 1% DV Sep-18 to 2021………………………1.45 30 Plendil ER
Tab long-acting 5 mg – 1% DV Dec-18 to 2021………………………..3.93 90 Felo 5 ER
Tab long-acting 10 mg – 1% DV Dec-18 to 2021………………………4.32 90 Felo 10 ER

ISRADIPINE
Tab 2.5 mg
Cap 2.5 mg

NICARDIPINE HYDROCHLORIDE – Restricted see terms below
↓ Inj 2.5 mg per ml, 10 ml vial
⇒ Restricted (RS1699)

Initiation
Anaesthetist, intensivist, cardiologist or paediatric cardiologist
Any of the following:
1. Patient has hypertension requiring urgent treatment with an intravenous agent; or
2. Patient has excessive ventricular afterload; or
3. Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass.

Item restricted (see ➥ above); Item restricted (see ➦ below)
e.g. Brand indicates brand example only. It is not a contracted product.
### NIFEDIPINE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab long-acting 10 mg – 1% DV Aug-17 to 2020</td>
<td>$10.63</td>
<td>Adalat 10</td>
</tr>
<tr>
<td>Tab long-acting 20 mg</td>
<td>$17.72</td>
<td>Nyefax Retard</td>
</tr>
<tr>
<td>Tab long-acting 30 mg</td>
<td>$3.14</td>
<td>Adalat Oros</td>
</tr>
<tr>
<td>Tab long-acting 60 mg – 1% DV Dec-17 to 2020</td>
<td>$5.67</td>
<td>Adalat Oros</td>
</tr>
</tbody>
</table>

### NIMODIPINE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 30 mg – 1% DV Jul-20 to 2022</td>
<td>$350.00</td>
<td>Nimotop</td>
</tr>
<tr>
<td>Inj 200 mcg per ml, 50 ml vial – 1% DV Jul-20 to 2022</td>
<td>$67.50</td>
<td>Nimotop</td>
</tr>
</tbody>
</table>

### Other Calcium Channel Blockers

#### DILTIAZEM HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 30 mg</td>
<td>$4.60</td>
<td>Dilzem</td>
</tr>
<tr>
<td>Tab 60 mg</td>
<td>$8.50</td>
<td>Dilzem</td>
</tr>
<tr>
<td>Cap long-acting 120 mg – 1% DV Oct-18 to 2021</td>
<td>$33.42</td>
<td>Apo-Diltiazem CD</td>
</tr>
<tr>
<td>Cap long-acting 180 mg – 1% DV Oct-18 to 2021</td>
<td>$50.05</td>
<td>Apo-Diltiazem CD</td>
</tr>
<tr>
<td>Cap long-acting 240 mg – 1% DV Oct-18 to 2021</td>
<td>$66.76</td>
<td>Apo-Diltiazem CD</td>
</tr>
</tbody>
</table>

#### PERHEXILINE MALEATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg – 1% DV Oct-19 to 2022</td>
<td>$62.90</td>
<td>Pexsig</td>
</tr>
</tbody>
</table>

#### VERAPAMIL HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 40 mg</td>
<td>$7.01</td>
<td>Isoptin</td>
</tr>
<tr>
<td>Tab 80 mg</td>
<td>$11.74</td>
<td>Isoptin</td>
</tr>
<tr>
<td>Tab long-acting 120 mg</td>
<td>$36.02</td>
<td>Isoptin SR</td>
</tr>
<tr>
<td>Tab long-acting 240 mg</td>
<td>$66.76</td>
<td>Isoptin SR</td>
</tr>
</tbody>
</table>

### Centrally-Acting Agents

#### CLONIDINE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patch 2.5 mg, 100 mcg per day – 1% DV Sep-17 to 2020</td>
<td>$7.40</td>
<td>Mylan</td>
</tr>
<tr>
<td>Patch 5 mg, 200 mcg per day – 1% DV Sep-17 to 2020</td>
<td>$10.04</td>
<td>Mylan</td>
</tr>
<tr>
<td>Patch 7.5 mg, 300 mcg per day – 1% DV Sep-17 to 2020</td>
<td>$12.34</td>
<td>Mylan</td>
</tr>
</tbody>
</table>

#### CLONIDINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mcg – 1% DV Oct-18 to 2021</td>
<td>$8.75</td>
<td>Clonidine BNM</td>
</tr>
<tr>
<td>Tab 150 mcg</td>
<td>$34.32</td>
<td>Catapres</td>
</tr>
<tr>
<td>Inj 150 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021</td>
<td>$25.96</td>
<td>Medsurge</td>
</tr>
</tbody>
</table>

#### METHYLDOPA

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg</td>
<td>$15.10</td>
<td>Methyldopa Mylan</td>
</tr>
</tbody>
</table>

### Diuretics

#### Loop Diuretics

#### BUMETANIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg</td>
<td>$16.36</td>
<td>Burinex</td>
</tr>
<tr>
<td>Inj 500 mcg per ml, 4 ml vial</td>
<td>$25.00</td>
<td>Burinex</td>
</tr>
</tbody>
</table>

*Products with Hospital Supply Status (HSS) are in bold.

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.*
<table>
<thead>
<tr>
<th>CARDIOVASCULAR SYSTEM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Price</strong> (ex man. excl. GST)</td>
</tr>
<tr>
<td><strong>Per</strong></td>
</tr>
<tr>
<td><strong>Brand or Generic Manufacturer</strong></td>
</tr>
</tbody>
</table>

**FUROSEMIDE [FRUSEMIDE]**
- Tab 40 mg – 1% DV Dec-19 to 2022: $7.24 Per 1,000 Apo-Furosemide
- Tab 500 mg – 1% DV Mar-19 to 2021: $25.00 Per 50 Urex Forte
- Oral liq 10 mg per ml – 1% DV Jan-20 to 2022: $11.20 Per 30 ml Lasix
- Inj 10 mg per ml, 2 ml ampoule – 1% DV Oct-19 to 2022: $1.15 Per 5 Frusemid-Claris
- Inj 10 mg per ml, 25 ml ampoule – 1% DV Jan-20 to 2022: $60.65 Per 6 Lasix

**Osmotic Diuretics**

**MANNITOL**
- Inj 10%, 1,000 ml bag – 1% DV Jun-18 to 2021: $747.24 Per 12 Baxter
- Inj 20%, 500 ml bag – 1% DV Jun-18 to 2021: $1,096.92 Per 18 Baxter

**Potassium Sparing Combination Diuretics**

**AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE**
- Tab 5 mg with furosemide 40 mg

**AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE**
- Tab 5 mg with hydrochlorothiazide 50 mg

**Potassium Sparing Diuretics**

**AMILORIDE HYDROCHLORIDE**
- Tab 5 mg
- Oral liq 1 mg per ml: $30.00 Per 25 ml Biomed

**EPLERENONE – Restricted see terms below**
- Tab 25 mg – 1% DV Sep-18 to 2021: $11.87 Per 30 Inspra
- Tab 50 mg – 1% DV Dec-18 to 2021: $17.00 Per 30 Inspra

**SPIRONOLACTONE**
- Tab 25 mg: $4.38 Per 100 Spiractin
- Tab 100 mg: $11.80 Per 100 Spiractin
- Oral liq 5 mg per ml – 1% DV Nov-19 to 2022: $30.60 Per 25 ml Biomed

**Initiation**
- Both:
  1. Patient has heart failure with ejection fraction less than 40%; and
  2. Either:
     2.1 Patient is intolerant to optimal dosing of spironolactone; or
     2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone.

**Thiazide and Related Diuretics**

**BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]**
- Tab 2.5 mg – 1% DV Mar-18 to 2020: $12.50 Per 500 Arrow-Bendroflumethiaze
- Tab 5 mg – 1% DV Mar-18 to 2020: $20.42 Per 500 Arrow-Bendroflumethiazide

**CHLORTHIAZIDE**
- Oral liq 50 mg per ml: $26.00 Per 25 ml Biomed

**CHLORTALIDONE [CHLORTHALIDONE]**
- Tab 25 mg – 1% DV Dec-19 to 2022: $6.50 Per 50 Hygroton

**INDAPAMIDE**
- Tab 2.5 mg: $2.60 Per 90 Dapa-Tabs

**Note:**
- Item restricted (see ➥ above); Item restricted (see ➥ below)
- e.g. Brand indicates brand example only. It is not a contracted product.
## METOLAZONE
Tab 5 mg

### Lipid-Modifying Agents

#### Fibrates

**BEZAFIBRATE**
- Tab 200 mg – 1% DV Dec-18 to 2021 ................................................................. 19.01 90 Bezalip
- Tab long-acting 400 mg – 1% DV Dec-18 to 2021 ........................................ 12.89 30 Bezalip Retard

**GEMFIBROZIL**
- Tab 600 mg ..................................................................................................... 19.56 60 Lipazil

#### HMG CoA Reductase Inhibitors (Statins)

**ATORVASTATIN**
- Tab 10 mg – 1% DV Sep-18 to 2021 ............................................................... 6.96 500 Lorstat
- Tab 20 mg – 1% DV Sep-18 to 2021 ............................................................... 9.99 500 Lorstat
- Tab 40 mg – 1% DV Sep-18 to 2021 ............................................................... 15.93 500 Lorstat
- Tab 80 mg – 1% DV Sep-18 to 2021 ............................................................... 27.19 500 Lorstat

**PRAVASTATIN**
- Tab 10 mg
- Tab 20 mg – 1% DV Mar-18 to 2020 ............................................................... 4.72 100 Apo-Pravastatin
- Tab 40 mg – 1% DV Mar-18 to 2020 ............................................................... 8.06 100 Apo-Pravastatin

**SIMVASTATIN**
- Tab 10 mg – 1% DV Mar-18 to 2020 ............................................................... 0.95 90 Simvastatin Mylan
- Tab 20 mg – 1% DV Mar-18 to 2020 ............................................................... 1.52 90 Simvastatin Mylan
- Tab 40 mg – 1% DV Mar-18 to 2020 ............................................................... 2.63 90 Simvastatin Mylan
- Tab 80 mg – 1% DV Mar-18 to 2020 ............................................................... 6.00 90 Simvastatin Mylan

#### Resins

**CHOLESTYRAMINE**
Powder for oral liq 4 g

**COLESTIPOL HYDROCHLORIDE**
Grans for oral liq 5 g

### Selective Cholesterol Absorption Inhibitors

**EZETIMIBE – Restricted see terms below**
- Tab 10 mg – 1% DV Mar-18 to 2020 ............................................................... 2.00 30 Ezetimibe Sandoz

**Restricted (RS1005)**

**Initiation**
All of the following:
1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. Any of the following:
   3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
   3.2 The patient is intolerant to both simvastatin and atorvastatin; or
   3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
EZETIMIBE WITH SIMVASTATIN – Restricted see terms below

- Tab 10 mg with simvastatin 10 mg ................................................................. 5.15 30 Zimybe
- Tab 10 mg with simvastatin 20 mg ................................................................. 6.15 30 Zimybe
- Tab 10 mg with simvastatin 40 mg ................................................................. 7.15 30 Zimybe
- Tab 10 mg with simvastatin 80 mg ................................................................. 8.15 30 Zimybe

Restricted (RS1006)

Initiation

All of the following:
1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Other Lipid-Modifying Agents

ACIPIMOX

Cap 250 mg

NICOTINIC ACID

Tab 50 mg – 1% DV Oct-17 to 2020 ................................................................. 4.12 100 Apo-Nicotinic Acid
Tab 500 mg – 1% DV Oct-17 to 2020 ................................................................. 17.89 100 Apo-Nicotinic Acid

Nitrates

GLYCERYL TRINITRATE

Inj 1 mg per ml, 5 ml ampoule
Inj 1 mg per ml, 10 ml ampoule
Inj 1 mg per ml, 50 ml vial
Inj 5 mg per ml, 10 ml ampoule ...................................................................... 100.00 5 Hospira
Oral pump spray, 400 mcg per dose .............................................................. 4.45 250 dose Nitrolingual Pump Spray
Oral spray, 400 mcg per dose ......................................................................... 4.45 200 dose Glytrin
Patch 25 mg, 5 mg per day ........................................................................... 15.73 30 Nitroderm TTS 5
Patch 50 mg, 10 mg per day ......................................................................... 18.62 30 Nitroderm TTS 10

(Glytrin Oral spray, 400 mcg per dose to be delisted 1 May 2020)

ISOSORBIDE MONONITRATE

Tab 20 mg – 1% DV Oct-17 to 2020 ................................................................. 18.80 100 Ismo-20
Tab long-acting 40 mg .................................................................................. 8.20 30 Ismo 40 Retard
Tab long-acting 60 mg – 1% DV Sep-17 to 2020 ........................................... 8.29 90 Duride

Other Cardiac Agents

LEVOSIMENDAN – Restricted see terms below

- Inj 2.5 mg per ml, 5 ml vial
- Inj 2.5 mg per ml, 10 ml vial

Restricted (RS1007)

Initiation – Heart transplant

Either:
1. For use as a bridge to heart transplant, in patients who have been accepted for transplant; or
2. For the treatment of heart failure following heart transplant.

Initiation – Heart failure

Cardiologist or intensivist

For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.
### Sympathomimetics

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ADRENALINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 in 1,000, 1 ml ampoule</td>
<td></td>
<td>4.98</td>
<td>5 Aspen Adrenaline</td>
</tr>
<tr>
<td>Inj 1 in 1,000, 30 ml vial</td>
<td></td>
<td>10.76</td>
<td>DBL Adrenaline</td>
</tr>
<tr>
<td>Inj 1 in 10,000, 10 ml ampoule</td>
<td></td>
<td>49.00</td>
<td>10 Aspen Adrenaline</td>
</tr>
<tr>
<td>Inj 1 in 10,000, 10 ml syringe</td>
<td></td>
<td>27.00</td>
<td>Hospira</td>
</tr>
<tr>
<td><strong>DOBUTAMINE</strong></td>
<td>Inj 12.5 mg per ml, 20 ml ampoule – 1% DV Jan-19 to 2021</td>
<td>61.13</td>
<td>5 Dobutamine-hameLin</td>
</tr>
<tr>
<td><strong>DOPAMINE HYDROCHLORIDE</strong></td>
<td>Inj 40 mg per ml, 5 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>29.73</td>
<td>10 Max Health Ltd</td>
</tr>
<tr>
<td><strong>EPHEDRINE</strong></td>
<td>Inj 3 mg per ml, 10 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 30 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>36.04</td>
<td>10 Max Health</td>
<td></td>
</tr>
<tr>
<td><strong>ISOPRENALINE [ISOPROTERENOL]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 200 mcg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>METARAMINOL</strong></td>
<td>Inj 0.5 mg per ml, 10 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.5 mg per ml, 20 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.5 mg per ml, 5 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NORADRENALINE</strong></td>
<td>Inj 0.06 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.06 mg per ml, 50 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.1 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.1 mg per ml, 50 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.12 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.12 mg per ml, 50 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.16 mg per ml, 50 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 4 ml ampoule – 1% DV Oct-19 to 2022</td>
<td>45.00</td>
<td>10 Noradrenaline BNM</td>
<td></td>
</tr>
<tr>
<td><strong>PHENYLEPHRINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td></td>
<td>115.50</td>
<td>25 Neosynephrine HCL</td>
</tr>
</tbody>
</table>

### Vasodilators

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALPROSTADIL HYDROCHLORIDE</strong></td>
<td>Inj 500 mcg per ml, 1 ml ampoule – 1% DV Dec-18 to 2021</td>
<td>1,765.50</td>
<td>5 Prostin VR</td>
</tr>
<tr>
<td><strong>DIAZOXIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 15 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HYDRALAZINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Endothelin Receptor Antagonists

**AMBRISENTAN** – *Restricted* see terms below
- Tab 5 mg ................................................................. 4,585.00  30  Volibris
- Tab 10 mg .............................................................. 4,585.00  30  Volibris

**BOSENTAN** – *Restricted* see terms below
- Tab 62.5 mg – 1% DV Dec-18 to 2021 ............................................. 141.00  60  Bosentan Dr Reddy's
- Tab 125 mg – 1% DV Dec-18 to 2021 ............................................. 141.00  60  Bosentan Dr Reddy's

**Initiation – Pulmonary arterial hypertension**
*Re-assessment required after 6 months*

**Either:**
- 1. All of the following:
  - 1.1 Patient has pulmonary arterial hypertension (PAH); and
  - 1.2 PAH is in Group 1, 4 or 5 of the WHO (Venice) clinical classifications; and
  - 1.3 PAH is at NYHA/WHO functional class II, III, or IV; and
  - 1.4 Any of the following:
    - 1.4.1 Both:

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
continued...

1.4.1.1 Bosentan is to be used as PAH monotherapy; and
1.4.1.2 Either:
   1.4.1.2.1 Patient is intolerant or contraindicated to sildenafil; or
   1.4.1.2.2 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease; or

1.4.2 Both:
   1.4.2.1 Bosentan is to be used as PAH dual therapy; and
   1.4.2.2 Either:
      1.4.2.2.1 Patient has tried a PAH monotherapy for at least three months and failed to respond; or
      1.4.2.2.2 Patient deteriorated while on a PAH monotherapy; or

1.4.3 Both:
   1.4.3.1 Bosentan is to be used as PAH triple therapy; and
   1.4.3.2 Any of the following:
      1.4.3.2.1 Patient is on the lung transplant list; or
      1.4.3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New
      York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
      1.4.3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant
      recipients in the future, if their disease is stabilised; or
      1.4.3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have
      no major morbidities and are deteriorating despite combination therapy; or

2 In-hospital stabilisation in emergency situations.

Continuation – Pulmonary arterial hypertension
Re-assessment required after 6 months
Any of the following:
1 Both:
   1.1 Bosentan is to be used as PAH monotherapy; and
   1.2 Patient is stable or has improved while on bosentan; or

2 Both:
   2.1 Bosentan is to be used as PAH dual therapy; and
   2.2 Patient has tried a PAH monotherapy for at least three months and either failed to respond or later deteriorated; or

3 Both:
   3.1 Bosentan is to be used as PAH triple therapy; and
   3.2 Any of the following:
      3.2.1 Patient is on the lung transplant list; or
      3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart
      Association/World Health Organization (NYHA/WHO) Functional Class IV; or
      3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant
      recipients in the future, if their disease is stabilised; or
      3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have
      no major morbidities and are deteriorating despite combination therapy.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – Restricted see terms on the next page

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg</td>
<td>0.64</td>
<td>Vedafil</td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>0.64</td>
<td>Vedafil</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>6.60</td>
<td>Vedafil</td>
</tr>
<tr>
<td>Inj 0.8 mg per ml, 12.5 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
CARDIOVASCULAR SYSTEM

Price
(ex man. excl. GST)
Brand or Generic
Manufacturer

→ Restricted (RS1694)

Initiation – tablets Raynaud’s Phenomenon
All of the following:
1. Patient has Raynaud's phenomenon; and
2. Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
3. Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
4. Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

Initiation – tablets Pulmonary arterial hypertension
Any of the following:
1. All of the following:
   1.1 Patient has pulmonary arterial hypertension (PAH); and
   1.2 Any of the following:
      1.2.1 PAH is in Group 1 of the WHO (Venice) clinical classifications; or
      1.2.2 PAH is in Group 4 of the WHO (Venice) clinical classifications; or
      1.2.3 PAH is in Group 5 of the WHO (Venice) clinical classifications; and
   1.3 Any of the following:
      1.3.1 PAH is in NYHA/WHO functional class II; or
      1.3.2 PAH is in NYHA/WHO functional class III; or
      1.3.3 PAH is in NYHA/WHO functional class IV; and
   1.4 Either:
      1.4.1 All of the following:
         1.4.1.1 Patient has a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
         1.4.1.2 Either:
            1.4.1.2.1 Patient has a mean pulmonary artery pressure (PAPm) > 25 mmHg; or
            1.4.1.2.2 Patient is peri Fontan repair; and
         1.4.1.3 Patient has a pulmonary vascular resistance (PVR) of at least 3 Wood Units or at least 240 International Units (dyn s cm-5); or
      1.4.2 Testing for PCWP, PAPm, or PVR cannot be performed due to the patient’s young age; or
2. For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or
3. In-hospital stabilisation in emergency situations.

Initiation – tablets other conditions
Any of the following:
1. For use in weaning patients from inhaled nitric oxide; or
2. For perioperative use in cardiac surgery patients; or
3. For use in intensive care as an alternative to nitric oxide; or
4. For use in the treatment of erectile dysfunction secondary to spinal cord injury in patients being treated in a spinal unit.

Initiation – injection
Both:
1. For use in the treatment of pulmonary hypertension in infants or children being treated in paediatric intensive care units and neonatal intensive care units when the enteral route is not accessible; and
2. Any of the following:
   2.1 For perioperative use following cardiac surgery; or
   2.2 For use in persistent pulmonary hypertension of the newborn (PPHN); or
   2.3 For use in congenital diaphragmatic hernia.
Prostacyclin Analogues

EPOPROSTENOL – Restricted see terms below
- Inj 500 mcg vial .......................................................... $36.61
- Inj 1.5 mg vial .......................................................... $73.21

Restricted (RS1624)
Initiation
Either:
1. For use in patients with a valid Special Authority approval for epoprostenol by the Pulmonary Arterial Hypertension Panel;
   or
2. In-hospital stabilisation in emergency situations.

ILOPROST
- Inj 50 mcg in 0.5 ml ampoule – 1% DV Jan-20 to 2022 .................................................. $305.00
- Nebuliser soln 10 mcg per ml, 2 ml – 1% DV Jan-20 to 2022 ................................. $740.10

Restricted (RS1625)
Initiation
Any of the following:
1. For use in patients with a valid Special Authority approval for iloprost by the Pulmonary Arterial Hypertension Panel; or
2. For diagnostic use in catheter laboratories; or
3. For use following mitral or tricuspid valve surgery; or
4. In-hospital stabilisation in emergency situations.
## Anti-Infective Preparations

### Antibacterials

**HYDROGEN PEROXIDE**
- Crm 1% .......................................................... 8.56 15 g Crystaderm
- Soln 3% (10 vol) ........................................ 1.40 100 ml Pharmacy Health

*(Pharmacy Health Soln 3% (10 vol) to be delisted 1 July 2020)*

**MAFENIDE ACETATE** – Restricted see terms below
- Powder 50 g sachet
  - Restricted (RS1299)
  - Initiation
For the treatment of burns patients.

**MUPIROCIN**
- Oint 2%

**SODIUM FUSIDATE [FUSIDIC ACID]**
- Crm 2% – 1% DV May-19 to 2021 .................. 1.59 5 g Foban
- Oint 2% – 1% DV May-19 to 2021 .................. 1.59 5 g Foban

**SULFADIAZINE SILVER**
- Crm 1% – 1% DV Aug-17 to 2020 ................. 10.80 50 g Flamazine

### Antifungals

**AMOROLFINE**
- Nail soln 5% – 1% DV Sep-17 to 2020 .............. 15.95 5 ml MycoNail

**CICLOPIROX OLAMINE**
- Nail soln 8% – 1% DV Sep-18 to 2021 .............. 5.72 7 ml Apo-Ciclopirox
  - Soln 1% – Restricted: For continuation only

**CLOTIRAMAZOLE**
- Crm 1% – 1% DV Jan-18 to 2020 ................. 0.70 20 g Clomazol
  - Soln 1% – Restricted: For continuation only

**ECONAZOLE NITRATE**
  - Crm 1% – Restricted: For continuation only
    - Foaming soln 1%

**KETOCONAZOLE**
- Shampoo 2% – 1% DV Sep-17 to 2020 .............. 2.99 100 ml Sebizole

**METRONIDAZOLE**
- Gel 0.75%

**MICONAZOLE NITRATE**
- Crm 2% – 1% DV Jan-18 to 2020 ................. 0.74 15 g Multichem
  - Lotn 2% – Restricted: For continuation only
    - Tinc 2%

**NYSTATIN**
- Crm 100,000 u per g

### Antiparasitics

**DIMETHICONE**
- Lotn 4% – 1% DV Oct-19 to 2022 ................... 4.98 200 ml healthE Dimethicone 4% Lotion

---

*Item restricted (see ➡️ above); ▲ Item restricted (see ➡️ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**MALATHION [MALDISON]**
- Lotn 0.5%
- Shampoo 1%

**PERMETHRIN**
- Crm 5% – 1% DV Dec-17 to 2020 .................................................. 4.95 30 g Lyderm
- Lotn 5% – 1% DV Oct-17 to 2020 .................................................. 3.69 30 ml A-Scabies

**PHENOTHIN**
- Shampoo 0.5%

### Antiacne Preparations

**ADAPALENE**
- Crm 0.1%
- Gel 0.1%

**BENZOYL PEROXIDE**
- Soln 5%

**ISOTRETINOIN**
- Cap 5 mg – 1% DV Oct-18 to 2021 .................................................. 8.14 60 Oratane
- Cap 10 mg – 1% DV Oct-18 to 2021 ............................................. 13.34 120 Oratane
- Cap 20 mg – 1% DV Oct-18 to 2021 ............................................. 20.49 120 Oratane

**TRETINOIN**
- Crm 0.05% – 1% DV Jun-18 to 2021 ............................................. 13.90 50 g ReTrieve

### Antipruritic Preparations

**CALAMINE**
- Crm, aqueous, BP – 1% DV Nov-18 to 2021 .................................. 1.26 100 g healthE Calamine Aqueous Cream BP
- Lotn, BP .................................................................................. 12.94 2,000 ml PSM

(PSM Lotn, BP to be delisted 1 July 2020)

**CROTAMITON**
- Crm 10% – 1% DV Sep-18 to 2021 ............................................. 3.29 20 g Itch-Soothe

### Barrier Creams and Emollients

#### Barrier Creams

**DIMETHICONE**
- Crm 5% tube – 1% DV Oct-19 to 2022 ............................................. 1.53 100 g healthE Dimethicone 5%
- Crm 5% pump bottle .................................................................... 4.48 500 ml healthE Dimethicone 5%
- Crm 10% pump bottle – 1% DV Sep-18 to 2021 ............................. 4.52 500 ml healthE Dimethicone 10%

**ZINC**
- Crm
- Oint
- Paste

- e.g. Zinc Cream (Orion-)
- Zinc Cream (PSM)

- e.g. Zinc oxide (PSM)
DERMATOLOGICALS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ZINC AND CASTOR OIL

- **Crm** .................................................................................................................... 1.63 20 g Orion
- **Oint – 1% DV Jul-18 to 2020** ................................................................. 4.25 500 g Boucher
  - Note: DV limit applies to the pack sizes of greater than 30 g.
- **Oint, BP – 1% DV Nov-17 to 2020** ................................................................. 1.26 20 g healthE
  - Note: DV limit applies to the pack sizes of 30 g or less.

### ZINC WITH WOOL FAT

- **Crm zinc 15.25% with wool fat 4%** ................................................................. e.g. Sudocrem

### Emollients

#### AQUEOUS CREAM

- **Crm 100 g – 1% DV Oct-18 to 2021** ................................................................. 1.05 100 g Pharmacy Health SLS-free
  - Note: DV limit applies to the pack sizes of 100 g or less.
- **Crm 500 g – 1% DV Dec-18 to 2021** ................................................................. 1.92 500 g Boucher
  - Note: DV limit applies to the pack sizes of greater than 100 g.

#### CETOMACROGOL

- **Crm BP, 500 g – 1% DV Sep-18 to 2021** .......................................................... 2.48 500 g healthE
- **Crm BP, 100 g – 1% DV Sep-18 to 2021** .......................................................... 1.42 1 healthE

#### CETOMACROGOL WITH GLYCEROL

- **Crm 90% with glycerol 10%, – 1% DV Dec-19 to 2022** .................................... 1.65 100 g healthE
  - Note: DV limit applies to the pack sizes of 100 g or less.
- **Crm 90% with glycerol 10% – 1% DV Mar-20 to 2022** .................................... 2.35 500 ml Boucher
  - Note: DV limit applies to the pack sizes of greater than 100 g.

#### EMULSIFYING OINTMENT

- **Oint BP – 1% DV Oct-17 to 2020** ................................................................. 1.84 100 g Jaychem
  - Note: DV limit applies to pack sizes of less than 200 g.
- **Oint BP, 500 g – 1% DV Oct-17 to 2020** .......................................................... 3.59 500 g AFT
  - Note: DV limit applies to pack sizes of greater than 200 g.

#### GLYCEROL WITH PARAFFIN

- **Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10%** .......... e.g. QV cream

#### OIL IN WATER EMULSION

- **Crm, 500 g – 1% DV Jan-19 to 2021** ................................................................. 2.19 500 g O/W Fatty Emulsion Cream
  - Note: DV limit applies to the pack sizes of greater than 100 g.
- **Crm, 100 g – 1% DV Dec-18 to 2021** ................................................................. 1.44 1 healthE Fatty Cream

#### PARAFFIN

- **Oint liquid paraffin 50% with white soft paraffin 50% – 1% DV Jan-19 to 2021** ................................................................. 1.97 100 g healthE
  - Note: DV limit applies to the pack sizes of greater than 100 g.
- **White soft – 1% DV Sep-18 to 2021** ................................................................. 0.79 10 g healthE
  - Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.
- **White soft, – 1% DV Apr-20 to 2022** ................................................................. 4.99 450 g healthE

#### PARAFFIN WITH WOOL FAT

- **Lotn liquid paraffin 15.9% with wool fat 0.6%** .................................................. e.g. Alpha Keri Bath Oil
- **Lotn liquid paraffin 91.7% with wool fat 3%** .................................................. e.g. Alpha Keri Bath Oil

---

*Item restricted (see ➤ above); Item restricted (see ➤ below)*
*e.g. Brand indicates brand example only. It is not a contracted product.*
### UREA

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per 100 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cm 10%</td>
<td>healthE Urea Cream</td>
</tr>
</tbody>
</table>

### WOOL FAT

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cm</td>
<td></td>
</tr>
</tbody>
</table>

### Corticosteroids

#### BETAMETHASONE DIPROPIONATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per 50 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cm 0.05%</td>
<td></td>
</tr>
<tr>
<td>Oint 0.05%</td>
<td></td>
</tr>
</tbody>
</table>

#### BETAMETHASONE VALERATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per 50 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cm 0.1% – 1% DV Oct-18 to 2021</td>
<td>Beta Cream</td>
</tr>
<tr>
<td>Oint 0.1% – 1% DV Oct-18 to 2021</td>
<td>Beta Ointment</td>
</tr>
<tr>
<td>Lotn 0.1% – 1% DV Dec-18 to 2021</td>
<td>Betnovate</td>
</tr>
</tbody>
</table>

#### CLOBETASOL PROPIONATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per 30 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cm 0.1% – 1% DV Nov-19 to 2022</td>
<td>Dermol</td>
</tr>
<tr>
<td>Oint 0.05% – 1% DV Nov-19 to 2022</td>
<td>Dermol</td>
</tr>
</tbody>
</table>

#### CLOBETASONE BUTYRATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per 30 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cm 0.05%</td>
<td></td>
</tr>
</tbody>
</table>

#### DIFLUCORTOLONE VALERATE – Restricted: For continuation only

- **Cm 0.1%**
- **Fatty oint 0.1%**

#### HYDROCORTISONE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per 30 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cm 1%, 30 g</td>
<td>DermAssist</td>
</tr>
<tr>
<td>Cm 1%, 500 g</td>
<td>Pharmacy Health</td>
</tr>
</tbody>
</table>

#### HYDROCORTISONE ACETATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per 14.2 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cm 1%</td>
<td>AFT</td>
</tr>
</tbody>
</table>

#### HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per 250 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – 1% DV Sep-17 to 2020</td>
<td>DP Lotn HC</td>
</tr>
</tbody>
</table>

#### HYDROCORTISONE BUTYRATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per 15 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cm 0.1%</td>
<td>Advantan</td>
</tr>
<tr>
<td>Oint 0.1%</td>
<td>Advantan</td>
</tr>
</tbody>
</table>

#### METHYLREDNISOLONE ACEPONATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per 15 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cm 0.1%</td>
<td>Advantan</td>
</tr>
<tr>
<td>Oint 0.1%</td>
<td>Advantan</td>
</tr>
</tbody>
</table>

#### MOMETASONE FURATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per 15 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cm 0.1% – 1% DV Nov-18 to 2021</td>
<td>Elocon Alcohol Free</td>
</tr>
<tr>
<td>Oint 0.1% – 1% DV Nov-18 to 2021</td>
<td>Elocon</td>
</tr>
<tr>
<td>Lotn 0.1% – 1% DV Nov-18 to 2021</td>
<td>Elocon</td>
</tr>
</tbody>
</table>

#### TRIAMCINOLONE ACETONIDE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price Per 100 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cm 0.02% – 1% DV Sep-17 to 2020</td>
<td>Aristocort</td>
</tr>
<tr>
<td>Oint 0.02% – 1% DV Sep-17 to 2020</td>
<td>Aristocort</td>
</tr>
</tbody>
</table>
Corticosteroids with Anti-Infective Agents

BETAMETHASONE VALERATE WITH CLIOQUINOL – Restricted see terms below

- Crm 0.1% with clioquinol 3%
- Restricted (RS1125)

Initiation
Either:
1. For the treatment of intertrigo; or
2. For continuation use.

BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSIDIC ACID]
Crm 0.1% with sodium fusidate (fusidic acid) 2%

HYDROCORTISONE WITH MICONAZOLE
Crm 1% with miconazole nitrate 2% – 1% DV Sep-18 to 2021 .....................2.00 15 g Microme H

HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN
Crm 1% with natamycin 1% and neomycin sulphate 0.5% .........................3.35 15 g Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5% .........................3.35 15 g Pimafucort

TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GRAMICIDIN AND NYSTATIN
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g

Psoriasis and Eczema Preparations

ACITRETIN
Cap 10 mg – 1% DV Sep-17 to 2020..........................................................17.86 60 Novatretin
Cap 25 mg – 1% DV Sep-17 to 2020..........................................................41.36 60 Novatretin

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL
Gel 500 mcg with calcipotriol 50 mcg per g – 1% DV Dec-18 to 2021 ..........52.24 60 g Daivobet
Oint 500 mcg with calcipotriol 50 mcg per g – 1% DV Dec-18 to 2021 ..........19.95 30 g Daivobet

CALCIPOTRIOL
Oint 50 mcg per g – 1% DV Jul-17 to 2020.............................................45.00 100 g Daivonex

COAL TAR WITH SALICYLIC ACID AND SULPHUR
Oint 12% with salicylic acid 2% and sulphur 4%

METHOXSALEN [8-METHOXYPSORALEN]
Tab 10 mg
Lotn 1.2%

PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCIN
Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – 1% DV Oct-17 to 2020..........................3.86 500 ml Pinetarsol

POTASSIUM PERMANGANATE
Tab 400 mg
Crystals

Scalp Preparations

BETAMETHASONE VALERATE
Scalp app 0.1% – 1% DV Oct-18 to 2021..................................................7.75 100 ml Beta Scalp

CLOBETASOL PROPIONATE
Scalp app 0.05% – 1% DV Nov-19 to 2022.............................................5.69 30 ml Dermol
HYDROCORTISONE BUTYRATE
Scalp lotn 0.1% – 1% DV Mar-19 to 2021 ....................................................... 7.30 100 ml Locoid

**Wart Preparations**

IMIQUIMOD
Crm 5%, 250 mg sachet – 1% DV Aug-18 to 2020 ........................................ 21.72 24 Perrigo

PODOPHYLLOTOXIN
Soln 0.5% ........................................................................................................ 33.60 3.5 ml Condyline

SILVER NITRATE
Sticks with applicator

**Other Skin Preparations**

DIPHEMANIL METILSULFATE
Powder 2%

SUNSCREEN, PROPRIETARY
Lotn – 1% DV Mar-20 to 2022 ................................................................. 5.10 200 g Marine Blue Lotion SPF 50+

**Antineoplastics**

FLUOROURACIL SODIUM
Crm 5% – 1% DV Sep-18 to 2021 ............................................................... 7.95 20 g Efudix

METHYL AMINOLEVULINATE HYDROCHLORIDE – Restricted see terms below

Dermatologist or plastic surgeon

**Wound Management Products**

CALCIUM GLUCONATE
Gel 2.5% e.g. Orion
### GENITO-URINARY SYSTEM

#### Price

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

#### Anti-Infective Agents

**ACETIC ACID**
- Soln 3%
- Soln 5%

**ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID**
- Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator

**CHLORHEXIDINE GLUCONATE**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crt 1%</td>
<td>1.21</td>
<td>healthE</td>
</tr>
<tr>
<td>Lotn 1%, 200 ml</td>
<td>2.98</td>
<td>healthE</td>
</tr>
</tbody>
</table>

**CLOTRIMAZOLE**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaginal crm 1% with applicator – 1% DV Jan-20 to 2022</td>
<td>2.50</td>
<td>Clomazol</td>
</tr>
<tr>
<td>Vaginal crm 2% with applicator – 1% DV Jan-20 to 2022</td>
<td>3.00</td>
<td>Clomazol</td>
</tr>
</tbody>
</table>

**MICONAZOLE NITRATE**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaginal crm 2% with applicator – 1% DV Sep-17 to 2020</td>
<td>3.88</td>
<td>Micreme</td>
</tr>
</tbody>
</table>

**NYSTATIN**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaginal crm 100,000 u per 5 g with applicator(s) – 1% DV Aug-17 to 2020</td>
<td>4.45</td>
<td>Nilstat</td>
</tr>
</tbody>
</table>

#### Contraceptives

**Antiandrogen Oral Contraceptives**

**CYPROTERONE ACETATE WITH ETHINYLESTRADIOL**
- Tab 2 mg with ethinylestradiol 35 mcg and 7 inert tablets – 1% DV Sep-17 to 2020 | 4.67 | Ginet |

**Combined Oral Contraceptives**

**ETHINYLESTRAZOL WITH DESOGEJSTREL**
- Tab 20 mcg with desogestrel 150 mcg
- Tab 30 mcg with desogestrel 150 mcg

**ETHINYLESTRAZOL WITH LEVONORGESTREL**
- Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – 1% DV Jan-18 to 2020 | 2.18 | Microgynon 20 ED |
- Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – 1% DV Jan-18 to 2020 | 1.77 | Levlen ED |
- Tab 20 mcg with levonorgestrel 100 mcg
- Tab 30 mcg with levonorgestrel 150 mcg
- Tab 50 mcg with levonorgestrel 125 mcg | 9.45 | Microgynon 50 ED |

**ETHINYLESTRAZOL WITH NORETHISTERONE**
- Tab 35 mcg with norethisterone 1 mg
- Tab 35 mcg with norethisterone 1 mg and 7 inert tab – 1% DV Mar-20 to 2022 | 6.95 | Brevinor 1/28 |
- Tab 35 mcg with norethisterone 500 mcg

**NORETHISTERONE WITH MESTRANOL**
- Tab 1 mg with mestranol 50 mcg
### Contraceptive Devices

**INTRA-UTERINE DEVICE**

- IUD 29.1 mm length x 23.2 mm width – 1% DV Nov-19 to 2022 .......... 18.45 1 Choice TT380 Short
- IUD 33.6 mm length x 29.9 mm width – 1% DV Nov-19 to 2022 .......... 18.45 1 Choice TT380 Standard
- IUD 35.5 mm length x 19.6 mm width – 1% DV Nov-19 to 2022 .......... 15.50 1 Choice Load 375

### Emergency Contraception

**LEVONORGESTREL**

- Tab 1.5 mg ......................................................................................... 4.95 1 Postinor-1

### Progestogen-Only Contraceptives

**LEVONORGESTREL**

- Tab 30 mcg – 1% DV May-20 to 2022 ................................................. 16.50 84 Microlut
- Subdermal implant (2 x 75 mg rods) – 1% DV Mar-18 to 2020 ............... 106.92 1 Jadelle
- Intra-uterine device 52 mg – 1% DV Nov-19 to 31 Oct 2022 ................. 269.50 1 Mirena
- Intra-uterine device 13.5 mg – 1% DV Nov-19 to 31 Oct 2022 ............... 215.60 1 Jaydess

**MEDROXYPROGESTERONE ACETATE**

- Inj 150 mg per ml, 1 ml syringe – 1% DV Dec-19 to 2022 ................. 7.98 1 Depo-Provera

**NORETHISTERONE**

- Tab 350 mcg – 1% DV Sep-18 to 2021 ................................................. 6.25 84 Noriday 28

### Obstetric Preparations

#### Antiprogestogens

**MIFEPRISTONE**

- Tab 200 mg

#### Oxytocics

**CARBOPROST TROMETAMOL**

- Inj 250 mcg per ml, 1 ml ampoule

**DINOPROSTONE**

- Pessaries 10 mg
  - Vaginal gel 1 mg in 3 g ................................................................. 52.65 1 Prostin E2
  - Vaginal gel 2 mg in 3 g ................................................................. 64.60 1 Prostin E2

**ERGOMETRINE MALEATE**

- Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 ............... 105.00 5 DBL Ergometrine

**OXYTOCIN**

- Inj 5 iu per ml, 1 ml ampoule – 1% DV Nov-18 to 2021 ....................... 3.98 5 Oxytocin BNM
- Inj 10 iu per ml, 1 ml ampoule – 1% DV Nov-18 to 2021 ..................... 4.98 5 Oxytocin BNM

**OXYTOCIN WITH ERGOMETRINE MALEATE**

- Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1%
  - **DV Oct-18 to 2021** ......................................................................... 15.00 5 Syntometrine

### Tocolytics

**PROGESTERONE** – **Restricted** see terms on the next page

- Cap 100 mg ......................................................................................... 16.50 30 Utrogestan

---

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## GENITO-URINARY SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### Restricted (RS1533)

**Initiation**

Gynaecologist or obstetrician

*Re-assessment required after 12 months*

Both:

1. For the prevention of pre-term labour*; and
2. Either:
   2.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or
   2.2 The patient has a history of pre-term birth at less than 28 weeks.

**Continuation**

Gynaecologist or obstetrician

*Re-assessment required after 12 months*

All of the following:

1. For the prevention of pre-term labour*; and
2. Treatment is required for second or subsequent pregnancy; and
3. Either:
   3.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or
   3.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are unapproved indications.

**TERBUTALINE** – Restricted see terms below

- Inj 500 mcg ampoule

### Oestrogens

**OESTRIOL**

- Cm 1 mg per g with applicator – 1% DV Oct-17 to 2020 .................. 6.62 15 g Ovestin
- Pessaries 500 mcg – 1% DV Oct-17 to 2020 ................................. 6.86 15 Ovestin

### Urologicals

#### 5-Alpha Reductase Inhibitors

**FINASTERIDE** – Restricted see terms below

- Tab 5 mg – 1% DV Dec-17 to 2020 ........................................ 4.81 100 Ricit

### Alpha-1A Adrenoceptor Blockers

**TAMSULOSIN HYDROCHLORIDE** – Restricted see terms below

- Cap 400 mcg – 1% DV Jan-20 to 2022 .................................... 17.73 100 Tamsulosin-Rex

---

60 Item restricted (see above);  Item restricted (see below)

*e.g. Brand* indicates brand example only. It is not a contracted product.
continued...

1 Patient has symptomatic benign prostatic hyperplasia; and
2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

**Urinary Alkalisers**

POSSUM CITRATE – *Restricted* see terms below

- Oral liq 3 mmol per ml – 1% DV Oct-18 to 2021..................................................31.80 200 ml Biomed

  ➥ *Restricted (RS1133)*

  **Initiation**

  Both:

  1 The patient has recurrent calcium oxalate urolithiasis; and
  2 The patient has had more than two renal calculi in the two years prior to the application.

SODIUM CITRO-TARTRATE

- Grans eff 4 g sachets – 1% DV Sep-17 to 2020................................................2.34 28 Ural

**Urinary Antispasmodics**

OXYBUTYNIN

- Tab 5 mg ...........................................................................................................8.85 500 Apo-Oxybutynin
- Oral liq 5 mg per 5 ml .....................................................................................60.40 473 ml Apo-Oxybutynin

SOLIFENACIN SUCCINATE – *Some items restricted* see terms below

- Tab 5 mg – 1% DV Dec-18 to 2021.................................................................3.00 30 Solifenacin Mylan
- Tab 10 mg – 1% DV Dec-18 to 2021...............................................................5.50 30 Solifenacin Mylan

  ➥ *Restricted (RS1274)*

  **Initiation**

  Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.

TOLTERODINE TARTRATE – *Restricted* see terms below

- Tab 2 mg .........................................................................................................14.56 56 Arrow-Tolterodine

  *(Arrow-Tolterodine Tab 2 mg to be delisted 1 July 2020)*

  ➥ *Restricted (RS1273)*

  **Initiation**

  Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.
### Anabolic Agents

**OXANDROLONE**
- **Tab 2.5 mg**
  - **Restricted (RS1302)**

**Initiation**
For the treatment of burns patients.

### Androgen Agonists and Antagonists

**CYPROTERONE ACETATE**
- **Tab 50 mg – 1% DV Dec-18 to 2021**
  - **13.17 50** Siterone
- **Tab 100 mg – 1% DV Dec-18 to 2021**
  - **26.75 50** Siterone

**TESTOSTERONE**
- **Patch 5 mg per day**
  - **90.00 30** Androderm

**TESTOSTERONE CIPIONATE**
- **Inj 100 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020**
  - **76.50 1** Depo-Testosterone

**TESTOSTERONE ESTERS**
- **Inj testosterone decanoate 100 mg, testosterone isocaproate 60 mg, testosterone phenylpropionate 60 mg and testosterone propionate 30 mg per ml, 1 ml ampoule**

**TESTOSTERONE UNDECANOATE**
- **Cap 40 mg – 1% DV Nov-18 to 2021**
  - **21.00 60** Andriol Testocaps
- **Inj 250 mg per ml, 4 ml vial**
  - **86.00 1** Reandron 1000

### Calcium Homeostasis

**CALCITONIN**
- **Inj 100 iu per ml, 1 ml ampoule**
  - **121.00 5** Miacalcic

**CINACALCET**
- **Tab 30 mg – 1% DV Sep-18 to 2021**
  - **210.30 28** Sensipar
  - **Restricted (RS1540)**

**Initiation**
Nephrologist or endocrinologist
*Re-assessment required after 6 months*

Either:

1. All of the following:
   - 1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
   - 1.2 The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
   - 1.3 The patient is symptomatic; or

2. All of the following:
   - 2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriolopathy); and
   - 2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L); and
   - 2.3 The patient’s condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.
Continuation
Nephrologist or endocrinologist
Both:
1. The patient's serum calcium level has fallen to < 3mmol/L; and
2. The patient has experienced clinically significant symptom improvement.

Note: This does not include parathyroid adenomas unless these have become malignant.

Zoledronic Acid

<table>
<thead>
<tr>
<th>Product Details</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 4 mg per 5 ml, vial – 1% DV May-19 to 2021</td>
<td>$38.03</td>
<td>Zoledronic acid Mylan</td>
</tr>
</tbody>
</table>

- Restricted (RS1602)

Initiation – bone metastases
Oncologist, haematologist or palliative care specialist

Any of the following:
1. Patient has hypercalcaemia of malignancy; or
2. Both:
   2.1. Patient has bone metastases or involvement; and
   2.2. Patient has severe bone pain resistant to standard first-line treatments; or
3. Both:
   3.1. Patient has bone metastases or involvement; and
   3.2. Patient is at risk of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone).

Initiation – early breast cancer
Oncologist

All of the following:
1. Treatment to be used as adjuvant therapy for early breast cancer; and
2. Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
3. Treatment to be administered at a minimum interval of 6-monthly for a maximum of 2 years.

Corticosteroids

BETAMETHASONE
- Tab 500 mcg
- Inj 4 mg per ml, 1 ml ampoule

BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE
- Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule

DEXAMETHASONE
- Tab 0.5 mg – 1% DV Oct-18 to 2021 | $0.99 | 30 | Dexamethsone
- Tab 4 mg – 1% DV Oct-18 to 2021 | $1.90 | 30 | Dexamethsone
- Oral liq 1 mg per ml | $45.00 | 25 ml | Biomed
### HORMONE PREPARATIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DEXAMETHASONE PHOSPHATE</strong></td>
</tr>
<tr>
<td>Inj 4 mg per ml, 1 ml ampoule – 1% DV Jul-20 to 2022</td>
</tr>
<tr>
<td>Inj 4 mg per ml, 2 ml ampoule – 1% DV Jul-20 to 2022</td>
</tr>
<tr>
<td>(Max Health Inj 4 mg per ml, 1 ml ampoule to be delisted 1 July 2020)</td>
</tr>
<tr>
<td>(Max Health Inj 4 mg per ml, 2 ml ampoule to be delisted 1 July 2020)</td>
</tr>
</tbody>
</table>

| **FLUDROCORTISONE ACETATE**                                   |
| Tab 100 mcg                                                   | $14.32 100 Florinef                                       |

| **HYDROCORTISONE**                                            |
| Tab 5 mg – 1% DV Sep-18 to 2021                               | $8.10 100 Douglas                                         |
| Tab 20 mg – 1% DV Sep-18 to 2021                              | $20.32 100 Douglas                                        |
| Inj 100 mg vial                                               | $5.30 1 Solu-Cortef                                       |

| **METHYLPREDNISOLONE (AS SODIUM SUCCINATE)**                  |
| Tab 4 mg – 1% DV Dec-18 to 2021                               | $112.00 100 Medrol                                       |
| Tab 100 mg – 1% DV Dec-18 to 2021                             | $194.00 20 Medrol                                        |
| Inj 40 mg vial – 1% DV Dec-18 to 2021                         | $18.90 1 Solu-Medrol Act-O-Vial                          |
| Inj 125 mg vial – 1% DV Dec-18 to 2021                        | $28.90 1 Solu-Medrol Act-O-Vial                          |
| Inj 500 mg vial – 1% DV Dec-18 to 2021                        | $22.78 1 Solu-Medrol Act-O-Vial                          |
| Inj 1 g vial – 1% DV Dec-18 to 2021                           | $27.83 1 Solu-Medrol                                     |

| **METHYLPREDNISOLONE ACETATE**                                |
| Inj 40 mg per ml, 1 ml vial – 1% DV Dec-18 to 2021            | $44.40 5 Depo-Medrol                                     |

| **PREDNISOLONE**                                              |
| Oral liq 5 mg per ml – 1% DV Jun-18 to 2021                   | $6.00 30 ml Redipred                                     |
| Enema 200 mcg per ml, 100 ml                                 |

| **PREDNISONE**                                                |
| Tab 1 mg – 1% DV Jun-17 to 2020                               | $10.68 500 Apo-Prednisone                                |
| Tab 2.5 mg – 1% DV Jun-17 to 2020                             | $12.09 500 Apo-Prednisone                                |
| Tab 5 mg – 1% DV Jun-17 to 2020                               | $11.09 500 Apo-Prednisone                                |
| Tab 20 mg – 1% DV Jun-17 to 2020                              | $29.03 500 Apo-Prednisone                                |

| **TRIAMCINOLONE ACETONIDE**                                   |
| Inj 10 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020         | $20.80 5 Kenacort-A 10                                   |
| Inj 40 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020         | $51.10 5 Kenacort-A 40                                   |

| **TRIAMCINOLONE HEXACETONIDE**                                |
| Inj 20 mg per ml, 1 ml vial                                   |

### Hormone Replacement Therapy

#### Oestrogens

| **OESTRADIOL**                                                |
| Tab 1 mg                                                     |
| Tab 2 mg                                                     |
| Patch 25 mcg per day                                        | $6.12 8 Estradot                                         |
| Patch 50 mcg per day                                        | $7.04 8 Estradot                                         |
| Patch 75 mcg per day                                        | $7.91 8 Estradot                                         |
| Patch 100 mcg per day                                       | $7.91 8 Estradot                                         |
### Oestrogens

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oestradiol Valerate</td>
<td>Progynova</td>
</tr>
<tr>
<td>Tab 1 mg – 1% DV Sep-18 to 2021</td>
<td>$12.36 84</td>
</tr>
<tr>
<td>Tab 2 mg – 1% DV Sep-18 to 2021</td>
<td>$12.36 84</td>
</tr>
</tbody>
</table>

### Oestrogens (Conjugated Equine)

- **Tab 300 mcg**
- **Tab 625 mcg**

### Progestogen and Oestrogen Combined Preparations

### Progestogens

#### Medroxyprogesterone Acetate

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2.5 mg</td>
<td>Provera</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>Provera</td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>Provera</td>
</tr>
</tbody>
</table>

### Other Endocrine Agents

#### Cabergoline

- **Restricted** see terms below
- Tab 0.5 mg – 1% DV Sep-18 to 2021 | $3.75 2 Dostinex

#### Clomifene Citrate

- Tab 50 mg | Mylan Clomiphen |

#### Danazol

- Cap 100 mg | Azol |
- Cap 200 mg | Mylan |

(Azol Cap 100 mg to be delisted 1 June 2020)

#### Gestrinone

- Cap 2.5 mg

#### Metyrapone

- Cap 250 mg

#### Pentagastrin

- Inj 250 mcg per ml, 2 ml ampoule

---

**Products with Hospital Supply Status (HSS) are in bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th><strong>Other Oestrogen Preparations</strong></th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETHINYL Estradiol</td>
<td>Tab 10 mcg – 1% DV Sep-18 to 2021</td>
<td>$17.60</td>
<td>100 NZ Medical and Scientific</td>
</tr>
<tr>
<td>Oestradiol</td>
<td>Implant 50 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oestriol</td>
<td>Tab 2 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Other Progestogen Preparations</strong></th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medroxyprogesterone</td>
<td>Tab 100 mg</td>
<td>$101.00</td>
<td>100 Provera HD</td>
</tr>
<tr>
<td>Norlethisterone</td>
<td>Tab 5 mg – 1% DV Dec-19 to 2021</td>
<td>$18.29</td>
<td>100 Primolut N</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Pituitary and Hypothalamic Hormones and Analogues</strong></th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticotrelin (Ovine)</td>
<td>Inj 100 mcg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyrotropin Alfa</td>
<td>Inj 900 mcg vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Adrenocorticotropic Hormones</strong></th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetracosactide [Tetracosactrin]</td>
<td>Inj 250 mcg per ml, 1 ml ampoule</td>
<td>$75.00</td>
<td>1 Synacthen</td>
</tr>
<tr>
<td></td>
<td>Inj 1 mg per ml, 1 ml ampoule</td>
<td>$690.00</td>
<td>1 Synacthen Depot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>GnRH Agonists and Antagonists</strong></th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buserelin</td>
<td>Inj 1 mg per ml, 5.5 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gonadorelin</td>
<td>Inj 100 mcg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goserelin</td>
<td>Implant 3.6 mg, syringe</td>
<td>$66.48</td>
<td>1 Zoladex</td>
</tr>
<tr>
<td></td>
<td>Implant 10.8 mg, syringe</td>
<td>$177.50</td>
<td>1 Zoladex</td>
</tr>
<tr>
<td>Leuprolelin Acetate</td>
<td>Inj 3.75 mg prefilled dual chamber syringe</td>
<td>$221.60</td>
<td>1 Lucrin Depot 1-month</td>
</tr>
<tr>
<td></td>
<td>Inj 11.25 mg prefilled dual chamber syringe</td>
<td>$591.68</td>
<td>1 Lucrin Depot 3-month</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Gonadotrophins</strong></th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choriogonadotropin Alfa</td>
<td>Inj 250 mcg in 0.5 ml syringe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Item restricted (see above); Item restricted (see below)
* e.g. Brand indicates brand example only. It is not a contracted product.
**Growth Hormone**

<table>
<thead>
<tr>
<th>SOMATROPIN – <strong>Restricted</strong> see terms below</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 mg cartridge – 1% DV Oct-18 to 2021</td>
</tr>
<tr>
<td>........................................................................................................34.88</td>
</tr>
<tr>
<td>Inj 10 mg cartridge – 1% DV Oct-18 to 2021</td>
</tr>
<tr>
<td>........................................................................................................69.75</td>
</tr>
<tr>
<td>Inj 15 mg cartridge – 1% DV Oct-18 to 2021</td>
</tr>
<tr>
<td>........................................................................................................104.63</td>
</tr>
</tbody>
</table>

**Initiation – growth hormone deficiency in children**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

Either:

1. Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or

2. All of the following:
   1. Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
   2. A current bone age is < 14 years (female patients) or < 16 years (male patients); and
   3. Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
   4. If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
   5. Appropriate imaging of the pituitary gland has been obtained.

**Continuation – growth hormone deficiency in children**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

1. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
2. Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davies (1985); and
3. Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
4. No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5. No malignancy has developed since starting growth hormone.

**Initiation – Turner syndrome**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

1. The patient has a post-natal genotype confirming Turner Syndrome; and
2. Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
3. A current bone age is < 14 years.

**Continuation – Turner syndrome**

Endocrinologist or paediatric endocrinologist

*Re-assessment required after 12 months*

All of the following:

1. Height velocity greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke’s Turner Syndrome growth velocity charts); and

*Continued…*
continued...

2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
3 A current bone age is 14 years or under; and
4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5 No malignancy has developed since starting growth hormone.

Initiation – short stature without growth hormone deficiency
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:

1 The patient’s height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Continuation – short stature without growth hormone deficiency
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:

1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3 Current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4 No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initiation – short stature due to chronic renal insufficiency
Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of an endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
All of the following:

1 The patient’s height is more than 2 standard deviations below the mean; and
2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
3 A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
5 The patient is under the supervision of a specialist with expertise in renal medicine; and
6 Either:
   6.1 The patient has a GFR less than or equal to 30 ml/min/1.73 m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l × 40 = corrected GFR (ml/min/1.73 m²) in a child who may or may not be receiving dialysis; or
   6.2 The patient has received a renal transplant and has received < 5mg/ m²/day of prednisone or equivalent for at least 6 months.

Continuation – short stature due to chronic renal insufficiency
Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of an endocrinologist or paediatric...
continued...

endocrinologist

Re-assessment required after 12 months

All of the following:

1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone has occurred; and
5. No malignancy has developed after growth hormone therapy was commenced; and
6. The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
7. The patient has not received renal transplantation since starting growth hormone treatment; and
8. If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initiation – Prader-Willi syndrome

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

1. The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
2. The patient is aged six months or older; and
3. A current bone age is < 14 years (female patients) or < 16 years (male patients); and
4. Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
5. Either:
   5.1 Both:
      5.1.1 The patient is aged two years or older; and
      5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
   5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Continuation – Prader-Willi syndrome

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5. No malignancy has developed after growth hormone therapy was commenced; and
6. The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

continued…
**HORMONE PREPARATIONS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

continued...

### Initiation – adults and adolescents

Endocrinologist or paediatric endocrinologist

**Re-assessment required after 12 months**

All of the following:

1. The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
2. The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
3. The patient has severe growth hormone deficiency (see notes); and
4. The patient’s serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
5. The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

**Notes:** For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

### Continuation – adults and adolescents

Endocrinologist or paediatric endocrinologist

**Re-assessment required after 12 months**

Either:

1. All of the following:
   1.1 The patient has been treated with somatropin for < 12 months; and
   1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
   1.3 Serum IGF-I levels have increased to within ±1SD of the mean of the normal range for age and sex; and
   1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or
2. All of the following:
   2.1 The patient has been treated with somatropin for more than 12 months; and
   2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
   2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
   2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

### Thyroid and Antithyroid Preparations

**CARBIMAZOLE**

Tab 5 mg

**IODINE**

Soln BP 50 mg per ml
LEVOTHYROXINE
- Tab 25 mcg
- Tab 50 mcg
- Tab 100 mcg

LIOTHYRONINE SODIUM
- Tab 20 mcg
  ▼ **Restricted (RS1301)**

**Initiation**
For a maximum of 14 days’ treatment in patients with thyroid cancer who are due to receive radioiodine therapy.
- Inj 20 mcg vial

POTASSIUM IODATE
- Tab 170 mg

POTASSIUM PERCHLORATE
- Cap 200 mg

PROPYLTHIOURACIL – **Restricted** see terms below
- Tab 50 mg ............................................................................................... 35.00 100 PTU
  ▼ **Restricted (RS1276)**

**Initiation**
Both:
1. The patient has hyperthyroidism; and
2. The patient is intolerant of carbimazole or carbimazole is contraindicated.

Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

PROTIRELIN
- Inj 100 mcg per ml, 2 ml ampoule

**Vasopressin Agents**

ARGIPRESSIN [VASOPRESSIN]
- Inj 20 u per ml, 1 ml ampoule

DESMOPRESSIN ACETATE – **Some items restricted** see terms below
- Tab 100 mcg .................................................................................. 25.00 30 Minirin
- Tab 200 mcg .................................................................................. 54.45 30 Minirin
- Nasal spray 10 mcg per dose – 1% DV Oct-17 to 2020 .................. 23.95 6 ml Desmopressin-PH&T
- Inj 4 mcg per ml, 1 ml ampoule
- Inj 15 mcg per ml, 1 ml ampoule
- Nasal drops 100 mcg per ml
  ▼ **Restricted (RS1339)**

**Initiation – Nocturnal enuresis**
Either:
1. The nasal forms of desmopressin are contraindicated; or
2. An enuresis alarm is contraindicated.

Note: Cranial diabetes insipidus and the nasal forms of desmopressin are contraindicated.

TERLIPRESSIN
- Inj 0.1 mg per ml, 8.5 ml ampoule ............................................... 450.00 5 Glypressin
- Inj 1 mg per 8.5 ml ampoule .................................................. 215.00 5 Glypressin

Products with Hospital Supply Status (HSS) are in **bold**
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Antibacterials

#### Aminoglycosides

**AMIKACIN** – *Restricted* see terms below
- Inj 5 mg per ml, 10 ml syringe
- Inj 5 mg per ml, 5 ml syringe ................................................................. 18.50  1  Biomed
- Inj 15 mg per ml, 5 ml syringe
- Inj 250 mg per ml, 2 ml vial – 1% DV Aug-18 to 2021 .................. 265.00  5  DBL Amikacin

- **Restricted (RS1041)**
  Clinical microbiologist, infectious disease specialist or respiratory specialist

**GENTAMICIN SULPHATE**
- Inj 10 mg per ml, 1 ml ampoule ................................................................. 25.00  5  DBL Gentamicin
- Inj 40 mg per ml, 2 ml ampoule ......................................................... 17.50  10  Pfizer

**PAROMOMYCIN** – *Restricted* see terms below
- Cap 250 mg.................................................................................................. 126.00  16  Humatin

- **Restricted (RS1603)**
  Clinical microbiologist, infectious disease specialist or gastroenterologist

**STREPTOMYCIN SULPHATE** – *Restricted* see terms below
- Inj 400 mg per ml, 2.5 ml ampoule

- **Restricted (RS1043)**
  Clinical microbiologist, infectious disease specialist or respiratory specialist

**TOBRAMYCIN**
- Powder

  - **Restricted (RS1475)**
    Clinical microbiologist or infectious disease specialist

  - **Initiation**
    For addition to orthopaedic bone cement.

    - Inj 40 mg per ml, 2 ml vial – 1% DV Sep-18 to 2021 .................. 15.00  5  Tobramycin Mylan

  - **Restricted (RS1044)**
    Clinical microbiologist, infectious disease specialist or respiratory specialist

    - Inj 100 mg per ml, 5 ml vial

  - **Restricted (RS1044)**
    Clinical microbiologist, infectious disease specialist or respiratory specialist

    - Solution for inhalation 60 mg per ml, 5 ml ........................................ 2,200.00  56 dose  TOBI

- **Restricted (RS1435)**

  - **Initiation**
    Patient has cystic fibrosis.

#### Carbapenems

**ERTAPENEM** – * Restricted* see terms below
- Inj 1 g vial – 1% DV Aug-19 to 2022 ......................................................... 70.00  1  Invanz

- **Restricted (RS1045)**
  Clinical microbiologist or infectious disease specialist

**IMIPENEM WITH CILASTATIN** – *Restricted* see terms below
- Inj 500 mg with 500 mg cilastatin vial – 1% DV Jul-19 to 2022 .............. 60.00  1  Imipenem+Cilastatin RBX

- **Restricted (RS1046)**
  Clinical microbiologist or infectious disease specialist
### INFECTIONS

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEROPENEM – Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Oct-18 to 2020</td>
<td>4.00 1 Meropenem Ranbaxy</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Oct-18 to 2020</td>
<td>8.00 1 Meropenem Ranbaxy</td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
</tr>
</tbody>
</table>

#### Cephalosporins and Cephamycins - 1st Generation

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEFALEXIN</td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg – 1% DV Nov-19 to 2022</td>
<td>3.33 20 Cephalexin ABM</td>
</tr>
<tr>
<td>Cap 500 mg</td>
<td>3.95 20 Cephalexin ABM</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg per ml – 1% DV Oct-18 to 2021</td>
<td>8.75 100 ml Cefalexin Sandoz</td>
</tr>
<tr>
<td>Grans for oral liq 50 mg per ml – 1% DV Oct-18 to 2021</td>
<td>11.75 100 ml Cefalexin Sandoz</td>
</tr>
<tr>
<td>CEFAZOLIN</td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-17 to 2020</td>
<td>3.39 5 AFT</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-17 to 2020</td>
<td>3.29 5 AFT</td>
</tr>
</tbody>
</table>

#### Cephalosporins and Cephamycins - 2nd Generation

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEFACLOR</td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg – 1% DV Oct-19 to 2022</td>
<td>24.70 100 Ranbaxy-Cefaclor</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg per ml – 1% DV Oct-19 to 2022</td>
<td>3.53 100 ml Ranbaxy-Cefaclor</td>
</tr>
<tr>
<td>CEFOTAXIME</td>
<td></td>
</tr>
<tr>
<td>Inj 1 g vial</td>
<td>58.00 10 Cefotaxin Actavis</td>
</tr>
<tr>
<td>CEFUROXIME</td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg – 1% DV Feb-20 to 2022</td>
<td>45.93 50 Zinnat</td>
</tr>
<tr>
<td>Inj 750 mg vial – 1% DV Feb-18 to 2020</td>
<td>9.85 10 Cefuroxime Actavis</td>
</tr>
<tr>
<td>Inj 1.5 g vial – 1% DV Feb-18 to 2020</td>
<td>14.36 10 Cefuroxime Actavis</td>
</tr>
</tbody>
</table>

#### Cephalosporins and Cephamycins - 3rd Generation

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEFOTAXIME</td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial</td>
<td>1.90 1 Cefotaxime Sandoz</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-17 to 2020</td>
<td>14.60 10 DBL Cefotaxime</td>
</tr>
<tr>
<td>CEFTAZIDIME – Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Inj 1 g vial</td>
<td>34.00 5 Ceftazidime Mylan</td>
</tr>
<tr>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
<td></td>
</tr>
<tr>
<td>CEFTRIAXONE</td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Jan-20 to 2022</td>
<td>0.89 1 Ceftriaxone-AFT</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Jan-20 to 2022</td>
<td>3.99 5 Ceftriaxone-AFT</td>
</tr>
<tr>
<td>Inj 2 g vial – 1% DV Jan-20 to 2022</td>
<td>1.98 1 Ceftriaxone-AFT</td>
</tr>
</tbody>
</table>

#### Cephalosporins and Cephamycins - 4th Generation

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEFEPIME – Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-18 to 2021</td>
<td>3.75 1 Cefepime-AFT</td>
</tr>
<tr>
<td>Inj 2 g vial – 1% DV Sep-18 to 2021</td>
<td>5.69 1 Cefepime-AFT</td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
</tr>
</tbody>
</table>
INFECTIONS

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

#### Cephalosporins and Cephamycins - 5th Generation

**CEFTAROLINE FOSAMIL** – **Restricted** see terms below

- **Inj 600 mg vial** ............................................................................................1,450.00 10 Zinforo
- **Restricted (RS1446)**

**Initiation – multi-resistant organism salvage therapy**

Clinical microbiologist or infectious disease specialist

Either:

1. for patients where alternative therapies have failed; or
2. for patients who have a contraindication or hypersensitivity to standard current therapies.

#### Macrolides

**AZITHROMYCIN** – **Restricted** see terms below

- **Tab 250 mg** – 1% DV Sep-18 to 2021 .............................................................8.19 30 Apo-Azithromycin
- **Tab 500 mg** – 1% DV Sep-18 to 2021 .............................................................0.93 2 Apo-Azithromycin
- **Grans for oral liq 200 mg per 5 ml (40 mg per ml)** – 1% DV Dec-18 to 2021 .....................................................................................................14.38 15 ml Zithromax
- **Restricted (RS1598)**

**Initiation – bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections**

Any of the following:

1. Patient has received a lung transplant, stem cell transplant or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*; or
2. Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*; or
3. Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms*; or
4. Patient has an atypical Mycobacterium infection.

Note: Indications marked with * are unapproved indications

**Initiation – non-cystic fibrosis bronchiectasis**

Respiratory specialist or paediatrician

Re-assessment required after 12 months

All of the following:

1. For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*; and
2. Patient is aged 18 and under; and
3. Either:
   3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
   3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

**Continuation – non-cystic fibrosis bronchiectasis**

Respiratory specialist or paediatrician

Re-assessment required after 12 months

All of the following:

1. The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
2. Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and
3. The patient will not receive more than a total of 24 months' azithromycin cumulative treatment (see note).

continued...
continued...

Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

**Initiation – other indications**

*Re-assessment required after 5 days*

For any other condition.

**Continuation – other indications**

*Re-assessment required after 5 days*

For any other condition.

**CLARITHROMYCIN – Restricted** see terms below

- Tab 250 mg – 1% DV Sep-17 to 2020 ..................................................3.98 14 Apo-Clarithromycin
- Tab 500 mg – 1% DV Sep-17 to 2020 ..................................................10.40 14 Apo-Clarithromycin
- Grans for oral liq 50 mg per ml..................................................192.00 50 ml Klacid
- Inj 500 mg vial – 1% DV Dec-17 to 31 Aug 2020 ..........................................12.04 1 Martindale

**Initiation – Tab 250 mg and oral liquid**

Any of the following:

1. Atypical mycobacterial infection; or
2. Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or
3. Helicobacter pylori eradication; or
4. Prophylaxis of infective endocarditis associated with surgical or dental procedures if amoxicillin is contra-indicated.

**Initiation – Tab 500 mg**

Helicobacter pylori eradication.

**Initiation – Infusion**

Any of the following:

1. Atypical mycobacterial infection; or
2. Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or

**ERYTHROMYCIN (AS ETHYLSUCCINATE)**

- Tab 400 mg ..........................................................16.95 100 E-Mycin
- Grans for oral liq 200 mg per 5 ml..................................................5.00 100 ml E-Mycin
- Grans for oral liq 400 mg per 5 ml..................................................6.77 100 ml E-Mycin

**ERYTHROMYCIN (AS LACTOBIONATE)**

- Inj 1 g vial – 1% DV Dec-19 to 2022 ..................................................10.00 1 Erythrocin IV

**ERYTHROMYCIN (AS STEARATE) – Restricted:** For continuation only

- Tab 250 mg
- Tab 500 mg

**ROXITHROMYCIN – Some items restricted** see terms below

- Tab dispersible 50 mg ..........................................................8.29 10 Rulide D
- Tab 150 mg – 1% DV Sep-19 to 2022 ..............................................8.28 50 Arrow-Roxithromycin
- Tab 300 mg – 1% DV Sep-19 to 2022 .............................................16.33 50 Arrow-Roxithromycin

**Restricted (RS1569)**

**Initiation**

Only for use in patients under 12 years of age.
### INFECTIONS

<table>
<thead>
<tr>
<th>Penicillins</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMOXICILLIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg – 1% DV Apr-20 to 2022</td>
<td>22.50</td>
<td>Alphamox</td>
</tr>
<tr>
<td>Cap 500 mg – 1% DV Apr-20 to 2022</td>
<td>14.97</td>
<td>Apo-Amoxi</td>
</tr>
<tr>
<td>Grans for oral liq 125 mg per 5 ml – 1% DV Feb-18 to 2020</td>
<td>1.20</td>
<td>Alphamox 125</td>
</tr>
<tr>
<td>Grans for oral liq 250 mg per 5 ml – 1% DV Feb-18 to 2020</td>
<td>1.31</td>
<td>Alphamox 250</td>
</tr>
<tr>
<td>Inj 250 mg vial – 1% DV Sep-17 to 2020</td>
<td>10.67</td>
<td>Ibiamox</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-17 to 2020</td>
<td>12.41</td>
<td>Ibiamox</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-17 to 2020</td>
<td>17.29</td>
<td>Ibiamox</td>
</tr>
<tr>
<td>(Apo-Amoxi Cap 250 mg to be delisted 1 April 2020)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Apo-Amoxi Cap 500 mg to be delisted 1 April 2020)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMOXICILLIN WITH CLAVULANIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg with clavulanic acid 125 mg – 1% DV Oct-17 to 2020</td>
<td>1.88</td>
<td>Augmentin</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml</td>
<td>3.83</td>
<td>Augmentin</td>
</tr>
<tr>
<td>Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml</td>
<td>2.20</td>
<td>Curam</td>
</tr>
<tr>
<td>Inj 500 mg with clavulanic acid 100 mg vial</td>
<td>28.18</td>
<td>m-Amoxiclav</td>
</tr>
<tr>
<td>Inj 1,000 mg with clavulanic acid 200 mg vial</td>
<td>43.30</td>
<td>m-Amoxiclav</td>
</tr>
<tr>
<td>BENZATHINE BENZYL-PENICILLIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 900 mg (1.2 million units) in 2.3 ml syringe – 1% DV Dec-18 to 2021</td>
<td>344.93</td>
<td>Bicillin LA</td>
</tr>
<tr>
<td>BENZYL-PENICILLIN SODIUM [PENICILLIN G]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 600 mg (1 million units) vial – 1% DV Sep-17 to 2020</td>
<td>25.88</td>
<td>Pan-Penicillin G Sodium</td>
</tr>
<tr>
<td></td>
<td>10.35</td>
<td>Sandoz</td>
</tr>
<tr>
<td></td>
<td>103.50</td>
<td>Sandoz</td>
</tr>
<tr>
<td>FLUCLOXACILLIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg – 1% DV Sep-18 to 2021</td>
<td>16.83</td>
<td>Staphlex</td>
</tr>
<tr>
<td>Cap 500 mg – 1% DV Sep-18 to 2021</td>
<td>56.61</td>
<td>Staphlex</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg per ml – 1% DV Oct-18 to 2021</td>
<td>2.29</td>
<td>AFT</td>
</tr>
<tr>
<td>Grans for oral liq 50 mg per ml – 1% DV Oct-18 to 2021</td>
<td>3.68</td>
<td>AFT</td>
</tr>
<tr>
<td>Inj 250 mg vial – 1% DV Sep-17 to 2020</td>
<td>9.00</td>
<td>Flucloxin</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-17 to 2020</td>
<td>9.40</td>
<td>Flucloxin</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-17 to 2020</td>
<td>5.22</td>
<td>Flucil</td>
</tr>
<tr>
<td>PHENOXYMETHYL-PENICILLIN [PENICILLIN V]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg – 1% DV Sep-18 to 2021</td>
<td>2.59</td>
<td>Cilicaine VK</td>
</tr>
<tr>
<td>Cap 500 mg – 1% DV Sep-18 to 2021</td>
<td>4.26</td>
<td>Cilicaine VK</td>
</tr>
<tr>
<td>Grans for oral liq 125 mg per 5 ml – 1% DV Jan-20 to 2022</td>
<td>2.99</td>
<td>AFT</td>
</tr>
<tr>
<td>Grans for oral liq 250 mg per 5 ml – 1% DV Jan-20 to 2022</td>
<td>3.99</td>
<td>AFT</td>
</tr>
<tr>
<td>PIPERACILLIN WITH TAZOBACTAM – Restricted see terms below</td>
<td></td>
<td>PipTaz Sandoz</td>
</tr>
<tr>
<td>Inj 4 g with tazobactam 0.5 g vial</td>
<td>38.00</td>
<td>PipTaz Sandoz</td>
</tr>
<tr>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROCaine PENICILLIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1.5 g in 3.4 ml syringe – 1% DV Sep-17 to 2020</td>
<td>123.50</td>
<td>Cilicaine</td>
</tr>
<tr>
<td>TICARCILLIN WITH CLAVULANIC ACID – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 3 g with clavulanic acid 0.1 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see ➤ above); Item restricted (see ➤ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Quinolones

**CIPROFLOXACIN** – **Restricted** see terms below

- Tab 250 mg – 1% DV Sep-17 to 2020 ................................................................. 1.45 28 Cipflox
- Tab 500 mg – 1% DV Sep-17 to 2020 ................................................................. 1.99 28 Cipflox
- Tab 750 mg – 1% DV Sep-17 to 2020 ................................................................. 3.15 28 Cipflox
- Oral liq 50 mg per ml
- Oral liq 100 mg per ml
- Inj 2 mg per ml, 100 ml bag – 1% DV Oct-18 to 2021 ................................... 68.20 10 Cipflox

**MOXIFLOXACIN** – **Restricted** see terms below

- Tab 400 mg ................................................................................................. 52.00 5 Avelox
- Inj 1.6 mg per ml, 250 ml bottle – 1% DV Apr-20 to 2022 ......................... 70.00 1 Avelox IV 400
- 39.00 Moxifloxacin Kabi

### Clinical microbiologist or infectious disease specialist

**Initiation – Mycobacterium infection**

Infectious disease specialist, clinical microbiologist or respiratory specialist

Any of the following:

1. Both:
   1.1 Active tuberculosis; and
   1.2 Any of the following:
      1.2.1 Documented resistance to one or more first-line medications; or
      1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
      1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
      1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
      1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or

2. Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated; or

3. Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.

### Infectious disease specialist or clinical microbiologist

**Initiation – Pneumonia**

Either:

1. Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or
2. Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.

### Ophthalmologist

**Initiation – Penetrating eye injury**

Five days treatment for patients requiring prophylaxis following a penetrating eye injury.

**Initiation – Mycoplasma genitalium**

All of the following:

1. Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium and is symptomatic; and
2. Either:
   2.1 Has tried and failed to clear infection using azithromycin; or
   2.2 Has laboratory confirmed azithromycin resistance; and
3. Treatment is only for 7 days.

**NORFLOXACIN**

Tab 400 mg ................................................................................................. 135.00 100 Arrow-Norfloxacin
**Tetracyclines**

**DEMECLOCYLINE HYDROCHLORIDE**
- Tab 150 mg
- Cap 150 mg
- Cap 300 mg

**DOXYCYCLINE**
- Tab 50 mg – **Restricted**: For continuation only
  - Tab 100 mg
  - Inj 5 mg per ml, 20 ml vial

**MINOCYCLINE**
- Tab 50 mg
  - Cap 100 mg – **Restricted**: For continuation only

**TETRACYCLINE**
- Tab 250 mg
- Cap 500 mg

**TIGECYCLINE** – **Restricted** see terms below
- Inj 50 mg vial

**Other Antibacterials**

**AZTREONAM** – **Restricted** see terms below
- Inj 1 g vial

**CHLORAMPHENICOL** – **Restricted** see terms below
- Inj 1 g vial

**CLINDAMYCIN** – **Restricted** see terms below
- Cap 150 mg – 1% DV Apr-20 to 2022
- Oral liq 15 mg per ml
- Inj 150 mg per ml, 4 ml ampoule – 1% DV Oct-19 to 2022

**COLISTIN SULPHOMETHATE [COLESTIMETHATE]** – **Restricted** see terms below
- Inj 150 mg per ml, 1 ml vial

**DAPTOMYCIN** – **Restricted** see terms below
- Inj 500 mg vial

**FOSFOMYCIN** – **Restricted** see terms on the next page
- Powder for oral solution, 3 g sachet

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>Products</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LINCOMYCIN</strong> – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>35.77 2 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LINEZOLID</strong> – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 600 mg – 1% DV Oct-18 to 2021</td>
<td>553.77</td>
<td>10 Zyvox</td>
</tr>
<tr>
<td>Oral liq 20 mg per ml – 1% DV Dec-18 to 2021</td>
<td>1,879.00</td>
<td>150 ml Zyvox</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 300 ml bottle – 1% DV Feb-19 to 2021</td>
<td>18.50</td>
<td>1 Linezolid Kabi</td>
</tr>
<tr>
<td><strong>METHENAMINE (HEXAMINE) HIPPURATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 1 g</td>
<td>40.01</td>
<td>100 Hiprex</td>
</tr>
<tr>
<td><strong>NITROFURANTOIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Apr-19 to 2021</td>
<td>22.20</td>
<td>100 Nifuran</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Apr-19 to 2021</td>
<td>37.50</td>
<td>100 Nifuran</td>
</tr>
<tr>
<td><strong>PIVMECILLINAM</strong> – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM FUSIDATE [FUSIDIC ACID]</strong> – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg – 1% DV Jun-17 to 2020</td>
<td>34.50</td>
<td>12 Fucidin</td>
</tr>
<tr>
<td><strong>SULPHADIAZINE</strong> – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TEICOPLANIN</strong> – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 400 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TRIMETHOPRIM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 300 mg – 1% DV Oct-18 to 2021</td>
<td>16.50</td>
<td>50 TMP</td>
</tr>
<tr>
<td><strong>TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 80 mg with sulphamethoxazole 400 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 8 mg with sulphamethoxazole 40 mg per ml – 1% DV Oct-17 to 2020</td>
<td>2.97</td>
<td>100 ml Deprim</td>
</tr>
<tr>
<td>Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>VANCOMYCIN</strong> – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-17 to 2020</td>
<td>2.37</td>
<td>1 Mylan</td>
</tr>
</tbody>
</table>

**Products with Hospital Supply Status (HSS) are in bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

## Antifungals

### Imidazoles

**KETOCONAZOLE**  
- **Tab 200 mg**  
  - Restricted (RS1410)  
  Oncologist

### Polyene Antimycotics

**AMPHOTERICIN B**  
- **Inj (liposomal) 50 mg vial**  
  - $3,450.00 10 AmBisome  
  - Restricted (RS1071)  
  Initiation  
  Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist  
  Either:  
  1. Proven or probable invasive fungal infection, to be prescribed under an established protocol; or  
  2. Both:  
     2.1 Possible invasive fungal infection; and  
     2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

- **Inj 50 mg vial**  
  - Restricted (RS1316)  
  Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

**NYSTATIN**  
- **Tab 500,000 u**  
  - $17.09 50 Nilstat  
- **Cap 500,000 u**  
  - $15.47 50 Nilstat

### Triazoles

**FLUCONAZOLE — Restricted see terms below**  
- **Cap 50 mg — 1% DV Feb-18 to 2020**  
  - $2.09 28 Mylan  
- **Cap 150 mg — 1% DV Feb-18 to 2020**  
  - $0.33 1 Mylan  
- **Cap 200 mg — 1% DV Feb-18 to 2020**  
  - $5.08 28 Mylan  
- **Oral liquid 50 mg per 5 ml**  
  - $98.50 35 ml Diflucan  
- **Inj 2 mg per ml, 50 ml vial — 1% DV Oct-19 to 2022**  
  - $2.80 1 Fluconazole-Claris  
- **Inj 2 mg per ml, 100 ml vial — 1% DV Oct-19 to 2022**  
  - $3.45 1 Fluconazole-Claris  
  - Restricted (RS1072)  

**ITRACONAZOLE — Restricted see terms below**  
- **Cap 100 mg — 1% DV Nov-19 to 2022**  
  - $4.27 15 Itrazole  
- **Oral liquid 10 mg per ml**  
  - Restricted (RS1073)  

**POSACONAZOLE — Restricted see terms on the next page**  
- **Tab modified-release 100 mg**  
  - $869.86 24 Noxafil  
- **Oral liq 40 mg per ml**  
  - $761.13 105 ml Noxafil

---

- Item restricted (see ➥ above); ➥ Item restricted (see ➥ below)  
  e.g. Brand indicates brand example only. It is not a contracted product.
**INFECTIONS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**VORICONAZOLE – Restricted** see terms below

- **Tab 50 mg – 1% DV Sep-18 to 2021**
  - 91.00 56 Vtack
- **Tab 200 mg – 1% DV Sep-18 to 2021**
  - 350.00 56 Vtack
- **Powder for oral suspension 40 mg per ml – 1% DV Dec-18 to 2021**
  - 1,437.00 70 ml Vfend
- **Inj 200 mg vial – 1% DV Oct-19 to 2022**
  - 44.00 1 Neo Health

**CASPOFUNGIN – Restricted** see terms on the next page

- **Inj 50 mg vial – 1% DV Dec-19 to 2022**
  - 220.28 1 Max Health
- **Inj 70 mg vial – 1% DV Dec-19 to 2022**
  - 284.63 1 Max Health

---

**Restricted (RS1074)**

**Initiation**

Haematologist or infectious disease specialist

*Re-assessment required after 6 weeks*

**Both:**

1. Either:
   1.1 Patient has acute myeloid leukaemia; or
   1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and
2. Patient is to be treated with high dose remission induction therapy or re-induction therapy.

**Continuation**

Haematologist or infectious disease specialist

*Re-assessment required after 6 weeks*

**Both:**

1. Patient has previously received posaconazole prophylaxis during remission induction therapy; and
2. Any of the following:
   2.1 Patient is to be treated with high dose remission re-induction therapy; or
   2.2 Patient is to be treated with high dose consolidation therapy; or
   2.3 Patient is receiving a high risk stem cell transplant.

**VORICONAZOLE – Restricted** see terms below

- **Tab 50 mg – 1% DV Sep-18 to 2021**
  - 91.00 56 Vtack
- **Tab 200 mg – 1% DV Sep-18 to 2021**
  - 350.00 56 Vtack
- **Powder for oral suspension 40 mg per ml – 1% DV Dec-18 to 2021**
  - 1,437.00 70 ml Vfend
- **Inj 200 mg vial – 1% DV Oct-19 to 2022**
  - 44.00 1 Neo Health

---

**Restricted (RS1075)**

**Initiation – Proven or probable aspergillus infection**

Clinical microbiologist, haematologist or infectious disease specialist

**Both:**

1. Patient is immunocompromised; and
2. Patient has proven or probable invasive aspergillus infection.

**Initiation – Possible aspergillus infection**

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

1. Patient is immunocompromised; and
2. Patient has possible invasive aspergillus infection; and
3. A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

**Initiation – Resistant candidiasis infections and other moulds**

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

1. Patient is immunocompromised; and
2. Either:
   2.1 Patient has fluconazole resistant candidiasis; or
   2.2 Patient has mould strain such as Fusarium spp. and Scedosporium spp; and
3. A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.

---

**Other Antifungals**

**CASPOFUNGIN – Restricted** see terms on the next page

- **Inj 50 mg vial – 1% DV Dec-19 to 2022**
  - 220.28 1 Max Health
- **Inj 70 mg vial – 1% DV Dec-19 to 2022**
  - 284.63 1 Max Health

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**Restricted (RS1076)**

**Initiation**
Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

Either:
1. Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
2. Both:
   2.1 Possible invasive fungal infection; and
   2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

**FLUCYTOSINE** – **Restricted** see terms below
- Cap 500 mg

**Restricted (RS1279)**
Clinical microbiologist or infectious disease specialist

**TERBINAFINE**
- Tab 250 mg – 1% DV Jan-18 to 2020 ................................................. 1.33 14 Deolate

**Antimycobacterials**

**Antileprotics**

**CLOFAZIMINE** – **Restricted** see terms below
- Cap 50 mg

**Restricted (RS1077)**
Clinical microbiologist, dermatologist or infectious disease specialist

**DAPSONE** – **Restricted** see terms below
- Tab 25 mg ................................................................................. 268.50 100 Dapsone
- Tab 100 mg ............................................................................... 329.50 100 Dapsone

**Restricted (RS1078)**
Clinical microbiologist, dermatologist or infectious disease specialist

**Antituberculotics**

**CYCLOSERINE** – **Restricted** see terms below
- Cap 250 mg

**Restricted (RS1079)**
Clinical microbiologist, infectious disease specialist or respiratory specialist

**ETHAMBUTOL HYDROCHLORIDE** – **Restricted** see terms below
- Tab 100 mg
- Tab 400 mg ............................................................................. 49.34 56 Myambutol

**Restricted (RS1080)**
Clinical microbiologist, infectious disease specialist or respiratory specialist

**ISONIAZID** – **Restricted** see terms below
- Tab 100 mg – 1% DV Oct-18 to 2021 .................. 22.00 100 PSM

**Restricted (RS1281)**
Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician

**ISONIAZID WITH RIFAMPICIN** – **Restricted** see terms below
- Tab 100 mg with rifampicin 150 mg – 1% DV Sep-18 to 2021 ............... 85.54 100 Rifinah
- Tab 150 mg with rifampicin 300 mg – 1% DV Sep-18 to 2021 ............... 170.60 100 Rifinah

**Restricted (RS1282)**
Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician

---

*Item restricted (see ➥ above); ➥ Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARA-AMINOSALICYLIC ACID –</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grans for oral 4 g</td>
<td>$280.00</td>
<td>30 Paser</td>
</tr>
<tr>
<td><strong>Restricted</strong> (RS1083)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>infectious disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROTIONAMIDE – Restricted</td>
<td>$305.00</td>
<td>100 Peteha</td>
</tr>
<tr>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted</strong> (RS1084)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>infectious disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PYRAZINAMIDE – Restricted</td>
<td>$275.00</td>
<td>30 Mycobutin</td>
</tr>
<tr>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 150 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted</strong> (RS1085)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>infectious disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RIFABUTIN – Restricted</td>
<td>$275.00</td>
<td>30 Mycobutin</td>
</tr>
<tr>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 150 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted</strong> (RS1086)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>gastroenterologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>infectious disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RIFAMPICIN – Restricted</td>
<td>$55.75</td>
<td>100 Rifadin</td>
</tr>
<tr>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 150 mg – 1% DV Sep-17 to</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted</strong> (RS1087)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dermatologist, internal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>medicine physician,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>paediatrician or public</td>
<td></td>
<td></td>
</tr>
<tr>
<td>health physician</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALBENDAZOLE – Restricted</td>
<td>$12.00</td>
<td>60 ml Rifadin</td>
</tr>
<tr>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted</strong> (RS1088)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>infectious disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IVERMECTIN – Restricted</td>
<td>$12.00</td>
<td>60 ml Stromectol</td>
</tr>
<tr>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 3 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted</strong> (RS1283)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dermatologist or infectious</td>
<td></td>
<td></td>
</tr>
<tr>
<td>disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEBENDAZOLE</td>
<td>$24.19</td>
<td>24 De-Worm</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 100 mg per 5 ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAZIQUANTEL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 600 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARTEMETHER WITH LUMEFANTRINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 20 mg with lumefantrine 120 mg</td>
<td>$12.00</td>
<td>60 ml Stromectol</td>
</tr>
<tr>
<td>Product</td>
<td>Specification</td>
<td>Price (ex man. excl. GST)</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>ARTESEUNATE</td>
<td>Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Inj 60 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATOVUQUONE WITH PROGUANIL HYDROCHLORIDE</td>
<td>Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Tab 62.5 mg with proguanil hydrochloride 25 mg</td>
<td></td>
<td>25.00</td>
</tr>
<tr>
<td>Tab 250 mg with proguanil hydrochloride 100 mg</td>
<td></td>
<td>64.00</td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHLOROQUINE PHOSPHATE</td>
<td>Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEFLOQUINE</td>
<td>Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>METRONIDAZOLE</td>
<td>Tab 200 mg</td>
<td>10.45</td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td></td>
<td>18.15</td>
</tr>
<tr>
<td>Oral liq benzoate 200 mg per 5 ml</td>
<td></td>
<td>25.00</td>
</tr>
<tr>
<td>Injection 5 mg per ml, 100 ml bottle</td>
<td></td>
<td>1.39</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 100 ml bottle</td>
<td></td>
<td>34.80</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 100 ml bag</td>
<td></td>
<td>55.00</td>
</tr>
<tr>
<td>Suppos 500 mg</td>
<td></td>
<td>24.48</td>
</tr>
<tr>
<td>NITAZOXANIDE</td>
<td>Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td></td>
<td>1,680.00</td>
</tr>
<tr>
<td>Oral liq 100 mg per 5 ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORNIDAZOLE</td>
<td>Tab 500 mg</td>
<td>32.95</td>
</tr>
<tr>
<td>PENTAMIDINE ISETHIONATE</td>
<td>Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Inj 300 mg vial - 1% DV Nov-19 to 2022</td>
<td></td>
<td>216.00</td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRIMAQUINE PHOSPHATE</td>
<td>Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Tab 15 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 7.5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PYRIMETHAMINE</td>
<td>Restricted see terms below</td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>QUININE DIHYDROCHLORIDE</td>
<td>Restricted see terms on the next page</td>
<td></td>
</tr>
<tr>
<td>Inj 60 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 300 mg per ml, 2 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see above); Item restricted (see below) e.g. Brand indicates brand example only. It is not a contracted product.*
INFECTIONS

Price
(ex man. excl. GST)
$ Per
Brand or
Generic
Manufacturer

** → Restricted (RS1099)**
Clinical microbiologist or infectious disease specialist
QUININE SULPHATE
Tab 300 mg .......................................................... 61.91 500 Q 300
SODIUM STIBOGLUCONATE – **Restricted** see terms below
   - Inj 100 mg per ml, 1 ml vial
** → Restricted (RS1100)**
Clinical microbiologist or infectious disease specialist
SPIRAMYCIN – **Restricted** see terms below
   - Tab 500 mg
** → Restricted (RS1101)**
Maternal-foetal medicine specialist

Antiretrovirals

Non-Nucleoside Reverse Transcriptase Inhibitors

** → Restricted (RS1571)**
Initiation – Confirmed HIV
Patient has confirmed HIV infection.
Initiation – Prevention of maternal transmission
Either:
   1. Prevention of maternal foetal transmission; or
   2. Treatment of the newborn for up to eight weeks.
Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV
Both:
   1. Treatment course to be initiated within 72 hours post exposure; and
   2. Any of the following:
      2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
      2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
      2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.
Initiation – Percutaneous exposure
Patient has percutaneous exposure to blood known to be HIV positive.

**EFAVIRENZ** – **Restricted** see terms above
   - Tab 200 mg .......................................................... 190.15 90 Stocrin
   - Tab 600 mg .......................................................... 63.38 30 Stocrin
   - Oral liq 30 mg per ml

**ETRAVIRINE** – **Restricted** see terms above
   - Tab 200 mg .......................................................... 770.00 60 Intelence

**NEVIRAPINE** – **Restricted** see terms above
   - Tab 200 mg – 1% DV Sep-18 to 2021 .......................................................... 60.00 60 Nevirapine Alphapharm
   - Oral suspension 10 mg per ml .......................................................... 203.55 240 ml Viramune Suspension

Products with Hospital Supply Status (HSS) are in **bold**
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
INFECTIONS

Nucleoside Reverse Transcriptase Inhibitors

**Restricted (RS1572)**

**Initiation – Confirmed HIV**
Patient has confirmed HIV infection.

**Initiation – Prevention of maternal transmission**
Either:

1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

**Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**
Both:

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation – Percutaneous exposure**
Patient has percutaneous exposure to blood known to be HIV positive.

- **ABACAVIR SULPHATE** – Restricted see terms above
  - Tab 300 mg – 1% DV Jul-19 to 2022 ......................................................... 180.00 60 Ziagen
  - Oral liq 20 mg per ml ......................................................................... 256.31 240 ml Ziagen

- **ABACAVIR SULPHATE WITH LAMIVUDINE** – Restricted see terms above
  - Tab 600 mg with lamivudine 300 mg – 1% DV Jul-19 to 2022 ................. 63.00 30 Kivexa

- **EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL** – Restricted see terms above
  - Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) – 1% DV Jun-19 to 2022 .................... 106.88 30 Mylan

- **EMTRICITABINE** – Restricted see terms above
  - Cap 200 mg – 1% DV Jul-19 to 2022 ..................................................... 307.20 30 Emtriva

- **LAMIVUDINE** – Restricted see terms above
  - Oral liq 10 mg per ml
  - Cap 30 mg
  - Cap 40 mg
  - Powder for oral soln 1 mg per ml

- **STAVUDINE** – Restricted see terms above
  - Cap 30 mg
  - Cap 40 mg
  - Powder for oral soln 1 mg per ml

- **ZIDOVUDINE [AZT]** – Restricted see terms above
  - Cap 100 mg ......................................................................................... 152.25 100 Retrovir
  - Oral liq 10 mg per ml ........................................................................ 30.45 200 ml Retrovir
  - Inj 10 mg per ml, 20 ml vial .............................................................. 750.00 5 Retrovir IV

- **ZIDOVUDINE [AZT] WITH LAMIVUDINE** – Restricted see terms above
  - Tab 300 mg with lamivudine 150 mg – 1% DV Sep-17 to 2020 .......... 33.00 60 Alphapharm

Protease Inhibitors

**Restricted (RS1573)**

**Initiation – Confirmed HIV**
Patient has confirmed HIV infection.

continued…
### Strand Transfer Inhibitors

**Initiation – Confirmed HIV**

Patient has confirmed HIV infection.

**Initiation – Prevention of maternal transmission**

Either:

1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

**Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**

Both:

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   - Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   - Patient has shared intravenous injecting equipment with a known HIV positive person; or
   - Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

### ATAZANAVIR SULPHATE

**Restricted**

- **Cap 150 mg** – 1% DV Jun-19 to 2022.........................................................141.68 60 Teva
- **Cap 200 mg** – 1% DV Jun-19 to 2022.........................................................188.91 60 Teva

### DARUNAVIR

**Restricted**

- **Tab 400 mg** – 1% DV Jun-17 to 2020.........................................................335.00 60 Prezista
- **Tab 600 mg** – 1% DV Jun-17 to 2020.........................................................476.00 60 Prezista

### INDINAVIR

**Restricted**

- **Cap 200 mg**
- **Cap 400 mg**

### LOPINAVIR WITH RITONAVIR

**Restricted**

- **Tab 100 mg with ritonavir 25 mg** ............................................................183.75 60 Kaletra
- **Tab 200 mg with ritonavir 50 mg** – 1% DV Sep-17 to 2020.................463.00 120 Kaletra
- **Oral liq 80 mg with ritonavir 20 mg per ml** .............................................735.00 300 ml Kaletra

### RITONAVIR

**Restricted**

- **Tab 100 mg** – 1% DV Jul-19 to 2022.........................................................43.31 30 Norvir

**continued…**
2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation – Percutaneous exposure**

Patient has percutaneous exposure to blood known to be HIV positive.

**Dolutegravir** – Restricted see terms on the previous page

- Tab 50 mg $1,090.00 30 Tivicay

**Raltegravir Potassium** – Restricted see terms on the previous page

- Tab 400 mg $1,090.00 60 Isentress
- Tab 600 mg $1,090.00 60 Isentress HD

**Antivirals**

**Hepatitis B**

**Adefovir Diphosphil** – Restricted see terms below

- Tab 10 mg $670.00 30 Hepsera

- Restricted (RS1104)

**Initiation**

Gastroenterologist or infectious disease specialist

All of the following:

1. Patient has confirmed Hepatitis B infection (HBsAg+); and

   Documented resistance to lamivudine defined as:

2. Patient has raised serum ALT (> 1 × ULN); and

3. Patient has HBV DNA greater than 100,000 copies per mL, or viral load greater than or equal to 10-fold over nadir; and

4. Detection of M204I or M204V mutation; and

5. Either:

   5.1 Both:

      5.1.1 Patient is cirrhotic; and

      5.1.2 Adefovir diphosphil to be used in combination with lamivudine; or

   5.2 Both:

      5.2.1 Patient is not cirrhotic; and

      5.2.2 Adefovir diphosphil to be used as monotherapy.

**Entecavir**

- Tab 0.5 mg – 1% DV Nov-18 to 2021 $52.00 30 Entecavir Sandoz

**Lamivudine**

- Tab 100 mg – 1% DV Aug-18 to 2020 $4.20 28 Zetlam

- Oral liq 5 mg per ml $270.00 240 ml Zeffix

**Tenofovir Disoproxil**

- Tab 245 mg (300.6 mg as a succinate) – 1% DV Sep-18 to 2021 $38.10 30 Tenofovir Disoproxil Teva

**Hepatitis C**

**Glecaprevir With Pibrentasvir**

Note: the supply of treatment is via PHARMAC’s approved direct distribution supply. Further details can be found on PHARMAC’s website https://www.pharmac.govt.nz/hepatitis-c-treatments/.

- Tab 100 mg with pibrentasvir 40 mg $24,750.00 84 Maviret

**Ledipasvir With Sofosbuvir** – Restricted see terms on the next page

- Tab 90 mg with sofosbuvir 400 mg $24,363.46 28 Harvoni

*e.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>Herpesviridae</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aciclovir</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Cidofovir</strong> – Restricted see terms below</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Foscarnet Sodium</strong> – Restricted see terms below</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Ganciclovir</strong> – Restricted see terms below</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Valaciclovir</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Valganciclovir</strong> – Restricted see terms below</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Initiation** – Transplant cytomegalovirus prophylaxis

*Limited to 3 months treatment*

Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

**Initiation** – Lung transplant cytomegalovirus prophylaxis

*Limited to 6 months treatment*

Both:

1. Patient has undergone a lung transplant; and
2. Either:
   2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
   2.2 The recipient is cytomegalovirus positive.

**Initiation** – Cytomegalovirus in immunocompromised patients

Both:

1. Patient is immunocompromised; and
2. Any of the following:
   2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
   2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
   2.3 Patient has cytomegalovirus retinitis.
HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL – **Restricted** see terms below

- Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)
  - **1% DV Jun-19 to 2022** ................................................................. 61.15 30 **Teva**

**Initiation – Confirmed HIV**
Patient has confirmed HIV infection.

**Initiation – Prevention of maternal transmission**
Either:
1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

**Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**
Both:
1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation – Percutaneous exposure**
Patient has percutaneous exposure to blood known to be HIV positive.

**Initiation – Pre-exposure prophylaxis**
*Re-assessment required after 3 months*
All of the following:
1. Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and
2. Patient has undergone testing for HIV, syphilis, Hep B if not immune and a full STI screen in the previous two weeks; and
3. Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 3 months and is not contraindicated for treatment; and
4. Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
5. Patient has tested HIV negative and is not at risk of HIV seroconversion; and
6. Either:
   - 6.1 All of the following:
     - 6.1.1 Patient is male or transgender; and
     - 6.1.2 Patient has sex with men; and
     - 6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
     - 6.1.4 Any of the following:
       - 6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
       - 6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
       - 6.1.4.3 Patient has used methamphetamine in the last three months; or
   - 6.2 All of the following:
     - 6.2.1 Patient has a regular partner who has HIV infection; and
     - 6.2.2 Partner is either not on treatment or has a detectable viral load; and
     - 6.2.3 Condoms have not been consistently used.

continued…
continued...

Continuation – Pre-exposure prophylaxis

Re-assessment required after 3 months

All of the following:

1. Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and
2. Patient has undergone testing for HIV, syphilis, Hep B if not immune and a full STI screen in the previous two weeks; and
3. Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 12 months and is not contraindicated for treatment; and
4. Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
5. Patient has tested HIV negative and is not at risk of HIV seroconversion; and
6. Either:
   6.1 All of the following:
      6.1.1 Patient is male or transgender; and
      6.1.2 Patient has sex with men; and
      6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
      6.1.4 Any of the following:
         6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
         6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
         6.1.4.3 Patient has used methamphetamine in the last three months; or
   6.2 All of the following:
      6.2.1 Patient has a regular partner who has HIV infection; and
      6.2.2 Partner is either not on treatment or has a detectable viral load; and
      6.2.3 Condoms have not been consistently used.

Influenza

OSEL T AMIVIR – Restricted see terms below

Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

Tab 75 mg
Powder for oral suspension 6 mg per ml

Restricted (RS1307)

Initiation

Either:

1. Only for hospitalised patient with known or suspected influenza; or
2. For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

ZANAMIVIR

Note: The restriction on the use of zanamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

Powder for inhalation 5 mg

Restricted (RS1369)

Initiation

Either:

1. Only for hospitalised patient with known or suspected influenza; or
2. For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.
Immune Modulators

INTERFERON ALFA-2A
  Inj 3 m iu prefilled syringe
  Inj 6 m iu prefilled syringe
  Inj 9 m iu prefilled syringe

INTERFERON ALFA-2B
  Inj 18 m iu, 1.2 ml multidose pen
  Inj 30 m iu, 1.2 ml multidose pen
  Inj 60 m iu, 1.2 ml multidose pen

INTERFERON GAMMA – Restricted see terms below
  $ Inj 100 mcg in 0.5 ml vial
  → Restricted (RS1113)

Initiation
Patient has chronic granulomatous disease and requires interferon gamma.

PEGYLATED INTERFERON ALFA-2A – Restricted see terms below
  $ Inj 180 mcg prefilled syringe – 1% DV Oct-17 to 2020 ......................... 500.00 4
  → Restricted (RS1340)

Initiation – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant
Limited to 48 weeks treatment
Any of the following:
  1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
  2 Patient has chronic hepatitis C and is co-infected with HIV; or
  3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.

Notes: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

Continuation – Chronic hepatitis C - genotype 1 infection
Gastroenterologist, infectious disease specialist or general physician
Re-assessment required after 48 weeks
All of the following:
  1 Patient has chronic hepatitis C, genotype 1; and
  2 Patient has had previous treatment with pegylated interferon and ribavirin; and
  3 Either:
     3.1 Patient has responder relapsed; or
     3.2 Patient was a partial responder; and
  4 Patient is to be treated in combination with boceprevir.

Initiation – Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior
Gastroenterologist, infectious disease specialist or general physician
Limited to 48 weeks treatment
All of the following:
  1 Patient has chronic hepatitis C, genotype 1; and
  2 Patient has had previous treatment with pegylated interferon and ribavirin; and
  3 Any of the following:
     3.1 Patient has responder relapsed; or

continued…
continued...

3.2 Patient was a partial responder; or
3.3 Patient received interferon treatment prior to 2004; and

4 Patient is to be treated in combination with boceprevir.

**Initiation – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV**

*Limited to 6 months* treatment

Patient has chronic hepatitis C, genotype 2 or 3 infection.

**Initiation – Hepatitis B**

Gastroenterologist, infectious disease specialist or general physician

*Limited to 48 weeks* treatment

All of the following:

1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
2 Patient is Hepatitis B treatment-naive; and
3 ALT > 2 times Upper Limit of Normal; and
4 HBV DNA < 10 log10 IU/ml; and
5 Either:
   5.1 HBeAg positive; or
   5.2 Serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (greater than or equal to Metavir Stage F2 or moderate fibrosis); and
6 Compensated liver disease; and
7 No continuing alcohol abuse or intravenous drug use; and
8 Not co-infected with HCV, HIV or HDV; and
9 Neither ALT nor AST > 10 times upper limit of normal; and
10 No history of hypersensitivity or contraindications to pegylated interferon.

Notes: Approved dose is 180 mcg once weekly.

The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.

In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.

In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.

Pegylated Interferon alfa-2a is not approved for use in children.
## Anticholinesterases

**EDROPHONIUM CHLORIDE – Restricted** see terms below

- Inj 10 mg per ml, 15 ml vial
- Inj 10 mg per ml, 1 ml ampoule

*Restricted (RS1015)*

**Initiation**

For the diagnosis of myasthenia gravis.

**NEOSTIGMINE METILSULFATE**

- Inj 2.5 mg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 ................. 98.00 50 AstraZeneca
- Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule .... 20.90 10 Max Health

**PYRIDOSTIGMINE BROMIDE**

- Tab 60 mg – 1% DV Nov-19 to 2022 .................................................. 45.79 100 Mestinon

## Antirheumatoid Agents

**HYDROXYCHLOROQUINE**

- Tab 200 mg – 1% DV Sep-18 to 2021 .................................................. 7.98 100 Plaquenil

**LEFLUNOMIDE**

- Tab 10 mg – 1% DV Jun-17 to 2020 .................................................. 2.90 30 Apo-Leflunomide
- Tab 20 mg – 1% DV Jun-17 to 2020 .................................................. 2.90 30 Apo-Leflunomide

**PENCILLAMINE**

- Tab 125 mg ...................................................................................... 67.23 100 D-Penamine
- Tab 250 mg .................................................................................... 110.12 100 D-Penamine

**SODIUM AUROTHIOMALATE**

- Inj 10 mg in 0.5 ml ampoule
- Inj 20 mg in 0.5 ml ampoule
- Inj 50 mg in 0.5 ml ampoule

## Drugs Affecting Bone Metabolism

### Bisphosphonates

**ALENDRONATE SODIUM**

- Tab 70 mg – 1% DV Apr-19 to 2022 .................................................. 2.44 4 Fosamax

**ALENDRONATE SODIUM WITH COLECALCIFEROL**

- Tab 70 mg with colecalciferol 5,600 lu – 1% DV Apr-19 to 2022 .......... 1.51 4 Fosamax Plus

**PAMIDRONATE DISODIUM**

- Inj 3 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020 ....................... 5.98 1 Pamisol
- Inj 6 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020 ....................... 15.02 1 Pamisol
- Inj 9 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020 ....................... 17.05 1 Pamisol

**RISEDRONATE SODIUM**

- Tab 35 mg – 1% DV Oct-19 to 2022 ............................................... 3.10 4 Risedronate Sandoz

**ZOLEDRONIC ACID**

- Inj 5 mg per 100 ml, vial – 1% DV Oct-19 to 2022 ......................... 60.00 100 ml Aclasta

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*
→ Restricted (RS1663)

**Initiation – Inherited bone fragility disorders**

Any specialist

Patient has been diagnosed with an inherited bone fragility disorder (e.g. osteogenesis imperfecta).

**Initiation – Osteoporosis**

Any specialist

*Therapy limited to 3 doses*

Both:

1. Any of the following:
   1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
   1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
   1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
   1.4 Documented T-Score greater than or equal to -3.0 (see Note); or
   1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
   1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

2. The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

**Initiation – glucocorticosteroid therapy**

Any specialist

*Re-assessment required after 12 months*

All of the following:

1. The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and

2. Any of the following:
   2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or
   2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
   2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

3. The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

**Continuation – glucocorticosteroid therapy**

Any specialist

*Re-assessment required after 12 months*

Both:

1. The patient is continuing systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents); and

2. The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

**Initiation – Paget's disease**

Any specialist

*Re-assessment required after 12 months*

All of the following:

1. Paget's disease; and

continued…
continued…

2 Any of the following:
   2.1 Bone or articular pain; or
   2.2 Bone deformity; or
   2.3 Bone, articular or neurological complications; or
   2.4 Asymptomatic disease, but risk of complications; or
   2.5 Preparation for orthopaedic surgery; and

3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation – Paget’s disease

Any specialist

Re-assessment required after 12 months

Both:

1 Any of the following:
   1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
   1.2 The patient’s serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
   1.3 Symptomatic disease (prescriber determined); and

2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Notes:

1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.

3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Other Drugs Affecting Bone Metabolism

DENOSUMAB – Restricted see terms below

- Inj 60 mg prefilled syringe.................................................................326.00 1 Prolia

⇒ Restricted (RS1665)

Initiation

All of the following:

1 The patient has severe, established osteoporosis; and

2 Either:
   2.1 The patient is female and postmenopausal; or
   2.2 The patient is male or non-binary; and

3 Any of the following:
   3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or

continued…
continued...

3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or
densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
3.4 Documented T-Score less than or equal to -3.0 (see Note); or
3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm
(e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
3.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February
2019 or has had a Special Authority approval for raloxifene; and

4 Zoledronic acid is contraindicated because the patient’s creatinine clearance is less than 35 mL/min; and
5 The patient has experienced at least one symptomatic new fracture after at least 12 months’ continuous therapy with a
funded antiresorptive agent at adequate doses (see Notes); and
6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or
teriparatide.

Notes:
1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA).
Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture
demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD
measurement for treatment with denosumab.
3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO
definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below
-2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical
forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a
fall from a standing height or less.
4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body
relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral
body above or below the affected vertebral body.
5 Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate
sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly;
raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment
withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that
the patient achieves the minimum requirement of 12 months’ continuous therapy.

RALOXIFENE – Restricted see terms below

- Restricted (RS1666)
Initiation
Any of the following:

1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)
greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or
equal to -2.5) (see Notes); or
2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or
densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is
unlikely that this provision would apply to many patients under 75 years of age; or
3 History of two significant osteoporotic fractures demonstrated radiologically; or
4 Documented T-Score greater than or equal to -3.0 (see Notes); or
5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g.
FRAX or Garvan) which incorporates BMD measurements (see Notes); or

continued…
continued...

6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019.

Notes:
1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

TERIPARATIDE – Restricted see terms below

Inj 250 mcg per ml, 2.4 ml cartridge .............................................................. 490.00 1 Forteo

Initiation
Limited to 18 months treatment

All of the following:
1 The patient has severe, established osteoporosis; and
2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
3 The patient has had two or more fractures due to minimal trauma; and
4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:
1 The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
2 Antiresorptive agents and their adequate doses for the purposes of this restriction are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
3 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Enzymes

HYALURONIDASE

Inj 1,500 iu ampoule

Hyperuricaemia and Antigout

ALLOPURINOL

Tab 100 mg – 1% DV Jan-18 to 2020 .............................................................. 4.54 500 DP-Allopurinol
Tab 300 mg – 1% DV Jan-18 to 2020 .............................................................. 10.35 500 DP-Allopurinol
BENZBROMARONE – Restricted see terms below
- Tab 50 mg
- Tab 100 mg.................................................................45.00 100 Benzbromaron AL 100

Initiation
Any specialist
All of the following:
1 Patient has been diagnosed with gout; and
2 Any of the following:
   2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2.3 Both:
      2.3.1 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
      2.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
   2.4 All of the following:
      2.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
      2.4.2 Allopurinol is contraindicated; and
      2.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
3 The patient is receiving monthly liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at www.rheumatology.org.nz/home/resources-2/

COLCHICINE
- Tab 500 mcg – 1% DV Jan-19 to 2021.........................................................9.58 100 Colgout

FEBUXOSTAT – Restricted see terms below
- Tab 80 mg.................................................................39.50 28 Adenuric
- Tab 120 mg.................................................................39.50 28 Adenuric

Initiation
Any specialist
Both:
1 Patient has been diagnosed with gout; and
2 Any of the following:
   2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note).
continued…

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

PROBENECID

Tab 500 mg

RASBURICASE – Restricted see terms below

- Inj 1.5 mg vial

- Restricted (RS1016)

Haematologist

### Muscle Relaxants and Related Agents

<table>
<thead>
<tr>
<th>Medication</th>
<th>Formulation</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATRACURIUM BESYLALE</td>
<td>Inj 10 mg per ml, 2.5 ml ampoule – 1% DV Jun-18 to 2021</td>
<td>Tracrium</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 5 ml ampoule – 1% DV Jun-18 to 2021</td>
<td>Tracrium</td>
</tr>
<tr>
<td>BACLOFEN</td>
<td>Tab 10 mg – 1% DV Oct-18 to 2021</td>
<td>Pacifen</td>
</tr>
<tr>
<td></td>
<td>Oral liq 1 mg per ml</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 0.05 mg per ml, 1 ml ampoule</td>
<td>Lioresal Intrathecal</td>
</tr>
<tr>
<td></td>
<td>Inj 2 mg per ml, 5 ml ampoule – 1% DV Apr-19 to 2021</td>
<td>Medsurge</td>
</tr>
<tr>
<td>CLOSTRIUM BOUTULUM TYPE A TOXIN</td>
<td>Inj 100 u vial</td>
<td>Botox</td>
</tr>
<tr>
<td></td>
<td>Inj 300 u vial</td>
<td>Dysport</td>
</tr>
<tr>
<td></td>
<td>Inj 500 u vial</td>
<td>Dysport</td>
</tr>
<tr>
<td>DANTROLENE</td>
<td>Cap 25 mg</td>
<td>Dantrium</td>
</tr>
<tr>
<td></td>
<td>Cap 50 mg</td>
<td>Dantrium</td>
</tr>
<tr>
<td></td>
<td>Inj 20 mg vial</td>
<td>Dantrium IV</td>
</tr>
<tr>
<td>MIVACURIUM CHLORIDE</td>
<td>Inj 2 mg per ml, 5 ml ampoule</td>
<td>Mivacron</td>
</tr>
<tr>
<td></td>
<td>Inj 2 mg per ml, 10 ml ampoule</td>
<td>Mivacron</td>
</tr>
<tr>
<td>ORPHENADRINE CITRATE</td>
<td>Tab 100 mg – 1% DV Jun-18 to 2021</td>
<td>Norflex</td>
</tr>
<tr>
<td>PANCRURONIUM BROMIDE</td>
<td>Inj 2 mg per ml, 2 ml ampoule</td>
<td></td>
</tr>
<tr>
<td>ROCURONIUM BROMIDE</td>
<td>Inj 10 mg per ml, 5 ml ampoule – 1% DV Aug-20 to 2022</td>
<td>Hameln</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 5 ml vial</td>
<td>DBL Rocuronium Bromide</td>
</tr>
<tr>
<td>(DBL Rocuronium Bromide Inj 10 mg per ml, 5 ml vial to be delisted 1 August 2020)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SUXAMETHONIUM CHLORIDE</td>
<td>Inj 50 mg per ml, 2 ml ampoule – 1% DV Nov-17 to 2020</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>VECURONIUM BROMIDE</td>
<td>Inj 10 mg vial</td>
<td></td>
</tr>
</tbody>
</table>
Reversers of Neuromuscular Blockade

SUGAMMADEX – Restricted see terms below

- Inj 100 mg per ml, 2 ml vial .......................................................................................... 1,200.00 10 Bridion
- Inj 100 mg per ml, 5 ml vial .......................................................................................... 3,000.00 10 Bridion

Initiation

Any of the following:

1. Patient requires reversal of profound neuromuscular blockade following rapid sequence induction that has been undertaken using rocuronium (i.e. suxamethonium is contraindicated or undesirable); or
2. Severe neuromuscular degenerative disease where the use of neuromuscular blockade is required; or
3. Patient has an unexpectedly difficult airway that cannot be intubated and requires a rapid reversal of anaesthesia and neuromuscular blockade; or
4. The duration of the patient’s surgery is unexpectedly short; or
5. Neostigmine or a neostigmine/anticholinergic combination is contraindicated (for example the patient has ischaemic heart disease, morbid obesity or COPD); or
6. Patient has a partial residual block after conventional reversal.

Non-Steroidal Anti-Inflammatory Drugs

CELECOXIB

Note - The DV limit of 1% applies to the celecoxib chemical rather than each individual line item.

- Cap 100 mg .................................................................................................................. 3.63 60 Celecoxib Pfizer
- Cap 200 mg – 1% DV Aug-17 to 2020 ........................................................................ 2.30 30 Celecoxib Pfizer

DICLOFENAC SODIUM

- Tab EC 25 mg – 1% DV Oct-18 to 2021 .................................................................. 1.23 50 Diclofenac Sandoz
- Tab 50 mg dispersible ................................................................................................. 1.50 20 Voltaren D
- Tab EC 50 mg – 1% DV Oct-18 to 2021 .................................................................. 1.23 50 Diclofenac Sandoz
- Tab long-acting 75 mg – 1% DV Oct-18 to 2021 ...................................................... 22.80 500 Apo-Diclo SR
- Tab long-acting 100 mg – 1% DV Oct-18 to 2021 ..................................................... 25.15 500 Apo-Diclo SR
- Inj 25 mg per ml, 3 ml ampoule ................................................................................. 13.20 5 Voltaren
- Suppos 12.5 mg .......................................................................................................... 2.04 10 Voltaren
- Suppos 25 mg ............................................................................................................. 2.44 10 Voltaren
- Suppos 50 mg ............................................................................................................. 4.22 10 Voltaren
- Suppos 100 mg .......................................................................................................... 7.00 10 Voltaren

ETORICOXIB – Restricted see terms below

- Tab 30 mg
- Tab 60 mg
- Tab 90 mg
- Tab 120 mg

Initiation

For in-vivo investigation of allergy only.
### MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IBUPROFEN</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg – 1% DV Feb-18 to 2020</td>
<td>11.71 1,000 Relieve</td>
</tr>
<tr>
<td>Tab 400 mg – <strong>Restricted</strong>: For continuation only</td>
<td></td>
</tr>
<tr>
<td>Tab 600 mg – <strong>Restricted</strong>: For continuation only</td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 800 mg – 1% DV Apr-20 to 2021</td>
<td>7.99 30 Brufen SR</td>
</tr>
<tr>
<td>Oral liq 20 mg per ml – 1% DV May-19 to 2021</td>
<td>1.88 200 ml Ethics</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 2 ml ampoule</td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 2 ml vial</td>
<td></td>
</tr>
</tbody>
</table>

*(Brufen SR Tab long-acting 800 mg to be delisted 1 April 2020)*

<table>
<thead>
<tr>
<th><strong>INDOMETHACIN</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 25 mg</td>
<td></td>
</tr>
<tr>
<td>Cap 50 mg</td>
<td></td>
</tr>
<tr>
<td>Cap long-acting 75 mg</td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg vial</td>
<td></td>
</tr>
<tr>
<td>Suppos 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>KETOPROFEN</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap long-acting 200 mg</td>
<td>12.07 28 Oruvail SR</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>MEFENAMIC ACID</strong> – <strong>Restricted</strong>: For continuation only</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 250 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>NAPROXEN</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg – 1% DV Dec-18 to 2021</td>
<td>32.69 500 Noflam 250</td>
</tr>
<tr>
<td>Tab 500 mg – 1% DV Dec-18 to 2021</td>
<td>22.19 250 Noflam 500</td>
</tr>
<tr>
<td>Tab long-acting 750 mg – 1% DV Oct-18 to 2021</td>
<td>6.16 28 Naprosyn SR 750</td>
</tr>
<tr>
<td>Tab long-acting 1 g – 1% DV Oct-18 to 2021</td>
<td>8.21 28 Naprosyn SR 1000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>PARECOXIB</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 40 mg vial</td>
<td>100.00 10 Dynastat</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>SULINDAC</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>TENOXICAM</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 20 mg – 1% DV Oct-19 to 2022</td>
<td>9.15 100 Tilcotil</td>
</tr>
<tr>
<td>Inj 20 mg vial</td>
<td>9.95 1 AFT</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Topical Products for Joint and Muscular Pain</strong></th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>CAPSAICIN</strong> – <strong>Restricted</strong> see terms below</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 0.025%........................................</td>
<td>9.95 45 g Zostrix</td>
</tr>
<tr>
<td><strong>Restricted</strong> <em>(RS1309)</em></td>
<td></td>
</tr>
</tbody>
</table>

### Initiation

Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.
## Agents for Parkinsonism and Related Disorders

### Agents for Essential Tremor, Chorea and Related Disorders

**RILUZOLE** – Restricted see terms below

<table>
<thead>
<tr>
<th>Tab 50 mg – 1% DV Aug-18 to 2021</th>
<th>$130.00</th>
<th>56</th>
<th>Rilutek</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initiation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurologist or respiratory specialist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Re-assessment required after 6 months</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All of the following:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 The patient has not undergone a tracheostomy; and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 The patient has not experienced respiratory failure; and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Any of the following:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.1 The patient is ambulatory; or</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.2 The patient is able to use upper limbs; or</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.3 The patient is able to swallow.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Continuation**

**Re-assessment required after 18 months**

| All of the following:           |         |     |        |
| 1 The patient has not undergone a tracheostomy; and | | | |
| 2 The patient has not experienced respiratory failure; and | | | |
| 3 Any of the following:         |         |     |        |
| 3.1 The patient is ambulatory; or | | | |
| 3.2 The patient is able to use upper limbs; or | | | |
| 3.3 The patient is able to swallow. | | | |

**TETRABENAZINE**

<table>
<thead>
<tr>
<th>Tab 25 mg – 1% DV Oct-19 to 2022</th>
<th>$91.10</th>
<th>112</th>
<th>Motetis</th>
</tr>
</thead>
</table>

### Anticholinergics

**BENZATROPINE MESYLA TE**

<table>
<thead>
<tr>
<th>Tab 2 mg</th>
<th>$7.99</th>
<th>60</th>
<th>Benztrop</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg per ml, 2 ml ampoule</td>
<td>$95.00</td>
<td>5</td>
<td>Cogentin</td>
</tr>
</tbody>
</table>

**PROCYCLIDINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Tab 5 mg</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
</table>

### Dopamine Agonists and Related Agents

**AMANTADINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Cap 100 mg</th>
<th>$38.24</th>
<th>60</th>
<th>Symmetrel</th>
</tr>
</thead>
</table>

**APOMORPHINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Inj 10 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2023</th>
<th>$59.50</th>
<th>5</th>
<th>Movapo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 5 ml ampoule – 1% DV Feb-20 to 2023</td>
<td>$121.84</td>
<td>5</td>
<td>Movapo</td>
</tr>
</tbody>
</table>

**BROMOCRIPTINE**

<table>
<thead>
<tr>
<th>Tab 2.5 mg</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 5 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Products with Hospital Supply Status (HSS) are in bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENTACAPONE</strong></td>
<td>Tab 200 mg – 1% DV Sep-18 to 2021</td>
<td>$22.00</td>
<td>Entapone</td>
</tr>
<tr>
<td><strong>LEVODOPA WITH BENSERAZIDE</strong></td>
<td>Tab dispersible 50 mg with benserazide 12.5 mg</td>
<td>$13.25</td>
<td>Madopar Rapid</td>
</tr>
<tr>
<td></td>
<td>Cap 50 mg with benserazide 12.5 mg</td>
<td>$13.75</td>
<td>Madopar 62.5</td>
</tr>
<tr>
<td></td>
<td>Cap 100 mg with benserazide 25 mg</td>
<td>$15.80</td>
<td>Madopar 125</td>
</tr>
<tr>
<td></td>
<td>Cap long-acting 100 mg with benserazide 25 mg</td>
<td>$22.85</td>
<td>Madopar HBS</td>
</tr>
<tr>
<td></td>
<td>Cap 200 mg with benserazide 50 mg</td>
<td>$26.25</td>
<td>Madopar 250</td>
</tr>
<tr>
<td><strong>LEVODOPA WITH CARBIDOPA</strong></td>
<td>Tab 100 mg with carbidopa 25 mg – 1% DV Feb-18 to 2020</td>
<td>$17.97</td>
<td>Sinemet</td>
</tr>
<tr>
<td></td>
<td>Tab long-acting 100 mg with carbidopa 25 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 250 mg with carbidopa 25 mg – 1% DV Feb-18 to 2020</td>
<td>$37.15</td>
<td>Sinemet CR</td>
</tr>
<tr>
<td><strong>PRAMIPEXOLE HYDROCHLORIDE</strong></td>
<td>Tab 0.25 mg – 1% DV Oct-19 to 2022</td>
<td>$6.12</td>
<td>Ramipex</td>
</tr>
<tr>
<td></td>
<td>Tab 1 mg – 1% DV Oct-19 to 2022</td>
<td>$20.73</td>
<td>Ramipex</td>
</tr>
<tr>
<td><strong>ROPINIROLE HYDROCHLORIDE</strong></td>
<td>Tab 0.25 mg – 1% DV Mar-20 to 2022</td>
<td>$2.85</td>
<td>Ropin</td>
</tr>
<tr>
<td></td>
<td>Tab 1 mg – 1% DV Mar-20 to 2022</td>
<td>$3.95</td>
<td>Ropin</td>
</tr>
<tr>
<td></td>
<td>Tab 2 mg – 1% DV Mar-20 to 2022</td>
<td>$5.48</td>
<td>Ropin</td>
</tr>
<tr>
<td></td>
<td>Tab 5 mg – 1% DV Mar-20 to 2022</td>
<td>$12.50</td>
<td>Ropin</td>
</tr>
<tr>
<td><strong>SELEGILINE HYDROCHLORIDE</strong></td>
<td>Tab 5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOLCAPONE</strong></td>
<td>Tab 100 mg</td>
<td>$152.38</td>
<td>Tasmar</td>
</tr>
</tbody>
</table>

### Anaesthetics

#### General Anaesthetics

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DESFLURANE</strong></td>
<td>Soln for inhalation 100%, 240 ml bottle – 1% DV Sep-16 to 2020</td>
<td>$1,350.00</td>
<td>Suprane</td>
</tr>
<tr>
<td><strong>DEXMEDETOMIDINE</strong></td>
<td>Inj 100 mcg per ml, 2 ml vial – 1% DV Sep-17 to 2020</td>
<td>$357.00</td>
<td>Precedex</td>
</tr>
<tr>
<td><strong>ETOMIDATE</strong></td>
<td>Inj 2 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ISOFLURANE</strong></td>
<td>Soln for inhalation 100%, 250 ml bottle – 1% DV Sep-16 to 2020</td>
<td>$1,020.00</td>
<td>Aerrane</td>
</tr>
<tr>
<td><strong>KETAMINE</strong></td>
<td>Inj 1 mg per ml, 100 ml bag – 1% DV Feb-20 to 2022</td>
<td>$270.00</td>
<td>Biomed</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 10 ml syringe – 1% DV Feb-20 to 2022</td>
<td>$70.00</td>
<td>Biomed</td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 2 ml vial – 1% DV Jan-19 to 2021</td>
<td>$31.50</td>
<td>Ketalar</td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 2 ml vial – 1% DV Jan-19 to 2021</td>
<td>$155.60</td>
<td>Ketamine-Claris</td>
</tr>
<tr>
<td>** METHOHEXITAL SODIUM**</td>
<td>Inj 10 mg per ml, 50 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PROPOFOL</strong></td>
<td>Inj 10 mg per ml, 20 ml ampoule – 10% DV Dec-19 to 2022</td>
<td>$4.35</td>
<td>Fresofol 1% MCT/LCT</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 50 ml vial – 10% DV Oct-19 to 2022</td>
<td>$19.50</td>
<td>Fresofol 1% MCT/LCT</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 100 ml vial – 10% DV Oct-19 to 2022</td>
<td>$39.00</td>
<td>Fresofol 1% MCT/LCT</td>
</tr>
</tbody>
</table>
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th><strong>SEVOFLURANE</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Soln for inhalation 100%, 250 ml bottle</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Sep-16 to 2020</strong></td>
<td>840.00</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Baxter</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>THIOPENTAL [THIOPENTONE] SODIUM</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 500 mg ampoule</td>
<td></td>
</tr>
</tbody>
</table>

#### Local Anaesthetics

<table>
<thead>
<tr>
<th><strong>ARTICAINE HYDROCHLORIDE</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ARTICAINE HYDROCHLORIDE WITH ADRENALINE</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge</td>
<td></td>
</tr>
<tr>
<td>Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge</td>
<td></td>
</tr>
<tr>
<td>Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge</td>
<td></td>
</tr>
<tr>
<td>Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>BENZOCAINE</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel 20%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>BENZOCAINE WITH TETRACAINE HYDROCHLORIDE</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel 18% with tetracaine hydrochloride 2%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>BUPIVACAINE HYDROCHLORIDE</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 mg per ml, 4 ml ampoule</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Sep-17 to 2020</strong></td>
<td>50.00</td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 20 ml ampoule</td>
<td></td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 20 ml ampoule sterile pack</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Sep-17 to 2020</strong></td>
<td>29.20</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml ampoule sterile pack</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Sep-17 to 2020</strong></td>
<td>20.25</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 20 ml ampoule</td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 20 ml ampoule sterile pack</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Sep-17 to 2020</strong></td>
<td>20.70</td>
</tr>
<tr>
<td>Inj 1.25 mg per ml, 100 ml bag</td>
<td></td>
</tr>
<tr>
<td>Inj 1.25 mg per ml, 200 ml bag</td>
<td></td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 100 ml bag</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Sep-17 to 2020</strong></td>
<td>150.00</td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 200 ml bag</td>
<td></td>
</tr>
<tr>
<td>Inj 1.25 mg per ml, 500 ml bag</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Aug-19 to 2022</strong></td>
<td>94.50</td>
</tr>
<tr>
<td>Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Aug-19 to 2022</strong></td>
<td>80.50</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>BUPIVACAINE HYDROCHLORIDE WITH FENTANYL</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag</td>
<td></td>
</tr>
<tr>
<td>Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Apr-20 to 2022</strong></td>
<td>305.00</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe</td>
<td></td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Nov-19 to 2022</strong></td>
<td>225.00</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Nov-19 to 2022</strong></td>
<td>235.00</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe</td>
<td></td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Nov-19 to 2022</strong></td>
<td>72.00</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe</td>
<td></td>
</tr>
<tr>
<td><strong>– 1% DV Nov-19 to 2022</strong></td>
<td>92.00</td>
</tr>
<tr>
<td>Brand or Generic Manufacturer</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td></td>
</tr>
</tbody>
</table>

**NERVOUS SYSTEM**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
</table>

### BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE
- Inj 0.5% with glucose 8%, 4 ml ampoule
  - $38.00
  - 5 Marcain Heavy

### COCAINE HYDROCHLORIDE
- Paste 5%
  - Soln 15%, 2 ml syringe
  - Soln 4%, 2 ml syringe
  - $25.46
  - 1 Biomed

### COCAINE HYDROCHLORIDE WITH ADRENALINE
- Paste 15% with adrenaline 0.06%
- Paste 25% with adrenaline 0.06%

### ETHYL CHLORIDE
- Spray 100%

### LIDOCAINE [LIGNOCAINE]
- Crm 4%
  - $5.40
  - 5 g LMX4
  - 27.00
  - 30 g LMX4

### LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE
- Gel 2% – 1% DV Nov-18 to 2021
  - $4.87
  - 20 g Orion
- Soln 4%
  - $75.00
  - 50 ml Xylocaine
- Oral (gel) soln 2% – 1% DV Oct-17 to 2020
  - $38.00
  - 200 ml Mucosoothe
- Inj 1%, 20 ml ampoule, sterile pack
- Inj 2%, 20 ml ampoule, sterile pack
- Inj 1%, 5 ml ampoule
  - $8.75
  - 25 Lidoceone-Claris
- Inj 1%, 20 ml vial – 1% DV Jul-19 to 2022
  - $6.20
  - 5 Lidoceone-Claris
- Inj 2%, 5 ml ampoule – 1% DV Nov-19 to 2022
  - $8.25
  - 25 Lidoceone-Claris
- Inj 2%, 20 ml vial – 1% DV Jul-19 to 2022
  - $6.45
  - 5 Lidoceone-Claris
- Gel 2%, 10 ml urethral syringe – 1% DV Nov-19 to 2022
  - $105.00
  - 25 Cathejell
- Gel 2%, 11 ml urethral syringe – 1% DV Apr-20 to 2022
  - $42.00
  - 10 Instillagel Lido

*Cathejell Gel 2%, 10 ml urethral syringe to be delisted 1 April 2020*

### LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE
- Inj 1% with adrenaline 1:100,000, 5 ml ampoule – 1% DV Nov-19 to 2022
  - $29.00
  - 10 Xylocaine
- Inj 1% with adrenaline 1:200,000, 20 ml vial
  - $50.00
  - 5 Xylocaine
- Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge
- Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge
- Inj 2% with adrenaline 1:100,000, 5 ml ampoule
  - $60.00
  - 5 Xylocaine

### LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH TETRACAINE HYDROCHLORIDE
- Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – 1% DV Sep-17 to 2020
  - $17.50
  - 1 Topicaine

### LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINE
- Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe
  - $81.50
  - 10 Pfizer

### LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRINE HYDROCHLORIDE
- Nasal spray 5% with phenylephrine hydrochloride 0.5%

### LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE
- Crm 2.5% with prilocaine 2.5%
  - $45.00
  - 30 g EMLA
- Patch 25 mcg with prilocaine 25 mcg
  - $115.00
  - 20 EMLA
- Crm 2.5% with prilocaine 2.5%, 5 g
  - $45.00
  - 5 EMLA

### MEPIVACAINE HYDROCHLORIDE
- Inj 3%, 1.8 ml dental cartridge
  - $43.60
  - 50 Scandonest 3%
- Inj 3%, 2.2 ml dental cartridge
  - $43.60
  - 50 Scandonest 3%
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRILOCAINE HYDROCHLORIDE</td>
</tr>
<tr>
<td>Inj 0.5%, 50 ml vial .................................................... 100.00 5 Citanest</td>
</tr>
<tr>
<td>Inj 2%, 5 ml ampoule</td>
</tr>
<tr>
<td>PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN</td>
</tr>
<tr>
<td>Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge</td>
</tr>
<tr>
<td>ROPIVACAINE HYDROCHLORIDE</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020 .............. 8.80 5 Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020 .............. 9.20 5 Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 100 ml bag – 1% DV Sep-17 to 2020 ................. 29.50 5 Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 200 ml bag – 1% DV Sep-17 to 2020 ................. 39.00 5 Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 7.5 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020 .............. 9.90 5 Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 7.5 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020 .............. 12.15 5 Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020 .............. 10.55 5 Ropivacaine Kabi</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020 .............. 15.80 5 Ropivacaine Kabi</td>
</tr>
<tr>
<td>ROPIVACAINE HYDROCHLORIDE WITH FENTANYL</td>
</tr>
<tr>
<td>Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag ...................... 198.50 5 Naropin</td>
</tr>
<tr>
<td>Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag ...................... 270.00 5 Naropin</td>
</tr>
<tr>
<td>TETRACAINE [AMETHOCAINE] HYDROCHLORIDE</td>
</tr>
<tr>
<td>Gel 4%</td>
</tr>
</tbody>
</table>

Analgesics

Non-Opioid Analgesics

ASPIRIN
Tab dispersible 300 mg – 1% DV Oct-19 to 2022 ...................................... 4.50 100 Ethics Aspirin

CAPSICIN – Restricted see terms below
Crtn 0.075% ........................................................................... 12.50 45 g Zostrix HP

Restricted (RS1145)
Initiation
For post-herpetic neuralgia or diabetic peripheral neuropathy.

 METHOXYFLURANE – Restricted see terms below
Soln for inhalation 99.9%, 3 ml bottle
Restricted (RS1292)
Initiation
Both:
1 Patient is undergoing a painful procedure with an expected duration of less than one hour; and
2 Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane.

NEFOPAM HYDROCHLORIDE
Tab 30 mg
## NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ex man. excl. GST) $ Per</td>
<td></td>
</tr>
</tbody>
</table>

### PARACETAMOL – Some items restricted see terms below

Tab soluble 500 mg
- Oral liq 120 mg per 5 ml – 1% DV Dec-17 to 2020
  - 5.35 1,000 ml Paracare
- Oral liq 250 mg per 5 ml – 20% DV Aug-18 to 2020
  - 5.81 1,000 ml Paracare Double Strength

✈️ | Inj 10 mg per ml, 100 ml vial – 1% DV Sep-17 to 2020
- Suppos 25 mg – 1% DV Nov-19 to 2022
  - 58.50 20 Biomed
- Suppos 50 mg – 1% DV Nov-19 to 2022
  - 58.50 20 Biomed
- Suppos 125 mg – 1% DV Nov-18 to 2021
  - 3.29 10 Gacet
- Suppos 250 mg – 1% DV Nov-18 to 2021
  - 3.79 10 Gacet
- Suppos 500 mg – 1% DV Feb-19 to 2021
  - 12.40 50 Gacet

✈️ | Restricted (RS1146)
Initiation
Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours.

### Opioid Analgesics

#### ALFENTANIL
- Inj 0.5 mg per ml, 2 ml ampoule – 1% DV Sep-17 to 2020
  - 34.38 10 Hameln

#### CODEINE PHOSPHATE
- Tab 15 mg
  - 5.75 100 PSM
- Tab 30 mg
  - 6.80 100 PSM
- Tab 60 mg
  - 13.50 100 PSM

#### DIHYDROCODEINE TARTRATE
- Tab long-acting 60 mg – 1% DV Oct-19 to 2022
  - 8.60 60 DHC Continus

#### FENTANYL
- Inj 10 mcg per ml, 10 ml syringe
  - 3.56 10 Boucher and Muir
- Inj 50 mcg per ml, 2 ml ampoule – 1% DV Nov-18 to 2021
  - 210.00 10 Biomed
- Inj 10 mcg per ml, 50 ml bag
  - 165.00 10 Biomed
- Inj 50 mcg per ml, 10 ml ampoule – 1% DV Nov-18 to 2021
  - 9.41 10 Boucher and Muir
- Inj 10 mcg per ml, 100 ml bag – 1% DV Nov-19 to 2022
  - 220.00 10 Biomed
- Inj 20 mcg per ml, 50 ml syringe – 1% DV Oct-18 to 2021
  - 18.74 1 Biomed
- Inj 20 mcg per ml, 100 ml bag
- Patch 12.5 mcg per hour – 1% DV Oct-17 to 2020
  - 2.95 5 Fentanyl Sandoz
- Patch 25 mcg per hour – 1% DV Oct-17 to 2020
  - 3.66 5 Fentanyl Sandoz
- Patch 50 mcg per hour – 1% DV Oct-17 to 2020
  - 6.65 5 Fentanyl Sandoz
- Patch 75 mcg per hour – 1% DV Oct-17 to 2020
  - 9.25 5 Fentanyl Sandoz
- Patch 100 mcg per hour – 1% DV Oct-17 to 2020
  - 11.40 5 Fentanyl Sandoz

#### METHADONE HYDROCHLORIDE
- Tab 5 mg – 1% DV Sep-19 to 2022
  - 1.40 10 Methatabs
- Oral liq 2 mg per ml – 1% DV Oct-18 to 2021
  - 5.79 200 ml Biodone
- Oral liq 5 mg per ml – 1% DV Oct-18 to 2021
  - 5.79 200 ml Biodone Forte
- Oral liq 10 mg per ml – 1% DV Oct-18 to 2021
  - 6.79 200 ml Biodone Extra Forte
- Inj 10 mg per ml, 1 ml vial
  - 61.00 10 AFT
# NERVOUS SYSTEM

| Brand or Generic Manufacturer | Products with Hospital Supply Status (HSS) are in bold | Expiry date of HSS period is 30 June of the year indicated unless otherwise stated. |

## MORPHINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 1 mg per ml – 1% DV Dec-18 to 2021</td>
<td>$9.28 200 ml</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml – 1% DV Dec-18 to 2021</td>
<td>$16.24 200 ml</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml – 1% DV Dec-18 to 2021</td>
<td>$19.44 200 ml</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml – 1% DV Dec-18 to 2021</td>
<td>$27.74 200 ml</td>
</tr>
</tbody>
</table>

## MORPHINE SULPHATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab long-acting 10 mg</td>
<td>$1.93 10 Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab immediate-release 10 mg – 1% DV Sep-17 to 2020</td>
<td>$2.80 10 Sevredol</td>
</tr>
<tr>
<td>Tab immediate-release 20 mg – 1% DV Sep-17 to 2020</td>
<td>$5.52 10 Sevredol</td>
</tr>
<tr>
<td>Tab long-acting 30 mg</td>
<td>$2.85 10 Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab long-acting 60 mg</td>
<td>$5.60 10 Arrow-Morphine LA</td>
</tr>
<tr>
<td>Cap long-acting 10 mg – 1% DV Jan-20 to 2022</td>
<td>$2.05 10 m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 30 mg – 1% DV Jan-20 to 2022</td>
<td>$3.00 10 m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 60 mg – 1% DV Jan-20 to 2022</td>
<td>$6.12 10 m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 100 mg – 1% DV Jan-20 to 2022</td>
<td>$7.13 10 m-Eslon</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag – 1% DV Oct-17 to 2020</td>
<td>$97.25 5 Biomed</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml syringe – 1% DV Oct-17 to 2020</td>
<td>$24.00 5 Biomed</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 50 ml syringe – 1% DV Oct-17 to 2020</td>
<td>$50.75 5 Biomed</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 2 ml syringe</td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 30 ml syringe</td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$135.00 5 DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$4.47 5 DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 mg cassette</td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml bag</td>
<td></td>
</tr>
<tr>
<td>Inj 15 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$4.76 5 DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 30 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$6.19 5 DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 200 mcg in 0.4 ml syringe</td>
<td></td>
</tr>
<tr>
<td>Inj 300 mcg in 0.3 ml syringe</td>
<td></td>
</tr>
</tbody>
</table>

## MORPHINE TARTRATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 80 mg per ml, 1.5 ml ampoule</td>
<td>$42.72 5 DBL Morphine Tartrate</td>
</tr>
</tbody>
</table>

(DBL Morphine Tartrate Inj 80 mg per ml, 1.5 ml ampoule to be delisted 1 September 2020)

## OXYCODONE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab controlled-release 5 mg – 1% DV May-19 to 2021</td>
<td>$2.15 20 Oxycodone Sandoz</td>
</tr>
<tr>
<td>Tab controlled-release 10 mg – 1% DV May-19 to 2021</td>
<td>$2.15 20 Oxycodone Sandoz</td>
</tr>
<tr>
<td>Tab controlled-release 20 mg – 1% DV May-19 to 2021</td>
<td>$2.15 20 Oxycodone Sandoz</td>
</tr>
<tr>
<td>Tab controlled-release 40 mg – 1% DV May-19 to 2021</td>
<td>$3.20 20 Oxycodone Sandoz</td>
</tr>
<tr>
<td>Tab controlled-release 80 mg – 1% DV May-19 to 2021</td>
<td>$10.98 20 Oxycodone Sandoz</td>
</tr>
<tr>
<td>Cap immediate-release 5 mg – 1% DV Sep-18 to 2021</td>
<td>$2.15 20 Oxynorm</td>
</tr>
<tr>
<td>Cap immediate-release 10 mg – 1% DV Sep-18 to 2021</td>
<td>$3.20 20 Oxynorm</td>
</tr>
<tr>
<td>Cap immediate-release 20 mg – 1% DV Sep-18 to 2021</td>
<td>$5.81 20 Oxynorm</td>
</tr>
<tr>
<td>Oral liq 5 mg per 5 ml</td>
<td>$11.20 250 ml Oxynorm</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag</td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>$7.28 5 Oxynorm</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 2 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>$14.36 5 Oxynorm</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>$30.60 5 Oxynorm</td>
</tr>
<tr>
<td>NERVOUS SYSTEM</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td></td>
</tr>
<tr>
<td><strong>Price</strong></td>
<td><strong>Brand or Generic Manufacturer</strong></td>
</tr>
<tr>
<td>(ex man. excl. GST)</td>
<td>$</td>
</tr>
</tbody>
</table>

### PARACETAMOL WITH CODEINE
Tab paracetamol 500 mg with codeine phosphate 8 mg – 1% DV

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$18.21</td>
<td>Paracetamol + Codeine (Relieve)</td>
</tr>
</tbody>
</table>

### PETHIDINE HYDROCHLORIDE
Tab 50 mg – 1% DV Sep-18 to 2021

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.46</td>
<td>PSM</td>
</tr>
</tbody>
</table>

**Inj**
- 5 mg per ml, 10 ml syringe
- 5 mg per ml, 100 ml bag
- 10 mg per ml, 100 ml bag
- 10 mg per ml, 50 ml syringe
- 50 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.98</td>
<td>DBL Pethidine Hydrochloride</td>
</tr>
<tr>
<td>$5.12</td>
<td>DBL Pethidine Hydrochloride</td>
</tr>
</tbody>
</table>

### REMIFENTANIL

**Inj**
- 1 mg vial – 1% DV Oct-17 to 2020
- 2 mg vial – 1% DV Oct-17 to 2020

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$13.95</td>
<td>Remifentanil-AFT</td>
</tr>
<tr>
<td>$19.95</td>
<td>Remifentanil-AFT</td>
</tr>
</tbody>
</table>

### TRAMADOL HYDROCHLORIDE

**Tab sustained-release**
- 100 mg – 1% DV Sep-17 to 2020
- 150 mg – 1% DV Sep-17 to 2020
- 200 mg – 1% DV Sep-17 to 2020

**Cap**
- 50 mg – 1% DV Sep-17 to 2020

**Inj**
- 10 mg per ml, 1 ml ampoule
- 50 mg per ml, 1 ml ampoule
- 50 mg per ml, 2 ml ampoule

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1.55</td>
<td>Tramal SR 100</td>
</tr>
<tr>
<td>$2.10</td>
<td>Tramal SR 100</td>
</tr>
<tr>
<td>$2.75</td>
<td>Tramal SR 100</td>
</tr>
</tbody>
</table>

### Antidepressants

#### Cyclic and Related Agents

### AMITRIPTYLINE
Tab 10 mg – 1% DV Apr-18 to 2020
Tab 25 mg – 1% DV Apr-18 to 2020
Tab 50 mg – 1% DV Apr-18 to 2020

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1.96</td>
<td>Arrow-Amritptyline</td>
</tr>
<tr>
<td>$1.52</td>
<td>Arrow-Amritptyline</td>
</tr>
<tr>
<td>$2.51</td>
<td>Arrow-Amritptyline</td>
</tr>
</tbody>
</table>

### CLOMIPRAMINE HYDROCHLORIDE
Tab 10 mg – 1% DV Oct-18 to 2021
Tab 25 mg – 1% DV Oct-18 to 2021

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$13.99</td>
<td>Apo-Clomipramine</td>
</tr>
<tr>
<td>$9.46</td>
<td>Apo-Clomipramine</td>
</tr>
</tbody>
</table>

### DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE – **Restricted:** For continuation only

- **Tab** 75 mg
- **Cap** 25 mg

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$11.19</td>
<td>Dopress</td>
</tr>
<tr>
<td>$7.83</td>
<td>Dosulepin Mylan</td>
</tr>
</tbody>
</table>

*(Dopress Tab 75 mg to be delisted 1 August 2020)*

### DOXEPIHYDROCHLORIDE – **Restricted:** For continuation only

- **Cap** 10 mg
- **Cap** 25 mg
- **Cap** 50 mg

### IMIPRAMINE HYDROCHLORIDE
Tab 10 mg – 1% DV Oct-18 to 2021
Tab 25 mg – 1% DV Oct-18 to 2021

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5.48</td>
<td>Tofranil</td>
</tr>
<tr>
<td>$6.58</td>
<td>Tofranil</td>
</tr>
<tr>
<td>$8.80</td>
<td>Tofranil</td>
</tr>
</tbody>
</table>

---

*Item restricted (see ➔ above); Item restricted (see ➔ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
## NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### MAPROTILOLINE HYDROCHLORIDE
- Tab 25 mg
- Tab 75 mg

### MIANSERIN HYDROCHLORIDE – Restricted: For continuation only
- Tab 30 mg

### NORTRIPTYLINE HYDROCHLORIDE
- Tab 10 mg – 1% DV Oct-19 to 2022: 2.44 100 Norpress
- Tab 25 mg – 1% DV Oct-19 to 2022: 5.98 180 Norpress

## Monoamine-Oxidase Inhibitors - Non-Selective

### PHENELZINE SULPHATE
- Tab 15 mg

### TRANSLYMPROMINE SULPHATE
- Tab 10 mg

### Monoamine-Oxidase Type A Inhibitors

### MOCLOBEMIDE
- Tab 150 mg – 1% DV Apr-19 to 2021: 6.40 60 Aurorix
- Tab 300 mg – 1% DV Apr-19 to 2021: 9.80 60 Aurorix

### Other Antidepressants

### MIRTAZAPINE
- Tab 30 mg – 1% DV Oct-18 to 2021: 2.63 30 Apo-Mirtazapine
- Tab 45 mg – 1% DV Oct-18 to 2021: 3.48 30 Apo-Mirtazapine

### VENLAFAXINE
- Cap 37.5 mg – 1% DV Jun-17 to 2020: 6.38 84 Enlafax XR
- Cap 75 mg – 1% DV Jun-17 to 2020: 8.11 84 Enlafax XR
- Cap 150 mg – 1% DV Jun-17 to 2020: 11.16 84 Enlafax XR

## Selective Serotonin Reuptake Inhibitors

### CITALOPRAM HYDROBROMIDE
- Tab 20 mg – 1% DV Sep-18 to 2021: 1.52 84 PSM Citalopram

### ESCITALOPRAM
- Tab 10 mg – 1% DV Dec-17 to 2020: 1.11 28 Escitalopram-Apotex
- Tab 20 mg – 1% DV Dec-17 to 2020: 1.90 28 Escitalopram-Apotex

### FLUOXETINE HYDROCHLORIDE
- Tab dispersible 20 mg, scored: 2.47 30 Arrow-Fluoxetine
- Cap 20 mg: 7.49 90 Arrow-Fluoxetine

### PAROXETINE
- Tab 20 mg – 1% DV Mar-20 to 2022: 3.61 90 Loxamine

### SERTRALINE
- Tab 50 mg – 1% DV Mar-20 to 2022: 0.92 30 Setrona
- Tab 100 mg – 1% DV Mar-20 to 2022: 1.61 30 Setrona
NERVOUS SYSTEM

### Antiepilepsy Drugs

#### Agents for the Control of Status Epilepticus

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLONAZEPAM</strong></td>
<td>Inj 1 mg per ml, 1 ml ampoule</td>
<td>$21.00</td>
<td>5 Rivotril</td>
</tr>
<tr>
<td><strong>DIAZEPAM</strong></td>
<td>Inj 5 mg per ml, 2 ml ampoule</td>
<td>$11.83</td>
<td>5 Hospira</td>
</tr>
<tr>
<td></td>
<td>Rectal tubes 5 mg</td>
<td>$40.87</td>
<td>5 Stesolid</td>
</tr>
<tr>
<td></td>
<td>Rectal tubes 10 mg</td>
<td>$40.87</td>
<td>5 Stesolid</td>
</tr>
<tr>
<td><strong>LORAZEPAM</strong></td>
<td>Inj 2 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 4 mg per ml, 1 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PARALDEHYDE</strong></td>
<td>Inj 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PHENYTOIN SODIUM</strong></td>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
<td>$88.63</td>
<td>5 Hospira</td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg per ml, 5 ml ampoule</td>
<td>$133.92</td>
<td>5 Hospira</td>
</tr>
</tbody>
</table>

#### Control of Epilepsy

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CARBAMAZEPINE</strong></td>
<td>Tab 200 mg</td>
<td>$14.53</td>
<td>100 Tegretol</td>
</tr>
<tr>
<td></td>
<td>Tab long-acting 200 mg</td>
<td>$16.98</td>
<td>100 Tegretol CR</td>
</tr>
<tr>
<td></td>
<td>Tab 400 mg</td>
<td>$34.58</td>
<td>100 Tegretol</td>
</tr>
<tr>
<td></td>
<td>Tab long-acting 400 mg</td>
<td>$39.17</td>
<td>100 Tegretol CR</td>
</tr>
<tr>
<td></td>
<td>Oral liq 20 mg per ml</td>
<td>$26.37</td>
<td>250 ml Tegretol</td>
</tr>
<tr>
<td><strong>CLOBAZAM</strong></td>
<td>Tab 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CLONAZEPAM</strong></td>
<td>Oral drops 2.5 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ETHOSUXIMIDE</strong></td>
<td>Cap 250 mg</td>
<td>$140.88</td>
<td>100 Zarontin</td>
</tr>
<tr>
<td></td>
<td>Oral liq 50 mg per ml</td>
<td>$56.35</td>
<td>200 ml Zarontin</td>
</tr>
<tr>
<td><strong>GABAPENTIN</strong></td>
<td>Note: Gabapentin not to be given in combination with pregabalin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cap 100 mg – 1% DV Aug-18 to 2021</td>
<td>$2.65</td>
<td>100 Apo-Gabapentin</td>
</tr>
<tr>
<td></td>
<td>Cap 300 mg – 1% DV Aug-18 to 2021</td>
<td>$4.07</td>
<td>100 Apo-Gabapentin</td>
</tr>
<tr>
<td></td>
<td>Cap 400 mg – 1% DV Aug-18 to 2021</td>
<td>$5.64</td>
<td>100 Apo-Gabapentin</td>
</tr>
<tr>
<td><strong>LACOSAMIDE</strong></td>
<td>Restricted see terms on the next page</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 50 mg</td>
<td>$25.04</td>
<td>14 Vimpat</td>
</tr>
<tr>
<td></td>
<td>Tab 100 mg</td>
<td>$50.06</td>
<td>14 Vimpat</td>
</tr>
<tr>
<td></td>
<td></td>
<td>200.24</td>
<td>56 Vimpat</td>
</tr>
<tr>
<td></td>
<td>Tab 150 mg</td>
<td>$75.10</td>
<td>14 Vimpat</td>
</tr>
<tr>
<td></td>
<td></td>
<td>300.40</td>
<td>56 Vimpat</td>
</tr>
<tr>
<td></td>
<td>Tab 200 mg</td>
<td>$400.55</td>
<td>56 Vimpat</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 20 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
PRODUCTS

NERVOUS SYSTEM

Price
(ex man. excl. GST)
Brand or Generic Manufacturer

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Valproate Tab 150 mg</td>
<td>3.50</td>
<td>Arrow-VPA</td>
</tr>
<tr>
<td>Sodium Valproate Tab 250 mg</td>
<td>5.00</td>
<td>Arrow-VPA</td>
</tr>
<tr>
<td>Sodium Valproate Tab 500 mg</td>
<td>7.50</td>
<td>Arrow-VPA</td>
</tr>
<tr>
<td>Sodium Valproate Oral liq 5 mg per ml</td>
<td>22.50</td>
<td>300 ml Arrow-VPA</td>
</tr>
<tr>
<td>Sodium Valproate Oral liq 10 mg per ml</td>
<td>45.00</td>
<td>300 ml Arrow-VPA</td>
</tr>
<tr>
<td>Sodium Valproate Oral liq 15 mg per ml</td>
<td>67.50</td>
<td>300 ml Arrow-VPA</td>
</tr>
<tr>
<td>Sodium Valproate Oral liq 30 mg per ml</td>
<td>82.50</td>
<td>300 ml Arrow-VPA</td>
</tr>
<tr>
<td>Sodium Valproate Oral liq 50 mg per ml</td>
<td>137.50</td>
<td>500 ml Arrow-VPA</td>
</tr>
<tr>
<td>Sodium Valproate Oral liq 100 mg per ml</td>
<td>275.00</td>
<td>500 ml Arrow-VPA</td>
</tr>
<tr>
<td>Sodium Valproate Oral liq 200 mg per ml</td>
<td>550.00</td>
<td>500 ml Arrow-VPA</td>
</tr>
<tr>
<td>Sodium Valproate Oral liq 300 mg per ml</td>
<td>825.00</td>
<td>500 ml Arrow-VPA</td>
</tr>
</tbody>
</table>

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

LAMOTRIGINE

- Tab dispersible 2 mg:
  - 30
  - Lamictal
- Tab dispersible 5 mg:
  - 56
  - Arrow-Lamotrigine
- Tab dispersible 25 mg:
  - 56
  - Logem
- Tab dispersible 50 mg:
  - 56
  - Logem
- Tab dispersible 100 mg:
  - 56
  - Logem

LEVETIRACETAM

- Tab 250 mg:
  - 60
  - Everet
- Tab 500 mg:
  - 60
  - Everet
- Tab 750 mg:
  - 60
  - Everet
- Tab 1,000 mg:
  - 60
  - Everet
- Oral liq 100 mg per ml:
  - 300 ml
  - Levetiracetam-AFT
- Inj 100 mg per ml:
  - 10
  - Levetiracetam-AFT

PHENOBARBITONE

- Tab 15 mg:
  - 500
  - PSM
- Tab 30 mg:
  - 500
  - PSM

PHENYTOIN

- Tab 50 mg

PHENYTOIN SODIUM

- Cap 30 mg
- Cap 100 mg
- Oral liq 6 mg per ml

PREGABALIN

- Note: Pregabalin not to be given in combination with gabapentin
- Cap 25 mg:
  - 56
  - Pregabalin Pfizer
- Cap 50 mg:
  - 56
  - Pregabalin Pfizer
- Cap 75 mg:
  - 56
  - Pregabalin Pfizer
- Cap 150 mg:
  - 56
  - Pregabalin Pfizer
- Cap 300 mg:
  - 56
  - Pregabalin Pfizer

PRIMIDONE

- Tab 250 mg

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
SODIUM VALPROATE
Tab 100 mg
Tab EC 200 mg
Tab EC 500 mg
Oral liq 40 mg per ml
Inj 100 mg per ml, 4 ml vial – 1% DV Sep-18 to 2021 ................................................. 9.98 1 Epilim IV

STIRIPENTOL – Restricted see terms below
Cap 250 mg ........................................................................................................... 509.29 60 Diacomit
Powder for oral liq 250 mg sachet ................................................................. 509.29 60 Diacomit

⇒ Restricted (RS1152)
Initiation
Paediatric neurologist
Re-assessment required after 6 months
Both:
1 Patient has confirmed diagnosis of Dravet syndrome; and
2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Continuation
Paediatric neurologist
Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE
Tab 25 mg ....................................................................................................... 11.07 60 Arrow-Topiramate
26.04 Topamax
11.07 Topiramate Actavis
Tab 50 mg ....................................................................................................... 18.81 60 Arrow-Topiramate
44.26 Topamax
18.81 Topiramate Actavis
Tab 100 mg ..................................................................................................... 31.99 60 Arrow-Topiramate
75.25 Topamax
31.99 Topiramate Actavis
Tab 200 mg ..................................................................................................... 55.19 60 Arrow-Topiramate
129.85 Topamax
55.19 Topiramate Actavis
Cap sprinkle 15 mg .......................................................................................... 20.84 60 Topamax
Cap sprinkle 25 mg .......................................................................................... 26.04 60 Topamax

VIGABATRIN – Restricted see terms below
⇒ Tab 500 mg
⇒ Restricted (RS1153)
Initiation
Re-assessment required after 15 months
Both:
1 Either:
1.1 Patient has infantile spasms; or
1.2 Both:
1.2.1 Patient has epilepsy; and
1.2.2 Either:
1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from continued…
continued…

optimal treatment with other antiepilepsy agents; and

2 Either:
   2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a
       6-monthly basis thereafter); or
   2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are
indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features
affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Continuation

Both:

1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and

2 Either:
   2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration
       of treatment with vigabatrin; or
   2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with
anticonvulsant therapy and have assessed quality of life from the patient’s perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

Acute Migraine Treatment

DIHYDROERGOTAMINE MESYLATE
   Inj 1 mg per ml, 1 ml ampoule

ERGOTAMINE TARTRATE WITH CAFFEINE
   Tab 1 mg with caffeine 100 mg

METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL
   Tab 5 mg with paracetamol 500 mg

RIZATRIPTAN
   Tab orodispersible 10 mg – 1% DV Sep-17 to 2020..............................5.26 30 Rizamelt

SUMATRIPTAN
   Tab 50 mg – 1% DV Oct-19 to 2022......................................................24.44 100 Apo-Sumatriptan
   Tab 100 mg – 1% DV Oct-19 to 2022.....................................................46.23 100 Apo-Sumatriptan
   Inj 12 mg per ml, 0.5 ml prefilled pen .............................................81.15 2 Clustran

Prophylaxis of Migraine

PIZOTIFEN
   Tab 500 mcg.................................................................................23.21 100 Sandomigran

Antinausea and Vertigo Agents

APREPIRANT – Restricted see terms below
   Cap 2 x 80 mg and 1 x 125 mg – 1% DV Jul-18 to 2021...............84.00 3 Emend Tri-Pack

Initiation

Patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of
malignancy.

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
# NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BETAHISTINE DIHYDROCHLORIDE</strong></td>
<td>Vergo 16</td>
</tr>
<tr>
<td>Tab 16 mg – 1% DV Sep-17 to 2020</td>
<td>2.89 84</td>
</tr>
<tr>
<td><strong>CYCLIZINE HYDROCHLORIDE</strong></td>
<td>Nausicalm</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Jan-19 to 2021</td>
<td>0.55 10</td>
</tr>
<tr>
<td><strong>CYCLIZINE LACTATE</strong></td>
<td>Nausicalm</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule</td>
<td>14.95 5</td>
</tr>
<tr>
<td><strong>DOMPERIDONE</strong></td>
<td>Pharmacy Health</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Mar-19 to 2021</td>
<td>2.25 100</td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 1 ml ampoule – 1% DV May-20 to 2022</td>
<td>30.95 10 Droleptan</td>
</tr>
<tr>
<td>(Droperidol Panpharma Inj 2.5 mg per ml, 1 ml ampoule to be delisted 1 May 2020)</td>
<td></td>
</tr>
<tr>
<td><strong>GRANISETRON</strong></td>
<td>Scopoderm TTS</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 3 ml ampoule – 1% DV Dec-18 to 2020</td>
<td>0.40 1 Deva</td>
</tr>
<tr>
<td><strong>HYOSCINE HYDROBROMIDE</strong></td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 400 mcg per ml, 1 ml ampoule</td>
<td>46.50 5</td>
</tr>
<tr>
<td>➥ Patch 1.5 mg</td>
<td>14.11 2</td>
</tr>
<tr>
<td>➥ Restricted (RS1155)</td>
<td></td>
</tr>
<tr>
<td>Initiation</td>
<td></td>
</tr>
<tr>
<td>Any of the following:</td>
<td></td>
</tr>
<tr>
<td>1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or</td>
<td></td>
</tr>
<tr>
<td>2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective; or</td>
<td></td>
</tr>
<tr>
<td>3 For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT3 antagonist have proven ineffective, are not tolerated or are contraindicated.</td>
<td></td>
</tr>
<tr>
<td>(Hospira Inj 400 mcg per ml, 1 ml ampoule to be delisted 1 September 2020)</td>
<td></td>
</tr>
<tr>
<td><strong>METOCLOPRAMIDE HYDROCHLORIDE</strong></td>
<td>Metoclopramide</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Jan-18 to 2020</td>
<td>1.30 100 Actavis 10</td>
</tr>
<tr>
<td>Oral liq 5 mg per 5 ml</td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022</td>
<td>9.50 10 Pfizer</td>
</tr>
<tr>
<td><strong>ONDANSETRON</strong></td>
<td>Apo-Ondansetron</td>
</tr>
<tr>
<td>Tab 4 mg – 1% DV Apr-20 to 2022</td>
<td>3.36 50 Onrex</td>
</tr>
<tr>
<td>Tab dispersible 4 mg – 1% DV Apr-18 to 2020</td>
<td>0.95 10 Ondansetron ODT-DRLA</td>
</tr>
<tr>
<td>Tab 8 mg – 1% DV Apr-20 to 2022</td>
<td>4.77 50 Onrex</td>
</tr>
<tr>
<td>Tab dispersible 8 mg – 1% DV Apr-18 to 2020</td>
<td>4.57 10 Ondansetron ODT-DRLA</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 2 ml ampoule</td>
<td>1.50 5 Ondansetron-Claris</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 4 ml ampoule</td>
<td>2.20 5 Ondansetron Kabi</td>
</tr>
<tr>
<td>(Apo-Ondansetron Tab 4 mg to be delisted 1 April 2020)</td>
<td></td>
</tr>
<tr>
<td>(Apo-Ondansetron Tab 8 mg to be delisted 1 April 2020)</td>
<td></td>
</tr>
<tr>
<td><strong>PROCHLORPERAZINE</strong></td>
<td>Nausafix</td>
</tr>
<tr>
<td>Tab buccal 3 mg</td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Mar-18 to 2020</td>
<td>6.35 250</td>
</tr>
<tr>
<td>Inj 12.5 mg per ml, 1 ml ampoule</td>
<td></td>
</tr>
<tr>
<td>Suppos 25 mg</td>
<td></td>
</tr>
</tbody>
</table>
### Antipsychotic Agents

#### General

**AMISULPRIDE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg – 1% DV Nov-19 to 2022</td>
<td>5.15</td>
<td>30</td>
<td>Sulprix</td>
</tr>
<tr>
<td>Tab 200 mg – 1% DV Nov-19 to 2022</td>
<td>14.96</td>
<td>60</td>
<td>Sulprix</td>
</tr>
<tr>
<td>Tab 400 mg – 1% DV Feb-20 to 2022</td>
<td>29.78</td>
<td>60</td>
<td>Sulprix</td>
</tr>
<tr>
<td>Oral liq 100 mg per ml</td>
<td>65.53</td>
<td>60 ml</td>
<td>Solian</td>
</tr>
</tbody>
</table>

*(Sulian Oral liq 100 mg per ml to be delisted 1 July 2020)*

**ARIPIPRAZOLE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg – 1% DV Aug-18 to 2021</td>
<td>17.50</td>
<td>30</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Aug-18 to 2021</td>
<td>17.50</td>
<td>30</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 15 mg – 1% DV Aug-18 to 2021</td>
<td>17.50</td>
<td>30</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Aug-18 to 2021</td>
<td>17.50</td>
<td>30</td>
<td>Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 30 mg – 1% DV Aug-18 to 2021</td>
<td>17.50</td>
<td>30</td>
<td>Aripiprazole Sandoz</td>
</tr>
</tbody>
</table>

**CHLORPROMAZINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Jan-20 to 2022</td>
<td>14.83</td>
<td>100</td>
<td>Largactil</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Jan-20 to 2022</td>
<td>15.62</td>
<td>100</td>
<td>Largactil</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Jan-20 to 2022</td>
<td>36.73</td>
<td>100</td>
<td>Largactil</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 20 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022</td>
<td>30.79</td>
<td>10</td>
<td>Largactil</td>
</tr>
</tbody>
</table>

**CLOZAPINE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg</td>
<td>6.69</td>
<td>50</td>
<td>Clopine</td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>8.67</td>
<td>50</td>
<td>Clopine</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>17.33</td>
<td>100</td>
<td>Clopine</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>34.65</td>
<td>100</td>
<td>Clopine</td>
</tr>
<tr>
<td>Oral liq 50 mg per ml</td>
<td>69.30</td>
<td>100 ml</td>
<td>Clopine</td>
</tr>
</tbody>
</table>

**HALOPERIDOL**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mcg – 1% DV Oct-19 to 2022</td>
<td>6.23</td>
<td>100</td>
<td>Serenace</td>
</tr>
<tr>
<td>Tab 1.5 mg – 1% DV Oct-19 to 2022</td>
<td>9.43</td>
<td>100</td>
<td>Serenace</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Oct-19 to 2022</td>
<td>29.72</td>
<td>100</td>
<td>Serenace</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml – 1% DV Oct-19 to 2022</td>
<td>23.84</td>
<td>100 ml</td>
<td>Serenace</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 1ml ampoule – 1% DV Oct-19 to 2022</td>
<td>21.55</td>
<td>10</td>
<td>Serenace</td>
</tr>
</tbody>
</table>

**LEVOMEPRAMINE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg – 1% DV Sep-19 to 2022</td>
<td>16.10</td>
<td>100</td>
<td>Nozinan</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Sep-19 to 2022</td>
<td>41.75</td>
<td>100</td>
<td>Nozinan</td>
</tr>
<tr>
<td>NERVOUS SYSTEM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
<tr>
<td>(ex man. excl. GST)</td>
<td></td>
</tr>
</tbody>
</table>

### LEVOMEPROMAZINE HYDROCHLORIDE
- **Inj 25 mg per ml, 1 ml ampoule** – **1% DV Apr-20 to 2022**
  - $33.50 10 Nozinan
  - $47.89

*(Wockhardt Inj 25 mg per ml, 1 ml ampoule to be delisted 1 April 2020)*

### LITHIUM CARBONATE
- **Tab long-acting 400 mg**
  - Tab 250 mg .................................................. 34.30 500 Lithicarb FC
  - Cap 250 mg .................................................. 9.42 100 Douglas

*(Lithicarb FC Tab 250 mg to be delisted 1 November 2020)*

### OLANZAPINE
- **Tab 2.5 mg** – **1% DV Sep-17 to 2020**
  - $0.64 28 Zypine
- **Tab 5 mg** – **1% DV Sep-17 to 2020**
  - $1.15 28 Zypine
- **Tab orodispersible 5 mg** – **1% DV Sep-17 to 2020**
  - $1.65 28 Zypine ODT
- **Tab 10 mg** – **1% DV Sep-17 to 2020**
  - $2.05 28 Zypine ODT
- **Inj 10 mg vial**

### PERICYAZINE
- **Tab 2.5 mg**
- **Tab 10 mg**

### QUETIAPINE
- **Tab 25 mg** – **1% DV Sep-17 to 2020**
  - $1.79 90 Quetapel
- **Tab 100 mg** – **1% DV Sep-17 to 2020**
  - $3.45 90 Quetapel
- **Tab 200 mg** – **1% DV Sep-17 to 2020**
  - $5.75 90 Quetapel
- **Tab 300 mg** – **1% DV Sep-17 to 2020**
  - $9.60 90 Quetapel

### RISPERIDONE
- **Tab 0.5 mg** – **1% DV Dec-17 to 2020**
  - $1.86 60 Actavis
- **Tab 1 mg** – **1% DV Dec-17 to 2020**
  - $2.06 60 Actavis
- **Tab 2 mg** – **1% DV Dec-17 to 2020**
  - $2.29 60 Actavis
- **Tab 3 mg** – **1% DV Dec-17 to 2020**
  - $2.50 60 Actavis
- **Tab 4 mg** – **1% DV Dec-17 to 2020**
  - $3.43 60 Actavis
- **Oral liq 1 mg per ml** – **1% DV Sep-17 to 2020**
  - $7.66 30 ml Risperon

### ZIPRASIDONE
- **Cap 20 mg** – **1% DV Dec-18 to 2021**
  - $14.50 60 Zusdone
- **Cap 40 mg** – **1% DV Sep-18 to 2021**
  - $24.70 60 Zusdone
- **Cap 60 mg** – **1% DV Sep-18 to 2021**
  - $33.80 60 Zusdone
- **Cap 80 mg** – **1% DV Sep-18 to 2021**
  - $39.70 60 Zusdone

### ZUCLOPENTHIXOL ACETATE
- **Inj 50 mg per ml, 1 ml ampoule**
- **Inj 50 mg per ml, 2 ml ampoule**

### ZUCLOPENTHIXOL HYDROCHLORIDE
- **Tab 10 mg** .................................................. 31.45 100 Clopixol

### Depot Injections

### FLUPENTHIXOL DECANOATE
- **Inj 20 mg per ml, 1 ml ampoule** .................................................. 13.14 5 Fluanxol
- **Inj 20 mg per ml, 2 ml ampoule** .................................................. 20.90 5 Fluanxol
- **Inj 100 mg per ml, 1 ml ampoule** .................................................. 40.87 5 Fluanxol
HALOPERIDOL DECANOATE  

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule ...........................................28.39 5 Haldol</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml ampoule ..........................................55.90 5 Haldol Concentrate</td>
</tr>
</tbody>
</table>

OLANZAPINE – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 210 mg vial – 1% DV Oct-18 to 2021 ...................................252.00 1 Zyprexa Relprevv</td>
</tr>
<tr>
<td>Inj 300 mg vial – 1% DV Oct-18 to 2021 ...................................414.00 1 Zyprexa Relprevv</td>
</tr>
<tr>
<td>Inj 405 mg vial – 1% DV Oct-18 to 2021 ...................................504.00 1 Zyprexa Relprevv</td>
</tr>
</tbody>
</table>

# Restricted (RS1379)

Initiation

*Re-assessment required after 12 months*

 Either:

  1. The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
  2. All of the following:
     1. The patient has schizophrenia; and
     2. The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
     3. The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

*Re-assessment required after 12 months*

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 25 mg syringe ..................................................................194.25 1 Invega Sustenna</td>
</tr>
<tr>
<td>Inj 50 mg syringe ..................................................................271.95 1 Invega Sustenna</td>
</tr>
<tr>
<td>Inj 75 mg syringe ..................................................................357.42 1 Invega Sustenna</td>
</tr>
<tr>
<td>Inj 100 mg syringe ...............................................................435.12 1 Invega Sustenna</td>
</tr>
<tr>
<td>Inj 150 mg syringe ...............................................................435.12 1 Invega Sustenna</td>
</tr>
</tbody>
</table>

# Restricted (RS1381)

Initiation

*Re-assessment required after 12 months*

Either:

  1. The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
  2. All of the following:
     1. The patient has schizophrenia or other psychotic disorder; and
     2. The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
     3. The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

*Re-assessment required after 12 months*

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PIPOTHIAZINE PALMITATE – Restricted: For continuation only

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
</tr>
</tbody>
</table>

RISPERIDONE – Restricted see terms on the next page

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 25 mg vial ..................................................................135.98 1 Risperdal Consta</td>
</tr>
<tr>
<td>Inj 37.5 mg vial ...............................................................178.71 1 Risperdal Consta</td>
</tr>
<tr>
<td>Inj 50 mg vial ..................................................................217.56 1 Risperdal Consta</td>
</tr>
</tbody>
</table>
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

Restricted (RS1380)

Initiation

Re-assessment required after 12 months

Either:

1. The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
2. All of the following:
   2.1. The patient has schizophrenia or other psychotic disorder; and
   2.2. The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   2.3. The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

ZUCLOPENTHIXOL DECANOATE

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

BUSPIRONE HYDROCHLORIDE

V BUSPIRONE HYDROCHLORIDE

Tab 5 mg – 1% DV Sep-18 to 2021 ....................................................... 20.23 100 Orion
Tab 10 mg – 1% DV Sep-18 to 2021 ..................................................... 13.16 100 Orion

CLONAZEPAM

Tab 500 mcg – 1% DV Jun-18 to 2021 ............................................... 5.64 100 Paxam
Tab 2 mg – 1% DV Jun-18 to 2021 ..................................................... 10.78 100 Paxam

DIAZEPAM

Tab 2 mg – 1% DV Mar-18 to 2020 .................................................... 15.05 500 Arrow-Diazepam
Tab 5 mg – 1% DV Mar-18 to 2020 ..................................................... 16.18 500 Arrow-Diazepam

LORAZEPAM

Tab 1 mg – 1% DV Sep-18 to 2021 ................................................... 9.72 250 Ativan
Tab 2.5 mg – 1% DV Sep-18 to 2021 ................................................. 12.50 100 Ativan

OXAZEPAM

Tab 10 mg – 1% DV Sep-17 to 2020 ............................................... 6.17 100 Ox-Pam
Tab 15 mg – 1% DV Sep-17 to 2020 ............................................... 8.53 100 Ox-Pam

Multiple Sclerosis Treatments

DIMETHYL FUMARATE – Restricted see terms below

☒ Cap 120 mg ........................................................................ 520.00 14 Tecfidera
☒ Cap 240 mg ........................................................................ 2,000.00 56 Tecfidera

FINGOLIMOD – Restricted see terms on the next page

☒ Cap 0.5 mg ........................................................................ 2,200.00 28 Gilenya

Item restricted (see above); ☒ Item restricted (see below)

e.g. Brand indicates brand example only. It is not a contracted product.
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Restricted (RS1433)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initiation</strong></td>
<td>Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).</td>
</tr>
</tbody>
</table>

**NATALIZUMAB** – **Restricted** see terms below
- Inj 20 mg per ml, 15 ml vial................................................................. 1,750.00 1 Tysabri

<table>
<thead>
<tr>
<th>Restricted (RS1447)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initiation</strong></td>
<td>Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).</td>
</tr>
</tbody>
</table>

**OCRELIZUMAB** – **Restricted** see terms below
- Inj 30 mg per ml, 10 ml vial................................................................. 9,346.00 1 Ocrevus

<table>
<thead>
<tr>
<th>Restricted (RS1711)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initiation</strong></td>
<td>Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).</td>
</tr>
</tbody>
</table>

**TERIFLUNOMIDE** – **Restricted** see terms below
- Tab 14 mg ............................................................................................. 1,582.62 28 Aubagio

<table>
<thead>
<tr>
<th>Restricted (RS1505)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initiation</strong></td>
<td>Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).</td>
</tr>
</tbody>
</table>

**Other Multiple Sclerosis Treatments**

<table>
<thead>
<tr>
<th>Restricted (RS1434)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initiation</strong></td>
<td>Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).</td>
</tr>
</tbody>
</table>

**GLATIRAMER ACETATE** – **Restricted** see terms above
- Inj 40 mg prefilled syringe................................................................... 2,275.00 12 Copaxone

**INTERFERON BETA-1-ALPHA** – **Restricted** see terms above
- Inj 6 million iu in 0.5 ml pen injector.................................................. 1,170.00 4 Avonex Pen
- Inj 6 million iu in 0.5 ml syringe......................................................... 1,170.00 4 Avonex

**INTERFERON BETA-1-BETA** – **Restricted** see terms above
- Inj 8 million iu per ml, 1 ml vial

### Sedatives and Hypnotics

- **CHLORAL HYDRATE**
  - Oral liq 100 mg per ml
  - Oral liq 200 mg per ml

- **LORMETAZEPAM** – **Restricted**: For continuation only
  - Tab 1 mg

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MELATONIN – Restricted see terms below</td>
</tr>
<tr>
<td>▶ Tab modified-release 2 mg ......................................... 28.22 30 Circadin</td>
</tr>
<tr>
<td>▾ Tab 3 mg</td>
</tr>
<tr>
<td>Note: Only for use in compounding an oral liquid formulation, for in-hospital use only.</td>
</tr>
</tbody>
</table>

Restricted (RS1576)

Initiation – insomnia secondary to neurodevelopmental disorder
Psychiatrist, paediatrician, neurologist or respiratory specialist
Re-assessment required after 12 months
All of the following:
1 Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder); and
2 Behavioural and environmental approaches have been tried or are inappropriate; and
3 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and
4 Patient is aged 18 years or under.

Continuation – insomnia secondary to neurodevelopmental disorder
Psychiatrist, paediatrician, neurologist or respiratory specialist
Re-assessment required after 12 months
All of the following:
1 Patient is aged 18 years or under; and
2 Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined); and
3 Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia; and
4 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day.

Initiation – insomnia where benzodiazepines and zopiclone are contraindicated
Both:
1 Patient has insomnia and benzodiazepines and zopiclone are contraindicated; and
2 For in-hospital use only.

MIDAZOLAM
Tab 7.5 mg
Oral liq 2 mg per ml
Inj 1 mg per ml, 5 ml ampoule – 1% DV Jan-19 to 2021 ......................... 2.98 10 Mylan Midazolam
Inj 5 mg per ml, 3 ml ampoule – 1% DV Jan-19 to 2021 ......................... 2.36 5 Mylan Midazolam

NITRAZEPAM – Restricted: For continuation only
▶ Tab 5 mg ............................................................................... 5.22 100 Nitrados
(Nitrados Tab 5 mg to be delisted 1 September 2020)

PHENOBARBITONE
Inj 200 mg per ml, 1 ml ampoule

TEMAZEPAM
Tab 10 mg – 1% DV Sep-17 to 2020 .......................................................... 1.27 25 Normison

TRIAZOLAM – Restricted: For continuation only
▶ Tab 125 mcg
▶ Tab 250 mcg

ZOPICLONE
Tab 7.5 mg ....................................................................................... 0.98 30 Zopiclone Actavis
(Zopiclone Actavis Tab 7.5 mg to be delisted 1 July 2020)
Stimulants / ADHD Treatments

**ATOMOXETINE – Restricted** see terms below

- Cap 10 mg.................................................................107.03 28 Strattera
- Cap 18 mg.................................................................107.03 28 Strattera
- Cap 25 mg.................................................................107.03 28 Strattera
- Cap 40 mg.................................................................107.03 28 Strattera
- Cap 60 mg.................................................................107.03 28 Strattera
- Cap 80 mg.................................................................139.11 28 Strattera
- Cap 100 mg...............................................................139.11 28 Strattera

*Restricted (RS1371)*

**Initiation**

All of the following:

1. Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
2. Once-daily dosing; and
3. Any of the following:
   3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
   3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
   3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
   3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
4. The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Note: A "subsidised formulation of a stimulant" refers to currently listed methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

**CAFFEINE**

- Tab 100 mg

**DEXAMFETAMINE SULFATE – Restricted** see terms below

- Tab 5 mg – 1% DV Oct-18 to 2021.................................................20.00 100 PSM

*Restricted (RS1169)*

**Initiation – ADHD**

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

**Initiation – Narcolepsy**

Neurologist or respiratory specialist

Re-assessment required after 24 months

Patient suffers from narcolepsy.

**Continuation – Narcolepsy**

Neurologist or respiratory specialist

Re-assessment required after 24 months

The treatment remains appropriate and the patient is benefiting from treatment.
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>METHYLPHENIDATE HYDROCHLORIDE</strong> – <em>Restricted</em> see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab extended-release 18 mg</td>
<td>58.96</td>
<td>30 Concerta</td>
</tr>
<tr>
<td>Tab extended-release 27 mg</td>
<td>65.44</td>
<td>30 Concerta</td>
</tr>
<tr>
<td>Tab extended-release 36 mg</td>
<td>71.93</td>
<td>30 Concerta</td>
</tr>
<tr>
<td>Tab extended-release 54 mg</td>
<td>86.24</td>
<td>30 Concerta</td>
</tr>
<tr>
<td>Tab immediate-release 5 mg</td>
<td>3.20</td>
<td>30 Rubifen</td>
</tr>
<tr>
<td>Tab immediate-release 10 mg</td>
<td>3.00</td>
<td>30 Ritalin, Rubifen</td>
</tr>
<tr>
<td>Tab sustained-release 20 mg</td>
<td>10.95</td>
<td>30 Rubifen SR</td>
</tr>
<tr>
<td>Cap modified-release 10 mg</td>
<td>15.60</td>
<td>30 Ritalin LA</td>
</tr>
<tr>
<td>Cap modified-release 20 mg</td>
<td>20.40</td>
<td>30 Ritalin LA</td>
</tr>
<tr>
<td>Cap modified-release 30 mg</td>
<td>25.52</td>
<td>30 Ritalin LA</td>
</tr>
<tr>
<td>Cap modified-release 40 mg</td>
<td>30.60</td>
<td>30 Ritalin LA</td>
</tr>
<tr>
<td><strong>MODAFINIL</strong> – <em>Restricted</em> (RS1171)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>64.00</td>
<td>60 Modavigil</td>
</tr>
</tbody>
</table>

---

**Initiation – ADHD (immediate-release and sustained-release formulations)**

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

**Initiation – Narcolepsy (immediate-release and sustained-release formulations)**

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

Patient suffers from narcolepsy.

**Continuation – Narcolepsy (immediate-release and sustained-release formulations)**

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

The treatment remains appropriate and the patient is benefiting from treatment.

**Initiation – Extended-release and modified-release formulations**

Paediatrician or psychiatrist

Both:

1. Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria; and
2. Either:
   2.1 Patient is taking a currently listed formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
   2.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

---

**Initiation – Narcolepsy**

Neurologist or respiratory specialist

*Re-assessment required after 24 months*

All of the following:

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
continued...

1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and

2 Either:
   2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
   2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and

3 Either:
   3.1 An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
   3.2 Methylphenidate and dexamphetamine are contraindicated.

Continuation – Narcolepsy
Neurologist or respiratory specialist
Re-assessment required after 24 months

The treatment remains appropriate and the patient is benefiting from treatment.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donepezil-Rex</td>
<td>4.34</td>
</tr>
<tr>
<td>Donepezil-Rex</td>
<td>6.64</td>
</tr>
</tbody>
</table>

RIVASTIGMINE – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exelon</td>
<td>90.00</td>
</tr>
<tr>
<td>Generic Partners</td>
<td>90.00</td>
</tr>
</tbody>
</table>

(Exelon Patch 4.6 mg per 24 hour to be delisted 1 April 2020)
(Exelon Patch 9.5 mg per 24 hour to be delisted 1 April 2020)

Initiation
Re-assessment required after 6 months

Both:

1 The patient has been diagnosed with dementia; and
2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

Continuation
Re-assessment required after 12 months

Both:

1 The treatment remains appropriate; and
2 The patient has demonstrated a significant and sustained benefit from treatment.

Treatments for Substance Dependence

BUPRENORPHINE WITH NALOXONE – Restricted see terms on the next page

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine Naloxone BNM</td>
<td>18.37</td>
</tr>
<tr>
<td>Suboxone</td>
<td>57.40</td>
</tr>
<tr>
<td>Buprenorphine Naloxone BNM</td>
<td>53.12</td>
</tr>
<tr>
<td>Suboxone</td>
<td>166.00</td>
</tr>
</tbody>
</table>

(Suboxone Tab 2 mg with naloxone 0.5 mg to be delisted 1 April 2020)
(Suboxone Tab 8 mg with naloxone 2 mg to be delisted 1 April 2020)
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ex man. excl. GST)</td>
<td>$ Per Brand or Generic Manufacturer</td>
</tr>
</tbody>
</table>

**≤ Restricted (RS1172)**

**Initiation – Detoxification**

All of the following:
1. Patient is opioid dependent; and
2. Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
3. Prescriber works in an opioid treatment service approved by the Ministry of Health.

**Initiation – Maintenance treatment**

All of the following:
1. Patient is opioid dependent; and
2. Patient will not be receiving methadone; and
3. Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
4. Prescriber works in an opioid treatment service approved by the Ministry of Health.

**BUPROPION HYDROCHLORIDE**

Tab modified-release 150 mg – 1% DV Jun-17 to 2020

| 11.00 | 30 | Zyban |

**DISULFIRAM**

Tab 200 mg

| 153.00 | 100 | Antabuse |

**NALTREXONE HYDROCHLORIDE – Restricted see terms below**

| 112.55 | 30 | Naltraccord |

**≥ Restricted (RS1173)**

**Initiation – Alcohol dependence**

Both:
1. Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and
2. Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.

**Initiation – Constipation**

For the treatment of opioid-induced constipation.

**NICOTINE – Some items restricted see terms below**

Patch 7 mg per 24 hours – 1% DV Apr-18 to 2020

| 17.28 | 28 | Habitrol |

Patch 14 mg per 24 hours – 1% DV Apr-18 to 2020

| 19.00 | 28 | Habitrol |

Patch 21 mg per 24 hours – 1% DV Apr-18 to 2020

| 21.77 | 28 | Habitrol |

≥ Oral spray 1 mg per dose

≥ Lozenge 1 mg – 1% DV Apr-18 to 2020

| 18.27 | 216 | Habitrol |

≥ Lozenge 2 mg – 1% DV Apr-18 to 2020

| 20.02 | 216 | Habitrol |

≥ Soln for inhalation 15 mg cartridge

≥ Gum 2 mg – 1% DV Apr-18 to 2020

| 36.39 | 384 | Habitrol (Fruit) |

≥ Gum 4 mg – 1% DV Apr-18 to 2020

| 42.07 | 384 | Habitrol (Mint) |

≥ Restricted (RS1310)

**Initiation**

Any of the following:
1. For perioperative use in patients who have a ‘nil by mouth’ instruction; or
2. For use within mental health inpatient units; or
3. For acute use in agitated patients who are unable to leave the hospital facilities.

**VARENICLINE – Restricted see terms on the next page**

≥ Tab 0.5 mg x 11 and 1 mg x 42 – 1% DV Mar-19 to 2021

| 25.64 | 53 | Varenicline Pfizer |

≥ Tab 1 mg – 1% DV Mar-19 to 2021

| 27.10 | 56 | Varenicline Pfizer |

*Item restricted (see ≤ above); ≥ Item restricted (see ≥ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
Restricted (RS1702)

Initiation

All of the following:

1. Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and

2. The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and

3. Either:
   3.1. The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
   3.2. The patient has tried but failed to quit smoking using bupropion or nortriptyline; and

4. The patient has not had a Special Authority for varenicline approved in the last 6 months; and

5. Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and

6. The patient is not pregnant; and

7. The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period.
Chemotherapeutic Agents

Alkylating Agents

BENDAMUSTINE HYDROCHLORIDE – **Restricted** see terms below

Decision:

1. **Inj 25 mg vial**
   - Price: $271.35
   - Brand/Manufacturer: Ribomustin

2. **Inj 100 mg vial**
   - Price: $1,085.38
   - Brand/Manufacturer: Ribomustin

**Note:** ‘Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

**Initiation – treatment naive CLL**

All of the following:

1. The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment; and
2. The patient is chemotherapy treatment naive; and
3. The patient is unable to tolerate toxicity of full-dose FCR; and
4. Patient has ECOG performance status 0-2; and
5. Patient has a Cumulative Illness Rating Scale (CIRS) score of < 6; and
6. Bendamustine is to be administered at a maximum dose of 100 mg/m² on days 1 and 2 every 4 weeks for a maximum of 6 cycles.

**Initiation – Indolent, Low-grade lymphomas**

*Re-assessment required after 9 months*

All of the following:

1. The patient has indolent low grade NHL requiring treatment; and
2. Patient has a WHO performance status of 0-2; and
3. Either:
   3.1 Both:
      3.1.1 Patient is treatment naive; and
      3.1.2 Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+); or
   3.2 All of the following:
      3.2.1 Patient has relapsed refractory disease following prior chemotherapy; and
      3.2.2 The patient has not received prior bendamustine therapy; and
      3.2.3 Either:
         3.2.3.1 Both:
            3.2.3.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
            3.2.3.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or
         3.2.3.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Continuation – Indolent, Low-grade lymphomas

*Re-assessment required after 9 months*

Both:

1. Patients have not received a bendamustine regimen within the last 12 months; and
2. Either:
   2.1 Both:
      2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
      2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or

continued…
continued...

2.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients. Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström's macroglobulinaemia.

BUSULFAN
Tab 2 mg ............................................................................................................... 89.25 100 Myleran
Inj 6 mg per ml, 10 ml ampoule

CARMUSTINE
Inj 100 mg vial ................................................................................................. 1,387.00 1 BiCNU

CHLORAMBUCIL
Tab 2 mg

CYCLOPHOSPHAMIDE
Tab 50 mg ........................................................................................................... 79.00 50 Endoxan
Inj 1 g vial – 1% DV Oct-18 to 2021 .................................................................. 35.65 1 Endoxan
Inj 2 g vial – 1% DV Oct-18 to 2021 .................................................................. 71.25 1 Endoxan

IFOSFAMIDE
Inj 1 g vial ........................................................................................................... 96.00 1 Holoxan
Inj 2 g vial .......................................................................................................... 180.00 1 Holoxan

LOMUSTINE
Cap 10 mg .......................................................................................................... 132.59 20 Ceenu
Cap 40 mg ......................................................................................................... 399.15 20 Ceenu

MELPHALAN
Tab 2 mg
Inj 50 mg vial

THIOTEPA
Inj 15 mg vial
Inj 100 mg vial

Anthracyclines and Other Cytotoxic Antibiotics

BLEOMYCIN SULPHATE
Inj 15,000 iu vial – 1% DV Dec-18 to 2021 ..................................................... 161.01 1 DBL Bleomycin Sulfate

DACTINOMYCIN [ACTINOMYCIN D]
Inj 0.5 mg vial .................................................................................................. 255.00 1 Cosmegen

DAUNORUBICIN
Inj 2 mg per ml, 10 ml vial ............................................................................... 130.00 1 Pfizer

DOXORUBICIN HYDROCHLORIDE
Inj 2 mg per ml, 5 ml vial
Inj 2 mg per ml, 25 ml vial ................................................................................ 11.50 1 Doxorubicin Ebewe
Note: DV limit applies to all 50 mg presentations of doxorubicin hydrochloride.
Inj 50 mg vial
Inj 2 mg per ml, 50 ml vial ................................................................................ 23.00 1 Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial – 1% DV Jan-19 to 2021 .................................. 56.15 1 Doxorubicin Ebewe

EPIRUBICIN HYDROCHLORIDE
Inj 2 mg per ml, 5 ml vial ............................................................................... 25.00 1 Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial .............................................................................. 30.00 1 Epirubicin Ebewe
Inj 2 mg per ml, 100 ml vial – 1% DV Apr-19 to 2021 ................................ 85.00 1 Epirubicin Ebewe
IDARUBICIN HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 mg vial – 1% DV Sep-18 to 2021</td>
<td>$93.00</td>
<td>Zavedos</td>
</tr>
<tr>
<td>Inj 10 mg vial – 1% DV Sep-18 to 2021</td>
<td>$198.00</td>
<td>Zavedos</td>
</tr>
</tbody>
</table>

MITOMYCIN C

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 mg vial</td>
<td>$204.08</td>
<td>Arrow</td>
</tr>
<tr>
<td>Inj 20 mg vial</td>
<td>$816.32</td>
<td>Omegapharm</td>
</tr>
</tbody>
</table>

MITOZANTRONE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 10 ml vial</td>
<td>$97.50</td>
<td>Mitozantrone Ebewe</td>
</tr>
</tbody>
</table>

AZACITIDINE – Restricted see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 mg vial – 1% DV Dec-18 to 2021</td>
<td>$139.00</td>
<td>Azacitidine Dr Reddy’s</td>
</tr>
</tbody>
</table>

Antimetabolites

AZACITIDINE – Restricted see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 mg vial – 1% DV Dec-18 to 2021</td>
<td>$139.00</td>
<td>Azacitidine Dr Reddy’s</td>
</tr>
</tbody>
</table>

CAPECITABINE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 150 mg – 1% DV Jul-20 to 2022</td>
<td>$11.15</td>
<td>Brinov</td>
</tr>
<tr>
<td>Tab 500 mg – 1% DV Jul-20 to 2022</td>
<td>$62.28</td>
<td>Brinov</td>
</tr>
</tbody>
</table>

CLADRIBINE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 5 ml vial</td>
<td>$5,249.72</td>
<td>Leustatin</td>
</tr>
</tbody>
</table>

CYTARABINE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 20 mg per ml, 5 ml vial</td>
<td>$400.00</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 20 ml vial – 1% DV Dec-18 to 2021</td>
<td>$41.36</td>
<td>Pfizer</td>
</tr>
</tbody>
</table>

Item restricted (see ➥ above); Item restricted (see ➥ below)
e.g. Brand indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FLUDARABINE PHOSPHATE</strong></td>
<td>Tab 10 mg – 1% DV Sep-18 to 2021</td>
<td>$412.00</td>
<td>20 Fludara Oral</td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg vial – 1% DV Nov-19 to 2022</td>
<td>$576.45</td>
<td>5 Fludarabine Ebewe</td>
</tr>
<tr>
<td><strong>FLUOROURACIL</strong></td>
<td>Inj 50 mg per ml, 20 ml vial – 1% DV Oct-18 to 2021</td>
<td>$12.00</td>
<td>1 Fluorouracil Ebewe</td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg per ml, 100 ml vial – 1% DV Oct-18 to 2021</td>
<td>$30.00</td>
<td>1 Fluorouracil Ebewe</td>
</tr>
<tr>
<td><strong>GEMCITABINE</strong></td>
<td>Inj 10 mg per ml, 100 ml vial</td>
<td>$15.89</td>
<td>1 Gemcitabine Ebewe</td>
</tr>
<tr>
<td><strong>MERCAPTOPURINE</strong></td>
<td>Tab 50 mg – 1% DV Jul-19 to 2022</td>
<td>$37.00</td>
<td>25 Puri-nethol</td>
</tr>
<tr>
<td></td>
<td>Oral suspension 20 mg per ml</td>
<td>$428.00</td>
<td>100 ml Allmercap</td>
</tr>
<tr>
<td><strong>METHOTREXATE</strong></td>
<td>Tab 2.5 mg – 1% DV Jan-19 to 2021</td>
<td>$8.05</td>
<td>90 Trexate</td>
</tr>
<tr>
<td></td>
<td>Tab 10 mg – 1% DV Jan-19 to 2021</td>
<td>$31.75</td>
<td>90 Trexate</td>
</tr>
<tr>
<td></td>
<td>Inj 2.5 mg per ml, 2 ml vial</td>
<td>$14.61</td>
<td>1 Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 7.5 mg prefilled syringe</td>
<td>$14.66</td>
<td>1 Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg prefilled syringe</td>
<td>$14.77</td>
<td>1 Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 15 mg prefilled syringe</td>
<td>$14.88</td>
<td>1 Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 20 mg prefilled syringe</td>
<td>$14.99</td>
<td>1 Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 25 mg prefilled syringe</td>
<td>$15.09</td>
<td>1 Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 30 mg prefilled syringe</td>
<td>$30.00</td>
<td>5 DBL Methotrexate Onco-Vial</td>
</tr>
<tr>
<td></td>
<td>Inj 25 mg per ml, 20 ml vial</td>
<td>$45.00</td>
<td>1 DBL Methotrexate Onco-Vial</td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 10 ml vial</td>
<td>$25.00</td>
<td>1 Methotrexate Ebewe</td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 50 ml vial – 1% DV Sep-17 to 2020</td>
<td>$79.99</td>
<td>1 Methotrexate Ebewe</td>
</tr>
<tr>
<td><strong>PEMETREXED – Restricted</strong></td>
<td>Inj 100 mg vial</td>
<td>$60.89</td>
<td>1 Juno Pemetrexed</td>
</tr>
<tr>
<td></td>
<td>Inj 500 mg vial</td>
<td>$217.77</td>
<td>1 Juno Pemetrexed</td>
</tr>
</tbody>
</table>

**PEMETREXED – Restricted** see terms below

**Initiation – Mesothelioma**

*Re-assessment required after 8 months*

**Both:**

1. Patient has been diagnosed with mesothelioma; and
2. Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.

**Continued…**

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued…

**Continuation – Mesothelioma**

*Re-assessment required after 8 months*

All of the following:

1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment; and
3. Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles.

**Initiation – Non small cell lung cancer**

*Re-assessment required after 8 months*

Both:

1. Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and
2. Either:
   2.1 Both:
      2.1.1 Patient has chemotherapy-naïve disease; and
      2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles; or
   2.2 All of the following:
      2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and
      2.2.2 Patient has not received prior funded treatment with pemetrexed; and
      2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

**Continuation – Non small cell lung cancer**

*Re-assessment required after 8 months*

All of the following:

1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment; and
3. Pemetrexed is to be administered at a dose of 500mg/m² every 21 days.

**THIOGUANINE**

Tab 40 mg

**Other Cytotoxic Agents**

**AMSACRINE**

Inj 50 mg per ml, 1.5 ml ampoule

Inj 75 mg

**ANAGRELIDE HYDROCHLORIDE**

Cap 0.5 mg

**ARSENIC TRIOXIDE**

Inj 1 mg per ml, 10 ml vial.................................................................4,817.00 10 Phenasen

**BORTEZOMIB – Restricted see terms below**

- Inj 3.5 mg vial – 1% DV Aug-20 to 2022.............................................105.00 1 Bortezomib Dr-Reddy’s

(Velcade Inj 3.5 mg vial to be delisted 1 August 2020)

- Restricted (RS1725)

**Initiation – multiple myeloma/amyloidosis**

Either:

1. The patient has symptomatic multiple myeloma; or
2. The patient has symptomatic systemic AL amyloidosis.

**COLASPASE [L-ASPARAGINASE]**

Inj 10,000 iu vial.................................................................102.32 1 Leunase

(Leunase Inj 10,000 iu vial to be delisted 1 December 2020)
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Price (ex man excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DACARBAZINE</td>
<td>Inj 200 mg vial</td>
<td>$58.06</td>
<td>DBL Dacarbazine</td>
</tr>
<tr>
<td>ETOPOSIDE</td>
<td>Cap 50 mg – 1% DV Jul-19 to 2022</td>
<td>$340.73</td>
<td>Vepesid</td>
</tr>
<tr>
<td></td>
<td>Cap 100 mg – 1% DV Jul-19 to 2022</td>
<td>$340.73</td>
<td>Vepesid</td>
</tr>
<tr>
<td></td>
<td>Inj 20 mg per ml, 5 ml vial</td>
<td>$7.90</td>
<td>Rex Medical</td>
</tr>
<tr>
<td>ETOPOSIDE (AS PHOSPHATE)</td>
<td>Inj 100 mg vial</td>
<td>$40.00</td>
<td></td>
</tr>
<tr>
<td>HYDROXYUREA</td>
<td>Cap 500 mg</td>
<td>$31.76</td>
<td>Hydrea</td>
</tr>
<tr>
<td>IRINOTECAN HYDROCHLORIDE</td>
<td>Inj 20 mg per ml, 5 ml vial – 1% DV Apr-19 to 2021</td>
<td>$71.44</td>
<td>Irinotecan Actavis 100</td>
</tr>
<tr>
<td>LENALIDOMIDE – Restricted see terms below</td>
<td>Cap 10 mg</td>
<td>$6,207.00</td>
<td>Revlimid</td>
</tr>
<tr>
<td></td>
<td>Cap 15 mg</td>
<td>$7,239.18</td>
<td>Revlimid</td>
</tr>
<tr>
<td></td>
<td>Cap 25 mg</td>
<td>$7,627.00</td>
<td>Revlimid</td>
</tr>
<tr>
<td></td>
<td>Restricted (RS1419)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation</td>
<td>Haematologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re-assessment required after 6 months</td>
<td>All of the following:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 Patient has relapsed or refractory multiple myeloma with progressive disease; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 Either:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.2 Both:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>bortezomib or thalidomide that precludes further treatment with either of these treatments; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuation</td>
<td>Haematologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re-assessment required after 6 months</td>
<td>Both:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 No evidence of disease progression; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 The treatment remains appropriate and patient is benefitting from treatment.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OLAPARIB – Restricted see terms below</td>
<td>Tab 100 mg</td>
<td>$3,701.00</td>
<td>Lynparza</td>
</tr>
<tr>
<td></td>
<td>Tab 150 mg</td>
<td>$3,701.00</td>
<td>Lynparza</td>
</tr>
<tr>
<td></td>
<td>Cap 50 mg</td>
<td>$7,402.00</td>
<td>Lynparza</td>
</tr>
<tr>
<td></td>
<td>Restricted (RS1722)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation</td>
<td>Medical oncologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re-assessment required after 12 months</td>
<td>All of the following:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued...
continued...

1. Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
2. There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and
3. Patient has received at least two lines of previous treatment with platinum-based chemotherapy; and
4. Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line of platinum-based chemotherapy; and
5. Patient's disease must have achieved partial or complete response to treatment with the immediately preceding platinum-based regimen; and
6. Patient's disease has not progressed following prior treatment with olaparib; and
7. Treatment will be commenced within 8 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and
8. Treatment to be administered as maintenance treatment; and
9. Treatment not to be administered in combination with other chemotherapy.

Continuation
Medical oncologist
Re-assessment required after 12 months
All of the following:

1. Treatment remains clinically appropriate and patient is benefitting from treatment; and
2. No evidence of progressive disease; and
3. Treatment to be administered as maintenance treatment; and
4. Treatment not to be administered in combination with other chemotherapy.

Note: *Note “high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

PEGASPARGASE – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 750 iu per ml, 5 ml vial</td>
<td>3,005.00 1 Oncaspar Oncaspar LYO</td>
</tr>
</tbody>
</table>

(Oncaspar Inj 750 iu per ml, 5 ml vial to be delisted 1 May 2020)

Initiation – Newly diagnosed ALL
Limited to 12 months treatment
All of the following:

1. The patient has newly diagnosed acute lymphoblastic leukaemia; and
2. Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
3. Treatment is with curative intent.

Initiation – Relapsed ALL
Limited to 12 months treatment
All of the following:

1. The patient has relapsed acute lymphoblastic leukaemia; and
2. Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
3. Treatment is with curative intent.

PENTOSTATIN [DEOXYCOFORMYCIN]
Inj 10 mg vial

PROCARBAZINE HYDROCHLORIDE
Cap 50 mg.................................................................980.00 50 Natulan
**TEMZOLOMIDE** – **Restricted** see terms below

1. **Cap 5 mg** – 1% DV May-20 to 2022 .......................................................... 10.20 5 Orion Temozolomide Temaccord

2. **Cap 20 mg** – 1% DV May-20 to 2022 .......................................................... 18.30 5 Orion Temozolomide Temaccord

3. **Cap 100 mg** – 1% DV May-20 to 2022 .......................................................... 40.20 5 Orion Temozolomide Temaccord

4. **Cap 140 mg** – 1% DV May-20 to 2022 .......................................................... 50.12 5 Temaccord

5. **Cap 250 mg** – 1% DV May-20 to 2022 .......................................................... 96.80 5 Orion Temozolomide Temaccord

(Orion Temozolomide Cap 5 mg to be delisted 1 May 2020)
(Orion Temozolomide Cap 20 mg to be delisted 1 May 2020)
(Orion Temozolomide Cap 100 mg to be delisted 1 May 2020)
(Orion Temozolomide Cap 250 mg to be delisted 1 May 2020)

**Initiation – High grade gliomas**

*Re-assessment required after 12 months*

All of the following:

1. Either:
   1.1 Patient has newly diagnosed glioblastoma multiforme; or
   1.2 Patient has newly diagnosed anaplastic astrocytoma*; and

2. Temozolomide is to be (or has been) given concomitantly with radiotherapy; and

3. Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m$^2$ per day.

**Continuation – High grade gliomas**

*Re-assessment required after 12 months*

Either:

1. Both:
   1.1 Patient has glioblastoma multiforme; and
   1.2 The treatment remains appropriate and the patient is benefitting from treatment; or

2. All of the following:
   2.1 Patient has anaplastic astrocytoma*; and
   2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
   2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

**Initiation – Neuroendocrine tumours**

*Re-assessment required after 9 months*

All of the following:

1. Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and

2. Temozolomide is to be given in combination with capecitabine; and

3. Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m$^2$ per day; and

4. Temozolomide to be discontinued at disease progression.

**Continuation – Neuroendocrine tumours**

*Re-assessment required after 6 months*

Both:

1. No evidence of disease progression; and

2. The treatment remains appropriate and the patient is benefitting from treatment.

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

continued…

**Initiation – ewing’s sarcoma**

*Re-assessment required after 9 months*
Patient has relapse or refractory Ewing’s sarcoma.

**Continuation – ewing’s sarcoma**

*Re-assessment required after 6 months*
Both:

1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

Note: Indication marked with a * is an unapproved indication. Temozolomide is not funded for the treatment of relapsed high grade glioma.

**THALIDOMIDE – Restricted** see terms below

| Cap 50 mg | 378.00 | 28 Thalomid |
| Cap 100 mg | 756.00 | 28 Thalomid |

*Restricted (RS1192)*

**Initiation**

*Re-assessment required after 12 months*
Any of the following:

1. The patient has multiple myeloma; or
2. The patient has systemic AL amyloidosis*; or
3. The patient has erythema nodosum leprosum.

**Continuation**
Patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen

Indication marked with * is an unapproved indication

**TRETINOIN**

| Cap 10 mg | 479.50 | 100 Vesanoid |

**VENETOCLAX – Restricted** see terms below

| Tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg | 1,771.86 | 42 Venclexta |
| Tab 10 mg | 95.78 | 14 Venclexta |
| Tab 50 mg | 239.44 | 7 Venclexta |
| Tab 100 mg | 8,209.41 | 120 Venclexta |

*Restricted (RS1713)*

**Initiation – relapsed/refractory chronic lymphocytic leukaemia**

Haematologist

*Re-assessment required after 7 months*
All of the following:

1. Patient has chronic lymphocytic leukaemia requiring treatment; and
2. Patient has received at least one prior therapy for chronic lymphocytic leukaemia; and
3. Patient has not previously received funded venetoclax; and
4. The patient’s disease has relapsed within 36 months of previous treatment; and
5. Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax; and
6. Patient has an ECOG performance status of 0-2.

continued…
Continuation – relapsed/refractory chronic lymphocytic leukaemia

Haematologist
Re-assessment required after 6 months
Both:
1. Treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment; and
2. Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity.

Initiation – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*

Haematologist
Re-assessment required after 6 months
All of the following:
1. Patient has previously untreated chronic lymphocytic leukaemia; and
2. There is documentation confirming that patient has 17p deletion by FISH testing or TP53 mutation by sequencing; and
3. Patient has an ECOG performance status of 0-2.

Continuation – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*

Haematologist
Re-assessment required after 6 months
The treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment.

Note: ‘Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma (SLL)* and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are unapproved indications.

Platinum Compounds

CARBOPLATIN
Inj 10 mg per ml, 45 ml vial – 1% DV Jun-19 to 2021 ........................................ $45.20 1 Carboplatin Ebewe

CISPLATIN
Inj 1 mg per ml, 50 ml vial................................................................................ $12.29 1 DBL Cisplatin
Inj 1 mg per ml, 100 ml vial – 1% DV Sep-18 to 2021 .................................. $19.70 1 DBL Cisplatin

OXALIPLATIN
Inj 5 mg per ml, 20 ml vial – 1% DV Feb-20 to 2021 .................................... $46.32 1 Oxaliplatin Accord

Protein-Tyrosine Kinase Inhibitors

ALECTINIB – Restricted see terms below
Cap 150 mg............................................................................................. $7,935.00 224 Alecensa

Assessment required after 6 months
All of the following:
1. Patient has locally advanced, or metastatic, unresectable, non-small cell lung cancer; and
2. There is documentation confirming that the patient has an ALK tyrosine kinase gene rearrangement using an appropriate ALK test; and
3. Patient has an ECOG performance score of 0-2.

Continuation
Re-assessment required after 6 months
Both:
1. No evidence of progressive disease according to RECIST criteria; and
2. The patient is benefitting from and tolerating treatment.
DASATINIB – Restricted see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 20 mg</td>
<td>3,774.06</td>
<td>60 Sprycel</td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>6,214.20</td>
<td>60 Sprycel</td>
</tr>
<tr>
<td>Tab 70 mg</td>
<td>7,692.58</td>
<td>60 Sprycel</td>
</tr>
</tbody>
</table>

**Initiation**
Haematologist or any relevant practitioner on the recommendation of a haematologist

**Re-assessment required after 6 months**

Any of the following:

1. Both:
   1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and
   1.2 Maximum dose of 140 mg/day; or

2. Both:
   2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and
   2.2 Maximum dose of 140 mg/day; or

3. All of the following:
   3.1 The patient has a diagnosis of CML in chronic phase; and
   3.2 Maximum dose of 100 mg/day; and
   3.3 Any of the following:
      3.3.1 Patient has documented treatment failure* with imatinib; or
      3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
      3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or
      3.3.4 Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol.

**Continuation**
Haematologist or any relevant practitioner on the recommendation of a haematologist

**Re-assessment required after 6 months**

All of the following:

1. Lack of treatment failure while on dasatinib*; and
2. Dasatinib treatment remains appropriate and the patient is benefiting from treatment; and
3. Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up https://www.cancertrialsnz.ac.nz/kiss/

ERLOTINIB – Restricted see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>764.00</td>
<td>30 Tarceva</td>
</tr>
<tr>
<td>Tab 150 mg</td>
<td>1,146.00</td>
<td>30 Tarceva</td>
</tr>
</tbody>
</table>

**Initiation**

**Re-assessment required after 4 months**

All of the following:

1. Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
3. Either:
   3.1 Patient is treatment naive; or
   3.2 Both:
      3.2.1 The patient has discontinued gefitinib due to intolerance; and
      3.2.2 The cancer did not progress while on gefitinib; and
4. Erlotinib is to be given for a maximum of 3 months.
Continuation

Re-assessment required after 6 months

Both:
1. Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
2. Erlotinib is to be given for a maximum of 3 months.

GEFITINIB – Restricted see terms below

$ Tab 250 mg ................................................................................................. 1,700.00 30 Iressa

→ Restricted (RS1580)

Initiation

Re-assessment required after 4 months

All of the following:
1. Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. Either:
   2.1 Patient is treatment naive; or
   2.2 Both:
      2.2.1 The patient has discontinued erlotinib due to intolerance; and
      2.2.2 The cancer did not progress whilst on erlotinib; and
3. There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
4. Gefitinib is to be given for a maximum of 3 months.

Continuation

Re-assessment required after 6 months

Both:
1. Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
2. Gefitinib is to be given for a maximum of 3 months.

IMATINIB MESILATE

Imatinib-AFT is not registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule

$ Tab 100 mg ................................................................................................. 2,400.00 60 Glivec

→ Restricted (RS1402)

Initiation

Re-assessment required after 12 months

Both:
1. Patient has diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
2. Maximum dose of 400 mg/day.

Continuation

Re-assessment required after 12 months

Adequate clinical response to treatment with imatinib (prescriber determined).

Note: The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

Cap 100 mg – 1% DV Oct-17 to 2020 ................................................................. 98.00 60 Imatinib-AFT
Cap 400 mg – 1% DV Oct-17 to 2020 .............................................................197.50 30 Imatinib-AFT

LAPATINIB – Restricted see terms below

$ Tab 250 mg ................................................................................................. 1,899.00 70 Tykerb

→ Restricted (RS1197)

Initiation

Re-assessment required after 12 months

Either: continued…
continued…

1 All of the following:
   1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
   1.3 Lapatinib not to be given in combination with trastuzumab; and
   1.4 Lapatinib to be discontinued at disease progression; or

2 All of the following:
   2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
   2.3 The cancer did not progress whilst on trastuzumab; and
   2.4 Lapatinib not to be given in combination with trastuzumab; and
   2.5 Lapatinib to be discontinued at disease progression.

Continuation
Re-assessment required after 12 months
All of the following:

1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
3. Lapatinib not to be given in combination with trastuzumab; and
4. Lapatinib to be discontinued at disease progression.

NILOTINIB – Restricted see terms below

| Cap 150 mg | 4,680.00 | 120 Tasigna |
| Cap 200 mg | 6,532.00 | 120 Tasigna |

Restricted (RS1437)

Initiation
Haematologist
Re-assessment required after 6 months
All of the following:

1. Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
2. Either:
   2.1 Patient has documented CML treatment failure* with imatinib; or
   2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
3. Maximum nilotinib dose of 800 mg/day; and
4. Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

Continuation
Haematologist
Re-assessment required after 6 months
All of the following:

1. Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
2. Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
3. Maximum nilotinib dose of 800 mg/day; and
4. Subsidised for use as monotherapy only.

PAZOPANIB – Restricted see terms on the next page

| Tab 200 mg | 1,334.70 | 30 Votrient |
| Tab 400 mg | 2,669.40 | 30 Votrient |
Restricted (RS1198)

Initiation
Re-assessment required after 3 months
All of the following:
1. The patient has metastatic renal cell carcinoma; and
2. Any of the following:
   2.1. The patient is treatment naive; or
   2.2. The patient has only received prior cytokine treatment; or
   2.3. Both:
      2.3.1. The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
      2.3.2. The cancer did not progress whilst on sunitinib; and
3. The patient has good performance status (WHO/ECOG grade 0-2); and
4. The disease is of predominant clear cell histology; and
5. All of the following:
   5.1. Lactate dehydrogenase level > 1.5 times upper limit of normal; and
   5.2. Haemoglobin level < lower limit of normal; and
   5.3. Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
   5.4. Interval of < 1 year from original diagnosis to the start of systemic therapy; and
   5.5. Karnofsky performance score of less than or equal to 70; and
   5.6. 2 or more sites of organ metastasis.

Continuation
Re-assessment required after 3 months
Both:
1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.
Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

RUXOLITINIB – Restricted see terms below

Tab 5 mg ..........................................................2,500.00 56 Jakavi
Tab 15 mg ..........................................................5,000.00 56 Jakavi
Tab 20 mg ..........................................................5,000.00 56 Jakavi

Restricted (RS1726)

Initiation
Haematologist
Re-assessment required after 12 months
All of the following:
1. The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
2. Either:
   2.1. A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; or
   2.2. Both:
      2.2.1. A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
      2.2.2. Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy;
### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

continued…

and

3 A maximum dose of 20 mg twice daily is to be given.

### Continuation

Relevant specialist or medical practitioner on the recommendation of a Relevant specialist

*Re-assessment required after 12 months*

Both:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. A maximum dose of 20 mg twice daily is to be given.

**SUNITINIB – Restricted** see terms below

<table>
<thead>
<tr>
<th>Cap 12.5 mg</th>
<th>2,315.38</th>
<th>28</th>
<th>Sutent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 25 mg</td>
<td>4,630.77</td>
<td>28</td>
<td>Sutent</td>
</tr>
<tr>
<td>Cap 50 mg</td>
<td>9,261.54</td>
<td>28</td>
<td>Sutent</td>
</tr>
</tbody>
</table>

*Restricted (RS1199)*

**Initiation – RCC**

*Re-assessment required after 3 months*

All of the following:

1. The patient has metastatic renal cell carcinoma; and
2. Any of the following:
   2.1 The patient is treatment naive; or
   2.2 The patient has only received prior cytokine treatment; or
   2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
   2.4 Both:
      2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
      2.4.2 The cancer did not progress whilst on pazopanib; and
3. The patient has good performance status (WHO/ECOG grade 0-2); and
4. The disease is of predominant clear cell histology; and
5. All of the following:
   5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
   5.2 Haemoglobin level < lower limit of normal; and
   5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
   5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
   5.5 Karnofsky performance score of less than or equal to 70; and
   5.6 2 or more sites of organ metastasis; and
6. Sunitinib to be used for a maximum of 2 cycles.

Notes: RCC - Sunitinib treatment should be stopped if disease progresses. Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

### Continuation – RCC

*Re-assessment required after 3 months*

Both:

1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

**Initiation – GIST**

*Re-assessment required after 3 months*

Both:

continued…
continued...

1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
2 Either:
   2.1 The patient’s disease has progressed following treatment with imatinib; or
   2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Continuation – GIST

Re-assessment required after 6 months

Both:

The patient has responded to treatment or has stable disease as determined by Choi’s modified CT response evaluation criteria as follows:
1 Any of the following:
   1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
   1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non-measurable disease); or
   1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: GIST - It is recommended that response to treatment be assessed using Choi’s modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Taxanes

**DOCETAXEL**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per Brand</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 2 ml vial – 1% DV Sep-17 to 2020</td>
<td>12.40</td>
<td>DBL Docetaxel</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 8 ml vial – 1% DV Sep-17 to 2020</td>
<td>26.95</td>
<td>DBL Docetaxel</td>
</tr>
</tbody>
</table>

**PACLITAXEL**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per Brand</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 6 mg per ml, 5 ml vial – 1% DV Oct-17 to 2020</td>
<td>47.30</td>
<td>Paclitaxel Ebewe</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 16.7 ml vial – 1% DV Oct-17 to 2020</td>
<td>20.00</td>
<td>Paclitaxel Ebewe</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 25 ml vial – 1% DV Oct-17 to 2020</td>
<td>26.69</td>
<td>Paclitaxel Ebewe</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 50 ml vial – 1% DV Oct-17 to 2020</td>
<td>35.35</td>
<td>Paclitaxel Ebewe</td>
</tr>
</tbody>
</table>

Treatment of Cytotoxic-Induced Side Effects

**CALCICUM FOLINATE**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per Brand</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 15 mg</td>
<td>104.26</td>
<td>DBL Leucovorin Calcium</td>
</tr>
<tr>
<td>Inj 3 mg per ml, 1 ml ampoule</td>
<td>18.25</td>
<td>Calcium Folinate Ebewe</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml ampoule – 1% DV Jan-20 to 2022</td>
<td>7.28</td>
<td>Calcium Folinate Sandoz</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml vial – 1% DV Jan-20 to 2022</td>
<td>9.49</td>
<td>Calcium Folinate Sandoz</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 30 ml vial</td>
<td>22.51</td>
<td>Calcium Folinate Sandoz</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 35 ml vial – 1% DV Nov-19 to 2022</td>
<td>25.14</td>
<td>Calcium Folinate Sandoz</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml vial – 1% DV Mar-20 to 2022</td>
<td>72.00</td>
<td>Calcium Folinate Sandoz</td>
</tr>
</tbody>
</table>

**DEXRAZOXANE** – Restricted see terms on the next page

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per Brand</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 500 mg</td>
<td>e.g. Cardioxane</td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic</td>
<td></td>
</tr>
</tbody>
</table>

**→ Restricted (RS1695)**

**Initiation**

Medical oncologist, paediatric oncologist, haematologist or paediatric haematologist

All of the following:

1. Patient is to receive treatment with high dose anthracycline given with curative intent; and
2. Based on current treatment plan, patient’s cumulative lifetime dose of anthracycline will exceed 250mg/m² doxorubicin equivalent or greater; and
3. Dexrazoxane to be administered only whilst on anthracycline treatment; and
4. Either:
   4.1 Treatment to be used as a cardioprotectant for a child or young adult; or
   4.2 Treatment to be used as a cardioprotectant for secondary malignancy.

**MESNA**

- Tab 400 mg – 1% DV Nov-19 to 2022 ......................................................... 314.00 50 Uromitexan
- Tab 600 mg – 1% DV Nov-19 to 2022 ......................................................... 448.50 50 Uromitexan
- Inj 100 mg per ml, 4 ml ampoule – 1% DV Nov-19 to 2022 ......................... 177.45 15 Uromitexan
- Inj 100 mg per ml, 10 ml ampoule – 1% DV Nov-19 to 2022 ....................... 407.40 15 Uromitexan

**Vinca Alkaloids**

**VINBLASTINE SULPHATE**

- Inj 1 mg per ml, 10 ml vial .............................................................................. 186.46 5 Hospira

**VINCRISTINE SULPHATE**

- Inj 1 mg per ml, 1 ml vial .............................................................................. 74.52 5 DBL Vincristine Sulfate
- Inj 1 mg per ml, 2 ml vial .............................................................................. 85.61 5 DBL Vincristine Sulfate

**VINORELBINE**

- Inj 10 mg per ml, 1 ml vial .............................................................................. 12.00 1 Navelbine
- Inj 10 mg per ml, 5 ml vial .............................................................................. 56.00 1 Navelbine

**Endocrine Therapy**

**ABIRATERONE ACETATE – Restricted see terms below**

- Tab 250 mg ................................................................................................ 4,276.19 120 Zytiga

**→ Restricted (RS1658)**

**Initiation**

Medical oncologist, radiation oncologist or urologist

*Re-assessment required after 6 months*

All of the following:

1. Patient has prostate cancer; and
2. Patient has metastases; and
3. Patient’s disease is castration resistant; and
4. Either:
   4.1 All of the following:
      4.1.1 Patient is symptomatic; and
      4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
      4.1.3 Patient has ECOG performance score of 0-1; and
      4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
   4.2 All of the following:

continued…
continued…

4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
4.2.2 Patient has ECOG performance score of 0-2; and
4.2.3 Patient has not had prior treatment with abiraterone.

Continuation

Medical oncologist, radiation oncologist or urologist

Re-assessment required after 6 months

All of the following:

1 Significant decrease in serum PSA from baseline; and
2 No evidence of clinical disease progression; and
3 No initiation of taxane chemotherapy with abiraterone; and
4 The treatment remains appropriate and the patient is benefiting from treatment.

BICALUTAMIDE

Tab 50 mg – 1% DV Feb-18 to 2020 ................................................................. 3.80 28 Binarex

FLUTAMIDE

Tab 250 mg ......................................................................................................... 119.50 100 Flutamin

MEGESTROL ACETATE

Tab 160 mg – 1% DV Oct-18 to 2021 ............................................................. 63.53 30 Apo-Megestrol

OCTREOTIDE – Some items restricted see terms below

Inj 50 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 ..................... 30.64 5 DBL Octreotide
Inj 100 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 .................. 18.69 5 DBL Octreotide
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020 ................. 72.50 5 DBL Octreotide

Inj 10 mg vial .................................................................................................. 1,772.50 1 Sandostatin LAR
Inj 20 mg vial .................................................................................................. 2,358.75 1 Sandostatin LAR
Inj 30 mg vial .................................................................................................. 2,951.25 1 Sandostatin LAR

↓ Restricted (RS1201)

Initiation – Malignant bowel obstruction

All of the following:

1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has
   failed; and
3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are unapproved indications

Initiation – acromegaly

Re-assessment required after 3 months

Both:

1 The patient has acromegaly; and
2 Any of the following:
   2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
   2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist
      has failed; or
   2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Continuation – acromegaly

Both:

1 IGF1 levels have decreased since starting octreotide; and
2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months

continued…
treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

**Initiation – Other indications**

Any of the following:

1. VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
2. Both:
   2.1 Gastrinoma; and
   2.2 Either:
      2.2.1 Patient has failed surgery; or
      2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
3. Both:
   3.1 Insulinomas; and
   3.2 Surgery is contraindicated or has failed; or
4. For pre-operative control of hypoglycaemia and for maintenance therapy; or
5. Both:
   5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
   5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: restriction applies only to the long-acting formulations of octreotide.

**TAMOXIFEN CITRATE**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Jan-19 to 2020</td>
<td>11.75</td>
<td>60 Tamoxifen Sandoz</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Jan-19 to 2020</td>
<td>5.60</td>
<td>60 Tamoxifen Sandoz</td>
</tr>
</tbody>
</table>

**Aromatase Inhibitors**

**ANASTROZOLE**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg – 1% DV Jan-18 to 2020</td>
<td>5.04</td>
<td>30 Rolin</td>
</tr>
</tbody>
</table>

**EXEMESTANE**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg – 1% DV Sep-17 to 2020</td>
<td>14.50</td>
<td>30 Pfizer Exemestane</td>
</tr>
</tbody>
</table>

**LETROZOLE**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2.5 mg – 1% DV Nov-18 to 2021</td>
<td>4.68</td>
<td>30 Letrole</td>
</tr>
</tbody>
</table>

**Imaging Agents**

**AMINOLEVULINIC ACID HYDROCHLORIDE – Restricted** see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for oral soln, 30 mg per ml, 1.5 g vial</td>
<td>4,400.00</td>
<td>1 Gliolan</td>
</tr>
<tr>
<td></td>
<td>44,000.00</td>
<td>10 Gliolan</td>
</tr>
</tbody>
</table>

**→ Restricted (RS1565)**

**Initiation – high grade malignant glioma**

All of the following:

1. Patient has newly diagnosed, untreated, glioblastoma multiforme; and
2. Treatment to be used as adjuvant to fluorescence-guided resection; and
3. Patient's tumour is amenable to complete resection.
## Immunosuppressants

### Calcineurin Inhibitors

<table>
<thead>
<tr>
<th>Product</th>
<th>Dosage</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CICLOSPORIN</td>
<td>Cap 25 mg</td>
<td>$44.63</td>
<td>Neoral</td>
</tr>
<tr>
<td></td>
<td>Cap 50 mg</td>
<td>$88.91</td>
<td>Neoral</td>
</tr>
<tr>
<td></td>
<td>Cap 100 mg</td>
<td>$177.81</td>
<td>Neoral</td>
</tr>
<tr>
<td></td>
<td>Oral liq 100 mg per ml</td>
<td>$198.13</td>
<td>Neoral</td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg per ml, 5 ml ampoule</td>
<td>$276.30</td>
<td>Sandimmun</td>
</tr>
</tbody>
</table>

**TACROLIMUS** — **Restricted** see terms **below**

- Cap 0.5 mg | $49.60 | 100 Tacrolimus Sandoz
- Cap 0.75 mg | $99.30 | 100 Tacrolimus Sandoz
- Cap 1 mg | $84.30 | 100 Tacrolimus Sandoz
- Cap 5 mg | $248.20 | 50 Tacrolimus Sandoz
- Inj 5 mg per ml, 1 ml ampoule

**Initiation** — **organ transplant recipients**
Any specialist
For use in organ transplant recipients.

**Initiation** — **non-transplant indications**
Any specialist
Both:
1. Patient requires long-term systemic immunosuppression; and
2. Ciclosporin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response.

Note: Indications marked with * are unapproved indications

### Fusion Proteins

<table>
<thead>
<tr>
<th>Product</th>
<th>Dosage</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETANERCEPT</td>
<td>Inj 25 mg vial</td>
<td>$799.96</td>
<td>Enbrel</td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg autoinjector</td>
<td>$1,599.96</td>
<td>Enbrel</td>
</tr>
<tr>
<td></td>
<td>Inj 50 mg syringe</td>
<td>$1,599.96</td>
<td>Enbrel</td>
</tr>
</tbody>
</table>

**Initiation** — **juvenile idiopathic arthritis**
Rheumatologist or named specialist

*Re-assessment required after 6 months*

Either:
1. Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or
2. All of the following:
   2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
   2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity

continued…
continued…

or intolerance; and

2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.5 Both:

2.5.1 Either:

2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or

2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician's global assessment indicating severe disease.

Continuation – juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Both:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation – rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or

2 All of the following:

2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and

2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

2.5 Any of the following:

2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or

2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or

continued…
2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:
   2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:
   2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Continuation – rheumatoid arthritis**

**Rheumatologist**

**Re-assessment required after 6 months**

All of the following:

1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2. Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3. Etanercept to be administered at doses no greater than 50 mg every 7 days.

**Initiation – ankylosing spondylitis**

**Rheumatologist**

**Re-assessment required after 6 months**

Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or

2. All of the following:
   2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
   2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
   2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
   2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
   2.5 Either:
      2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

continued…
2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

Continuation – ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

1. Following 12 weeks initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
2. Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
3. Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
2. All of the following:
   2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
   2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
   2.4 Either:
      2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
      2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

continued…
continued...

2.5 Any of the following:

2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or

2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months

Both:

1 Either:

1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – severe chronic plaque psoriasis, prior TNF use
Dermatologist
Limited to 4 months treatment

All of the following:

1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and

2 Either:

2.1 The patient has experienced intolerable side effects from adalimumab; or

2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and

3 Patient must be reassessed for continuation after 3 doses.

Initiation – severe chronic plaque psoriasis, treatment-naive
Dermatologist
Limited to 4 months treatment

All of the following:

1 Either:

1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or

1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

continued…
Continuation – severe chronic plaque psoriasis

Dermatologist

Re-assessment required after 6 months

Both:

1 Either:
   1.1 Both:
      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
      1.1.2 Either:
         1.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-eta
         nercept treatment baseline value; or
         1.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment base
         line value; or

1.2 Both:

   1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
   1.2.2 Either:
      1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
      1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-eta
      nercept treatment baseline value; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – pyoderma gangrenosum

Dermatologist

All of the following:

1 Patient has pyoderma gangrenosum*; and
2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
3 A maximum of 4 doses.

Note: Indications marked with * are unapproved indications.

Continuation – pyoderma gangrenosum

Dermatologist

All of the following:

1 Patient has shown clinical improvement; and
2 Patient continues to require treatment; and
3 A maximum of 4 doses.

Initiation – adult-onset Still’s disease

Rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still’s disease (AOSD); or

continued…
continued...

1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or

1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2 All of the following:

2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and

2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and

2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation – adult-onset Still’s disease

Rheumatologist

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

Initiation – undifferentiated spondyloarthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day (or maximum tolerated dose); and

4 Patient has tried and not responded to at least three months of leflunomide at a dose of up to 20 mg daily (or maximum tolerated dose); and

5 Any of the following:

5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour measured no more than one month prior to the date of this application; or

5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with * are unapproved indications.

Continuation – undifferentiated spondyloarthritis

Rheumatologist or medical practitioner on the recommendation of a Rheumatologist

Re-assessment required after 6 months

All of the following:

1 Either:

1.1 Applicant is a rheumatologist; or

1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

2 Either:

2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically
significant response to prior etanercept treatment in the opinion of the treating physician; and
3 Etanercept to be administered at doses no greater than 50 mg dose every 7 days.

Monoclonal Antibodies

**ABCIXIMAB – Restricted** see terms below

- Inj 2 mg per ml, 5 ml vial.................................................................579.53 1 ReoPro

Restricted (RS1202)

**Initiation**

Either:
1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
2 For use in patients undergoing intra-cranial intervention.

**ADALIMUMAB – Restricted** see terms below

- Inj 20 mg per 0.4 ml syringe..............................................................1,599.96 2 Humira
- Inj 40 mg per 0.8 ml pen....................................................................1,599.96 2 HumiraPen
- Inj 40 mg per 0.8 ml syringe..............................................................1,599.96 2 Humira

Restricted (RS1701)

**Initiation – juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 6 months*

Either:
1 Either:
   1.1 Both:
      1.1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
      1.1.2 Either:
         1.1.2.1 The patient has experienced intolerable side effects from etanercept; or
         1.1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for JIA; or

2 All of the following:

2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
2.5 Both:
   2.5.1 Either:
      2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
      2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
   2.5.2 Physician's global assessment indicating severe disease.
Continuation – juvenile idiopathic arthritis
Rheumatologist or named specialist
Re-assessment required after 6 months
Both:
1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2. Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation – fistulising Crohn's disease
Gastroenterologist
Re-assessment required after 4 months
All of the following:
1. Patient has confirmed Crohn's disease; and
2. Either:
   2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
   2.2 Patient has one or more rectovaginal fistula(e); and
3. A Baseline Fistula Assessment (a copy of which is available at www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf) has been completed and is no more than 1 month old at the time of application.

Continuation – fistulising Crohn's disease
Gastroenterologist
Re-assessment required after 6 months
Either:
1. The number of open draining fistulae have decreased from baseline by at least 50%; or
2. There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initiation – Crohn's disease - adults
Gastroenterologist
Re-assessment required after 3 months
All of the following:
1. Patient has severe active Crohn's disease; and
2. Any of the following:
   2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
   2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
   2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
   2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation – Crohn's disease - adults
Gastroenterologist
Re-assessment required after 3 months
Both:

continued…
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

continued...

1 Either:
   1.1 Either:
      1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
      1.1.2 CDAI score is 150 or less; or
   1.2 Both:
      1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
      1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – Crohn’s disease - children
Gastroenterologist
Re-assessment required after 3 months
All of the following:

1 Paediatric patient has severe active Crohn’s disease; and
2 Either:
   2.1 Patient has a Paediatric Crohn’s Disease Activity Index (PCDAI) score of greater than or equal to 30; or
   2.2 Patient has extensive small intestine disease; and
3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation – Crohn’s disease - children
Gastroenterologist
Re-assessment required after 3 months
Both:

1 Any of the following:
   1.1 PCDAI score has reduced by 100 points from the PCDAI score when the patient was initiated on adalimumab; or
   1.2 PCDAI score is 150 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – rheumatoid arthritis
Rheumatologist
Re-assessment required after 6 months
Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
2 All of the following:
   2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
   2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

continued…
continued...

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

2.5 Any of the following:

2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or

2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or

2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:

2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or

2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:

2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Continuation – rheumatoid arthritis**

Rheumatologist

Re-assessment required after 6 months

All of the following:

1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2. Either:

   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – ankylosing spondylitis**

Rheumatologist

Re-assessment required after 6 months

Either:

1. Both:

   1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and

   1.2 Either:

      1.2.1 The patient has experienced intolerable side effects from etanercept; or

      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or

2. All of the following:

   2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and

   2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and

   2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and

   2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing continued…
continued...

2.5 Either:

2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober’s test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

Continuation – ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

1 Following 12 weeks’ initial treatment and subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and

2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept; or

1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or

2 All of the following:

2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and

2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and

continued…
continued...

2.4 Either:

2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or

2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.5 Any of the following:

2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or

2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months
Both:

1 Either:

1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – plaque psoriasis, prior TNF use
Dermatologist
Limited to 4 months treatment
Both:

1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and

2 Either:

2.1 The patient has experienced intolerable side effects from etanercept; or

2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis.

Initiation – plaque psoriasis, treatment-naive
Dermatologist
Limited to 4 months treatment
All of the following:

1 Either:

1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or

1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as continued…
assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation – plaque psoriasis**

**Dermatologist**

*Re-assessment required after 6 months*

**Both:**

1. **Either:**
   
   1. **Both:**
      
      1.1 **Either:**
         
         1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
         
         1.1.2 **Either:**
            
            1.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
            
            1.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
         
         1.2 **Both:**
            
            1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
            
            1.2.2 **Either:**
               
               1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
               
               1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
      
2. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – pyoderma gangrenosum**

**Dermatologist**

All of the following:

1. Patient has pyoderma gangrenosum*; and
2. Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
3. A maximum of 4 doses.

Note: Indications marked with * are unapproved indications.

**Continuation – pyoderma gangrenosum**

**Dermatologist**

All of the following:

1. Patient has shown clinical improvement; and
2. Patient continues to require treatment; and
3. A maximum of 4 doses.

**Initiation – adult-onset Still’s disease**

**Rheumatologist**

*Re-assessment required after 6 months*

**Either:**

1. **Both:**

continued…
continued...

1.1 Either:
   1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still’s disease (AOSD); or
   1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and

1.2 Either:
   1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
   1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2 All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation – adult-onset Still’s disease
Rheumatologist
Re-assessment required after 6 months
The patient has a sustained improvement in inflammatory markers and functional status.

Initiation – severe Behcet’s disease
Any relevant practitioner
Re-assessment required after 3 months
All of the following:
   1 The patient has severe Behcet’s disease that is significantly impacting the patient’s quality of life (see Notes); and
   2 Either:
      2.1 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has not responded adequately to treatment with infliximab (see Notes); or
      2.2 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has experienced intolerable side effects from treatment with infliximab; and
   3 The patient is experiencing significant loss of quality of life; and
   4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.


Continuation – severe Behcet’s disease
Any relevant practitioner
Re-assessment required after 6 months
Both:
   1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
   2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – severe ocular inflammation
Re-assessment required after 4 months
Either:
   1 Both:
      1.1 The patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; and
      1.2 Either:
         1.2.1 The patient has experienced intolerable side effects from infliximab; or

continued…
continued...

1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for severe ocular inflammation; or

2 Both:

2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and

2.2 Any of the following:

2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or

2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or

2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Continuation – severe ocular inflammation

Re-assessment required after 12 months

Both:

1 Any of the following:

1.1 The patient has had a good clinical response following 3 initial doses; or

1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

Initiation – chronic ocular inflammation

Re-assessment required after 4 months

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from infliximab; or

1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for chronic ocular inflammation; or

2 Both:

2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and

2.2 Any of the following:

2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or

2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or

2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation – chronic ocular inflammation

Re-assessment required after 12 months

Both:

1 Any of the following:

continued…
1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation
   (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active
   vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in
   prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
2. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

Initiation – hidradenitis suppurativa
Dermatologist
Re-assessment required after 4 months
All of the following:
1. Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
2. Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has
   demonstrated intolerance to or has contraindications for systemic antibiotics; and
3. The patient has 3 or more active lesions (e.g. inflammatory nodules, abscesses, draining fistulae); and
4. The patient has a Dermatology Quality of Life Index of 10 or more and the assessment is no more than 1 month old at time
   of application; and
5. Following the initial loading doses, adalimumab is to be administered at doses no greater than 40mg every 7 days.

Continuation – hidradenitis suppurativa
Dermatologist
Re-assessment required after 6 months
All of the following:
1. The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more
   from baseline; and
2. The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
3. Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

AFLIBERCEPT – Restricted see terms below

$  Inj 40 mg per ml, 0.1 ml vial.................................................................1,250.00 1 Eylea

Initiation – Wet Age Related Macular Degeneration
Ophthalmologist
Re-assessment required after 3 months
Either:
1. All of the following:
   1.1 Any of the following:
      1.1.1 Wet age-related macular degeneration (wet AMD); or
      1.1.2 Polypoidal choroidal vasculopathy; or
      1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
   1.2 Either:
      1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with
          bevacizumab; or
      1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab
          four weeks apart; and
   1.3 There is no structural damage to the central fovea of the treated eye; and

continued…
continued…

1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or

2 Either:
   2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
   2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Continuation – Wet Age Related Macular Degeneration
Ophthalmologist
Re-assessment required after 12 months
All of the following:

1 Documented benefit must be demonstrated to continue; and
2 Patient’s vision is 6/36 or better on the Snellen visual acuity score; and
3 There is no structural damage to the central fovea of the treated eye.

Initiation – Diabetic Macular Oedema
Ophthalmologist
Re-assessment required after 4 months
All of the following:

1 Patient has centre involving diabetic macular oedema (DMO); and
2 Patient’s disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
3 Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Continuation – Diabetic Macular Oedema
Ophthalmologist
Re-assessment required after 12 months
All of the following:

1 There is stability or two lines of Snellen visual acuity gain; and
2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
3 Patient’s vision is 6/36 or better on the Snellen visual acuity score; and
4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
5 After each consecutive 12 months treatment with aflibercept, patient has retrialled with at least one injection of bevacizumab and had no response.

BASILIXIMAB – Restricted see terms below

- Inj 20 mg vial .................................................................2,560.00 1 Simulect

BEVACIZUMAB – Restricted see terms below

- Inj 25 mg per ml, 4 ml vial
- Inj 25 mg per ml, 16 ml vial

Initiation – Recurrent Respiratory Papillomatosis
Otolaryngologist
Re-assessment required after 12 months
All of the following:

continued…
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

continued...

1 Maximum of 6 doses; and
2 The patient has recurrent respiratory papillomatosis; and
3 The treatment is for intra-lesional administration.

Continuation – Recurrent Respiratory Papillomatosis
Otolaryngologist
Re-assessment required after 12 months
All of the following:
1 Maximum of 6 doses; and
2 The treatment is for intra-lesional administration; and
3 There has been a reduction in surgical treatments or disease regrowth as a result of treatment.

Initiation – ocular conditions
Either:
1 Ocular neovascularisation; or
2 Exudative ocular angiopathy.

CETUXIMAB – Restricted see terms below

- Inj 5 mg per ml, 20 ml vial.................................................................364.00 1 Erbitux
- Inj 5 mg per ml, 100 ml vial............................................................1,820.00 1 Erbitux

⇒ Restricted (RS1613)

Initiation
Medical oncologist
All of the following:
1 Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck; and
2 Patient is contraindicated to, or is intolerant of, cisplatin; and
3 Patient has good performance status; and
4 To be administered in combination with radiation therapy.

INFLIXIMAB – Restricted see terms below

- Inj 100 mg.............................................................806.00 1 Remicade

⇒ Restricted (RS1697)

Initiation – Graft vs host disease
Patient has steroid-refractory acute graft vs. host disease of the gut.

Initiation – rheumatoid arthritis
Rheumatologist
Re-assessment required after 4 months
All of the following:
1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
2 Either:
   2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

Continuation – rheumatoid arthritis
Rheumatologist
Re-assessment required after 6 months
All of the following:
1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by
continued...

toxicity or intolerance; and

2 Either:
   2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Initiation – ankylosing spondylitis
Rheumatologist
Re-assessment required after 3 months

Both:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and

2 Either:
   2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Continuation – ankylosing spondylitis
Rheumatologist
Re-assessment required after 6 months

All of the following:

1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and

2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initiation – psoriatic arthritis
Rheumatologist
Re-assessment required after 4 months

Both:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and

2 Either:
   2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

Continuation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months

Both:

1 Either:
   1.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and

2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation – severe ocular inflammation
Re-assessment required after 3 doses

Either:

1 Both:

continued…
1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
1.2 Either:
   1.2.1 The patient has experienced intolerable side effects from adalimumab; or
   1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or

2 Both:
   2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
   2.2 Any of the following:
      2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
      2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
      2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Continuation – severe ocular inflammation
Re-assessment required after 12 months

Any of the following:
1 The patient has had a good clinical response following 3 initial doses; or
2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initiation – chronic ocular inflammation
Re-assessment required after 3 doses

Either:
1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation; or

2 Both:
   2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
   2.2 Any of the following:
      2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
      2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at therapeutic dose; or
      2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation – chronic ocular inflammation
Re-assessment required after 12 months

Any of the following:

continued…
continued…

1 The patient has had a good clinical response following 3 initial doses; or
2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

**Initiation – Pulmonary sarcoidosis**

Both:

1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

**Initiation – Crohn's disease (adults)**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

1 Patient has severe active Crohn's disease; and
2 Any of the following:
   1. Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
   2. Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
   3. Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
   4. Patient has an ileostomy or colostomy, and has intestinal inflammation; and
3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4 Surgery (or further surgery) is considered to be clinically inappropriate; and
5 Patient must be reassessed for continuation after 3 months of therapy.

**Continuation – Crohn's disease (adults)**

Gastroenterologist

*Re-assessment required after 6 months*

Both:

1 Any of the following:
   1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
   1.2 CDAI score is 150 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

**Initiation – Crohn's disease (children)**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

1 Paediatric patient has severe active Crohn's disease; and
2 Either:
   1. Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
2.2 Patient has extensive small intestine disease; and

continued…
continued...

3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and

4 Surgery (or further surgery) is considered to be clinically inappropriate; and

5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation – Crohn’s disease (children)
Gastroenterologist

Re-assessment required after 6 months

Both:

1 Any of the following:
   1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
   1.2 PCDAI score is 15 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and

2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – fistulising Crohn’s disease
Gastroenterologist

Re-assessment required after 4 months

Both:

1 Patient has confirmed Crohn’s disease; and

2 Either:
   2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
   2.2 Patient has one or more rectovaginal fistula(e).

Continuation – fistulising Crohn’s disease
Gastroenterologist

Re-assessment required after 6 months

Both:

1 Either:
   1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
   1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and

2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – acute severe fulminant ulcerative colitis
Gastroenterologist

Limited to 6 weeks treatment

Both:

1 Patient has acute, severe fulminant ulcerative colitis; and

2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

Continuation – severe fulminant ulcerative colitis
Gastroenterologist

Re-assessment required after 6 months

Both:

1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and

continued…
continued...

2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – severe ulcerative colitis
Gastroenterologist
Re-assessment required after 3 months
All of the following:

1 Patient has histologically confirmed ulcerative colitis; and
2 Either:
   2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is greater than or equal to 4; or
   2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is greater than or equal to 65; and
3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation – severe ulcerative colitis
Gastroenterologist
Re-assessment required after 6 months
All of the following:

1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
2 Either:
   2.1 Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
   2.2 Patient is under 18 years and the PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab; and
3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – plaque psoriasis
Dermatologist
Re-assessment required after 3 doses
Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
      1.2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis; or
2 All of the following:
   2.1 Either:
      2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
      2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

continued…
continued...

2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and

2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – plaque psoriasis

Dermatologist

Re-assessment required after 3 doses

Both:

1 Either:

1.1 Both:

1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or

1.2 Both:

1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and

1.2.2 Either:

1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or

1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and

2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation – neurosarcoïdosis

Neurologist

Re-assessment required after 18 months

All of the following:

1 Biopsy consistent with diagnosis of neurosarcoïdosis; and

2 Patient has CNS involvement; and

3 Patient has steroid-refractory disease; and

4 Either:

4.1 IV cyclophosphamide has been tried; or

4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

Continuation – neurosarcoïdosis

Neurologist

Re-assessment required after 18 months

Either:

1 A withdrawal period has been tried and the patient has relapsed; or

continued…
continued...

2 All of the following:
   2.1 A withdrawal period has been considered but would not be clinically appropriate; and
   2.2 There has been a marked reduction in prednisone dose; and
   2.3 Either:
      2.3.1 There has been an improvement in MRI appearances; or
      2.3.2 Marked improvement in other symptomology.

Initiation – severe Behcet’s disease
Re-assessment required after 4 months
All of the following:

1. The patient has severe Behcet’s disease which is significantly impacting the patient’s quality of life (see Notes); and
2. Either:
   2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one
       or more treatment(s) appropriate for the particular symptom(s) (see Notes); or
   2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded
       adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and
3. The patient is experiencing significant loss of quality of life.

Notes:

2. Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for
   these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine,
   steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and
   methotrexate for rheumatological symptoms.

Continuation – severe Behcet’s disease
Re-assessment required after 6 months
Both:

1. Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
2. Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

OBLINUTZUMAB – Restricted see terms below

● Inj 25 mg per ml, 40 ml vial..........................................................5,910.00 1 Gazyva

Restricted (RS1550)

Initiation
Haematologist
Limited to 6 months treatment
All of the following:

1. The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
2. The patient is obinutuzumab treatment naive; and
3. The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale
   (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
4. Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by
   CLL; and
5. Patient has good performance status; and
6. Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a
   maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other

continued…
than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* greater than or equal to 1.5 \times 10^9/L and platelets greater than or equal to 75 \times 10^9/L

OMALIZUMAB – Restricted see terms below

- Inj 150 mg prefilled syringe ................................................................. 450.00 1 Xolair
- Inj 150 mg vial ..................................................................................... 450.00 1 Xolair

**Restricted (RS1652)**

Initiation – severe asthma

Clinical immunologist or respiratory specialist

*Re-assessment required after 6 months*

All of the following:

1. Patient must be aged 6 years or older; and
2. Patient has a diagnosis of severe asthma; and
3. Past or current evidence of atopy, documented by skin prick testing or RAST; and
4. Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
5. Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
6. Either:
   6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
   6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
7. Patient has an Asthma Control Test (ACT) score of 10 or less; and
8. Baseline measurements of the patient’s asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Continuation – severe asthma

Respiratory specialist

*Re-assessment required after 6 months*

Both:

1. An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
2. A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Initiation – severe chronic spontaneous urticaria

Clinical immunologist or dermatologist

*Re-assessment required after 6 months*

All of the following:

1. Patient must be aged 12 years or older; and
2. Either:
   2.1 Both:
      2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
      2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; and
3. Any of the following:
   3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
   3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic
continued…

corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or

3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and

4 Either:
   4.1 Treatment to be stopped if inadequate response* following 4 doses; or
   4.2 Complete response* to 6 doses of omalizumab.

Continuation – severe chronic spontaneous urticaria
Clinical immunologist or dermatologist
Re-assessment required after 6 months
Either:
   1 Patient has previously had a complete response* to 6 doses of omalizumab; or
   2 Both:
      2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
      2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PERTUZUMAB – Restricted see terms below
↓ Inj 30 mg per ml, 14 ml vial..................................................3,927.00 1 Perjeta
⇒ Restricted (RS1551)

Initiation
Re-assessment required after 12 months
All of the following:
   1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   2 Either:
      2.1 Patient is chemotherapy treatment naive; or
      2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
   3 The patient has good performance status (ECOG grade 0-1); and
   4 Pertuzumab to be administered in combination with trastuzumab; and
   5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
   6 Pertuzumab to be discontinued at disease progression.

Continuation
Re-assessment required after 12 months
Both:
   1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

RANIBIZUMAB – Restricted see terms below
↓ Inj 10 mg per ml, 0.23 ml vial
↓ Inj 10 mg per ml, 0.3 ml vial
⇒ Restricted (RS1637)

Initiation – Wet Age Related Macular Degeneration
Ophthalmologist
Re-assessment required after 3 months
Either:

continued…
continued...

1 All of the following:
   1.1 Any of the following:
       1.1.1 Wet age-related macular degeneration (wet AMD); or
       1.1.2 Polypoidal choroidal vasculopathy; or
       1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
   1.2 Either:
       1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
       1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
   1.3 There is no structural damage to the central fovea of the treated eye; and
   1.4 Patient has not previously been treated with aflibercept for longer than 3 months; or
2 Patient has current approval to use aflibercept for treatment of wAMD and was found to be intolerant to aflibercept within 3 months.

Continuation – Wet Age Related Macular Degeneration
Ophthalmologist
Re-assessment required after 12 months
All of the following:
   1 Documented benefit must be demonstrated to continue; and
   2 Patient’s vision is 6/36 or better on the Snellen visual acuity score; and
   3 There is no structural damage to the central fovea of the treated eye.

RITUXIMAB (MABTHERA) – Restricted see terms below
* Inj 10 mg per ml, 10 ml vial.................................................................1,075.50 2 Mabthera
* Inj 10 mg per ml, 50 ml vial.................................................................2,688.30 1 Mabthera

Initiation – haemophilia with inhibitors
No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – haemophilia with inhibitors
Haematologist
All of the following:
   1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
   2 An initial response lasting at least 12 months was demonstrated; and
   3 Patient now requires repeat treatment.

Initiation – post-transplant
No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – post-transplant
All of the following:
   1 The patient has had a rituximab treatment-free interval of 12 months or more; and
   2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
   3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

Initiation – indolent, low-grade lymphomas or hairy cell leukaemia*
No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – indolent, low-grade lymphomas or hairy cell leukaemia*
Re-assessment required after 9 months
All of the following:

continued…
continued…

1 The patient has had a rituximab treatment-free interval of 12 months or more; and
2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. ‘Hairy cell leukaemia’ also includes hairy cell leukaemia variant.

Initiation – aggressive CD20 positive NHL
No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – aggressive CD20 positive NHL
All of the following:

1 The patient has had a rituximab treatment-free interval of 12 months or more; and
2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Initiation – Chronic lymphocytic leukaemia
No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – Chronic lymphocytic leukaemia
Re-assessment required after 12 months
Both:

1 Either:
   1.1 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; or
   1.2 All of the following:
      1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
      1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
      1.2.3 The patient does not have chromosome 17p deletion CLL; and
      1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and
2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initiation – rheumatoid arthritis - prior TNF inhibitor use
Rheumatologist
Limited to 4 months treatment
All of the following:

1 Both:
   1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
      1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
2 Either:

continued…
continued...

2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – rheumatoid arthritis - TNF inhibitors contraindicated
Rheumatologist

Limited to 4 months treatment
All of the following:

1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
5 Any of the following:
   5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
   5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
   5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

6 Either:
   6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

7 Either:
   7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and

8 Either:
   8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis - re-treatment in 'partial responders' to rituximab
Rheumatologist

Re-assessment required after 4 months
All of the following:

1 Any of the following:
   1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

continued…
continued...

3 Either:
   3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis - re-treatment in ‘responders’ to rituximab

Rheumatologist

Re-assessment required after 4 months

All of the following:

1 Either:
   1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:
   3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – severe cold haemagglutinin disease (CHAD)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 4 weeks

Either:

1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or

2 All of the following:
   2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
   2.2 An initial response lasting at least 12 months was demonstrated; and
   2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – warm autoimmune haemolytic anaemia (warm AIHA)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 4 weeks

Either:

1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or

2 All of the following:
   2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
   2.2 An initial response lasting at least 12 months was demonstrated; and
   2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – immune thrombocytopenic purpura (ITP)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

continued…
Continuation – immune thrombocytopenic purpura (ITP)

Haematologist

Re-assessment required after 4 weeks

Either:

1. Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m$^2$ weekly for 4 weeks) is now planned; or
2. All of the following:
   2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
   2.2 An initial response lasting at least 12 months was demonstrated; and
   2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – thrombotic thrombocytopenic purpura (TTP)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Re-assessment required after 4 weeks

All of the following:

1. Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
2. An initial response lasting at least 12 months was demonstrated; and

Note: Indications marked with * are unapproved indications.

Initiation – pure red cell aplasia (PRCA)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – pure red cell aplasia (PRCA)

Haematologist

Re-assessment required after 6 weeks

Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initiation – ANCA associated vasculitis

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – ANCA associated vasculitis

Re-assessment required after 4 weeks

All of the following:

1. Patient has been diagnosed with ANCA associated vasculitis*; and
2. Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
3. The total rituximab dose would not exceed the equivalent of 375 mg/m$^2$ of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initiation – treatment refractory systemic lupus erythematosus (SLE)

No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

1. Patient’s SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
2. The disease has subsequently relapsed; and
3. Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.
continued…

Initiation – Antibody-mediated renal transplant rejection
No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Initiation – ABO-incompatible renal transplant
No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)
No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)
Nephrologist
Re-assessment required after 4 weeks
All of the following:
1. Patient who was previously treated with rituximab for nephrotic syndrome*; and
2. Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Initiation – Steroid resistant nephrotic syndrome (SRNS)
No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – Steroid resistant nephrotic syndrome (SRNS)
Nephrologist
Re-assessment required after 4 weeks
All of the following:
1. Patient who was previously treated with rituximab for nephrotic syndrome*; and
2. Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Initiation – Neuromyelitis Optica Spectrum Disorder (NMOSD)
No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – Neuromyelitis Optica Spectrum Disorder (NMOSD)
Relevant specialist or medical practitioner on the recommendation of a Relevant specialist
Re-assessment required after 2 years
All of the following:
1. One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
2. The patient has responded to the most recent course of rituximab; and
3. The patient has not received rituximab in the previous 6 months.

Initiation – Severe Refractory Myasthenia Gravis
No new patient can start on rituximab (Mabthera brand) under this Initiation criteria from 1 March 2020.

Continuation – Severe Refractory Myasthenia Gravis
Neurologist or medical practitioner on the recommendation of a Neurologist
Re-assessment required after 2 years
All of the following:
1. One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
2. An initial response lasting at least 12 months was demonstrated; and
3. Either:

continued…
continued...

3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or

3.2 Both:

3.2.1 The patient’s myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and

3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

RITUXIMAB (RIXIMYO) – Restricted see terms below

- Inj 10 mg per ml, 10 ml vial ................................................................. 275.33 2 Riximyo
- Inj 10 mg per ml, 50 ml vial ................................................................. 688.20 1 Riximyo

Restricted (RS1729)

Initiation – haemophilia with inhibitors

Haematologist

Any of the following:

1. Patient has mild congenital haemophilia complicated by inhibitors; or
2. Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
3. Patient has acquired haemophilia.

Continuation – haemophilia with inhibitors

Haematologist

All of the following:

1. Patient was previously treated with rituximab for haemophilia with inhibitors; and
2. An initial response lasting at least 12 months was demonstrated; and

Initiation – post-transplant

Both:

1. The patient has B-cell post-transplant lymphoproliferative disorder*; and
2. To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are unapproved indications.

Continuation – post-transplant

All of the following:

1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has B-cell post-transplant lymphoproliferative disorder*; and
3. To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

Initiation – indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 9 months

Either:

1. Both:

1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
1.2 To be used for a maximum of 6 treatment cycles; or

2. Both:

2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
2.2 To be used for a maximum of 6 treatment cycles.

Note: ‘Indolent, low-grade lymphomas’ includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. ‘Hairy cell leukaemia’ also includes hairy cell leukaemia variant.

continued…
Continuation – indolent, low-grade lymphomas or hairy cell leukaemia*
Re-assessment required after 12 months
Either:

1. All of the following:
   1.1 The patient has had a rituximab treatment-free interval of 12 months or more; and
   1.2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
   1.3 To be used for no more than 6 treatment cycles; or

2. Both:
   2.1 Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy; and
   2.2 Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m2 every 8 weeks (maximum of 12 cycles).

Note: *Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. *Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Initiation – aggressive CD20 positive NHL
Either:

1. All of the following:
   1.1 The patient has treatment naive aggressive CD20 positive NHL; and
   1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
   1.3 To be used for a maximum of 8 treatment cycles; or

2. Both:
   2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
   2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Continuation – aggressive CD20 positive NHL
All of the following:

1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has relapsed refractory/aggressive CD20 positive NHL; and
3. To be used with a multi-agent chemotherapy regimen given with curative intent; and
4. To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Initiation – Chronic lymphocytic leukaemia
Re-assessment required after 12 months
All of the following:

1. The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
2. Any of the following:
   2.1 The patient is rituximab treatment naive; or
   2.2 Either:
      2.2.1 The patient is chemotherapy treatment naive; or
      2.2.2 Both:
         2.2.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
         2.2.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; or
   2.3 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; and

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Initiation – Chronic lymphocytic leukaemia
Re-assessment required after 12 months
All of the following:

1. The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
2. Any of the following:
   2.1 The patient is rituximab treatment naive; or
   2.2 Either:
      2.2.1 The patient is chemotherapy treatment naive; or
      2.2.2 Both:
         2.2.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
         2.2.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; or
   2.3 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; and

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.
continued...

3 The patient has good performance status; and

4 Either:
   4.1 The patient does not have chromosome 17p deletion CLL; or
   4.2 Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia; and

5 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles; and

6 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax.

Note: ‘Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. ‘Good performance status’ means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

Continuation – Chronic lymphocytic leukaemia
Re-assessment required after 12 months
Both:

1 Either:
   1.1 The patient’s disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; or
   1.2 All of the following:
      1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
      1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
      1.2.3 The patient does not have chromosome 17p deletion CLL; and
      1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and

2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.

Note: ‘Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initiation – severe cold haemagglutinin disease (CHAD)
Haematologist
Re-assessment required after 4 weeks
Both:

1 Patient has cold haemagglutinin disease*; and

2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms.

Note: Indications marked with * are unapproved indications.

Continuation – severe cold haemagglutinin disease (CHAD)
Haematologist
Re-assessment required after 4 weeks
Either:

1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or

2 All of the following:
   2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and

continued…
continued…

2.2 An initial response lasting at least 12 months was demonstrated; and
2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

**Initiation – warm autoimmune haemolytic anaemia (warm AIHA)**

Haematologist

*Re-assessment required after 4 weeks*

**Both:**

1. Patient has warm autoimmune haemolytic anaemia*; and
2. One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin.

Note: Indications marked with * are unapproved indications.

**Continuation – warm autoimmune haemolytic anaemia (warm AIHA)**

Haematologist

*Re-assessment required after 4 weeks*

**Either:**

1. Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
2. All of the following:
   1.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
   2.2 An initial response lasting at least 12 months was demonstrated; and
   2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

**Initiation – immune thrombocytopenic purpura (ITP)**

Haematologist

*Re-assessment required after 4 weeks*

**Both:**

1. Either:
   1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
   1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
2. Any of the following:
   2.1 Treatment with steroids and splenectomy have been ineffective; or
   2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
   2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy).

Note: Indications marked with * are unapproved indications.

**Continuation – immune thrombocytopenic purpura (ITP)**

Haematologist

*Re-assessment required after 4 weeks*

**Either:**

1. Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
2. All of the following:
   2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
   2.2 An initial response lasting at least 12 months was demonstrated; and

continued…
continued...

2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

**Initiation – thrombotic thrombocytopenic purpura (TTP)**

Haematologist

*Re-assessment required after 4 weeks*

Either:

1. Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or

2. Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are unapproved indications.

**Continuation – thrombotic thrombocytopenic purpura (TTP)**

Haematologist

*Re-assessment required after 4 weeks*

All of the following:

1. Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and

2. An initial response lasting at least 12 months was demonstrated; and


Note: Indications marked with * are unapproved indications.

**Initiation – pure red cell aplasia (PRCA)**

Haematologist

*Re-assessment required after 6 weeks*

Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

**Continuation – pure red cell aplasia (PRCA)**

Haematologist

*Re-assessment required after 6 weeks*

Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

**Initiation – ANCA associated vasculitis**

*Re-assessment required after 4 weeks*

All of the following:

1. Patient has been diagnosed with ANCA associated vasculitis*; and

2. The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and

3. Any of the following:

   3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or

   3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or

   3.3 Cyclophosphamide and methotrexate are contraindicated; or

   3.4 Patient is a female of child-bearing potential; or

   3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

**Continuation – ANCA associated vasculitis**

*Re-assessment required after 4 weeks*

All of the following:

continued…
continued...

1 Patient has been diagnosed with ANCA associated vasculitis*; and
2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

**Initiation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

1 The patient has severe, immediately life- or organ-threatening SLE*; and
2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
4 Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

**Continuation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

1 Patient’s SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
2 The disease has subsequently relapsed; and
3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

**Initiation – Antibody-mediated organ transplant rejection**

Patient has been diagnosed with antibody-mediated organ transplant rejection*.

Note: Indications marked with * are unapproved indications.

**Initiation – ABO-incompatible organ transplant**

Patient is to undergo an ABO-incompatible solid organ transplant*.

Note: Indications marked with * are unapproved indications.

**Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

1 Patient is a child with SDNS* or FRNS*; and
2 Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
3 Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
4 Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
5 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

**Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
2 Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and

continued…
continued...

3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Initiation – Steroid resistant nephrotic syndrome (SRNS)

Nephrologist

Re-assessment required after 4 weeks

All of the following:

1 Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
2 Treatment with tacrolimus for at least 3 months has been ineffective; and
3 Genetic causes of nephrotic syndrome have been excluded; and
4 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Continuation – Steroid resistant nephrotic syndrome (SRNS)

Nephrologist

Re-assessment required after 4 weeks

All of the following:

1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Initiation – Neuromyelitis Optica Spectrum Disorder (NMOSD)

Re-assessment required after 6 months

Both:

1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
2 Either:
   2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
   2.2 All of the following:
      2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
      2.2.2 The patient is receiving treatment with mycophenolate; and
      2.2.3 The patients is receiving treatment with corticosteroids.

Continuation – Neuromyelitis Optica Spectrum Disorder (NMOSD)

Re-assessment required after 2 years

All of the following:

1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
2 The patients has responded to the most recent course of rituximab; and
3 The patient has not received rituximab in the previous 6 months.

Initiation – Severe Refractory Myasthenia Gravis

Neurologist

Re-assessment required after 2 years

Both:

continued…
continued…

1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
2 Either:
   2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
   2.2 Both:
      2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
      2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Continuation – Severe Refractory Myasthenia Gravis
Neurologist
Re-assessment required after 2 years

All of the following:
1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
2 An initial response lasting at least 12 months was demonstrated; and
3 Either:
   3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
   3.2 Both:
      3.2.1 The patient’s myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
      3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Initiation – Severe antisynthetase syndrome
Re-assessment required after 12 months

All of the following:
1 Patient has confirmed antisynthetase syndrome; and
2 Patient has severe, immediately life or organ threatening disease, including interstitial lung disease; and
3 Either:
   3.1 Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not be effective at controlling active disease; or
   3.2 Rapid treatment is required due to life threatening complications; and
4 Maximum of four 1,000 mg infusions of rituximab.

Continuation – Severe antisynthetase syndrome
Re-assessment required after 12 months

All of the following:
1 Patient’s disease has responded to the previous rituximab treatment with demonstrated improvement in inflammatory markers, muscle strength and pulmonary function; and
2 The patient has not received rituximab in the previous 6 months; and
3 Maximum of two cycles of 2 × 1,000 mg infusions of rituximab given two weeks apart.

Initiation – graft versus host disease

All of the following:
1 Patient has refractory graft versus host disease following transplant; and
2 Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not be effective at controlling active disease; and

continued…
continued...

3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Initiation – severe chronic inflammatory demyelinating polyneuropathy

Neurologist

Re-assessment required after 6 months

All of the following:

1 Patient has severe chronic inflammatory demyelinating polyneuropathy (CIPD); and
2 Either:
   2.1 Both:
      2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
      2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
   2.2 Rapid treatment is required due to life threatening complications; and
3 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Continuation – severe chronic inflammatory demyelinating polyneuropathy

Neurologist or medical practitioner on the recommendation of a Neurologist

Re-assessment required after 6 months

All of the following:

1 Patient’s disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function compared to baseline; and
2 The patient has not received rituximab in the previous 6 months; and
3 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initiation – anti-NMDA receptor autoimmune encephalitis

Neurologist

Re-assessment required after 6 months

All of the following:

1 Patient has severe anti-NMDA receptor autoimmune encephalitis; and
2 Either:
   2.1 Both:
      2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
      2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
   2.2 Rapid treatment is required due to life threatening complications; and
3 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Continuation – anti-NMDA receptor autoimmune encephalitis

Neurologist

Re-assessment required after 6 months

All of the following:

1 Patient’s disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function; and
2 The patient has not received rituximab in the previous 6 months; and
3 The patient has experienced a relapse and now requires further treatment; and

continued…
### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**continued…**

4 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

### SECUKINUMAB – Restricted see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>☑ Inj 150 mg per ml, 1 ml prefilled syringe</td>
<td>1,599.00</td>
<td></td>
</tr>
</tbody>
</table>

**Initiation – severe chronic plaque psoriasis, second-line biologic**

**Dermatologist**

*Re-assessment required after 4 months*

**All of the following:**

1. The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule, for severe chronic plaque psoriasis; and

2. Either:
   1. The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
   2. The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and

3. A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4. The most recent PASI or DLQI assessment is no more than 1 month old at the time of application.

**Continuation – severe chronic plaque psoriasis, second-line biologic**

**Dermatologist**

*Re-assessment required after 6 months*

**Both:**

1. Either:
   1.1 Patient’s PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
   1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and

2. Secukinumab to be administered at a maximum dose of 300 mg monthly.

**Initiation – severe chronic plaque psoriasis, first-line biologic**

**Dermatologist**

*Re-assessment required after 4 months*

**All of the following:**

1. Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2. Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

3. A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4. The most recent PASI or DLQI assessment is no more than 1 month old at the time of application.

**Note:** A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand

continued…
continued...

or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and
the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment
but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – severe chronic plaque psoriasis, first-line biologic

Dermatologist

Re-assessment required after 6 months

Both:

1 Either:
   1.1 Patient’s PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing
       secukinumab; or
   1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI
       prior to commencing secukinumab; and

2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

SILTUXIMAB – Restricted see terms below

Initiation

Haematologist or rheumatologist

Re-assessment required after 6 months

All of the following:

1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and
2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Continuation

Haematologist or rheumatologist

Re-assessment required after 12 months

The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

TOCILIZUMAB – Restricted see terms below

Initiation – cytokine release syndrome

Therapy limited to 3 doses

Either:

1 All of the following:
   1.1 The patient is enrolled in the Children’s Oncology Group AALL1731 trial; and
   1.2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of
       blinatumomab for the treatment of acute lymphoblastic leukaemia; and
   1.3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg,
       maximum of 12 mg/kg); or

2 All of the following:
   2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
   2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the
       administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and

continued…
2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

**Initiation – previous use**

*Any relevant practitioner*

*Limited to 6 months treatment*

**Both:**

1. Patient was being treated with tocilizumab prior to 1 February 2019; and
2. Any of the following:
   1.1 rheumatoid arthritis; or
   1.2 systemic juvenile idiopathic arthritis; or
   1.3 adult-onset Still's disease; or
   1.4 polyarticular juvenile idiopathic arthritis; or
   1.5 idiopathic multicentric Castleman's disease.

**Initiation – Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)**

*Rheumatologist or Practitioner on the recommendation of a rheumatologist*

*Limited to 6 months treatment*

**All of the following:**

1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
2. Either:
   2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
   2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
3. Either:
   3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
   3.2 Both:
      3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and
      3.2.2 Either:
         3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
         3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

**Initiation – Rheumatoid Arthritis**

*Rheumatologist or Practitioner on the recommendation of a rheumatologist*

*Re-assessment required after 6 months*

**All of the following:**

1. Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
2. Tocilizumab is to be used as monotherapy; and
3. Either:
   3.1 Treatment with methotrexate is contraindicated; or
   3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
4. Either:
   4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or
   4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
5. Either:

continued…
continued…

5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

6 Either:
6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Initiation – systemic juvenile idiopathic arthritis**
Rheumatologist or Practitioner on the recommendation of a rheumatologist
*Re-assessment required after 6 months*

Both:
1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

**Initiation – adult-onset Still’s disease**
Rheumatologist or Practitioner on the recommendation of a rheumatologist
*Re-assessment required after 6 months*

Either:
1 Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still’s disease (AOSD); or
      1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
      1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
2 All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**Initiation – polyarticular juvenile idiopathic arthritis**
Rheumatologist or Practitioner on the recommendation of a rheumatologist
*Re-assessment required after 4 months*

Either:
1 Both:
   1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for juvenile idiopathic arthritis (JIA); and
   1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or
2 All of the following:
   2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
   2.2 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

continued…
continued...

2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.4 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.5 Both:

2.5.1 Either:

2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or

2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician's global assessment indicating severe disease.

Initiation – idiopathic multicentric Castleman's disease
Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist

Re-assessment required after 6 months

All of the following:

1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and

2 Treatment with an adequate trial of corticosteroids has proven ineffective; and

3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

Continuation – Rheumatoid Arthritis
Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Either:

1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Continuation – systemic juvenile idiopathic arthritis
Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Either:

1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or

2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Continuation – adult-onset Still's disease
Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

the patient has a sustained improvement in inflammatory markers and functional status.

Continuation – polyarticular juvenile idiopathic arthritis
Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Both:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

continued…
continued...

2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician’s global assessment from baseline.

Continuation – idiopathic multicentric Castleman’s disease
Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist

Re-assessment required after 12 months
the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB – Restricted see terms below

Inj 150 mg vial ............................................................................................ 1,350.00 1 Herceptin
Inj 440 mg vial ............................................................................................ 3,875.00 1 Herceptin

Restricted (RS1554)

Initiation – Early breast cancer

Limited to 12 months treatment
All of the following:

1 The patient has early breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 Maximum cumulative dose of 106 mg/kg (12 months’ treatment); and
3 Any of the following:
   3.1 9 weeks’ concurrent treatment with adjuvant chemotherapy is planned; or
   3.2 12 months’ concurrent treatment with adjuvant chemotherapy is planned; or
   3.3 12 months’ sequential treatment following adjuvant chemotherapy is planned; or
   3.4 12 months’ treatment with neoadjuvant and adjuvant chemotherapy is planned; or
   3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Initiation – metastatic breast cancer (trastuzumab-naive patients)

Limited to 12 months treatment
All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 Either:
   2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
   2.2 Both:
      2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
      2.2.2 The cancer did not progress whilst on lapatinib; and
3 Either:
   3.1 Trastuzumab will not be given in combination with pertuzumab; or
   3.2 All of the following:
      3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
      3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
      3.2.3 The patient has good performance status (ECOG grade 0-1); and
4 Trastuzumab not to be given in combination with lapatinib; and
5 Trastuzumab to be discontinued at disease progression.

Initiation – metastatic breast cancer (patients previously treated with trastuzumab)

Limited to 12 months treatment
All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
continued…

2 Either:
   2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
   2.2 Both:
      2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within
           3 months of starting treatment due to intolerance; and
      2.2.2 The cancer did not progress whilst on lapatinib; and

3 Either:
   3.1 Trastuzumab will not be given in combination with pertuzumab; or
   3.2 All of the following:
      3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
      3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of
           at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast
           cancer; and
      3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab not to be given in combination with lapatinib; and

5 Trastuzumab to be discontinued at disease progression.

Continuation – metastatic breast cancer

Re-assessment required after 12 months

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
3 Trastuzumab not to be given in combination with lapatinib; and
4 Trastuzumab to be discontinued at disease progression.

TRASTUZUMAB EMTANSINE – Restricted see terms below

Initiation

Re-assessment required after 6 months

All of the following:

1 Patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
3 Either:
   3.1 The patient has received prior therapy for metastatic disease*; or
   3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy*; and
4 Patient has a good performance status (ECOG 0-1); and
5 Either:
   5.1 Patient does not have symptomatic brain metastases; or
   5.2 Patient has brain metastases and has received prior local CNS therapy; and
6 Treatment to be discontinued at disease progression.

Continuation

Re-assessment required after 6 months

Both:

1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab emtansine; and
2 Treatment to be discontinued at disease progression.

Note: *Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.
Programmed Cell Death-1 (PD-1) Inhibitors

NIVOLUMAB – Restricted see terms below

- Inj 10 mg per ml, 4 ml vial ................................................................. 1,051.98 1 Opdivo
- Inj 10 mg per ml, 10 ml vial .............................................................. 2,629.96 1 Opdivo

Initiation

Medical oncologist

Re-assessment required after 4 months

All of the following:

1. Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
2. Patient has measurable disease as defined by RECIST version 1.1; and
3. The patient has ECOG performance score of 0-2; and
4. Either:
   4.1 Patient has not received funded pembrolizumab; or
   4.2 Both:
      4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
      4.2.2 The cancer did not progress while the patient was on pembrolizumab; and
5. Nivolumab is to be used at a maximum dose of no greater than the equivalent of 3 mg/kg every 2 weeks; and
6. Baseline measurement of overall tumour burden is documented (see Note); and
7. Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of nivolumab will not be continued beyond 12 weeks (6 cycles) if their disease progresses during this time.

Continuation

Medical oncologist

Re-assessment required after 4 months

Either:

1. All of the following:
   1.1 Any of the following:
      1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
      1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
      1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
   1.2 Either:
      1.2.1 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; or
      1.2.2 Both:
         1.2.2.1 Patient has measurable disease as defined by RECIST version 1.1; and
         1.2.2.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and
   1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
   1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and
   1.5 Nivolumab will be used at a maximum dose of no greater than the equivalent of 3 mg/kg every 2 weeks; or
2. All of the following:
   2.1 Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and
   2.2 Patient has signs of disease progression; and
   2.3 Disease has not progressed during previous treatment with nivolumab; and
   2.4 Nivolumab will be used at a maximum dose of no greater than the equivalent of 3 mg/kg every 2 weeks.

continued…
Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB – Restricted see terms below

- Inj 25 mg per ml, 4 ml vial.................................................................4,680.00 1 Keytruda

Initiation

Medical oncologist

Re-assessment required after 4 months

All of the following:

1. Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and
2. Patient has measurable disease as defined by RECIST version 1.1; and
3. The patient has ECOG performance score of 0-2; and
4. Either:
   4.1 Patient has not received funded nivolumab; or
   4.2 Both:
      4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
      4.2.2 The cancer did not progress while the patient was on nivolumab; and
5. Pembrolizumab is to be used at a maximum dose of no greater than the equivalent of 2 mg/kg every 3 weeks; and
6. Baseline measurement of overall tumour burden is documented (see Note); and
7. Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of pembrolizumab will not be continued beyond 12 weeks (4 cycles) if their disease progresses during this time.

Continuation

Medical oncologist

Re-assessment required after 4 months

Either:

1. All of the following:
   1.1 Any of the following:
      1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
      1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
      1.1.3 Patient has stable disease according to RECIST criteria (see Note); and

continued…
continued...

1.2 Either:

1.2.1 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; or

1.2.2 Both:

1.2.2.1 Patient has measurable disease as defined by RECIST version 1.1; and

1.2.2.2 Patient’s disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and

1.3 No evidence of progressive disease according to RECIST criteria (see Note); and

1.4 The treatment remains clinically appropriate and the patient is benefiting from the treatment; and

1.5 Pembrolizumab will be used at a maximum dose of no greater than the equivalent of 2 mg/kg every 3 weeks; or

2 All of the following:

2.1 Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and

2.2 Patient has signs of disease progression; and

2.3 Disease has not progressed during previous treatment with pembrolizumab; and

2.4 Pembrolizumab will be used at a maximum dose of no greater than the equivalent of 2 mg/kg every 3 weeks.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Other Immunosuppressants

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANTITHYMOCYTE GLOBULIN (EQUINE)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 5 ml ampoule</td>
<td>2,351.25</td>
<td>5 ATGAM</td>
</tr>
<tr>
<td>ANTITHYMOCYTE GLOBULIN (RABBIT)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AZATHIOPRINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Jan-20 to 2022</td>
<td>7.35</td>
<td>60 Azamun</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Jan-20 to 2022</td>
<td>7.60</td>
<td>100 Azamun</td>
</tr>
<tr>
<td>Inj 50 mg vial – 1% DV Nov-19 to 2022</td>
<td>199.00</td>
<td>1 Imuran</td>
</tr>
<tr>
<td>BACILLUS CALMETTE-GUERIN (BCG) – Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2-8 x 10^8 CFU vial</td>
<td>149.37</td>
<td>1 OncoTICE</td>
</tr>
<tr>
<td>For use in bladder cancer.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**EVEROLIMUS** – **Restricted** see terms below

- **Tab 5 mg**: 4,555.76 30 Afinitor
- **Tab 10 mg**: 6,512.29 30 Afinitor

**Initiation**
Neurologist or oncologist

*Re-assessment required after 3 months*

Both:

1. Patient has tuberous sclerosis; and
2. Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

**Continuation**
Neurologist or oncologist

*Re-assessment required after 12 months*

All of the following:

1. Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
2. The treatment remains appropriate and the patient is benefiting from treatment; and
3. Everolimus to be discontinued at progression of SEGAs.

**Note:** MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.

**MYCOPHENOLATE MOFETIL**

- **Tab 500 mg**: 25.00 50 CellCept
- **Cap 250 mg**: 25.00 100 CellCept
- **Powder for oral liq 1 g per 5 ml**: 187.25 165 ml CellCept
- **Inj 500 mg vial**: 133.33 4 CellCept

**PICIBANIL**

- **Inj 100 mg vial**

**SIROLIMUS** – **Restricted** see terms below

- **Tab 1 mg**: 749.99 100 Rapamune
- **Tab 2 mg**: 1,499.99 100 Rapamune
- **Oral liq 1 mg per ml**: 449.99 60 ml Rapamune

**Initiation**
For rescue therapy for an organ transplant recipient.

**Notes:** Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease
Antiallergy Preparations

**Allergic Emergencies**

**ICATIBANT** – **Restricted** see terms below

- Inj 10 mg per ml, 3 ml prefilled syringe ............................................................... 2,668.00  
  1 Firazyr

  **Restricted (RS1501)**

**Initiation**

Clinical immunologist or relevant specialist

*Re-assessment required after 12 months*

**Both:**

1. Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and
2. The patient has undergone product training and has agreed upon an action plan for self-administration.

**Continuation**

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient is benefiting from treatment.

**Allergy Desensitisation**

**BEE VENOM** – **Restricted** see terms below

- Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent
- Inj 550 mcg vial with diluent

  **Restricted (RS1117)**

**Initiation**

Both:

1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

**PAPER WASP VENOM** – **Restricted** see terms below

- Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent
- Inj 550 mcg vial with diluent

  **Restricted (RS1118)**

**Initiation**

Both:

1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

**YELLOW JACKET WASP VENOM** – **Restricted** see terms below

- Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent
- Inj 550 mcg vial with diluent

  **Restricted (RS1119)**

**Initiation**

Both:

1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

**Allergy Prophylactics**

**BECLOMETHASONE DIPROPIONATE**

<table>
<thead>
<tr>
<th>Nasal spray 50 mcg per dose</th>
<th>5.26</th>
<th>200 dose</th>
<th>Alanase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasal spray 100 mcg per dose</td>
<td>6.00</td>
<td>200 dose</td>
<td>Alanase</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
# RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th><strong>Price</strong> (ex man. excl. GST)</th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Per</strong></td>
<td></td>
</tr>
</tbody>
</table>

## BUDESONIDE

- Nasal spray 50 mcg per dose – **1% DV Oct-18 to 2020** ........................................... 2.59 200 dose **SteroClear**
- Nasal spray 100 mcg per dose – **1% DV Oct-18 to 2020** ........................................... 2.87 200 dose **SteroClear**

## FLUTICASONE PROPIONATE

- Nasal spray 50 mcg per dose – **1% DV Nov-18 to 2021** ........................................... 1.98 120 dose **Flixonase Hayfever & Allergy**

## IPRATROPIUM BROMIDE

- Aqueous nasal spray 0.03% – **1% DV Oct-17 to 2020** ........................................... 4.61 15 ml **Univent**

## SODIUM CROMOGLUCICATE

- Nasal spray 4%

## Antihistamines

### CETIRIZINE HYDROCHLORIDE

- Tab 10 mg – **1% DV Nov-19 to 2022** ............................................................ 1.12 100 **Zista**
- Oral liq 1 mg per ml ...................................................................................... 2.99 200 ml **Histaclear**

### CHLORPHENIRAMINE MALEATE

- Oral liq 0.4 mg per ml
- Inj 10 mg per ml, 1 ml ampoule

### CYPROHEPTADINE HYDROCHLORIDE

- Tab 4 mg

### FEXOFENADINE HYDROCHLORIDE

- Tab 60 mg
- Tab 120 mg
- Tab 180 mg

### LORATADINE

- Tab 10 mg – **1% DV Feb-20 to 2022** ............................................................ 1.69 100 **Lorafix**
- Oral liq 1 mg per ml ...................................................................................... 2.15 120 ml **Lorfast**

### PROMETHAZINE HYDROCHLORIDE

- Tab 10 mg – **1% DV Sep-18 to 2021** ............................................................ 1.68 50 **Allersoothe**
- Tab 25 mg – **1% DV Sep-18 to 2021** ............................................................ 1.89 50 **Allersoothe**
- Oral liq 1 mg per ml – **1% DV Sep-18 to 2021** ............................................. 2.69 100 ml **Allersoothe**
- Inj 25 mg per ml, 2 ml ampoule ..................................................................... 15.54 5 **Hospira**

## Anticholinergic Agents

### IPRATROPIUM BROMIDE

- Aerosol inhaler 20 mcg per dose
- Nebuliser soln 250 mcg per ml, 1 ml ampoule ..................................................... 3.35 20 **Univent**
- Nebuliser soln 250 mcg per ml, 2 ml ampoule – **1% DV Jan-20 to 2022** .......... 11.73 20 **Univent**

## Anticholinergic Agents with Beta-Adrenoceptor Agonists

### SALBUTAMOL WITH IPRATROPIUM BROMIDE

- Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose
- Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – **1% DV Oct-18 to 2021** ....................................................... 5.20 20 **Duolin**
### RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Product Details</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Long-Acting Muscarinic Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GLYCOPYRRONIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Note: inhaled glycopyrronium treatment must not be used if the patient is also receiving treatment with subsidised tiotropium or umeclidinium.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 50 mcg per dose...........................................................61.00 30 dose Seebri Breezhaler</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TIOTROPIUM BROMIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln for inhalation 2.5 mcg per dose...............................................................50.37 60 dose Spiriva Respimat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 18 mcg per dose...........................................................50.37 30 dose Spiriva</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>UMECLIDINIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Note: Umeclidinium must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder for inhalation 62.5 mcg per dose........................................................61.50 30 dose Incruse Ellipta</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GLYCOPYRRONIUM WITH INDACATEROL</strong> – Restricted see terms above</td>
<td></td>
<td></td>
</tr>
<tr>
<td>← Powder for Inhalation 50 mcg with indacaterol 110 mcg......................................81.00 30 dose Ultibro Breezhaler</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TIOTROPIUM BROMIDE WITH OLODATEROL</strong> – Restricted see terms above</td>
<td></td>
<td></td>
</tr>
<tr>
<td>← Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg........................................81.00 60 dose Spiolto Respimat</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>UMECLIDINIUM WITH VILANTEROL</strong> – Restricted see terms above</td>
<td></td>
<td></td>
</tr>
<tr>
<td>← Powder for inhalation 62.5 mcg with vilanterol 25 mcg....................................77.00 30 dose Anoro Ellipta</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antifibrotics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NINTEDANIB</strong> – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>↓ Cap 100 mg....................................................................................................2,554.00 60 Ofev</td>
<td></td>
<td></td>
</tr>
<tr>
<td>↓ Cap 150 mg...................................................................................................3,870.00 60 Ofev</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Products with Hospital Supply Status (HSS) are in bold*

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued...

1. Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
2. Forced vital capacity is between 50% and 90% predicted; and
3. Nintedanib is to be discontinued at disease progression (See Note); and
4. Nintedanib is not to be used in combination with subsidised pirfenidone; and
5. Any of the following:
   5.1 The patient has not previously received treatment with pirfenidone; or
   5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
   5.3 Patient has previously received pirfenidone, but the patient’s disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

**Continuation – idiopathic pulmonary fibrosis**

Respiratory specialist

*Re-assessment required after 12 months*

All of the following:

1. Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2. Nintedanib is not to be used in combination with subsidised pirfenidone; and
3. Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

**PIRFENIDONE – Restricted see terms below**

<table>
<thead>
<tr>
<th>Tab 801 mg</th>
<th>3,645.00</th>
<th>90</th>
<th>Esbriet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 267 mg</td>
<td>3,645.00</td>
<td>270</td>
<td>Esbriet</td>
</tr>
</tbody>
</table>

**Initiation – idiopathic pulmonary fibrosis**

Respiratory specialist

*Re-assessment required after 12 months*

All of the following:

1. Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
2. Forced vital capacity is between 50% and 90% predicted; and
3. Pirfenidone is to be discontinued at disease progression (See Notes); and
4. Pirfenidone is not to be used in combination with subsidised nintedanib; and
5. Any of the following:
   5.1 The patient has not previously received treatment with nintedanib; or
   5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
   5.3 Patient has previously received nintedanib, but the patient’s disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

**Continuation – idiopathic pulmonary fibrosis**

Respiratory specialist

*Re-assessment required after 12 months*

All of the following:

1. Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2. Pirfenidone is not to be used in combination with subsidised nintedanib; and
3. Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.
### Beta-Adrenoceptor Agonists

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Expiry</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SALBUTAMOL</strong></td>
<td>Oral liq 400 mcg per ml</td>
<td>1% DV Nov-18 to 2021</td>
<td>20.00</td>
<td>150 ml Ventolin</td>
</tr>
<tr>
<td></td>
<td>Inj 500 mcg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 1 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aerosol inhaler, 100 mcg per dose</td>
<td></td>
<td>3.80</td>
<td>200 dose SalAir</td>
</tr>
<tr>
<td></td>
<td>Nebuliser soln 1 mg per ml, 2.5 ml ampoule</td>
<td>1% DV Oct-18 to 2021</td>
<td>3.93</td>
<td>20 Asthalin</td>
</tr>
<tr>
<td></td>
<td>Nebuliser soln 2 mg per ml, 2.5 ml ampoule</td>
<td>1% DV Oct-18 to 2021</td>
<td>4.03</td>
<td>20 Asthalin</td>
</tr>
</tbody>
</table>

**TERBUTALINE SULPHATE**
- Powder for inhalation 250 mcg per dose
- Inj 0.5 mg per ml, 1 ml ampoule

### Cough Suppressants

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Expiry</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PHOLCODINE</strong></td>
<td>Oral liq 1 mg per ml</td>
<td>1% DV Jun-20 to 2022</td>
<td>3.09</td>
<td>200 ml AFT Pholcodine Linctus BP</td>
</tr>
</tbody>
</table>

### Decongestants

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OXYMETAZOLINE HYDROCHLORIDE</strong></td>
<td>Aqueous nasal spray 0.25 mg per ml</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aqueous nasal spray 0.5 mg per ml</td>
<td></td>
</tr>
<tr>
<td><strong>PSEUDOEPHEDRINE HYDROCHLORIDE</strong></td>
<td>Tab 60 mg</td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM CHLORIDE</strong></td>
<td>Aqueous nasal spray isotonic</td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM CHLORIDE WITH SODIUM BICARBONATE</strong></td>
<td>Soln for nasal irrigation</td>
<td></td>
</tr>
<tr>
<td><strong>XYLOMETAZOLINE HYDROCHLORIDE</strong></td>
<td>Aqueous nasal spray 0.05%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aqueous nasal spray 0.1%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nasal drops 0.05%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nasal drops 0.1%</td>
<td></td>
</tr>
</tbody>
</table>

### Inhaled Corticosteroids

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Expiry</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BECLOMETHASONE DIPROPIONATE</strong></td>
<td>Aerosol inhaler 50 mcg per dose</td>
<td></td>
<td>8.54</td>
<td>200 dose Beclazone 50</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>9.30</td>
<td>Qvar</td>
</tr>
<tr>
<td></td>
<td>Aerosol inhaler 100 mcg per dose</td>
<td></td>
<td>12.50</td>
<td>200 dose Beclazone 100</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>15.50</td>
<td>Qvar</td>
</tr>
<tr>
<td></td>
<td>Aerosol inhaler 250 mcg per dose</td>
<td></td>
<td>22.67</td>
<td>200 dose Beclazone 250</td>
</tr>
</tbody>
</table>

**BUDESONIDE**
- Nebuliser soln 250 mcg per ml, 2 ml ampoule
- Nebuliser soln 500 mcg per ml, 2 ml ampoule
- Powder for inhalation 100 mcg per dose
- Powder for inhalation 200 mcg per dose
- Powder for inhalation 400 mcg per dose

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th><strong>Respiratory System and Allergies</strong></th>
<th><strong>Price</strong> (ex man. excl. GST) $ Per</th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fluticasone</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aerosol inhaler 50 mcg per dose – 1% DV Sep-20 to 2023</td>
<td>7.19</td>
<td>120 dose Flixotide</td>
</tr>
<tr>
<td>Powder for inhalation 50 mcg per dose</td>
<td>4.68</td>
<td>Floair</td>
</tr>
<tr>
<td>Powder for inhalation 100 mcg per dose</td>
<td>8.67</td>
<td>60 dose Flixotide Accuhaler</td>
</tr>
<tr>
<td>Aerosol inhaler 125 mcg per dose – 1% DV Sep-20 to 2023</td>
<td>13.60</td>
<td>120 dose Flixotide</td>
</tr>
<tr>
<td>Aerosol inhaler 250 mcg per dose – 1% DV Sep-20 to 2023</td>
<td>24.62</td>
<td>120 dose Flixotide</td>
</tr>
<tr>
<td>Powder for inhalation 250 mcg per dose</td>
<td>7.22</td>
<td>Floair</td>
</tr>
<tr>
<td>Powder for inhalation 250 mcg per dose</td>
<td>10.18</td>
<td>Floair</td>
</tr>
<tr>
<td>Powder for inhalation 250 mcg per dose</td>
<td>24.51</td>
<td>60 dose Flixotide Accuhaler</td>
</tr>
</tbody>
</table>

*Floair Aerosol inhaler 50 mcg per dose to be delisted 1 September 2020*
*Floair Aerosol inhaler 125 mcg per dose to be delisted 1 September 2020*
*Floair Aerosol inhaler 250 mcg per dose to be delisted 1 September 2020*

### Leukotriene Receptor Antagonists

**Montelukast**

<table>
<thead>
<tr>
<th>Item</th>
<th>Dosage</th>
<th>Price</th>
<th>Quantity</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 4 mg – 1% DV Jan-20 to 2022</td>
<td>4.25</td>
<td>28</td>
<td>Montelukast Mylan</td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Jan-20 to 2022</td>
<td>4.25</td>
<td>28</td>
<td>Montelukast Mylan</td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Jan-20 to 2022</td>
<td>3.95</td>
<td>28</td>
<td>Montelukast Mylan</td>
<td></td>
</tr>
</tbody>
</table>

### Long-Acting Beta-Adrenoceptor Agonists

**Eformoterol Fumarate**
- Powder for inhalation 12 mcg per dose

**Eformoterol Fumarate Dihydrate**
- Powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose)

**Indacaterol**
- Powder for inhalation 150 mcg per dose – 61.00 30 dose Onbrez Breezhaler
- Powder for inhalation 300 mcg per dose – 61.00 30 dose Onbrez Breezhaler

**Salmeterol**
- Aerosol inhaler 25 mcg per dose – 9.90 120 dose Meterol
- Powder for inhalation 50 mcg per dose – 25.00 60 dose Serevent

### Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

**Budesonide with Eformoterol**
- Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg
- Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg
- Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg
- Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg
- Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg

**Fluticasone Furoate with Vilanterol**
- Powder for inhalation 100 mcg with vilanterol 25 mcg – 44.08 30 dose Breo Ellipta
## RESPIRATORY SYSTEM AND ALLERGIES

### Price

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

### FLUTICASONE WITH SALMETEROL

<table>
<thead>
<tr>
<th>Product Details</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerosol inhaler 50 mcg with salmeterol 25 mcg – <strong>1% DV Sep-20 to 2023</strong></td>
<td>14.58</td>
<td>RexAir</td>
</tr>
<tr>
<td>Powder for inhalation 100 mcg with salmeterol 50 mcg</td>
<td>25.79</td>
<td>Seretide Accuhaler</td>
</tr>
<tr>
<td>Aerosol inhaler 125 mcg with salmeterol 25 mcg – <strong>1% DV Sep-20 to 2023</strong></td>
<td>16.83</td>
<td>RexAir</td>
</tr>
<tr>
<td>Powder for inhalation 250 mcg with salmeterol 50 mcg</td>
<td>44.08</td>
<td>Seretide Accuhaler</td>
</tr>
</tbody>
</table>

*(RexAir Aerosol inhaler 50 mcg with salmeterol 25 mcg to be delisted 1 September 2020)*

*(RexAir Aerosol inhaler 125 mcg with salmeterol 25 mcg to be delisted 1 September 2020)*

### Mast Cell Stabilisers

- **NEDOCROMIL**
  - Aerosol inhaler 2 mg per dose
- **SODIUM CROMOGLICATE**
  - Aerosol inhaler 5 mg per dose

### Methylxanthines

- **AMINOPHYLLINE**
  - Inj 25 mg per ml, 10 ml ampoule – **1% DV Nov-17 to 2020** | 124.37 | 5 | DBL Aminophylline |
- **CAFFEINE CITRATE**
  - Oral liq 20 mg per ml (caffeine 10 mg per ml) – **1% DV Nov-19 to 2022** | 15.10 | 25 ml | Biomed |
  - Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule – **1% DV Nov-19 to 2022** | 63.25 | 5 | Biomed |
- **THEOPHYLLINE**
  - Tab long-acting 250 mg – **1% DV Jan-20 to 2022** | 23.02 | 100 | Nuelin-SR |
  - Oral liq 80 mg per 15 ml – **1% DV Jan-20 to 2022** | 16.60 | 500 ml | Nuelin |

### Mucolytics and Expectorants

- **DORNASE ALFA** – **Restricted** see terms below
  - Nebuliser soln 2.5 mg per 2.5 ml ampoule | 250.00 | 6 | Pulmozyme |
  - **Restricted (RS1352)**
- **SODIUM CHLORIDE**
  - Nebuliser soln 7%, 90 ml bottle – **1% DV Nov-19 to 2022** | 24.50 | 90 ml | Biomed |
## RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### Pulmonary Surfactants

**BERACTANT**  
Soln 200 mg per 8 ml vial

**PORACTANT ALFA**  
Soln 120 mg per 1.5 ml vial ........................................ 425.00  1  Curosurf  
Soln 240 mg per 3 ml vial ........................................ 695.00  1  Curosurf

### Respiratory Stimulants

**DOXAPRAM**  
Inj 20 mg per ml, 5 ml vial

### Sclerosing Agents

**TALC**  
Powder  
Soln (slurry) 100 mg per ml, 50 ml
## Anti-Infective Preparations

### Antibacterials

**CHLORAMPHENICOL**

- Eye oint 1% – 1% DV May-20 to 2022.................................2.48 4 g Chlorsig
- Ear drops 0.5%.................................1.55 5 g Devatis
- Eye drops 0.5% – 1% DV Nov-19 to 2022.................................1.54 10 ml Chlorafast
- Eye drops 0.5%, single dose

*(Chlorsig Eye oint 1% to be delisted 1 May 2020)*

**CIPROFLOXACIN**

- Eye drops 0.3% – 1% DV Jun-18 to 2020.................................9.99 5 ml Ciprofloxacin Teva

**FRAMYCETIN SULPHATE**

- Ear/eye drops 0.5%

**GENTAMICIN SULPHATE**

- Eye drops 0.3%.................................11.40 5 ml Genoptic

**PROPAMIDINE ISETHIONATE**

- Eye drops 0.1%

**SODIUM FUSIDATE [FUSIDIC ACID]**

- Eye drops 1%.................................5.29 5 g Fucithalmic

**SULPHACETAMIDE SODIUM**

- Eye drops 10%

**TOBRAMYCIN**

- Eye oint 0.3%.................................10.45 3.5 g Tobrex
- Eye drops 0.3%.................................11.48 5 ml Tobrex

### Antifungals

**NATAMYCIN**

- Eye drops 5%

### Antivirals

**ACICLOVIR**

- Eye oint 3%.................................14.92 4.5 g ViruPOS

### Combination Preparations

**CIPROFLOXACIN WITH HYDROCORTISONE**

- Ear drops ciprofloxacin 0.2% with 1% hydrocortisone.................................16.30 10 ml Ciproxin HC Otic

**DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN**

- Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin
- 50 mcg per ml

**DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE**

- Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate
- 6,000 u per g.................................5.39 3.5 g Maxitrol
- Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b
- sulphate 6,000 u per ml.................................4.50 5 ml Maxitrol
SENSORY ORGANS

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
<tr>
<td>(ex man. excl. GST)</td>
<td></td>
</tr>
</tbody>
</table>

**DEXAMETHASONE WITH TOBRAMYCIN**
Eye drops 0.1% with tobramycin 0.3%................................. 12.64 5 ml Tobradex

**FLUMETASONE PIVALATE WITH CLIOQUINOL**
Ear drops 0.02% with clioquinol 1%

**TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN**
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g .................................................... 5.16 7.5 ml Kenacomb

### Anti-Inflammatory Preparations

#### Corticosteroids

**DEXAMETHASONE**
Eye oint 0.1% ........................................................................... 5.86 3.5 g Maxidex
Eye drops 0.1% ........................................................................... 4.50 5 ml Maxidex

F Ocular implant 700 mcg..................................................... 1,444.50 1 Ozurdex

**Restricted (RS1606)**

**Initiation – Diabetic macular oedema**
Ophthalmologist
Re-assessment required after 12 months

All of the following:

1. Patients have diabetic macular oedema with pseudophakic lens; and
2. Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
3. Either:
   3.1 Patient's disease has progressed despite 3 injections with bevacizumab; or
   3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and
4. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

**Continuation – Diabetic macular oedema**
Ophthalmologist
Re-assessment required after 12 months

Both:

1. Patient's vision is stable or has improved (prescriber determined); and
2. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

**Initiation – Women of child bearing age with diabetic macular oedema**
Ophthalmologist
Re-assessment required after 12 months

All of the following:

1. Patients have diabetic macular oedema; and
2. Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
3. Patient is of child bearing potential and has not yet completed a family; and
4. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

continued...
Continuation – Women of child bearing age with diabetic macular oedema

Ophthalmologist

Re-assessment required after 12 months

All of the following:

1. Patient’s vision is stable or has improved (prescriber determined); and
2. Patient is of child bearing potential and has not yet completed a family; and
3. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

**FLUOROMETHOLONE**

- Eye drops 0.1% ................................................................. 3.09 5 ml FML

**PREDNISOLONE ACETATE**

- Eye drops 0.12%
  - Eye drops 1% ................................................................. 7.00 5 ml Pred Forte
  - 5.93 10 ml Prednisolone- AFT

**PREDNISOLONE SODIUM PHOSPHATE**

- Eye drops 0.5%, single dose (preservative free) ........................................ 38.50 20 dose Minims Prednisolone

**Non-Steroidal Anti-Inflammatory Drugs**

**DICLOFENAC SODIUM**

- Eye drops 0.1% ................................................................. 13.80 5 ml Voltaren Ophtha

**KETOROLAC TROMETAMOL**

- Eye drops 0.5%

**Decongestants and Antiallergics**

**Antiallergic Preparations**

**LEVOCABASTINE**

- Eye drops 0.05%

**LODOXAMIDE**

- Eye drops 0.1% ................................................................. 8.71 10 ml Lomide

**OLOPATADINE**

- Eye drops 0.1% ................................................................. 10.00 5 ml Patanol

**SODIUM CROMOGlicate**

- Eye drops 2% – 1% DV Jan-20 to 2022 ........................................ 1.79 5 ml Rexacrom

**Decongestants**

**NAPHAZOLINE HYDROCHLORIDE**

- Eye drops 0.1% ................................................................. 4.15 15 ml Naphcon Forte

**Diagnostic and Surgical Preparations**

**Diagnostic Dyes**

**FLUORESCEIN SODIUM**

- Eye drops 2%, single dose
  - Inj 10%, 5 ml vial ........................................................... 125.00 12 Flourescite
  - Ophthalmic strips 1 mg
### Sensory Organs

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**Fluorescein Sodium with Lignocaine Hydrochloride**
Eye drops 0.25% with lignocaine hydrochloride 4%, single dose

**LiSSamine Green**
Ophthalmic strips 1.5 mg

**Rose Bengal SODIUM**
Ophthalmic strips 1%

### Irrigation Solutions

**Mixed Salt Solution for Eye Irrigation**
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 15 ml dropper bottle

- 5.00 15 ml Balanced Salt Solution

Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml
e.g. Balanced Salt Solution

- 10.50 500 ml Balanced Salt Solution

### Ocular Anaesthetics

**Oxybuprocaine Hydrochloride**
Eye drops 0.4%, single dose

**Proxymetacaine Hydrochloride**
Eye drops 0.5%

**Tetracaine [Amethocaine] Hydrochloride**
Eye drops 0.5%, single dose
Eye drops 1%, single dose

### Viscoelastic Substances

**Hypromellose**
Inj 2%, 1 ml syringe
Inj 2%, 2 ml syringe

**Sodium Hyaluronate [Hyaluronic Acid]**
Inj 14 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022

- 50.00 1 Healon GV

Inj 14 mg per ml, 0.55 ml syringe – 1% DV Oct-19 to 2022

- 50.00 1 Healon GV

Inj 23 mg per ml, 0.6 ml syringe – 1% DV Oct-19 to 2022

- 60.00 1 Healon 5

Inj 10 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022

- 28.50 1 Healon

**Sodium Hyaluronate [Hyaluronic Acid] with Chondroitin Sulphate**
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe

- 64.00 1 Duovisc

Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe

- 74.00 1 Duovisc

Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml syringe

- 67.00 1 Viscoat

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*
e.g. Brand indicates brand example only. It is not a contracted product.
### Other

**DISODIUM EDETATE**  
- Inj 150 mg per ml, 20 ml ampoule  
- Inj 150 mg per ml, 20 ml vial  
- Inj 150 mg per ml, 100 ml vial

**RIBOFLAVIN 5-PHOSPHATE**  
- Soln trans epithelial riboflavin  
- Inj 0.1%  
- Inj 0.1% plus 20% dextran T500

### Glaucoma Preparations

#### Beta Blockers

**BETAXOLOL**  
- Eye drops 0.25%  
- Eye drops 0.5%  

**TIMOLOL**  
- Eye drops 0.25% – 1% DV Sep-17 to 2020  
- Eye drops 0.5% – 1% DV Sep-17 to 2020  
- Eye drops 0.5%, gel forming

#### Carbonic Anhydrase Inhibitors

**ACETAZOLAMIDE**  
- Tab 250 mg – 1% DV Sep-17 to 2020  
- Inj 500 mg

**BRINZOLAMIDE**  
- Eye drops 1%

**DORZOLAMIDE**  
- Eye drops 2%

**DORZOLAMIDE WITH TIMOLOL**  
- Eye drops 2% with timolol 0.5% – 1% DV Jan-19 to 2021

#### Miotics

**ACETYLCHOLINE CHLORIDE**  
- Inj 20 mg vial with diluent

**CARBACHOL**  
- Inj 150 mcg vial

**PILOCARPINE HYDROCHLORIDE**  
- Eye drops 1%  
- Eye drops 2%  
- Eye drops 2%, single dose  
- Eye drops 4%

#### Prostaglandin Analogues

**BIMATOPROST**  
- Eye drops 0.03% – 1% DV Feb-19 to 2021

---

Products with Hospital Supply Status (HSS) are in **bold**  
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### SENSORY ORGANS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>LATANOPROST</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.005% – 1% DV Apr-19 to 2021</td>
<td>1.57</td>
<td>2.5 ml</td>
</tr>
<tr>
<td>TRAVOPROST</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.004% – 1% DV Jan-18 to 2020</td>
<td>7.30</td>
<td>5 ml</td>
</tr>
</tbody>
</table>

### Sympathomimetics

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>APRACLONIDINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td>19.77</td>
<td>5 ml</td>
</tr>
<tr>
<td>BRIMONIDINE TARTRATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.2% – 1% DV Feb-18 to 2020</td>
<td>4.29</td>
<td>5 ml</td>
</tr>
<tr>
<td>BRIMONIDINE TARTRATE WITH TIMOLOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.2% with timolol 0.5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Mydriatics and Cycloplegics

#### Anticholinergic Agents

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATROPINE SULPHATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1% – 1% DV Sep-17 to 2020</td>
<td>17.36</td>
<td>15 ml</td>
</tr>
<tr>
<td>CYCLOPENTOLATE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%</td>
<td>8.76</td>
<td>15 ml</td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TROPICAMIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td>7.15</td>
<td>15 ml</td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%</td>
<td>8.66</td>
<td>15 ml</td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Sympathomimetics

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHENYLEPHRINE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 2.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 10%, single dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Ocular Lubricants

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBOMER</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophthalmic gel 0.3%, single dose</td>
<td>8.25</td>
<td>30</td>
</tr>
<tr>
<td>CARBOMER</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophthalmic gel 0.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARMELLOSE SODIUM WITH PECTIN AND GELATINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYPROMELLOSE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td>3.92</td>
<td>15 ml</td>
</tr>
<tr>
<td>Product Description</td>
<td>Price</td>
<td>Brand or Generic Manufacturer</td>
</tr>
<tr>
<td>---------------------</td>
<td>-------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td><strong>SENSORY ORGANS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYDROMELLOSE WITH DEXTRAN</td>
<td>$2.30</td>
<td>Poly-Tears</td>
</tr>
<tr>
<td>Eye drops 0.3% with dextran 0.1%</td>
<td>15 ml</td>
<td>Poly-Tears</td>
</tr>
<tr>
<td>Eye drops 0.3% with dextran 0.1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MACROCOL 400 AND PROPYLENE GLYCOL</td>
<td>$4.30</td>
<td>Systane Unit Dose</td>
</tr>
<tr>
<td>Eye drops 0.4% with propylene glycol 0.3% preservative free, single dose</td>
<td>24</td>
<td>Systane Unit Dose</td>
</tr>
<tr>
<td>PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN</td>
<td>$3.63</td>
<td>Poly-Visc</td>
</tr>
<tr>
<td>Eye oint 42.5% with soft white paraffin 57.3%</td>
<td>3.5 g</td>
<td>Poly-Visc</td>
</tr>
<tr>
<td>PARAFFIN LIQUID WITH WOOL FAT</td>
<td>$3.80</td>
<td>VitA-POS</td>
</tr>
<tr>
<td>Eye oint 3% with wool fat 3%</td>
<td>5 g</td>
<td>VitA-POS</td>
</tr>
<tr>
<td>POLYVINYL ALCOHOL WITH POVIDONE</td>
<td>$3.80</td>
<td>VitA-POS</td>
</tr>
<tr>
<td>Eye drops 1.4% with povidone 0.6%, single dose</td>
<td>5 g</td>
<td>VitA-POS</td>
</tr>
<tr>
<td>RETINOL PALMITATE</td>
<td>$3.80</td>
<td>VitA-POS</td>
</tr>
<tr>
<td>Oint 138 mcg per g</td>
<td>5 g</td>
<td>VitA-POS</td>
</tr>
<tr>
<td>SODIUM HYALURONATE [HYALURONIC ACID]</td>
<td>$22.00</td>
<td>Hylo-Fresh</td>
</tr>
<tr>
<td>Eye drops 1 mg per ml</td>
<td>10 ml</td>
<td>Hylo-Fresh</td>
</tr>
<tr>
<td><strong>Other Otological Preparations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACETIC ACID WITH PROPYLENE GLYCOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear drops 2.3% with propylene glycol 2.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOCUSATE SODIUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear drops 0.5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>Agents Used in the Treatment of Poisonings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antidotes</strong></td>
</tr>
<tr>
<td>ACETYLICYSTEINE</td>
</tr>
<tr>
<td>Tab eff 200 mg</td>
</tr>
<tr>
<td>Inj 200 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021.......................58.76 10 DBL Acetylcysteine</td>
</tr>
<tr>
<td>AMYL NITRITE</td>
</tr>
<tr>
<td>Liq 98% in 3 ml capsule</td>
</tr>
<tr>
<td>DIGOXIN IMMUNE FAB</td>
</tr>
<tr>
<td>Inj 38 mg vial</td>
</tr>
<tr>
<td>Inj 40 mg vial</td>
</tr>
<tr>
<td>ETHANOL</td>
</tr>
<tr>
<td>Liq 96%</td>
</tr>
<tr>
<td>ETHANOL WITH GLUCOSE</td>
</tr>
<tr>
<td>Inj 10% with glucose 5%, 500 ml bottle</td>
</tr>
<tr>
<td>ETHANOL, DEHYDRATED</td>
</tr>
<tr>
<td>Inj 100%, 5 ml ampoule</td>
</tr>
<tr>
<td>Inj 96%</td>
</tr>
<tr>
<td>FLUMAZENIL</td>
</tr>
<tr>
<td>Inj 0.1 mg per ml, 5 ml ampoule – 1% DV Dec-18 to 2021.......................132.68 10 Hameln</td>
</tr>
<tr>
<td>HYDROXOCOBALAMIN</td>
</tr>
<tr>
<td>Inj 5 g vial</td>
</tr>
<tr>
<td>Inj 2.5 g vial</td>
</tr>
<tr>
<td>NALOXONE HYDROCHLORIDE</td>
</tr>
<tr>
<td>Inj 400 mcg per ml, 1 ml ampoule – 1% DV Aug-18 to 2021.......................22.60 5 DBL Naloxone Hydrochloride</td>
</tr>
<tr>
<td>PRALIDOXIME IODIDE</td>
</tr>
<tr>
<td>Inj 25 mg per ml, 20 ml ampoule</td>
</tr>
<tr>
<td>SODIUM NITRITE</td>
</tr>
<tr>
<td>Inj 30 mg per ml, 10 ml ampoule</td>
</tr>
<tr>
<td>SODIUM THIOSULFATE</td>
</tr>
<tr>
<td>Inj 250 mg per ml, 10 ml vial</td>
</tr>
<tr>
<td>Inj 250 mg per ml, 50 ml vial</td>
</tr>
<tr>
<td>Inj 500 mg per ml, 10 ml vial</td>
</tr>
<tr>
<td>Inj 500 mg per ml, 20 ml ampoule</td>
</tr>
<tr>
<td>SOYA OIL</td>
</tr>
<tr>
<td>Inj 20%, 500 ml bag</td>
</tr>
<tr>
<td>Inj 20%, 500 ml bottle</td>
</tr>
<tr>
<td><strong>Antitoxins</strong></td>
</tr>
<tr>
<td>BOTULISM ANTITOXIN</td>
</tr>
<tr>
<td>Inj 250 ml vial</td>
</tr>
<tr>
<td>DIPHTHERIA ANTITOXIN</td>
</tr>
<tr>
<td>Inj 10,000 iu vial</td>
</tr>
</tbody>
</table>
# Antivenoms

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>RED BACK SPIDER ANTIVENOM</td>
<td>Inj 500 u vial</td>
<td>$43.50</td>
<td></td>
</tr>
<tr>
<td>SNAKE ANTIVENOM</td>
<td>Inj 50 ml vial</td>
<td>$43.50</td>
<td></td>
</tr>
</tbody>
</table>

## Removal and Elimination

### CHARCOAL

- Oral liq 200 mg per ml .............................................................. 43.50

### DEFERASIROX – **Restricted** see terms below

- Tab 125 mg dispersible .............................................................. 276.00
- Tab 250 mg dispersible .............................................................. 552.00
- Tab 500 mg dispersible .............................................................. 1,105.00

**Restricted (RS1444)**

### Initiation

Haematologist

*Re-assessment required after 2 years*

All of the following:

1. The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
2. Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
3. Any of the following:
   1. Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or
   2. Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
   3. Treatment with deferiprone has resulted in arthritis; or
   4. Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per µL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per µL).

### Continuation

Haematologist

*Re-assessment required after 2 years*

Either:

1. For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
2. For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

### DEFERRIPRONE – **Restricted** see terms below

- Tab 500 mg .............................................................................. 533.17
- Oral liq 100 mg per ml .............................................................. 266.59

**Restricted (RS1445)**

### Initiation

Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia.

### DESFERRIOXAMINE MESILATE

- Inj 500 mg vial – 1% DV Mar-19 to 2021 ........................................ 84.53

### DICOBALT EDETATE

- Inj 15 mg per ml, 20 ml ampoule
VARIOUS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**DIMERCAPROL**
Inj 50 mg per ml, 2 ml ampoule

**DIMERCAPTOSUCCINIC ACID**
Cap 100 mg
Cap 200 mg

**SODIUM CALCIUM EDETATE**
Inj 200 mg per ml, 2.5 ml ampoule
Inj 200 mg per ml, 5 ml ampoule

### Antiseptics and Disinfectants

**CHLORHEXIDINE**
Soln 4% ................................................................. 1.86 50 ml healthE
Soln 5% ................................................................. 15.50 500 ml healthE

**CHLORHEXIDINE WITH CETRIMIDE**
Crm 0.1% with cetrimide 0.5%
Foaming soln 0.5% with cetrimide 0.5%

**CHLORHEXIDINE WITH ETHANOL**
Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml ........................................... 2.65 1 healthE
Soln 2% with ethanol 70%, non-staining (pink) 100 ml ........................................... 3.54 1 healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml ........................................... 1.55 1 healthE
Soln 0.5% with ethanol 70%, staining (red) 100 ml ................................................... 2.90 1 healthE
Soln 2% with ethanol 70%, staining (red) 100 ml ................................................... 3.86 1 healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml ..................................... 5.45 1 healthE
Soln 0.5% with ethanol 70%, staining (red) 500 ml ........................................... 5.90 1 healthE
Soln 2% with ethanol 70%, staining (red) 500 ml ........................................... 9.56 1 healthE

**IODINE WITH ETHANOL**
Soln 1% with ethanol 70%, 100 ml ........................................................................ 9.30 1 healthE

**ISOPROPYL ALCOHOL**
Soln 70%, 500 ml .............................................................................................. 5.65 1 healthE

**POVIDONE-IODINE**
† Vaginal tab 200 mg
≥ Restricted (RS1354)
Initiation
Rectal administration pre-prostate biopsy.
Oint 10% ................................................................. 3.27 25 g Betadine
Soln 10% – 1% DV Nov-19 to 2021 ................................................... 2.55 100 ml Riodine
Soln 5%
Soln 7.5%
Soln 10%, – 1% DV Dec-19 to 2022 ................................................... 3.83 15 ml Riodine
5.40 500 ml Riodine
Pad 10%
Swab set 10%

**POVIDONE-IODINE WITH ETHANOL**
Soln 10% with ethanol 30% ................................................................. 10.00 500 ml Betadine Skin Prep
Soln 10% with ethanol 70%
### Contrast Media

#### Iodinated X-ray Contrast Media

**DIATRIZOATE MEGLUMINE WITH SODIUM AMIODRIZOATE**
- Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle .........................................................22.50
  - 100 ml Gastrografin
- Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle .................80.00
  - 1 Urografin

**DIATRIZOATE SODIUM**
- Oral liq 370 mg per ml, 10 ml sachet .....................................................156.12
  - 50 Ioscan

**IODISED OIL**
- Inj 38% w/w (480 mg per ml), 10 ml ampoule ...........................................410.00
  - 1 Lipiodol Ultra Fluid

**IODIXANOL**
- Inj 270 mg per ml (iodine equivalent), 50 ml bottle ...................................220.00
  - 10 Visipaque
- Inj 270 mg per ml (iodine equivalent), 100 ml bottle .................................430.00
  - 10 Visipaque
- Inj 320 mg per ml (iodine equivalent), 50 ml bottle ...................................220.00
  - 10 Visipaque
- Inj 320 mg per ml (iodine equivalent), 100 ml bottle .................................430.00
  - 10 Visipaque
- Inj 320 mg per ml (iodine equivalent), 200 ml bottle .................................850.00
  - 10 Visipaque

**IOHEXOL**
- Inj 240 mg per ml (iodine equivalent), 50 ml bottle ...................................75.00
  - 10 Omnipaque
- Inj 300 mg per ml (iodine equivalent), 20 ml bottle ...................................57.00
  - 10 Omnipaque
- Inj 300 mg per ml (iodine equivalent), 50 ml bottle ...................................75.00
  - 10 Omnipaque
- Inj 300 mg per ml (iodine equivalent), 100 ml bottle ..................................150.00
  - 10 Omnipaque
- Inj 350 mg per ml (iodine equivalent), 20 ml bottle ...................................59.00
  - 10 Omnipaque
- Inj 350 mg per ml (iodine equivalent), 50 ml bottle ...................................75.00
  - 10 Omnipaque
- Inj 350 mg per ml (iodine equivalent), 75 ml bottle ..................................114.00
  - 10 Omnipaque
- Inj 350 mg per ml (iodine equivalent), 100 ml bottle ..................................150.00
  - 10 Omnipaque
- Inj 350 mg per ml (iodine equivalent), 200 ml bottle ..................................290.00
  - 10 Omnipaque

#### Non-iodinated X-ray Contrast Media

**BARIUM SULPHATE**
- Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet ....................................507.50
  - 50 E-Z-Cat Dry
- Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle ..................................17.39
  - 148 g Varibar - Thin Liquid
- Oral liq 600 mg per g (60% w/w), tube ..................................................36.51
  - 454 g E-Z-Paste
- Oral liq 400 mg per ml (40% w/v), bottle ...........................................155.35
  - 250 ml Varibar - Honey
  - 38.40
  - 240 ml Varibar - Nectar
  - 145.04
  - 230 ml Varibar - Pudding

- Enema 1,250 mg per ml (125% w/v), 500 ml bag ......................................282.30
  - 12 Liquibar
- Oral liq 22 mg per g (2.2% w/w), 250 ml bottle .......................................175.00
  - 24 CT Plus+
- Oral liq 22 mg per g (2.2% w/v), 450 ml bottle ........................................220.00
  - 24 CT Plus+
- Oral liq 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle .........................441.12
  - 24 VoLumen
- Oral liq 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle .........................140.94
  - 24 Readi-CAT 2
- Powder for oral soln 97.65% w/w, 300 g bottle .......................................237.76
  - 24 X-Opaque-HD
- Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle .........................52.35
  - 3 Tagitol V
- Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle .................................91.77
  - 1 Liquibar

**BARIUM SULPHATE WITH SODIUM BICARBONATE**
- Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet ..............................................................102.93
  - 50 E-Z-Gas II

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiration date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CITRIC ACID WITH SODIUM BICARBONATE</strong></td>
<td></td>
<td>Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet</td>
</tr>
<tr>
<td>e.g. E-Z-GAS II</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Paramagnetic Contrast Media</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GADOBENIC ACID</strong></td>
<td></td>
<td>Inj 334 mg per ml, 10 ml vial..................................................324.74 10 Multihance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 334 mg per ml, 20 ml vial....................................................636.28 10 Multihance</td>
</tr>
<tr>
<td><strong>GADOBUTROL</strong></td>
<td></td>
<td>Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 5 ml prefilled syringe...........................................120.00 5 Gadovist 1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled syringe..............................................180.00 5 Gadovist 1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled syringe................................................700.00 10 Gadovist 1.0</td>
</tr>
<tr>
<td><strong>GADODIAMIDE</strong></td>
<td></td>
<td>Inj 287 mg per ml, 10 ml prefilled syringe................................200.00 10 Omniscan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 287 mg per ml, 10 ml vial.....................................................170.00 10 Omniscan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 287 mg per ml, 5 ml vial.......................................................120.00 10 Omniscan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 287 mg per ml, 15 ml prefilled syringe................................320.00 10 Omniscan</td>
</tr>
<tr>
<td><strong>GADOTERIC ACID</strong></td>
<td></td>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe.......................24.50 1 Dotarem</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle........................34.50 1 Dotarem</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe..................41.00 1 Dotarem</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe................55.00 1 Dotarem</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle........................23.20 1 Dotarem</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle........................46.30 1 Dotarem</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle.............................12.30 1 Dotarem</td>
</tr>
<tr>
<td><strong>GADOXETATE DISODIUM</strong></td>
<td></td>
<td>Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefilled syringe..................300.00 1 Primovist</td>
</tr>
<tr>
<td><strong>MEGLUMINE GADOPENTETATE</strong></td>
<td></td>
<td>Inj 469 mg per ml, 10 ml prefilled syringe...................................95.00 5 Magnevist</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 469 mg per ml, 10 ml vial.......................................................185.00 10 Magnevist</td>
</tr>
<tr>
<td><strong>MEGLUMINE IOTROXATE</strong></td>
<td></td>
<td>Inj 105 mg per ml, 100 ml bottle..................................................150.00 100 ml Biliscopin</td>
</tr>
<tr>
<td><strong>Ultrasound Contrast Media</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PERFLUTREX</strong></td>
<td></td>
<td>Inj 1.1 mg per ml, 1.5 ml vial....................................................180.00 1 Definity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 1.1 mg per ml, 1.5 ml vial....................................................720.00 4 Definity</td>
</tr>
<tr>
<td><strong>Diagnostic Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ARGININE</strong></td>
<td></td>
<td>Inj 50 mg per ml, 500 ml bottle</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inj 100 mg per ml, 300 ml bottle</td>
</tr>
</tbody>
</table>

Item restricted (see above); Item restricted (see below) | e.g. Brand indicates brand example only. It is not a contracted product. |
VARIOUS

<table>
<thead>
<tr>
<th>HISTAMINE ACID PHOSPHATE</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nebuliser soln 0.6%, 10 ml vial</td>
<td>240.35 5 Proveblue</td>
</tr>
<tr>
<td>Nebuliser soln 2.5%, 10 ml vial</td>
<td></td>
</tr>
<tr>
<td>Nebuliser soln 5%, 10 ml vial</td>
<td></td>
</tr>
</tbody>
</table>

MANNITOL

- Powder for inhalation
  - e.g. Aridol

METHACHOLINE CHLORIDE

- Powder 100 mg

SECRETIN PENTAHYDROCHLORIDE

- Inj 100 u ampoule

SINCALIDE

- Inj 5 mcg per vial

TABLE

<table>
<thead>
<tr>
<th>Diagnostic Dyes</th>
</tr>
</thead>
<tbody>
<tr>
<td>BONNEY’S BLUE DYE</td>
</tr>
<tr>
<td>Soln</td>
</tr>
</tbody>
</table>

INDIGO CARMINE

- Inj 4 mg per ml, 5 ml ampoule
- Inj 8 mg per ml, 5 ml ampoule

INDOCYANINE GREEN

- Inj 25 mg vial

METHYLTHIONINIUM CHLORIDE [METHYLENE BLUE]

- Inj 5 mg per ml, 10 ml ampoule

****

PATENT BLUE V

- Inj 2.5%, 2 ml ampoule
- Inj 2.5%, 5 ml prefilled syringe

<table>
<thead>
<tr>
<th>Irrigation Solutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHLORHEXIDINE WITH CETRIMIDE</td>
</tr>
<tr>
<td>Irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle</td>
</tr>
</tbody>
</table>

**Restricted (RS1683)**

Initiation

Re-assessment required after 3 months

All of the following:

1. Patient has burns that are greater than 30% of total body surface area (BSA); and
2. For use in the perioperative preparation and cleansing of large burn areas requiring debridement/skin grafting; and
3. The use of 30 ml ampoules is impractical due to the size of the area to be covered.

Continuation

Re-assessment required after 3 months

The treatment remains appropriate for the patient and the patient is benefiting from the treatment.

Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule – 1% DV

**Aug-18 to 2021** ................................................................. 29.76 30 Pfizer

GLYCINE

- Irrigation soln 1.5%, 3,000 ml bag

**Sep-18 to 2021** ................................................................. 31.20 4 B Braun

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SODIUM CHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 3,000 ml bag – 1% DV Sep-18 to 2021</td>
<td>26.80</td>
<td>B Braun</td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 30 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>7.00</td>
<td>Interpharma</td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 1,000 ml bottle – 1% DV Jun-18 to 2021</td>
<td>14.90</td>
<td>Baxter Sodium Chloride 0.9%</td>
</tr>
<tr>
<td>Irrigation soln 0.9%, 250 ml bottle – 1% DV Aug-18 to 2021</td>
<td>17.64</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td><strong>WATER</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irrigation soln, 3,000 ml bag – 1% DV Sep-18 to 2021</td>
<td>28.80</td>
<td>B Braun</td>
</tr>
<tr>
<td>Irrigation soln, 1,000 ml bottle – 1% DV Jun-18 to 2021</td>
<td>17.30</td>
<td>Baxter Water for Irrigation</td>
</tr>
<tr>
<td>Irrigation soln, 250 ml bottle – 1% DV Aug-18 to 2021</td>
<td>17.64</td>
<td>Fresenius Kabi</td>
</tr>
</tbody>
</table>

**Surgical Preparations**

**BISMUTH SUBNITRATE AND IODOFORM PARAFFIN**
- Paste

**DIMETHYL SULFOXIDE**
- Soln 50%
- Soln 99%

**PHENOL**
- Inj 6%, 10 ml ampoule

**PHENOL WITH Ioxaglic Acid**
- Inj 12%, 10 ml ampoule

**TROMETAMOL**
- Inj 36 mg per ml, 500 ml bottle

*Item restricted (see ➡ above); Item restricted (see ➡ below)
*E.g. Brand indicates brand example only. It is not a contracted product.*
### Cardioplegia Solutions

<table>
<thead>
<tr>
<th>ELECTROLYTES</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 15 mmol/l sodium chloride, 9 mmol/l potassium chloride, 1 mmol/l potassium hydrogen 2-ketoglutarate, 4 mmol/l magnesium chloride, 18 mmol/l histidine hydrochloride, 180 mmol/l histidine, 2 mmol/l tryptophan, 30 mmol/l mannitol, 0.015 mmol/l calcium chloride, 1,000 ml bag</td>
<td>e.g. Custodiol-HTK</td>
</tr>
<tr>
<td>Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, glutamic acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.80768 mg per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2369 mg per ml, 364 ml bag</td>
<td>e.g. Cardioplegia Enriched Paed. Soln.</td>
</tr>
<tr>
<td>Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, glutamic acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg per ml, sodium hydroxide 5.133 mg per ml and trometamol 9.097 mg per ml, 527 ml bag</td>
<td>e.g. Cardioplegia Enriched Solution</td>
</tr>
<tr>
<td>Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg per ml, potassium chloride 2.181 mg per ml, sodium chloride 1.788 mg ml, sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per ml, 523 ml bag</td>
<td>e.g. Cardioplegia Base Solution</td>
</tr>
<tr>
<td>Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml bag</td>
<td>e.g. Cardioplegia Solution AHB7832</td>
</tr>
<tr>
<td>Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magnesium and 1.2 mmol/l calcium, 1,000 ml bag</td>
<td>e.g. Cardioplegia Electrolyte Solution</td>
</tr>
</tbody>
</table>

### Cold Storage Solutions

<table>
<thead>
<tr>
<th>SODIUM WITH POTASSIUM</th>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag</td>
<td></td>
</tr>
</tbody>
</table>
### Extemporaneously Compounded Preparations

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Per</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>(ex man. excl. GST)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### ACETIC ACID
- Liq

#### ALUM
- Powder BP

#### ARACHIS OIL [PEANUT OIL]
- Liq

#### ASCORBIC ACID
- Powder

#### BENZOIN
- Tincture compound BP

#### BISMUTH SUBGALLATE
- Powder

#### BORIC ACID
- Powder

#### CARBOXYMETHYLCELLULOSE
- Sol 1.5%

#### CETRIMIDE
- Soln 40%

#### CHLORHEXIDINE GLUCONATE
- Soln 20%

#### CHLOROFORM
- Liq BP

#### CITRIC ACID
- Powder BP

#### CLOVE OIL
- Liq

#### COAL TAR
- Soln BP – 1% DV Nov-19 to 2022 ................................................................. 36.25 200 ml Midwest

#### CODEINE PHOSPHATE
- Powder

#### COLLODION FLEXIBLE
- Liq

#### COMPOUND HYDROXYBENZOATE
- Soln – 1% DV Aug-19 to 2022 ................................................................. 30.00 100 ml Midwest

#### CYSTEAMINE HYDROCHLORIDE
- Powder

#### DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHOSPHATE
- Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml ampoule

#### DITHRANOL
- Powder

#### GLUCOSE [DEXTROSE]
- Powder

---

*Item restricted (see ➪ above); Item restricted (see ➪ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLYCERIN WITH SODIUM SACCHARIN Suspension – 1% DV Jul-19 to 2022</td>
<td>30.95</td>
<td>Ora-Sweet SF</td>
</tr>
<tr>
<td>GLYCERIN WITH SUCROSE Suspension – 1% DV Jul-19 to 2022</td>
<td>30.95</td>
<td>Ora-Sweet</td>
</tr>
<tr>
<td>GLYCEROL Liq – 1% DV Sep-17 to 2020</td>
<td>3.28</td>
<td>healthE Glycerol BP Liquid</td>
</tr>
<tr>
<td>HYDROCORTISONE Powder – 1% DV Sep-17 to 2020</td>
<td>49.95</td>
<td>ABM</td>
</tr>
<tr>
<td>LACTOSE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAGNESIUM HYDROXIDE Paste</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MENTHOL Crystals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>METHADONE HYDROCHLORIDE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>METHYL HYDROXYBENZOATE Powder – 1% DV Jul-19 to 2022</td>
<td>8.98</td>
<td>Midwest</td>
</tr>
<tr>
<td>METHYLCHELULOSE Powder – 1% DV Jul-19 to 2022</td>
<td>36.95</td>
<td>Midwest</td>
</tr>
<tr>
<td>METHYLCHELULOSE Suspension – 1% DV Jul-19 to 2022</td>
<td>30.95</td>
<td>Ora-Plus</td>
</tr>
<tr>
<td>METHYLCHELULOSE WITH GLYCERIN AND SODIUM SACCHARIN Suspension – 1% DV Jul-19 to 2022</td>
<td>30.95</td>
<td>Ora-Blend SF</td>
</tr>
<tr>
<td>METHYLCHELULOSE WITH GLYCERIN AND SUCROSE Suspension – 1% DV Jul-19 to 2022</td>
<td>30.95</td>
<td>Ora-Blend</td>
</tr>
<tr>
<td>OLIVE OIL Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PARAFFIN Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHENOBARBITONE SODIUM Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHENOL Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PILOCARPINE NITRATE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>POLYHEXAMETHYLENE BIGUANIDE Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Povidone K30 Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SALICYLIC ACID Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SILVER NITRATE Crystals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM BICARBONATE Powder BP – 1% DV Jan-20 to 2022</td>
<td>10.05</td>
<td>Midwest</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## EXTEMPORANEously COMPOUNDED PREPARATIONS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CITRATE</td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM METABISULFITE</td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STARCH</td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SULPHUR</td>
<td>Precipitated</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sublimed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SYRUP</td>
<td>Liq (pharmaceutical grade) – 1% DV Jan-20 to 2022</td>
<td>14.95</td>
<td>Midwest</td>
</tr>
<tr>
<td>THEOBROMA OIL</td>
<td>Oint</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRI-SODIUM CITRATE</td>
<td>Crystals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRICHLORACETIC ACID</td>
<td>Grans</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UREA</td>
<td>Powder BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WOOL FAT</td>
<td>Oint, anhydrous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XANTHAN</td>
<td>Gum 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZINC OXIDE</td>
<td>Powder</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see above); Item restricted (see below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
Food Modules

Carbohydrate

→ **Restricted (RS1467)**

Initiation – Use as an additive

Any of the following:

1. Cystic fibrosis; or
2. Chronic kidney disease; or
3. Cancer in children; or
4. Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
5. Faltering growth in an infant/child; or
6. Bronchopulmonary dysplasia; or
7. Premature and post premature infant; or
8. Inborn errors of metabolism.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

CARBOHYDRATE SUPPLEMENT – **Restricted** see terms above

- Powder 95 g carbohydrate per 100 g, 368 g can
- Powder 96 g carbohydrate per 100 g, 400 g can

*e.g. Polycal*

Fat

→ **Restricted (RS1468)**

Initiation – Use as an additive

Any of the following:

1. Patient has inborn errors of metabolism; or
2. Faltering growth in an infant/child; or
3. Bronchopulmonary dysplasia; or
4. Fat malabsorption; or
5. Lymphangiecstasy; or
6. Short bowel syndrome; or
7. Infants with necrotising enterocolitis; or
8. Biliary atresia; or
9. For use in a ketogenic diet; or
10. Chyle leak; or
11. Ascites; or
12. Patient has increased energy requirements, and for whom dietary measures have not been successful.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

LONG-CHAIN TRIGLYCERIDE SUPPLEMENT – **Restricted** see terms above

- Liquid 50 g fat per 100 ml, 200 ml bottle
- Liquid 50 g fat per 100 ml, 500 ml bottle

*e.g. Calogen*
MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT – Restricted see terms on the previous page
*
- Liquid 50 g fat per 100 ml, 250 ml bottle
- Liquid 95 g fat per 100 ml, 500 ml bottle

WALNUT OIL – Restricted see terms on the previous page
*
- Liq

Protein

− Restricted (RS1469)
Initiation – Use as an additive
Either:

  1 Protein losing enteropathy; or
  2 High protein needs.

Initiation – Use as a module
For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

PROTEIN SUPPLEMENT – Restricted see terms above
*
- Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can
- Powder 6 g protein per 7 g, can ........................................8.95 227 g Resource Beneprotein
e.g. Protifar

Other Supplements

BREAST MILK FORTIFIER
- Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet
e.g. FM 85
- Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet
e.g. S26 Human Milk Fortifier
- Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet
e.g. Nutricia Breast Milk Fortifer

CARBOHYDRATE AND FAT SUPPLEMENT – Restricted see terms below
*
- Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can
e.g. Super Soluble Duocal

− Restricted (RS1212)
Initiation
Both:

  1 Infant or child aged four years or under; and
  2 Any of the following:
    2.1 Cystic fibrosis; or
    2.2 Cancer in children; or
    2.3 Faltering growth; or
    2.4 Bronchopulmonary dysplasia; or
    2.5 Premature and post premature infants.
### Food/Fluid Thickeners

**NOTE:**
While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:

- use was established prior to 1 July 2013; and
- the product has not been specifically considered and excluded by PHARMAC; and
- use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

PHARMAC intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

**CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN**
- Powder
  - e.g. Feed Thickener Karicare Aptamil

**GUAR GUM**
- Powder
  - e.g. Guarcol

**MAIZE STARCH**
- Powder
  - e.g. Resource Thicken Up; Nutilis

**MALTODEXTRIN WITH XANTHAN GUM**
- Powder
  - e.g. Instant Thick

**MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID**
- Powder
  - e.g. Easy Thick

### Metabolic Products

**→ Restricted (RS1232)**

**Initiation**

Any of the following:

1. For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidemia, propionic acidemia, methylmalonic acidemia, tyrosinaemia or urea cycle disorders; or
2. Patient has adrenoleukodystrophy; or
3. For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

### Glutaric Aciduria Type 1 Products

**AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN)** – **Restricted** see terms above

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
  - e.g. GA1 Anamix Infant

- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can
  - e.g. XLYS Low TRY Maxamaid
### Homocystinuria Products

AMINO ACID FORMULA (WITHOUT METHIONINE) – **Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Item</th>
<th>Description</th>
<th>Quantity</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$ Per Manufacturer</td>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can</td>
<td>e.g. HCU Anamix Infant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. XMET Maxamaid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. XMET Maxamum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle</td>
<td>e.g. HCU Anamix Junior LQ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Isovaleric Acidaemia Products

AMINO ACID FORMULA (WITHOUT LEUCINE) – **Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Item</th>
<th>Description</th>
<th>Quantity</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$ Per Manufacturer</td>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can</td>
<td>e.g. IVA Anamix Infant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. XLEU Maxamaid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. XLEU Maxamum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Maple Syrup Urine Disease Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) – **Restricted** see terms on the previous page

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Item</th>
<th>Description</th>
<th>Quantity</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$ Per Manufacturer</td>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can</td>
<td>e.g. MSUD Anamix Infant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>e.g. MSUD Maxamum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle</td>
<td>e.g. MSUD Anamix Junior LQ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see ➸ above); Item restricted (see ➸ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Phenylketonuria Products

<table>
<thead>
<tr>
<th>AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – <strong>Restricted</strong> see terms on page 229</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tab 8.33 mg</strong></td>
</tr>
<tr>
<td>Powder 20 g protein, 2.5 g carbohydrate and 0.22 g fibre per 27.8 g sachet</td>
</tr>
<tr>
<td>e.g. Phlexy-10</td>
</tr>
<tr>
<td><strong>Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet</strong></td>
</tr>
<tr>
<td>e.g. PKU Lophlex Powder (unflavoured)</td>
</tr>
<tr>
<td><strong>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can</strong></td>
</tr>
<tr>
<td>e.g. PKU Anamix Infant (van/choc/unfl)</td>
</tr>
<tr>
<td><strong>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</strong></td>
</tr>
<tr>
<td>e.g. XP Maxamum</td>
</tr>
<tr>
<td><strong>Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet</strong></td>
</tr>
<tr>
<td>e.g. Phlexy-10</td>
</tr>
<tr>
<td><strong>Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle</strong></td>
</tr>
<tr>
<td>e.g. PKU Lophlex LQ 10</td>
</tr>
<tr>
<td><strong>Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle</strong></td>
</tr>
<tr>
<td>e.g. PKU Lophlex LQ 20</td>
</tr>
<tr>
<td><strong>Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle…………………13.10 125 ml</strong></td>
</tr>
<tr>
<td>PKU Anamix Junior LQ (Berry)</td>
</tr>
<tr>
<td>PKU Anamix Junior LQ (Orange)</td>
</tr>
<tr>
<td>PKU Anamix Junior LQ (Unflavoured)</td>
</tr>
<tr>
<td><strong>Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle</strong></td>
</tr>
<tr>
<td>e.g. PKU Lophlex LQ 20</td>
</tr>
<tr>
<td><strong>Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle</strong></td>
</tr>
<tr>
<td>e.g. PKU Lophlex LQ 10</td>
</tr>
<tr>
<td><strong>Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle</strong></td>
</tr>
<tr>
<td>e.g. PKU Lophlex LQ 20</td>
</tr>
<tr>
<td><strong>Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle</strong></td>
</tr>
<tr>
<td>e.g. PKU Lophlex LQ 10</td>
</tr>
<tr>
<td><strong>Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton</strong></td>
</tr>
<tr>
<td>e.g. Easiphen</td>
</tr>
<tr>
<td><strong>Semi-solid 18.3 g protein, 18.5 g carbohydrate and 0.92 g fibre per 100 g, 109 g pot</strong></td>
</tr>
<tr>
<td>e.g. PKU Lophlex Sensations 20 (berries)</td>
</tr>
</tbody>
</table>

### Propionic Acidaemia and Methylmalonic Acidaemia Products

<table>
<thead>
<tr>
<th>AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) – <strong>Restricted</strong> see terms on page 229</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can</strong></td>
</tr>
<tr>
<td>e.g. MMA/PA Anamix Infant</td>
</tr>
<tr>
<td><strong>Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can</strong></td>
</tr>
<tr>
<td>e.g. XMTVI Maxamaid</td>
</tr>
<tr>
<td><strong>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</strong></td>
</tr>
<tr>
<td>e.g. XMTVI Maxamum</td>
</tr>
</tbody>
</table>
**SPECIAL FOODS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

## Protein Free Supplements

**PROTEIN FREE SUPPLEMENT** – **Restricted** see terms on page 229

- Powder nil added protein and 67 g carbohydrate per 100 g, 400 g can
  
  *e.g.* Energivit

## Tyrosinaemia Products

**AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE)** – **Restricted** see terms on page 229

- Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet
  
  *e.g.* TYR Anamix Junior

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
  
  *e.g.* XPHEN, TYR Maxamaid

- Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can
  
  *e.g.* TYR Anamix Infant

- Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle
  
  *e.g.* TYR Anamix Junior LQ

## Urea Cycle Disorders Products

**AMINO ACID SUPPLEMENT** – **Restricted** see terms on page 229

- Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can
  
  *e.g.* Dialamine

- Powder 79 g protein per 100 g, 200 g can
  
  *e.g.* Essential Amino Acid Mix

## X-Linked Adrenoleukodystrophy Products

**GLYCEROL TRIERUCATE** – **Restricted** see terms on page 229

- Liquid, 1,000 ml bottle

**GLYCEROL TRIOLEATE** – **Restricted** see terms on page 229

- Liquid, 500 ml bottle

## Specialised Formulas

### Diabetic Products

**⇒ Restricted (RS1215)**

Initiation:

Any of the following:

1. For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
2. For patients with pancreatic insufficiency; or
3. For patients who have, or are expected to, eat little or nothing for 5 days; or
4. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
5. For use pre- and post-surgery; or
6. For patients being tube-fed; or
7. For tube-feeding as a transition from intravenous nutrition.

---

Item restricted (see ⇒ above); Item restricted (see ⇒ below)

*e.g.* Brand indicates brand example only. It is not a contracted product.
## Elemental and Semi-Elemental Products

### Restricted (RS1216)

**Initiation**

Any of the following:

1. Malabsorption; or
2. Short bowel syndrome; or
3. Enterocutaneous fistulas; or
4. Eosinophilic enteritis (including oesophagitis); or
5. Inflammatory bowel disease; or
6. Acute pancreatitis where standard feeds are not tolerated; or
7. Patients with multiple food allergies requiring enteral feeding.

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1,000 ml bottle</td>
<td>7.50</td>
<td>Glucerna Select RTH (Vanilla)</td>
</tr>
<tr>
<td>Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag</td>
<td></td>
<td>e.g. Nutrison Advanced Disan</td>
</tr>
<tr>
<td>Liquid 4.5 g protein, 9.8 g carbohydrate, 4.4 g fat and 1.9 g fibre per 100 ml, can</td>
<td>2.10</td>
<td>Sustagen Diabetic (Vanilla)</td>
</tr>
<tr>
<td>Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 250 ml bottle</td>
<td>1.88</td>
<td>Glucerna Select (Vanilla)</td>
</tr>
<tr>
<td>Liquid 6 g protein, 9.5 g carbohydrate, 4.7 g fat and 2.6 g fibre per 100 ml, can</td>
<td>2.10</td>
<td>Resource Diabetic (Vanilla)</td>
</tr>
<tr>
<td>Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle</td>
<td></td>
<td>e.g. Diasip</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet</td>
<td>4.50</td>
<td>Vivonex TEN</td>
</tr>
<tr>
<td>Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton</td>
<td></td>
<td>e.g. Elemental 028 Extra</td>
</tr>
<tr>
<td>Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag</td>
<td></td>
<td>e.g. Nutrison Advanced Peptisorb</td>
</tr>
<tr>
<td>Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle</td>
<td>18.06</td>
<td>Vital</td>
</tr>
<tr>
<td>Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can</td>
<td></td>
<td>e.g. Peptamen Junior</td>
</tr>
<tr>
<td>Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can</td>
<td></td>
<td>e.g. MCT Pepdite; MCT Pepdite 1+</td>
</tr>
</tbody>
</table>
SPECIAL FOODS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

PEPTIDE-BASED ORAL FEED 1 KCAL/ML – Restricted see terms on the previous page

- Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, carton...........4.95 237 ml Peptamen OS 1.0 (Vanilla)

Fat Modified Products

FAT-MODIFIED FEED – Restricted see terms below

- Powder 12.9 g protein, 69.1 g carbohydrate and 12.9 g fat per 100 g, 400 g can
  - Restricted (RS1470)

Initiation

Any of the following:

1. Patient has metabolic disorders of fat metabolism; or
2. Patient has a chyle leak; or
3. Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Hepatic Products

- Restricted (RS1217)

Initiation

For children (up to 18 years) who require a liver transplant.

HEPATIC ORAL FEED – Restricted see terms above

- Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can ..........78.97 400 g Heparon Junior

High Calorie Products

- Restricted (RS1317)

Initiation

Any of the following:

1. Patient is fluid volume or rate restricted; or
2. Patient requires low electrolyte; or
3. Both:
   3.1 Any of the following:
      3.1.1 Cystic fibrosis; or
      3.1.2 Any condition causing malabsorption; or
      3.1.3 Faltering growth in an infant/child; or
      3.1.4 Increased nutritional requirements; and
   3.2 Patient has substantially increased metabolic requirements.

ENTERAL FEED 2 KCAL/ML – Restricted see terms above

- Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle ..........5.50 500 ml Nutrison Concentrated
- Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle .........................................................11.00 1,000 ml TwoCal HN RTH (Vanilla)

ORAL FEED 2 KCAL/ML – Restricted see terms above

- Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle .........................................................1.90 200 ml Two Cal HN

---

Item restricted (see ➥ above); Item restricted (see ➥ below)

e.g. Brand indicates brand example only. It is not a contracted product.
## High Protein Products

**HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML** – **Restricted** see terms below

Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml, 1,000 ml bottle

*→ Restricted (RS1327)*

**Initiation**

Both:

1. The patient has a high protein requirement; and
2. Any of the following:
   1. Patient has liver disease; or
   2. Patient is obese (BMI > 30) and is undergoing surgery; or
   3. Patient is fluid restricted; or
   4. Patient’s needs cannot be more appropriately met using high calorie product.

**HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML** – **Restricted** see terms below

Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag

*→ Restricted (RS1327)*

**Initiation**

Both:

1. The patient has a high protein requirement; and
2. Any of the following:
   1. Patient has liver disease; or
   2. Patient is obese (BMI > 30) and is undergoing surgery; or
   3. Patient is fluid restricted; or
   4. Patient’s needs cannot be more appropriately met using high calorie product.

## Infant Formulas

**AMINO ACID FORMULA** – **Restricted** see terms on the next page

- Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can
- Powder 13 g protein, 49 g carbohydrate and 23 g fat per 100 g, 400 g can
- Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can
- Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can .........53.00 400 g Neocate
- Powder 14.8 g protein, 51.4 g carbohydrate and 23 g fat per 100 g, can .........53.00 400 g Neocate SYNEO unflavoured
- Powder 15 g protein, 56 g carbohydrate and 20 g fat per 100 g, can .............43.60 400 g Alfamino Junior
- Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can ...........43.60 400 g Neocate Junior Vanilla
- Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can .............43.60 400 g Neocate Junior Vanilla
- Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can ........53.00 400 g Elecare LCP (Unflavoured)
- Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can ........53.00 400 g Elecare (Unflavoured)
- Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can ........53.00 400 g Elecare (Vanilla)

*(Neocate Junior Vanilla Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can to be delisted 1 April 2020)*
**Restricted (RS1471)**

**Initiation**

Any of the following:

1. Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
2. History of anaphylaxis to cows' milk protein formula or dairy products; or
3. Eosinophilic oesophagitis.

**Note:** A reasonable trial is defined as a 2-4 week trial.

**Continuation**

Both:

1. An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
2. The outcome of the assessment is that the infant continues to require an amino acid infant formula.

**Extensively Hydrolysed Formula – Restricted** see terms below

- Powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can
  - Price: $30.42 Per 900 g
  - Brand or Manufacturer: Allerpro 1

- Powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can
  - Price: $30.42 Per 900 g
  - Brand or Manufacturer: Allerpro 2

- Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can
  - e.g. Aptamil Gold+ Pepti Junior

**Restricted (RS1502)**

**Initiation**

Any of the following:

1. Both:
   1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
   1.2 Either:
      1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
      1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
2. Severe malabsorption; or
3. Short bowel syndrome; or
4. Intractable diarrhoea; or
5. Biliary atresia; or
6. Cholestatic liver diseases causing malabsorption; or
7. Cystic fibrosis; or
8. Proven fat malabsorption; or
9. Severe intestinal motility disorders causing significant malabsorption; or
10. Intestinal failure; or
11. For step down from Amino Acid Formula.

**Note:** A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

**Continuation**

Both:

1. An assessment as to whether the infant can be transitioned to a cows’ milk protein or soy infant formula has been undertaken; and
2. The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.

**Fructose-Based Formula**

Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g, 400 g can

- e.g. Galactomin 19
### LACTOSE-FREE FORMULA
- Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml, 900 g can
  - e.g. Karicare Aptamil Gold De-Lact
- Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g can
  - e.g. S26 Lactose Free

### LOW-CALCIUM FORMULA
- Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g, 400 g can
  - e.g. Locasol

### PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML – Restricted see terms below
- Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, bottle
  - 2.35 125 ml Infatrini
- Initiation – Fluid restricted or volume intolerance with faltering growth
  Both:
  1. Either:
     1.1 The patient is fluid restricted or volume intolerant; or
     1.2 The patient has increased nutritional requirements due to faltering growth; and
  2. Patient is under 18 months old and weighs less than 8kg.

Note: ‘Volume intolerant’ patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

### PRETERM FORMULA – Restricted see terms below
- Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, bottle
  - 0.75 100 ml S26 LBW Gold RTF
- Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 90 ml bottle
  - e.g. Pre Nan Gold RTF
- Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml, 70 ml bottle
  - e.g. Karicare Aptamil Gold+Preterm

### THICKENED FORMULA
- Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can
  - e.g. Karicare Aptamil Thickened AR

### Ketogenic Diet Products

#### HIGH FAT FORMULA – Restricted see terms below
- Powder 14.4 g protein, 2.9 g carbohydrate and 69.2 g fat per 100 g, can
  - 35.50 300 g Ketocal 4:1 (Unflavoured)
- Powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can
  - 35.50 300 g Ketocal 3:1 (Unflavoured)

- Initiation
  For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.
PEDIATRIC PRODUCTS

**Restricted (RS1473)**

**Initiation**

Both:

1. Child is aged one to ten years; and
2. Any of the following:
   1. The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
   2. Any condition causing malabsorption; or
   3. Faltering growth in an infant/child; or
   4. Increased nutritional requirements; or
   5. The child is being transitioned from TPN or tube feeding to oral feeding; or
   6. The child has eaten, or is expected to eat, little or nothing for 3 days.

**PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – Restricted see terms above**

- Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag.................................................................................................4.00 500 ml Nutrini Low Energy Multifibre RTH

**PAEDIATRIC ENTERAL FEED 1 KCAL/ML – Restricted see terms above**

- Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag..............2.68 500 ml Pediasure RTH
- Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag

**PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – Restricted see terms above**

- Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bag.................................................................................................6.00 500 ml Nutrini Energy Multi Fibre
- Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag

**PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted see terms above**

- Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle........1.07 200 ml Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla)
- Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, can...........1.34 250 ml Pediasure (Vanilla)

(Pediasure (Chocolate) Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle to be delisted 1 September 2020)
(Pediasure (Strawberry) Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle to be delisted 1 September 2020)
(Pediasure (Vanilla) Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle to be delisted 1 September 2020)

**PAEDIATRIC ORAL FEED 1.5 KCAL/ML – Restricted see terms above**

- Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle
- Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle

**RENAAL PRODUCTS**

**LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML – Restricted see terms below**

- Liquid 8.1 g protein, 14.7 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle.................................................................................................6.08 500 ml Nepro HP RTH

**Restricted (RS1229)**

**Initiation**

For patients with acute or chronic kidney disease.

---

*Item restricted (see – above); Item restricted (see – below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Special Foods

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**Low Electrolyte Oral Feed – Restricted** see terms below

- **Powder** 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can

  - Restricted (RS1227)

  **Initiation**
  For children (up to 18 years) with acute or chronic kidney disease.

**Low Electrolyte Oral Feed 1.8 KCAL/ML**

- **Liquid** 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton

  - Restricted (RS1228)

  **Initiation**
  For patients with acute or chronic kidney disease.

**Low Electrolyte Oral Feed 2 KCAL/ML – Restricted** see terms below

- **Liquid** 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, carton

  - Restricted (RS1228)

  **Initiation**
  For patients with acute or chronic kidney disease.

**Respiratory Products**

**Low Carbohydrate Oral Feed 1.5 KCAL/ML – Restricted** see terms below

- **Liquid** 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, bottle

  - Restricted (RS1230)

  **Initiation**
  For patients with CORD and hypercapnia, defined as a CO2 value exceeding 55 mmHg.

**Surgical Products**

**High Arginine Oral Feed 1.4 KCAL/ML – Restricted** see terms below

- **Liquid** 10.1 g protein, 15 g carbohydrate, 4.5 g fat and 0 g fibre per 100 ml, carton

  - Restricted (RS1231)

  **Initiation**
  Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery.

**Preoperative Carbohydrate Feed 0.5 KCAL/ML – Restricted** see terms below

- **Oral liq** 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml bottle

  - Restricted (RS1415)

  **Initiation**
  Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery.
## Standard Feeds

### Restricted (RS1214)

**Initiation**

Any of the following:

1. Any of the following:
   - BMI < 18.5; or
   - Greater than 10% weight loss in the last 3-6 months; or
   - BMI < 20 with greater than 5% weight loss in the last 3-6 months; or

2. For patients who have, or are expected to, eat little or nothing for 5 days; or

3. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or

4. For use pre- and post-surgery; or

5. For patients being tube-fed; or

6. For tube-feeding as a transition from intravenous nutrition; or

7. For any other condition that meets the community Special Authority criteria.

### ENTERAL FEED 1.5 KCAL/ML – Restricted see terms above

<table>
<thead>
<tr>
<th>Liquid</th>
<th>Protein (g)</th>
<th>Carbohydrate (g)</th>
<th>Fat (g)</th>
<th>Fibre (g)</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutrison Energy</td>
<td>6</td>
<td>18.3</td>
<td>5.8</td>
<td>1.5</td>
<td>7.00</td>
<td>1,000 ml</td>
</tr>
<tr>
<td>Nutrison Energy Multi Fibre</td>
<td>6</td>
<td>18.4</td>
<td>5.8</td>
<td>1.5</td>
<td>7.00</td>
<td>1,000 ml</td>
</tr>
</tbody>
</table>

### ENTERAL FEED 1 KCAL/ML – Restricted see terms above

<table>
<thead>
<tr>
<th>Liquid</th>
<th>Protein (g)</th>
<th>Carbohydrate (g)</th>
<th>Fat (g)</th>
<th>Fibre (g)</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osmolite RTH</td>
<td>4</td>
<td>13.6</td>
<td>3.4</td>
<td>0.5</td>
<td>5.29</td>
<td>1,000 ml</td>
</tr>
<tr>
<td>Jevity RTH</td>
<td>4</td>
<td>14.1</td>
<td>3.47</td>
<td>1.76</td>
<td>5.29</td>
<td>1,000 ml</td>
</tr>
</tbody>
</table>

### ENTERAL FEED 1.2 KCAL/ML – Restricted see terms above

<table>
<thead>
<tr>
<th>Liquid</th>
<th>Protein (g)</th>
<th>Carbohydrate (g)</th>
<th>Fat (g)</th>
<th>Fibre (g)</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jevity Plus RTH</td>
<td>5.55</td>
<td>15.1</td>
<td>3.93</td>
<td>2</td>
<td>5.29</td>
<td>1,000 ml</td>
</tr>
</tbody>
</table>

### ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Restricted see terms above

<table>
<thead>
<tr>
<th>Liquid</th>
<th>Protein (g)</th>
<th>Carbohydrate (g)</th>
<th>Fat (g)</th>
<th>Fibre (g)</th>
<th>Price</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutrison 800 Complete Multi Fibre</td>
<td>5.5</td>
<td>8.8</td>
<td>2.5</td>
<td>1.5</td>
<td>5.29</td>
<td>1,000 ml</td>
</tr>
</tbody>
</table>

---

*Item restricted (see above); Item restricted (see below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ORAL FEED</strong> – Restricted see terms on the previous page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder 15.9 g protein, 57.4 g carbohydrate and 14 g fat per 100 g, can</td>
<td>26.00</td>
<td>Ensure (Chocolate)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ensure (Vanilla)</td>
</tr>
<tr>
<td>Powder 20.8 g protein, 61 g carbohydrate and 9.4 g fat per 100 g, can</td>
<td>8.54</td>
<td>Fortisip (Vanilla)</td>
</tr>
<tr>
<td>Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can</td>
<td>26.00</td>
<td>Sustagen Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Formula Active</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Choc)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sustagen Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Formula Active</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Van)</td>
</tr>
<tr>
<td><strong>Note:</strong> Community subsidy of Sustagen Hospital Formula is subject to both</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Special Authority criteria and a manufacturer's surcharge. Higher subsidy by</td>
<td></td>
<td></td>
</tr>
<tr>
<td>endorsement is available for patients meeting the following endorsement criteria;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>fat malabsorption, fat intolerance or chyle leak.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ORAL FEED 1 KCAL/ML</strong> – Restricted see terms on the previous page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml,</td>
<td></td>
<td>e.g. Resource Fruit</td>
</tr>
<tr>
<td>237 ml carton</td>
<td></td>
<td>Beverage</td>
</tr>
<tr>
<td><strong>ORAL FEED 1.5 KCAL/ML</strong> – Restricted see terms on the previous page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can</td>
<td>1.33</td>
<td>Ensure Plus (Vanilla)</td>
</tr>
<tr>
<td>237 ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml,</td>
<td>1.26</td>
<td>Ensure Plus (Banana)</td>
</tr>
<tr>
<td>carton</td>
<td></td>
<td>Ensure Plus (Chocolate)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ensure Plus (Fruit of the Forest)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ensure Plus (Vanilla)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>e.g. Fortijuice</td>
</tr>
<tr>
<td></td>
<td></td>
<td>e.g. Fortisip</td>
</tr>
<tr>
<td></td>
<td></td>
<td>e.g. Fortisip Multi Fibre</td>
</tr>
</tbody>
</table>

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**Bacterial and Viral Vaccines**

**DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – Restricted see terms below**

- Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe
  - 0% DV Sep-17 to 2020

  ![ ]

  **Initiation**

  Any of the following:

  1. A single dose for children up to the age of 7 who have completed primary immunisation; or
  2. A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
  3. An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
  4. Five doses will be funded for children requiring solid organ transplantation.

  Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes

**DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Restricted see terms below**

- Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial
  - 0% DV Sep-17 to 2020

  ![ ]

  **Initiation**

  Any of the following:

  1. Up to four doses for children up to and under the age of 10 for primary immunisation; or
  2. An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
  3. Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

  Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

**Bacterial Vaccines**

**ADULT DIPHTHERIA AND TETANUS VACCINE**

- Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe
  - 0% DV Jul-17 to 2020

  ![ ]

  **Initiation**

  Any of the following:

  1. For vaccination of patients aged 45 and 65 years old; or
  2. For vaccination of previously unimmunised or partially immunised patients; or

  continued…
continued...

3 For revaccination following immunosuppression; or
4 For boosting of patients with tetanus-prone wounds; or
5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

**BACILLUS CALMETTE-GUERIN VACCINE – Restricted** see terms below

- **Inj** Mycobacterium bovis BCG (Baillirius Calmette-Guerin), Danish strain 1331, live attenuated, vial Danish strain 1331, live attenuated, vial with diluent. 

  0.00 10 BCG Vaccine

**Initiation**

All of the following:

1. Living in a house or family with a person with current or past history of TB; and
2. Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; and
3. During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.


**DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – Restricted** see terms below

- **Inj** 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemaglutinin and 2.5 mcg pertactin in 0.5 ml syringe – 0% DV Sep-17 to 2020

  0.00 1 Boostrix

  **10 Boostrix**

**Initiation**

Any of the following:

1. A single dose for pregnant women in the second or third trimester of each pregnancy; or; or
2. A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or; or
3. A course of up to four doses is funded for children from age 7 up the age of 18 years inclusive to complete full primary immunisation; or
4. An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens.

Note: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

**HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Restricted** see terms below

- **Inj** Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml – 0% DV Sep-17 to 2020

  0.00 1 Hiberix

**Initiation**

*Therapy limited to 1 dose*

Any of the following:

1. For primary vaccination in children; or
continued…

2 An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or

3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE – Restricted see terms below

Inj 4 mcg or each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial –

0% DV Jul-17 to 2020.................................0.00 1 Menactra

Initiation
Either:

1 Any of the following:
   1.1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
   1.2 One dose for close contacts of meningococcal cases; or
   1.3 A maximum of two doses for bone marrow transplant patients; or
   1.4 A maximum of two doses for patients following immunosuppression*; or

2 Both:
   2.1 Person is aged between 13 and 25 years, inclusive; and
   2.2 Either:
      2.2.1 One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons; or
      2.2.2 One dose for individuals who are currently living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons, from 1 December 2019 to 30 November 2020.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL C CONJUGATE VACCINE – Restricted see terms below

Inj 10 mcg in 0.5 ml syringe –

0% DV Jul-17 to 2020.................................0.00 1 Neisvac-C

Initiation
Any of the following:

1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or

2 One dose for close contacts of meningococcal cases; or

3 A maximum of two doses for bone marrow transplant patients; or

4 A maximum of two doses for patients following immunosuppression*.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE – Restricted see terms on the next page

mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V,
14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4,
18C and 19F in 0.5 ml prefilled syringe –

0% DV Sep-17 to 2020.........0.00 10 Synflorix
**VACCINES**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**⇒ Restricted (RS1585)**

**Initiation**

Either:

1. A primary course of four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or
2. Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of 59 months who have received one to three doses of PCV13.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – **Restricted** see terms below

- Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe.................................................0.00 1 Prevenar 13
  10 Prevenar 13

**⇒ Restricted (RS1586)**

**Initiation – High risk children who have received PCV10**

*Therapy limited to 1 dose*

One dose is funded for high risk children (over the age of 17 months and under 18 years) who have previously received four doses of PCV10.

**Initiation – High risk children aged under 5 years**

*Therapy limited to 4 doses*

Both:

1. Up to an additional four doses (as appropriate) are funded for children aged under 5 years for (re-)immunisation; and
2. Any of the following:
   2.1 On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
   2.2 With primary immune deficiencies; or
   2.3 With HIV infection; or
   2.4 With renal failure, or nephrotic syndrome; or
   2.5 Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
   2.6 With cochlear implants or intracranial shunts; or
   2.7 With cerebrospinal fluid leaks; or
   2.8 Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
   2.9 With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
   2.10 Pre-term infants, born before 28 weeks gestation; or
   2.11 With cardiac disease, with cyanosis or failure; or
   2.12 With diabetes; or
   2.13 With Down syndrome; or
   2.14 Who are pre-or post-splenectomy, or with functional asplenia.

**Initiation – High risk adults and children 5 years and over**

*Therapy limited to 4 doses*

Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients 5 years and over with HIV, for patients pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

**Initiation – Testing for primary immunodeficiency diseases**

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – **Restricted** see terms on the next page

- Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) – 0% DV Jul-17 to 2020..........................................................0.00 1 Pneumovax 23
VACCINES

Price
(ex man. excl. GST) $ Per
Brand or
Generic
Manufacturer

Restricted (RS1587)
Initiation – High risk patients
Therapy limited to 3 doses
For patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy; or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

Initiation – High risk children
Therapy limited to 2 doses
Both:
1 Patient is a child under 18 years for (re-)immunisation; and
2 Any of the following:
   2.1 On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
   2.2 With primary immune deficiencies; or
   2.3 With HIV infection; or
   2.4 With renal failure, or nephrotic syndrome; or
   2.5 Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
   2.6 With cochlear implants or intracranial shunts; or
   2.7 With cerebrospinal fluid leaks; or
   2.8 Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
   2.9 With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
   2.10 Pre term infants, born before 28 weeks gestation; or
   2.11 With cardiac disease, with cyanosis or failure; or
   2.12 With diabetes; or
   2.13 With Down syndrome; or
   2.14 Who are pre-or post-splenectomy, or with functional asplenia.

Initiation – Testing for primary immunodeficiency diseases
For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

SALMONELLA TYPHI VACCINE – Restricted see terms below
Inj 25 mcg in 0.5 ml syringe

Initiation
For use during typhoid fever outbreaks.

Viral Vaccines

HEPATITIS A VACCINE – Restricted see terms below
Inj 720 ELISA units in 0.5 ml syringe – 0% DV Sep-17 to 2020 ............................... 0.00 1 Havrix Junior
Inj 1440 ELISA units in 1 ml syringe – 0% DV Sep-17 to 2020 ............................... 0.00 1 Havrix

Initiation
Any of the following:
1 Two vaccinations for use in transplant patients; or
2 Two vaccinations for use in children with chronic liver disease; or
3 One dose of vaccine for close contacts of known hepatitis A cases.

HEPATITIS B RECOMBINANT VACCINE
Inj 5 mcg in 0.5 ml vial – 0% DV Jul-17 to 2020 ............................................. 0.00 1 HBvaxPRO
<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**:Restricted** *(RS1588)*

**Initiation**

Any of the following:

1. For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3. For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4. For HIV positive patients; or
5. For hepatitis C positive patients; or
6. For patients following non-consensual sexual intercourse; or
7. For patients following immunosuppression; or
8. For solid organ transplant patients; or
9. For post-haematopoietic stem cell transplant (HSCT) patients; or
10. Following needle stick injury.

| Inj 10 mcg in 1 ml vial | 0.00 1 HBvaxPRO |

**Initiation**

Any of the following:

1. For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3. For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4. For HIV positive patients; or
5. For hepatitis C positive patients; or
6. For patients following non-consensual sexual intercourse; or
7. For patients following immunosuppression; or
8. For solid organ transplant patients; or
9. For post-haematopoietic stem cell transplant (HSCT) patients; or
10. Following needle stick injury; or
11. For dialysis patients; or
12. For liver or kidney transplant patients.

| Inj 20 mcg per 1 ml prefilled syringe | 0.00 1 Engerix-B |

**Initiation**

Any of the following:

1. For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3. For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4. For HIV positive patients; or
5. For hepatitis C positive patients; or
6. For patients following non-consensual sexual intercourse; or
7. For patients following immunosuppression; or
8. For solid organ transplant patients; or
9. For post-haematopoietic stem cell transplant (HSCT) patients; or
10. Following needle stick injury; or
11. For dialysis patients; or
12. For liver or kidney transplant patients.

| Inj 40 mcg per 1 ml vial – 0% DV Jul-17 to 2020 | 0.00 1 HBvaxPRO |
HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] – Restricted see terms below

**Initiation**

**Both:**
1. For dialysis patients; and
2. For liver or kidney transplant patient.

**Inj 270 mcg in 0.5 ml syringe – 0% DV Jun-17 to 2020**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$0.00</td>
<td>10 Gardasil 9</td>
</tr>
</tbody>
</table>
continued...

1. Diabetes; or
2. Chronic renal disease; or
3. Any cancer, excluding basal and squamous skin cancers if not invasive; or
4. Autoimmune disease; or
5. Immune suppression or immune deficiency; or
6. HIV; or
7. Transplant recipient; or
8. Neuromuscular and CNS diseases/disorders; or
9. Haemoglobinopathies; or
10. Is a child on long term aspirin; or
11. Has a cochlear implant; or
12. Errors of metabolism at risk of major metabolic decompensation; or
13. Pre and post splenectomy; or
14. Down syndrome; or
15. Child who has been hospitalised for respiratory illness or has a history of significant respiratory illness.

Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine).........................................90.00 10 Afluria Quad
(2020 Formualtion)

**Restricted (RS1674)**

**Initiation – People over 65**
The patient is 65 years of age or over.

**Initiation – cardiovascular disease for patients 3 years and over**
Any of the following:

1. Ischaemic heart disease; or
2. Congestive heart failure; or
3. Rheumatic heart disease; or
4. Congenital heart disease; or
5. Cerebro-vascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

**Initiation – chronic respiratory disease for patients 3 years and over**
Either:

1. Asthma, if on a regular preventative therapy; or
2. Other chronic respiratory disease with impaired lung function.

Note: asthma not requiring regular preventative therapy is excluded from funding.

**Initiation – Other conditions for patients 3 years and over**
Either:

1. Any of the following:
   1.1 Diabetes; or
   1.2 Chronic renal disease; or
   1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
   1.4 Autoimmune disease; or
   1.5 Immune suppression or immune deficiency; or
   1.6 HIV; or
   1.7 Transplant recipient; or
   1.8 Neuromuscular and CNS diseases/disorders; or
   1.9 Haemoglobinopathies; or
   1.10 Is a child on long term aspirin; or
   1.11 Has a cochlear implant; or

continued…
**VACCINES**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

continued…

1.12 Errors of metabolism at risk of major metabolic decompensation; or
1.13 Pre and post splenectomy; or
1.14 Down syndrome; or
1.15 Is pregnant; or
1.16 Is a child aged four and under who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or

2 Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a DHB hospital.

MEASLES, MUMPS AND RUBELLA VACCINE – **Restricted** see terms below

- Injection, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent
  - 0.5 ml – **0% DV Sep-17 to 2020** ...............................................................0.00 10 Priorix

**Initiation** – first dose prior to 12 months

*Therapy limited to 3 doses*

Any of the following:
1. For primary vaccination in children; or
2. For revaccination following immunosuppression; or
3. For any individual susceptible to measles, mumps or rubella.

**Initiation** – first dose after 12 months

*Therapy limited to 2 doses*

Any of the following:
1. For primary vaccination in children; or
2. For revaccination following immunosuppression; or
3. For any individual susceptible to measles, mumps or rubella.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

POLIOMYELITIS VACCINE – **Restricted** see terms below

- Inj 80 D-antigen units in 0.5 ml syringe – **0% DV Jul-17 to 2020** ....................0.00 1 IPOL

**Initiation**

*Therapy limited to 3 doses*

Either:
1. For partially vaccinated or previously unvaccinated individuals; or
2. For revaccination following immunosuppression.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

RABIES VACCINE

- Inj 2.5 IU vial with diluent

ROTA VIRUS ORAL VACCINE – **Restricted** see terms below

- Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, prefilled oral applicator – **0% DV Sep-17 to 2020** ..........................................................0.00 10 Rotarix

**Initiation**

*Therapy limited to 2 doses*

Both:
1. First dose to be administered in infants aged under 14 weeks of age; and
2. No vaccination being administered to children aged 24 weeks or over.
VARICELLA VACCINE [CHICKENPOX VACCINE] – Restricted see terms below

- Inj 2000 PFU prefilled syringe plus vial – 0% DV Sep-17 to 2020 ................. 0.00 1 Varilrix

**→ Restricted (RS1591)**

Initiation – primary vaccinations

*Therapy limited to 1 dose*

Either:

1. Any infant born on or after 1 April 2016; or
2. For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella infection (chickenpox).

Initiation – other conditions

*Therapy limited to 2 doses*

Any of the following:

1. Any of the following:
   - for non-immune patients:
     1.1 With chronic liver disease who may in future be candidates for transplantation; or
     1.2 With deteriorating renal function before transplantation; or
     1.3 Prior to solid organ transplant; or
     1.4 Prior to any elective immunosuppression*; or
     1.5 For post exposure prophylaxis who are immune competent inpatients; or
2. For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or
3. For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or
4. For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
5. For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or
6. For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
7. For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

VARICELLA ZOSTER VACCINE [SHINGLES VACCINE] – Restricted see terms below

- Varicella zoster virus (Oka strain) live attenuated vaccine [shingles vaccine] ................................................................. 0.00 1 Zostavax

**→ Restricted (RS1720)**

Initiation – people aged 65 years

*Therapy limited to 1 dose*

One dose for all people aged 65 years.

Initiation – people aged between 66 and 80 years

*Therapy limited to 1 dose*

One dose for all people aged between 66 and 80 years inclusive from 1 April 2018 and 31 December 2020.

### Diagnostic Agents

TUBERCULIN PPD [MANTOUX] TEST

- Inj 5 TU per 0.1 ml, 1 ml vial – 0% DV Jul-17 to 2020 ........................................ 0.00 1 Tubersol
## Optional Pharmaceuticals

**NOTE:**
In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a range of hospital medical devices are listed in an addendum to Part III which is available at [www.pharmac.govt.nz](http://www.pharmac.govt.nz). The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand/Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BLOOD GLUCOSE DIAGNOSTIC TEST METER</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips........</td>
<td>$20.00</td>
<td>CareSens N Premier</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caresens N</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caresens N POP</td>
</tr>
<tr>
<td><strong>BLOOD GLUCOSE DIAGNOSTIC TEST STRIP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood glucose test strips</td>
<td>$10.56</td>
<td>CareSens N</td>
</tr>
<tr>
<td>Test strips</td>
<td>$10.56</td>
<td>CareSens PRO</td>
</tr>
<tr>
<td><strong>BLOOD KETONE DIAGNOSTIC TEST STRIP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test strips</td>
<td>$15.50</td>
<td>KetoSens</td>
</tr>
<tr>
<td><strong>DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meter with 50 lancets, a lancing device, and 10 blood glucose diagnostic test strips</td>
<td>$20.00</td>
<td>CareSens Dual</td>
</tr>
<tr>
<td><strong>MASK FOR SPACER DEVICE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small</td>
<td>$2.20</td>
<td>e-chamber Mask</td>
</tr>
<tr>
<td><strong>PEAK FLOW METER</strong></td>
<td>$9.54</td>
<td>Mini-Wright AFS Low Range</td>
</tr>
<tr>
<td>Normal Range</td>
<td>$9.54</td>
<td>Mini-Wright Standard</td>
</tr>
<tr>
<td><strong>PREGNANCY TEST - HCG URINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cassette</td>
<td>$12.00</td>
<td>Smith BioMed Rapid Pregnancy Test</td>
</tr>
<tr>
<td><strong>SODIUM NITROPRUSSIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test strip</td>
<td>$22.00</td>
<td>Ketostix</td>
</tr>
<tr>
<td><strong>SPACER DEVICE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>220 ml (single patient)</td>
<td>$2.95</td>
<td>e-chamber Turbo</td>
</tr>
<tr>
<td>510 ml (single patient)</td>
<td>$5.12</td>
<td>e-chamber La Grande</td>
</tr>
<tr>
<td>800 ml</td>
<td>$6.50</td>
<td>Volumatic</td>
</tr>
</tbody>
</table>

*Item restricted (see above); Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
INDEX: Generic Chemicals and Brands

- Symbols -
8-methoxypsoralen ......................... 56
A-Scabies .................................. 53
Abacavir sulphate ......................... 86
Abacavir sulphate with lamivudine ...... 86
Abciximab .................................. 154
Abraterone acetate ......................... 144
Acarbose ................................... 9
Accuretic 10 ................................ 38
Accuretic 20 ................................ 38
Acetazolamide ............................. 213
Acetec ........................................ 38
Acetic acid
Extemporaneously Compounded Preparations 224
Genito-Urinary .............................. 58
Acetic acid with hydroxyquinoline, glycol ........................................... 215
glycerol and ricinoleic acid ............... 58
Acetic acid with propylene glycol ........ 215
Acetylcholine chloride ..................... 213
Acetylcysteine ............................. 216
Aciclovir
Infections ................................... 89
Sensory ...................................... 209
Aciclovir-Claris ................................ 89
Acid Citrate Dextrose A ................... 30
Acidex ....................................... 5
Acipimox .................................... 46
Acitretin ..................................... 56
Aclasta ....................................... 94
Actemra ...................................... 191
Actinomycin D ............................... 129
Aclidal 10 .................................... 43
Aclidal Oros .................................. 43
Adalimumab .................................. 154
Adapalene .................................... 53
Adefovir dipivoxil ......................... 88
Adenocor ..................................... 40
Adenosine .................................... 40
Adenuric ..................................... 99
Adrenalin ..................................... 47
ADT Booster ................................ 242
Adult diphtheria and tetanus vaccine .... 242
Advantan ..................................... 55
Advate ....................................... 29
Adynovate ................................... 29
Aerrane ....................................... 104
Afinitor ...................................... 200
Alibibercept ................................. 163
Afluria Quad
(2020 Formulation) ......................... 249
Afluria Quad Junior
(2020 Formulation) ......................... 248
AFT Pholcodine Linctus BP ............... 205
Agents Affecting the Renin-Angiotensin System .......................................... 38
Agents for Parkinsonism and Related Disorders ........................................... 103
Agents Used in the Treatment of Poisonings ............................................... 216
Ajmaline ...................................... 40
Alanase ....................................... 201
Albendazole .................................. 83
Aldurazyme ................................... 16
Alecsena ...................................... 137
Alectinib ...................................... 137
Aclidronate sodium ......................... 94
Aclidronate sodium with colecalciferol .................................................. 94
Alfacaclidol ................................... 22
Alfamino Junior .............................. 235
Alfentanil ..................................... 108
Aliglucosidase alfa .......................... 13
Alicina ........................................ 84
Allerpro 1 ..................................... 236
Allerpro 2 ..................................... 236
Allersoothe .................................. 202
Almecap ...................................... 131
Allopurinol ................................... 98
Alpha tocopherol ............................ 22
Alpha tocopheryl acetate .................. 23
Alpha-Adrenoceptor Blockers .......... 39
Alphamox .................................... 76
Alphamox 125 ................................ 76
Alphamox 250 ................................ 76
Alprolix ....................................... 28
Alprostadil hydrochloride ................. 47
Alteplase ..................................... 33
Alum .......................................... 224
Aluminium chloride ......................... 26
Aluminium hydroxide ...................... 5
Aluminium hydroxide with magnesium hydroxide and simeticone .............. 5
Amantadine hydrochloride ............... 103
AmBisome .................................... 80
Ambrisentan .................................. 48
Amethocaine
Nervous ...................................... 107
Sensory ...................................... 212
Amikacin ..................................... 72
Amiloride hydrochloride ................. 44
Amiloride hydrochloride with furosemide 44
Amiloride hydrochloride with hydrochlorothiazide ................................. 44
Aminolevulinic acid hydrochloride .... 146
Aminophylline............................... 207
Amiodarone hydrochloride ............... 40
Amisulpride ................................ 117
Amisulpride hydrochloride ............... 117
Amipiptoline .................................. 42
Amiodarone .................................. 117
Amorolfine .................................... 52
Amoxicillin ................................... 76
Amoxicillin with clavulanic acid ....... 76
Amphotericin B
Alimentary ................................... 19
Infections .................................... 80
Amsacrine .................................... 132
Amyl nitrite ................................... 216
Anabolic Agents ............................... 62
Anaesthetics .................................. 104
Anagrelide hydrochloride ................. 132
Analgesics .................................... 107
Anastrozole ................................... 146
Andriol Testocaps ........................... 62
Androderm .................................... 62
Androgen Agonists and Antagonists .... 62
Anor Oelipta .................................. 203
Antabuse ...................................... 126
Antacids and Antiflatulents ............... 5
Anti-Infective Agents ....................... 58
Anti-Infective Preparations ................
Dermatological ................................ 52
Sensory ........................................ 209
Anti-Inflammatory Preparations ......... 210
Antiarrhythmics ............................. 40
Antibacterials ................................ 72
Anticholinergic Agents .................... 202
Anticholinesterases ......................... 94
Antidepressants ............................. 110
Antidiarrhoeals and Intestinal Anti-Inflammatory Agents .......... 5
Antiarrhythmics ............................. 40
Antibacterials ................................ 72
Antihyperactive Drugs ..................... 112
Antifibrinolytics, Haemostatics and Local Sclerosants ......................... 26
Antiarrhythmics ............................. 40
Antibacterials ................................ 72
Antifungal .................................... 88
Antithyopetensives ......................... 41
Antimigraine Preparations ............... 115
Antimycobacterials ......................... 82
Antinausea and Vertigo Agents ........ 115
Antiparasitics ............................... 83
<table>
<thead>
<tr>
<th>INDEX: Generic Chemicals and Brands</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antipruritic Preparations</strong> ........ 53</td>
</tr>
<tr>
<td><strong>Antipsychotic Agents</strong> .............. 117</td>
</tr>
<tr>
<td><strong>Antiretrovirals</strong> .................... 85</td>
</tr>
<tr>
<td><strong>Antirheumatoid Agents</strong> ............ 94</td>
</tr>
<tr>
<td><strong>Antiseptics and Disinfectants</strong> ..... 218</td>
</tr>
<tr>
<td><strong>Antispasmodics and Other Agents</strong></td>
</tr>
<tr>
<td>Altering Gut Motility ................. 7</td>
</tr>
<tr>
<td><strong>Antithrombotics</strong> .................... 30</td>
</tr>
<tr>
<td><strong>Antithymocyte globulin</strong> ............</td>
</tr>
<tr>
<td>(equine) ................................... 199</td>
</tr>
<tr>
<td><strong>Antithymocyte globulin (rabbit)</strong>  199</td>
</tr>
<tr>
<td><strong>Antulcerants</strong> ........................ 7</td>
</tr>
<tr>
<td><strong>Antivirals</strong> ........................... 88</td>
</tr>
<tr>
<td><strong>Anxiolytics</strong> .......................... 120</td>
</tr>
<tr>
<td><strong>Apida</strong> .................................. 10</td>
</tr>
<tr>
<td><strong>Apida Solostar</strong> ...................... 10</td>
</tr>
<tr>
<td><strong>Apo-Amlodipine</strong> ..................... 42</td>
</tr>
<tr>
<td><strong>Apo-Amoxi</strong> ............................ 76</td>
</tr>
<tr>
<td><strong>Apo-Azithromycin</strong> ................... 74</td>
</tr>
<tr>
<td><strong>Apo-Ciclopix</strong> .......................... 52</td>
</tr>
<tr>
<td><strong>Apo-Cilazaptop/ Hydrochlorothiazide</strong></td>
</tr>
<tr>
<td>............................................ 38</td>
</tr>
<tr>
<td><strong>Apo-Clarithromycin</strong> ................ 75</td>
</tr>
<tr>
<td><strong>Apo-Clomipramine</strong> .................. 110</td>
</tr>
<tr>
<td><strong>Apo-Dicro SR</strong> ......................... 101</td>
</tr>
<tr>
<td><strong>Apo-Diltiazem CD</strong> ................... 43</td>
</tr>
<tr>
<td><strong>Apo-Doxazosin</strong> ...................... 39</td>
</tr>
<tr>
<td><strong>Apo-Folic Acid</strong> ...................... 25</td>
</tr>
<tr>
<td><strong>Apo-Furosamide</strong> ..................... 44</td>
</tr>
<tr>
<td><strong>Apo-Gabapentin</strong> ..................... 112</td>
</tr>
<tr>
<td><strong>Apo-Leflunomide</strong> ................... 94</td>
</tr>
<tr>
<td><strong>Apo-Megestrol</strong> ....................... 145</td>
</tr>
<tr>
<td><strong>Apo-Metoprolol</strong> ..................... 42</td>
</tr>
<tr>
<td><strong>Apo-Mirtazapine</strong> .................... 111</td>
</tr>
<tr>
<td><strong>Apo-Nadolol</strong> .......................... 42</td>
</tr>
<tr>
<td><strong>Apo-Nicotinic Acid</strong> ............... 46</td>
</tr>
<tr>
<td><strong>Apo-Ofloxacin</strong> ...................... 45</td>
</tr>
<tr>
<td><strong>Apo-Oxybutynin</strong> ..................... 61</td>
</tr>
<tr>
<td><strong>Apo-Perindopril</strong> .................... 38</td>
</tr>
<tr>
<td><strong>Apo-Pindolol</strong> ........................ 42</td>
</tr>
<tr>
<td><strong>Apo-Pravastatin</strong> .................... 45</td>
</tr>
<tr>
<td><strong>Apo-Prazosin</strong> ........................ 40</td>
</tr>
<tr>
<td><strong>Apo-Prednisone</strong> ..................... 64</td>
</tr>
<tr>
<td><strong>Apo-Propranolol</strong> .................... 42</td>
</tr>
<tr>
<td><strong>Apo-Pyridoxine</strong> ..................... 22</td>
</tr>
<tr>
<td><strong>Apo-Sumatriptan</strong> ................... 115</td>
</tr>
<tr>
<td><strong>Apo-Terazosin</strong> ...................... 40</td>
</tr>
<tr>
<td><strong>Apopomorphine hydrochloride</strong> ......</td>
</tr>
<tr>
<td>........................................... 103</td>
</tr>
<tr>
<td><strong>Apcrilonidene</strong> ...................... 214</td>
</tr>
<tr>
<td><strong>Aprepitant</strong> ........................... 115</td>
</tr>
<tr>
<td><strong>Apresoline</strong> ........................... 48</td>
</tr>
<tr>
<td><strong>Aprotinin</strong> ............................. 26</td>
</tr>
<tr>
<td><strong>Aqueous cream</strong> ...................... 54</td>
</tr>
<tr>
<td><strong>Arachis oil [Peanut oil]</strong> .......... 224</td>
</tr>
<tr>
<td><strong>Aratac</strong> ................................. 40</td>
</tr>
<tr>
<td><strong>Arginine</strong> ................................ 14</td>
</tr>
<tr>
<td><strong>Arginine [Alimentary]</strong> ............ 24</td>
</tr>
<tr>
<td><strong>Arginine [Various]</strong> ................. 220</td>
</tr>
<tr>
<td><strong>Argipressin [Vasopressin]</strong> ...... 71</td>
</tr>
<tr>
<td><strong>Aripiprazole</strong> ....................... 117</td>
</tr>
<tr>
<td><strong>Aripiprazole Sandoz</strong> .............. 117</td>
</tr>
<tr>
<td><strong>Aristocort</strong> ........................... 55</td>
</tr>
<tr>
<td><strong>Arrow - Clopid</strong> ..................... 32</td>
</tr>
<tr>
<td><strong>Arrow-Amirupryline</strong> .............. 110</td>
</tr>
<tr>
<td><strong>Arrow-Bendrofluazide</strong> ............ 44</td>
</tr>
<tr>
<td><strong>Arrow-Brimonidine</strong> ............... 214</td>
</tr>
<tr>
<td><strong>Arrow-Calciurn</strong> ..................... 17</td>
</tr>
<tr>
<td><strong>Arrow-Diazepam</strong> .................... 120</td>
</tr>
<tr>
<td><strong>Arrow-Fluxetine</strong> ................. 111</td>
</tr>
<tr>
<td><strong>Arrow-Lamotrigine</strong> ............... 113</td>
</tr>
<tr>
<td><strong>Arrow-Losartan &amp; Hydrochlorothiazide</strong></td>
</tr>
<tr>
<td>........................................... 39</td>
</tr>
<tr>
<td><strong>Arrow-Morphe LA</strong> ................. 109</td>
</tr>
<tr>
<td><strong>Arrow-Norfloracin</strong> ............... 77</td>
</tr>
<tr>
<td><strong>Arrow-Omidazole</strong> ................... 84</td>
</tr>
<tr>
<td><strong>Arrow-Quinapril 10</strong> .............. 38</td>
</tr>
<tr>
<td><strong>Arrow-Quinapril 20</strong> .............. 38</td>
</tr>
<tr>
<td><strong>Arrow-Quinapril 5</strong> ............... 38</td>
</tr>
<tr>
<td><strong>Arrow-Roxithromycin</strong> ............ 75</td>
</tr>
<tr>
<td><strong>Arrow-Timolol</strong> ..................... 213</td>
</tr>
<tr>
<td><strong>Arrow-Toludine</strong> .................... 61</td>
</tr>
<tr>
<td><strong>Arrow-Topiramate</strong> ............... 114</td>
</tr>
<tr>
<td><strong>Arrow-Tramadol</strong> .................... 110</td>
</tr>
<tr>
<td><strong>Arsenic trioxide</strong> ................. 132</td>
</tr>
<tr>
<td><strong>Artemether with lumefantrine</strong> ... 83</td>
</tr>
<tr>
<td><strong>Artesunate</strong> ........................... 84</td>
</tr>
<tr>
<td><strong>Articaine hydrochloride</strong> .......... 105</td>
</tr>
<tr>
<td><strong>Articaine hydrochloride with adrenaline</strong></td>
</tr>
<tr>
<td>........................................... 105</td>
</tr>
<tr>
<td><strong>Asacol</strong> .............................. 6</td>
</tr>
<tr>
<td><strong>Asamex</strong> .............................. 6</td>
</tr>
<tr>
<td><strong>Ascorbic acid</strong> ...................... 22</td>
</tr>
<tr>
<td><strong>Alimentary</strong> ........................... 22</td>
</tr>
<tr>
<td><strong>Extemporaneously Compounded</strong> ... 224</td>
</tr>
<tr>
<td><strong>Preparations</strong> ........................ 224</td>
</tr>
<tr>
<td><strong>Aspen Adrenaline</strong> .................. 47</td>
</tr>
<tr>
<td><strong>Aspirin</strong> ................................ 31</td>
</tr>
<tr>
<td><strong>Blood</strong> ................................. 31</td>
</tr>
<tr>
<td><strong>Nervous</strong> .............................. 107</td>
</tr>
<tr>
<td><strong>Asthalin</strong> ............................. 205</td>
</tr>
<tr>
<td><strong>Azataniv sulphate</strong> ............... 87</td>
</tr>
<tr>
<td><strong>Atenolol</strong> ............................. 41</td>
</tr>
<tr>
<td><strong>Atenolol-AFT</strong> ....................... 41</td>
</tr>
<tr>
<td><strong>ATGAM</strong> ............................... 199</td>
</tr>
<tr>
<td><strong>Ativan</strong> ............................... 120</td>
</tr>
<tr>
<td><strong>Atomeetine</strong> ......................... 123</td>
</tr>
<tr>
<td><strong>Atorvastatin</strong> ....................... 45</td>
</tr>
<tr>
<td><strong>Atovaquone with proguanil</strong> ...... 84</td>
</tr>
<tr>
<td><strong>hydrochloride</strong> .................... 84</td>
</tr>
<tr>
<td><strong>Atracurium besylate</strong> ............. 100</td>
</tr>
<tr>
<td><strong>Atropine sulphate</strong> .............. 100</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong> ................... 40</td>
</tr>
<tr>
<td><strong>Sensory</strong> .............................. 214</td>
</tr>
<tr>
<td><strong>Atropy</strong> ................................ 214</td>
</tr>
<tr>
<td><strong>Aubagio</strong> .............................. 121</td>
</tr>
<tr>
<td><strong>Augmentin</strong> ........................... 76</td>
</tr>
<tr>
<td><strong>Aurox</strong> ............................... 111</td>
</tr>
<tr>
<td><strong>Avelox</strong> ................................ 77</td>
</tr>
<tr>
<td><strong>Avelox IV 400</strong> ..................... 77</td>
</tr>
<tr>
<td><strong>Avenex</strong> ................................. 121</td>
</tr>
<tr>
<td><strong>Avenex Pen</strong> ......................... 121</td>
</tr>
<tr>
<td><strong>Azactam</strong> ............................. 78</td>
</tr>
<tr>
<td><strong>Azamun</strong> .............................. 199</td>
</tr>
<tr>
<td><strong>Aziphtoprine</strong> ....................... 199</td>
</tr>
<tr>
<td><strong>Azithromycin</strong> ...................... 74</td>
</tr>
<tr>
<td><strong>Azol</strong> ................................. 65</td>
</tr>
<tr>
<td><strong>AZT</strong> .................................. 86</td>
</tr>
<tr>
<td><strong>Aztreamom</strong> ........................... 78</td>
</tr>
<tr>
<td><strong>Bacillus calmette-gerin (BCG)</strong> ..... 199</td>
</tr>
<tr>
<td><strong>Bacillus calmette-gerin vaccine</strong> ... 243</td>
</tr>
<tr>
<td><strong>Baclafen</strong> ........................... 243</td>
</tr>
<tr>
<td><strong>Bacterial and Viral Vaccines</strong> ..... 242</td>
</tr>
<tr>
<td><strong>Bacterial Vaccines</strong> ................ 242</td>
</tr>
<tr>
<td><strong>Balanced Salt Solution</strong> .......... 212</td>
</tr>
<tr>
<td><strong>Barium sulphate</strong> ................... 219</td>
</tr>
<tr>
<td><strong>Barium sulphate with sodium bicarbonate</strong></td>
</tr>
<tr>
<td>........................................... 219</td>
</tr>
<tr>
<td><strong>Barrier Creams and Emollients</strong> ... 53</td>
</tr>
<tr>
<td><strong>Basiliximab</strong> ....................... 164</td>
</tr>
<tr>
<td><strong>BCG Vaccine</strong> ........................ 243</td>
</tr>
<tr>
<td><strong>BD PosiFlush</strong> ....................... 36</td>
</tr>
<tr>
<td><strong>Beclazone 100</strong> ..................... 205</td>
</tr>
<tr>
<td><strong>Beclazone 250</strong> ..................... 205</td>
</tr>
<tr>
<td><strong>Beclazone 50</strong> ....................... 205</td>
</tr>
<tr>
<td><strong>Beclomethasone dipropionate</strong> ... 201, 205</td>
</tr>
<tr>
<td><strong>Bee venom</strong> ........................... 201</td>
</tr>
<tr>
<td><strong>Bendamustine hydrochloride</strong> ...... 128</td>
</tr>
<tr>
<td><strong>Bendroflazide</strong> ...................... 44</td>
</tr>
<tr>
<td><strong>Bendroflumethiazide</strong> ............. 44</td>
</tr>
<tr>
<td><strong>Benzathine benzylpenicillin</strong> ..... 76</td>
</tr>
<tr>
<td><strong>Benzatropine mesylate</strong> .......... 103</td>
</tr>
<tr>
<td><strong>Benzbromaron AL 100</strong> ............ 99</td>
</tr>
<tr>
<td><strong>Benzbromaronone</strong> ................. 99</td>
</tr>
<tr>
<td><strong>Benzocaine</strong> .......................... 105</td>
</tr>
<tr>
<td><strong>Benzocaine with tetracaine</strong> ......</td>
</tr>
<tr>
<td><strong>hydrochloride</strong> .................... 105</td>
</tr>
<tr>
<td><strong>Benzoine</strong> ............................ 224</td>
</tr>
<tr>
<td><strong>Benzoyl peroxide</strong> ................. 53</td>
</tr>
<tr>
<td><strong>Benztrap</strong> ............................. 103</td>
</tr>
<tr>
<td><strong>Benzydamine hydrochloride</strong> ...... 19</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

Benzylamine hydrochloride with... 19
Benzylpenicillin sodium [Penicillin G]... 76
Beractant.................................. 208
Beta Cream ................................ 55
Beta Ointment................................ 55
Beta Scalp.................................. 56
Beta-Adrenoceptor Agonists........ 205
Beta-Adrenoceptor Blockers......... 218
Betadine.................................. 218
Betadine Skin Prep........................ 218
Betahistine dihydrochloride ...... 116
Betaine ...................................... 14
Betalog CR.................................. 41
Betamethasone........................... 63
Betamethasone dipropionate....... 55
Betamethasone dipropionate with... 56
Betamethasone sodium phosphate... 129
with betamethasone acetate ...... 63
Betamethasone valerate........ 55-56
Betamethasone valerate with... 56
Betamethasone valerate with... 56
Betaxolol.................................... 213
Betnovate.................................... 55
Betoptic..................................... 213
Betoptic S.................................... 213
Bevacizumab.............................. 164
Bezafibrate.................................. 45
Bezalip...................................... 45
Bezalip Retard............................. 45
Bicalutamide................................. 145
Bicillin LA.................................... 76
BiCNU....................................... 129
Bicnu Heritage............................ 129
Bile and Liver Therapy................. 9
Biliscopin.................................... 220
Bimatoprost................................. 213
Bimatoprost Multichem................. 213
Binarex...................................... 145
Binocrit...................................... 24
Biodone..................................... 108
Biodone Extra Forte...................... 108
Biodone Forte.............................. 108
Biotin......................................... 15
Bisacodyl.................................... 13
Bismuth subgallate....................... 224
Bismuth subnitrate and iodoform... 222
Bisoprolol fumarate........................ 41
Bivalirudin................................... 30
Bleomycin sulphate........................ 129
Blood glucose diagnostic test....... 252
Blood glucose diagnostic test... 252
Blood ketone diagnostic test ...... 252
Bonney's blue dye........................ 221
Boostrix..................................... 243
Boric acid.................................... 224
Bortezomib.................................... 132
Bortezomib Dr-Reddy's................. 132
Bosentan.................................... 48
Bosentan Dr Reddy's.................... 48
Bosvate..................................... 41
Botox.......................................... 100
Botulism antitoxin......................... 216
Bpex........................................... 22
Breo Ellipta.................................. 206
Brevinor 1/28................................. 58
Bridion....................................... 101
Brilinta........................................ 32
Brimonidine tartrate..................... 214
Brimonidine tartrate with timolol... 214
Brinov......................................... 130
Bromazolamide.............................. 213
Bromocriptine............................... 103
Brufen SR...................................... 102
Budesonide................................... 5
Budesonide with efomterol......... 206
Burnetanide.................................. 43
Bupafulen.................................... 105
Bupivacaine hydrochloride........ 105
Bupivacaine hydrochloride with... 105
Bupivacaine hydrochloride with... 105
Bupivacaine hydrochloride with... 105
Bupropion hydrochloride.............. 126
Bupropion hydrochloride with... 126
Buscaribbean................................ 66
Buscopan..................................... 7
Busilane...................................... 129
Buspirone hydrochloride............. 120
Calcitriol-AFT.............................. 252
Calcium carbonate......................... 22
Calcium Channel Blockers ............ 5, 17
Calcium chloride........................... 34
Calcium folinate............................ 143
Calcium Folinate Ebewe .............. 143
Calcium Folinate Sandoz............... 143
Calcium gluconate........................
Calcium Homeostasis....................... 62
Calcium polystyrene sulphonate.... 37
Calcium Resonium......................... 37
Candesartan cilexetil..................... 39
Candesartan................................. 39
Capacitabine................................ 130
Capercit.......................... 130
Capoten....................................... 38
Capsaicin....................................
Musculoskeletal............................ 102
Nervous....................................... 107
Captopril...................................... 38
Carbachol.................................... 213
Carbamazepine....................... 112
Carbaset-X.................................... 217
Carbimazole................................. 70
Carbomer..................................... 214
Carboplatin................................. 137
Carboplatin Ebewe......................... 137
Carboprost trometamol............... 59
Carboxymethylcellulose.................
Alimentary.......................... 19
Extemporaneously Compounded... 224
Sensory....................................... 214
Carmellose sodium with pectin and
gelatine............................. 19
Cardinol LA................................. 42
CareSens Dual............................. 252
Caresens N................................. 252
Caresens N POP.......................... 252
CareSens N Premier...................... 252
CareSens PRO............................. 252
Catheter..................................... 106
Cefazolin.................................... 73
Cefazolin.................................... 73
Cefalexin.................................... 73
Cefalexin Sandoz......................... 73
Cefapin..................................... 73
Ceftriaxone................................. 73
### INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefepime-AFT</td>
<td>73</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>73</td>
</tr>
<tr>
<td>Cefotaxime Sandoz</td>
<td>73</td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>73</td>
</tr>
<tr>
<td>Cefoxitin Actavis</td>
<td>73</td>
</tr>
<tr>
<td>Cefotaroline fosamil</td>
<td>74</td>
</tr>
<tr>
<td>Cefazidime</td>
<td>73</td>
</tr>
<tr>
<td>Cefazidime Mylan</td>
<td>73</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>73</td>
</tr>
<tr>
<td>Ceftriaxone-AFT</td>
<td>73</td>
</tr>
<tr>
<td>Cefuroxime</td>
<td>73</td>
</tr>
<tr>
<td>Cefuroxime Actavis</td>
<td>73</td>
</tr>
<tr>
<td>Celecoxib</td>
<td>101</td>
</tr>
<tr>
<td>Celecoxib Pfizer</td>
<td>101</td>
</tr>
<tr>
<td>Celiprolol</td>
<td>41</td>
</tr>
<tr>
<td>CellCept</td>
<td>200</td>
</tr>
<tr>
<td>Celol</td>
<td>41</td>
</tr>
<tr>
<td>Centrally-Acting Agents</td>
<td>43</td>
</tr>
<tr>
<td>Cephalexin ABM</td>
<td>73</td>
</tr>
<tr>
<td>Cetirizine hydrochloride</td>
<td>202</td>
</tr>
<tr>
<td>Cetomacrogol</td>
<td>54</td>
</tr>
<tr>
<td>Cetomacrogol with glycerol</td>
<td>54</td>
</tr>
<tr>
<td>Cetrimide</td>
<td>224</td>
</tr>
<tr>
<td>Cetuximab</td>
<td>165</td>
</tr>
<tr>
<td>Charcoal</td>
<td>217</td>
</tr>
<tr>
<td>Chemotherapeutic Agents</td>
<td>128</td>
</tr>
<tr>
<td>Chickenpox vaccine</td>
<td>251</td>
</tr>
<tr>
<td>Chlorfast</td>
<td>209</td>
</tr>
<tr>
<td>Chloral hydrate</td>
<td>121</td>
</tr>
<tr>
<td>Chlorambucil</td>
<td>129</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>78</td>
</tr>
<tr>
<td>Infections</td>
<td>78</td>
</tr>
<tr>
<td>Sensory</td>
<td>209</td>
</tr>
<tr>
<td>Chlorhexidine</td>
<td>218</td>
</tr>
<tr>
<td>Chlorhexidine gluconate</td>
<td>218</td>
</tr>
<tr>
<td>Alimentary</td>
<td>19</td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td>224</td>
</tr>
<tr>
<td>Genito-Urinary</td>
<td>58</td>
</tr>
<tr>
<td>Chlorhexidine with cetrimide</td>
<td>218, 221</td>
</tr>
<tr>
<td>Chlorhexidine with ethanol</td>
<td>218</td>
</tr>
<tr>
<td>Chlorform</td>
<td>224</td>
</tr>
<tr>
<td>Chlororaphine phosphate</td>
<td>84</td>
</tr>
<tr>
<td>Chlorothiazide</td>
<td>44</td>
</tr>
<tr>
<td>Chlorpheniramine maleate</td>
<td>202</td>
</tr>
<tr>
<td>Chlorpromazine hydrochloride</td>
<td>117</td>
</tr>
<tr>
<td>Chlorsig</td>
<td>209</td>
</tr>
<tr>
<td>Chlortalidone [Chlorthalidone]</td>
<td>44</td>
</tr>
<tr>
<td>Chlorthalidone</td>
<td>44</td>
</tr>
<tr>
<td>Choice Load 375</td>
<td>59</td>
</tr>
<tr>
<td>Choice TT380 Short</td>
<td>59</td>
</tr>
<tr>
<td>Choice TT380 Standard</td>
<td>59</td>
</tr>
<tr>
<td>Cholestyramine</td>
<td>45</td>
</tr>
<tr>
<td>Choline salicylate with cetyldimethyl</td>
<td>19</td>
</tr>
<tr>
<td>Chlorogonadotropin alfa</td>
<td>66</td>
</tr>
<tr>
<td>Ciclopirox olamine</td>
<td>52</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>147</td>
</tr>
<tr>
<td>Ciclofovir</td>
<td>89</td>
</tr>
<tr>
<td>Cilazapril</td>
<td>38</td>
</tr>
<tr>
<td>Cilazapril with hydrochlorothiazide</td>
<td>38</td>
</tr>
<tr>
<td>Cilicaine</td>
<td>76</td>
</tr>
<tr>
<td>Clicaine VK</td>
<td>76</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>8</td>
</tr>
<tr>
<td>Cinaclacet</td>
<td>62</td>
</tr>
<tr>
<td>Cinchocaine hydrochloride with hydrocortisone</td>
<td>7</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>209</td>
</tr>
<tr>
<td>Ciprofloxacin with hydrocortisone</td>
<td>209</td>
</tr>
<tr>
<td>Ciprofloxacin Teva</td>
<td>209</td>
</tr>
<tr>
<td>Ciprofloxacin with hydrocortisone</td>
<td>209</td>
</tr>
<tr>
<td>Ciprox HC Otic</td>
<td>209</td>
</tr>
<tr>
<td>Cisaprid</td>
<td>122</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>137</td>
</tr>
<tr>
<td>Citalopram hydrobromide</td>
<td>111</td>
</tr>
<tr>
<td>Citaten</td>
<td>107</td>
</tr>
<tr>
<td>Citrate sodium</td>
<td>30</td>
</tr>
<tr>
<td>Citric acid</td>
<td>224</td>
</tr>
<tr>
<td>Citric acid with magnesium oxide and sodium picosulfate</td>
<td>12</td>
</tr>
<tr>
<td>Citric acid with sodium bicarbonate</td>
<td>220</td>
</tr>
<tr>
<td>Cladribine</td>
<td>130</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>75</td>
</tr>
<tr>
<td>Clexane</td>
<td>31</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>78</td>
</tr>
<tr>
<td>Clindamycin ABM</td>
<td>78</td>
</tr>
<tr>
<td>Clinect</td>
<td>51</td>
</tr>
<tr>
<td>Clinicians Multivit &amp; Mineral Boost</td>
<td>20</td>
</tr>
<tr>
<td>Clinicians Renal Vit</td>
<td>20</td>
</tr>
<tr>
<td>Clofibrate</td>
<td>112</td>
</tr>
<tr>
<td>Clobetasol propionate</td>
<td>55–56</td>
</tr>
<tr>
<td>Clobetasone butyrate</td>
<td>55</td>
</tr>
<tr>
<td>Clofazimine</td>
<td>82</td>
</tr>
<tr>
<td>Clomazol</td>
<td>82</td>
</tr>
<tr>
<td>Dermatological</td>
<td>52</td>
</tr>
<tr>
<td>Genito-Urinary</td>
<td>58</td>
</tr>
<tr>
<td>Cimifene citrate</td>
<td>65</td>
</tr>
<tr>
<td>Clopimidine hydrochloride</td>
<td>110</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>112, 120</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>32</td>
</tr>
<tr>
<td>Clopidogrel Multichem</td>
<td>32</td>
</tr>
<tr>
<td>Clopine</td>
<td>117</td>
</tr>
<tr>
<td>Clopixol</td>
<td>118, 120</td>
</tr>
<tr>
<td>Clostridium botulinum type A toxin</td>
<td>100</td>
</tr>
<tr>
<td>Cotrimoxazole</td>
<td>52</td>
</tr>
<tr>
<td>Dermatological</td>
<td>58</td>
</tr>
<tr>
<td>Genito-Urinary</td>
<td>58</td>
</tr>
<tr>
<td>Clove oil</td>
<td>224</td>
</tr>
<tr>
<td>Clozapine</td>
<td>117</td>
</tr>
<tr>
<td>Clozaril</td>
<td>117</td>
</tr>
<tr>
<td>Custran</td>
<td>115</td>
</tr>
<tr>
<td>Co-trimoxazole</td>
<td>79</td>
</tr>
<tr>
<td>Coal tar</td>
<td>224</td>
</tr>
<tr>
<td>Coal tar with salicylic acid and sulphur</td>
<td>56</td>
</tr>
<tr>
<td>Codeine phosphate</td>
<td>106</td>
</tr>
<tr>
<td>Codeine</td>
<td>106</td>
</tr>
<tr>
<td>Codeine</td>
<td>106</td>
</tr>
<tr>
<td>Codeine phosphate with extemporaneously compounded preparations</td>
<td>224</td>
</tr>
<tr>
<td>Nervous</td>
<td>108</td>
</tr>
<tr>
<td>Cogentin</td>
<td>103</td>
</tr>
<tr>
<td>Colaspase [L-asparaginase]</td>
<td>132</td>
</tr>
<tr>
<td>Colchicine</td>
<td>99</td>
</tr>
<tr>
<td>Colecalciferol</td>
<td>22</td>
</tr>
<tr>
<td>Colestibemate</td>
<td>78</td>
</tr>
<tr>
<td>Colestipol hydrochloride</td>
<td>45</td>
</tr>
<tr>
<td>Cologut</td>
<td>99</td>
</tr>
<tr>
<td>Colfoam</td>
<td>6</td>
</tr>
<tr>
<td>Colistin sulphomethate</td>
<td>78</td>
</tr>
<tr>
<td>Codeine</td>
<td>78</td>
</tr>
<tr>
<td>Collagen</td>
<td>224</td>
</tr>
<tr>
<td>Collodial bismuth subcitrate</td>
<td>8</td>
</tr>
<tr>
<td>Colfoc</td>
<td>7</td>
</tr>
<tr>
<td>Colony-Stimulating Factors</td>
<td>33</td>
</tr>
<tr>
<td>Coloxyl</td>
<td>12</td>
</tr>
<tr>
<td>Colpolin-T</td>
<td>84</td>
</tr>
<tr>
<td>Compound electrolytes</td>
<td>34, 37</td>
</tr>
<tr>
<td>Compound electrolytes with glucose [Dextrose]</td>
<td>35, 37</td>
</tr>
<tr>
<td>Compound hydroxybenzoate</td>
<td>224</td>
</tr>
<tr>
<td>Compound sodium lactate [Hartmann’s solution]</td>
<td>35</td>
</tr>
<tr>
<td>Concerta</td>
<td>124</td>
</tr>
<tr>
<td>Condyline</td>
<td>57</td>
</tr>
<tr>
<td>Contraceptives</td>
<td>58</td>
</tr>
<tr>
<td>Contrast Media</td>
<td>219</td>
</tr>
<tr>
<td>Copaxone</td>
<td>121</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>63</td>
</tr>
<tr>
<td>Dermatological</td>
<td>55</td>
</tr>
<tr>
<td>Hormone Preparations</td>
<td>63</td>
</tr>
<tr>
<td>Corticotrophin (ovine)</td>
<td>66</td>
</tr>
<tr>
<td>Cosentyx</td>
<td>190</td>
</tr>
<tr>
<td>Cosmegen</td>
<td>129</td>
</tr>
<tr>
<td>Cough Suppressants</td>
<td>205</td>
</tr>
</tbody>
</table>
Creon 10000 ........................................ 11
Creon 25000 ........................................ 11
Crotamiton ........................................ 53
Crystaderm .......................................... 52
CT Plus+ ........................................... 219
Cubicin ............................................. 78
Curam ............................................... 76
Curosurf ........................................... 208
Cvite .................................................. 22
Cyclazine hydrochloride ....................... 116
Cyclazine lactate ................................ 116
Cyclogyl ............................................. 214
Cyclophosphamide .............................. 129
Cycloserine ........................................ 82
Cyklokapron ....................................... 27
Cymevane .......................................... 89
Cyproheptadine hydrochloride ............... 202
Cyproterone acetate ............................ 62
Cyproterone acetate with ethinylestradiol. 58
Cystadane .......................................... 14
Cysteamine hydrochloride ................... 224
Cytarabine ......................................... 130
Cytotec ............................................. 7
D - P -
D-Penamine ........................................ 94
Dabigatran ........................................ 30
Dacarbazine ....................................... 133
Dactinomycin [Actinomycin D] ............. 129
Daiobet ............................................. 56
Dainonex .......................................... 56
Dalacin C ........................................... 78
Dalteparin .......................................... 30
Danaparoid ........................................ 30
Danazol ............................................ 65
Dantrolium ......................................... 100
Dantrolene ......................................... 100
Daonil ............................................... 10
Dapa-Tabs ......................................... 44
Dapsone ........................................... 82
Daptomycin ....................................... 78
Darunavir .......................................... 87
Dasatinib .......................................... 138
Daunorubicin ..................................... 129
DBL Acetlycysteine ......................... 216
DBL Adrenalin ................................... 47
DBL Amikacin .................................... 72
DBL Aminophylline ............................. 207
DBL Bleomycin Sulfate ....................... 129
DBL Cefotaxime ................................ 73
DBL Cisplatin .................................... 137
DBL Dacarbazine ................................ 133
DBL Desferrioxamine Mesylate for Inj BP 217
DBL Docetaxel .................................... 143
DBL Ergometrine ................................ 59
DBL Gentamicin .................................. 72
DBL Leucovorin Calcium .................... 143
DBL Methotrexate Onco-Vial ............... 131
DBL Morphine Sulphate ..................... 109
DBL Morphine Tartrate ....................... 109
DBL Naloxone Hydrochloride ............ 216
DBL Pethidine Hydrochloride ............. 110
DBL Rocuronium Bromide ................. 100
DBL Vincristine Sulfate ...................... 144
De-Worm .......................................... 83
Decongestants .................................. 205
Decongestants and Antihistaminics ....... 211
Deco.... ............................................ 19
Deferasirox ....................................... 217
Deferprone ....................................... 217
Defibrotide ....................................... 30
Definity ........................................... 220
Demeclocycline hydrochloride ............ 78
Denosumab ....................................... 96
Deolate ............................................ 82
Deoxycoformycin ............................... 134
Depo-Medrol ..................................... 64
Depo-Provera .................................... 59
Depo-Testosterone .............................. 62
Deprim ............................................ 79
DermAssist ....................................... 55
Dermol ........................................... 55-56
Desferrioxamine mesilate .................. 217
Desflurane ....................................... 104
Desmopressin acetate ....................... 71
Desmopressin-PH&TP ......................... 71
Devitis ........................................... 209
Dexamethasone .................................. 64
Dexamethasone phosphate .................. 64
Dexamethasone Phosphate Panpharma ... 64
Dexamethasone with framycetin and garamicin ........................................... 209
Dexamethasone with neomycin sulphate and polymyxin B sulphate ..................... 209
Dexamethasone with tobramycin .......... 210
Dexamethasone phosphate .................. 210
Dexmethasone ................................. 209
Dexmedetomidine .............................. 104
Dexamethasone .................................. 63
Dexrazoxane .................................... 143
Dextrose ........................................... 9
Blood ............................................... 35,37
Extemporaneously Compounded
Preparations ..................................... 224
Dextrose with sodium citrate and
 citric acid [Acid Citrate Dextrose A] .......... 30
DHC Continus .................................... 108
Diabetes .......................................... 9
Diacomit .......................................... 114
Diagnostic Agents
Vaccines ......................................... 251
Various ........................................... 220
Diagnostic and Surgical
Preparations ..................................... 211
Diamox ............................................. 213
Diatrizoate meglumine with sodium
amidotrizoate .................................. 219
Diatrizoate sodium ............................. 219
Diazepam ........................................ 112,120
Diazoxide .......................................... 10
Alimentary ........................................ 9
Cardiovascular .................................. 47
Dichlorobenzyl alcohol with
amylmetacresol ................................ 19
Diclofenac Sandoz ................................ 101
Diclofenac sodium .............................. 101
Musculoskeletal ................................ 101
Sensory ........................................... 211
Dicobalt edetate ................................ 217
Diflucan .......................................... 80
Diflucorolone valerate ........................ 55
Digestives Including Enzymes ............ 11
Digoxin ............................................. 40
Digoxin immune Fab ............................ 216
Dihydrocodeine tartrate .................... 108
Dihydroergotamine mesylate ............ 115
Diltiazem hydrochloride .................... 43
Dilzem ............................................. 43
Dimeracaprol ................................... 218
Dimercapto-succinic acid ................... 218
Dimethicone ....................................... 52-53
Dimethyl fumarate ............................. 120
Dimethyl sulfoxide ............................. 222
Dinoprost ......................................... 59
Dipentum ......................................... 7
Diphemanil methylsulfate ................... 57
Diphenoxylate hydrochloride with
atropine sulphate ............................. 5
Diptheria antitoxin ............................. 216
Diptheria, tetanus and pertussis
vaccine ......................................... 243
Diptheria, tetanus, pertussis and
diphtheria vaccine ........................... 242
Diptheria, tetanus, pertussis, polio,
### INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>hepatitis B and haemophilus influenzae type B vaccine</td>
<td>242</td>
</tr>
<tr>
<td>Dipiridamole</td>
<td>32</td>
</tr>
<tr>
<td>Disodium edetate</td>
<td>213</td>
</tr>
<tr>
<td>Disodium hydrogen phosphate with sodium dihydrogen phosphate</td>
<td>224</td>
</tr>
<tr>
<td>Disopyramide phosphate</td>
<td>40</td>
</tr>
<tr>
<td>Disulfiram</td>
<td>126</td>
</tr>
<tr>
<td>Dithranol</td>
<td>224</td>
</tr>
<tr>
<td>Diuretics</td>
<td>43</td>
</tr>
<tr>
<td>Dobutamine</td>
<td>47</td>
</tr>
<tr>
<td>Dobutamine-hameln</td>
<td>47</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>143</td>
</tr>
<tr>
<td>Docusate sodium</td>
<td>12</td>
</tr>
<tr>
<td>Docusate sodium with sennosides</td>
<td>12</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>88</td>
</tr>
<tr>
<td>Domperidone</td>
<td>116</td>
</tr>
<tr>
<td>Donepezil hydrochloride</td>
<td>125</td>
</tr>
<tr>
<td>Donepezil-Rex</td>
<td>125</td>
</tr>
<tr>
<td>Dopamine hydrochloride</td>
<td>47</td>
</tr>
<tr>
<td>Dopenax</td>
<td>110</td>
</tr>
<tr>
<td>Domsetal</td>
<td>207</td>
</tr>
<tr>
<td>Dortimol</td>
<td>213</td>
</tr>
<tr>
<td>Dorzolamide</td>
<td>213</td>
</tr>
<tr>
<td>Dorzolamide with timolol</td>
<td>213</td>
</tr>
<tr>
<td>Dostinex</td>
<td>65</td>
</tr>
<tr>
<td>Dosulepin [Dothiepin] hydrochloride</td>
<td>110</td>
</tr>
<tr>
<td>Dosulepin Mylan</td>
<td>110</td>
</tr>
<tr>
<td>Dofetilide</td>
<td>220</td>
</tr>
<tr>
<td>Dothiepin</td>
<td>110</td>
</tr>
<tr>
<td>Doxapram</td>
<td>208</td>
</tr>
<tr>
<td>Doxazosin</td>
<td>39</td>
</tr>
<tr>
<td>Doxepin hydrochloride</td>
<td>110</td>
</tr>
<tr>
<td>Doxine</td>
<td>78</td>
</tr>
<tr>
<td>Doxorubicin Ebeve</td>
<td>129</td>
</tr>
<tr>
<td>Doxorubicin hydrochloride</td>
<td>129</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>78</td>
</tr>
<tr>
<td>DP Lotn HC</td>
<td>55</td>
</tr>
<tr>
<td>DP-Allopurinol</td>
<td>98</td>
</tr>
<tr>
<td>Dr Reddy’s Omeprazole</td>
<td>8</td>
</tr>
<tr>
<td>Drolopant</td>
<td>116</td>
</tr>
<tr>
<td>Droperidol</td>
<td>116</td>
</tr>
<tr>
<td>Droperidol Panpharma</td>
<td>116</td>
</tr>
<tr>
<td>Drugs Affecting Bone Metabolism</td>
<td>94</td>
</tr>
<tr>
<td>Dual blood glucose and blood ketone diagnostic test meter</td>
<td>252</td>
</tr>
<tr>
<td>Dulotril</td>
<td>202</td>
</tr>
<tr>
<td>Duovisc</td>
<td>212</td>
</tr>
<tr>
<td>Duride</td>
<td>46</td>
</tr>
<tr>
<td>Dynastat</td>
<td>102</td>
</tr>
<tr>
<td>Dysport</td>
<td>100</td>
</tr>
<tr>
<td>e-chamber La Grande</td>
<td>252</td>
</tr>
<tr>
<td>e-chamber Mask</td>
<td>252</td>
</tr>
<tr>
<td>e-chamber Turbo</td>
<td>252</td>
</tr>
<tr>
<td>E-Mycin</td>
<td>75</td>
</tr>
<tr>
<td>E-Z-Cat Dry</td>
<td>219</td>
</tr>
<tr>
<td>E-Z-Gas II</td>
<td>219</td>
</tr>
<tr>
<td>E-Z-Paste</td>
<td>219</td>
</tr>
<tr>
<td>Econazole nitrate</td>
<td>52</td>
</tr>
<tr>
<td>Edrophonium chloride</td>
<td>94</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>85</td>
</tr>
<tr>
<td>Efavirenz with emtricitabine and tenofovir disoproxil</td>
<td>86</td>
</tr>
<tr>
<td>Effient</td>
<td>32</td>
</tr>
<tr>
<td>Eforomoterol fumarate</td>
<td>206</td>
</tr>
<tr>
<td>Eforomoterol fumarate dihydrate</td>
<td>206</td>
</tr>
<tr>
<td>Eftrenonacog alfa [Recombinant factor IX]</td>
<td>28</td>
</tr>
<tr>
<td>Efdix</td>
<td>57</td>
</tr>
<tr>
<td>Elaprase</td>
<td>15</td>
</tr>
<tr>
<td>Elecare (Unflavoured)</td>
<td>235</td>
</tr>
<tr>
<td>Elecare (Vanilla)</td>
<td>235</td>
</tr>
<tr>
<td>Elecare LCP (Unflavoured)</td>
<td>235</td>
</tr>
<tr>
<td>Electrical</td>
<td>37</td>
</tr>
<tr>
<td>Electrolytes</td>
<td>223</td>
</tr>
<tr>
<td>Elelyso</td>
<td>17</td>
</tr>
<tr>
<td>Elcon</td>
<td>55</td>
</tr>
<tr>
<td>Elcon Alcohol Free</td>
<td>55</td>
</tr>
<tr>
<td>Etopropag</td>
<td>26</td>
</tr>
<tr>
<td>Emend Tri-Pack</td>
<td>115</td>
</tr>
<tr>
<td>EMLA</td>
<td>106</td>
</tr>
<tr>
<td>Emtricitabine</td>
<td>86</td>
</tr>
<tr>
<td>Emtricitabine with tenofovir disoproxil</td>
<td>90</td>
</tr>
<tr>
<td>Emtriva</td>
<td>86</td>
</tr>
<tr>
<td>Emulsifying ointment</td>
<td>54</td>
</tr>
<tr>
<td>Enalapril maleate</td>
<td>38</td>
</tr>
<tr>
<td>Enbrel</td>
<td>147</td>
</tr>
<tr>
<td>Endocrine Therapy</td>
<td>144</td>
</tr>
<tr>
<td>Endoxan</td>
<td>129</td>
</tr>
<tr>
<td>Enerlyte</td>
<td>37</td>
</tr>
<tr>
<td>Engerix-B</td>
<td>247</td>
</tr>
<tr>
<td>Enlafex Jr</td>
<td>111</td>
</tr>
<tr>
<td>Enoxaparin sodium</td>
<td>31</td>
</tr>
<tr>
<td>Ensure (Chocolate)</td>
<td>241</td>
</tr>
<tr>
<td>Ensure (Vanilla)</td>
<td>241</td>
</tr>
<tr>
<td>Ensure Plus (Banana)</td>
<td>241</td>
</tr>
<tr>
<td>Ensure Plus (Chocolate)</td>
<td>241</td>
</tr>
<tr>
<td>Ensure Plus (Fruit of the Forest)</td>
<td>241</td>
</tr>
<tr>
<td>Ensure Plus (Vanilla)</td>
<td>241</td>
</tr>
<tr>
<td>Ensure Plus HN</td>
<td>240</td>
</tr>
<tr>
<td>Ensure Plus HN RTH</td>
<td>240</td>
</tr>
<tr>
<td>Entacapone</td>
<td>104</td>
</tr>
<tr>
<td>Entapone</td>
<td>104</td>
</tr>
<tr>
<td>Entecavir</td>
<td>88</td>
</tr>
<tr>
<td>Entecavir Sandoz</td>
<td>88</td>
</tr>
<tr>
<td>Entresto 24/26</td>
<td>39</td>
</tr>
<tr>
<td>Entresto 49/51</td>
<td>39</td>
</tr>
<tr>
<td>Entresto 97/103</td>
<td>39</td>
</tr>
<tr>
<td>Enzymes</td>
<td>98</td>
</tr>
<tr>
<td>Ephedrine</td>
<td>47</td>
</tr>
<tr>
<td>Eplim IV</td>
<td>114</td>
</tr>
<tr>
<td>Epipubicin Ebeve</td>
<td>129</td>
</tr>
<tr>
<td>Epipubicin hydrochloride</td>
<td>129</td>
</tr>
<tr>
<td>Epilene</td>
<td>44</td>
</tr>
<tr>
<td>Epoetin alfa</td>
<td>24</td>
</tr>
<tr>
<td>Epoetin beta</td>
<td>25</td>
</tr>
<tr>
<td>Epoprostenol</td>
<td>51</td>
</tr>
<tr>
<td>Eptacog alfa [Recombinant factor VIIIa]</td>
<td>28</td>
</tr>
<tr>
<td>Epitablate</td>
<td>32</td>
</tr>
<tr>
<td>Erbitux</td>
<td>165</td>
</tr>
<tr>
<td>Ergometrine maleate</td>
<td>59</td>
</tr>
<tr>
<td>Ergotamine tartrate with caffeine</td>
<td>115</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>138</td>
</tr>
<tr>
<td>Ertepanem</td>
<td>72</td>
</tr>
<tr>
<td>Erythrocine IV</td>
<td>75</td>
</tr>
<tr>
<td>Erythromycin (as ethylsuccinate)</td>
<td>75</td>
</tr>
<tr>
<td>Erythromycin (as lactobionate)</td>
<td>75</td>
</tr>
<tr>
<td>Erythromycin (as stearate)</td>
<td>75</td>
</tr>
<tr>
<td>Esbriet</td>
<td>204</td>
</tr>
<tr>
<td>Escitalopram</td>
<td>111</td>
</tr>
<tr>
<td>Escitalopram-Apex</td>
<td>111</td>
</tr>
<tr>
<td>Esmolol hydrochloride</td>
<td>41</td>
</tr>
<tr>
<td>Estradot</td>
<td>64</td>
</tr>
<tr>
<td>Etanercept</td>
<td>147</td>
</tr>
<tr>
<td>Ethambutol hydrochloride</td>
<td>82</td>
</tr>
<tr>
<td>Ethanol</td>
<td>216</td>
</tr>
<tr>
<td>Ethanol with glucose</td>
<td>216</td>
</tr>
<tr>
<td>Ethanol, dehydrated</td>
<td>216</td>
</tr>
<tr>
<td>Ethics Aspirin</td>
<td>107</td>
</tr>
<tr>
<td>Ethics Aspirin EC</td>
<td>31</td>
</tr>
<tr>
<td>Ethics Enalapril</td>
<td>38</td>
</tr>
<tr>
<td>Ethics Lisinopril</td>
<td>38</td>
</tr>
<tr>
<td>Ethinylestradiol</td>
<td>66</td>
</tr>
<tr>
<td>Ethinylestradiol with desogestrel</td>
<td>58</td>
</tr>
<tr>
<td>Ethinylestradiol with levonorgestrel</td>
<td>58</td>
</tr>
<tr>
<td>Ethinylestradiol with norethisterone</td>
<td>58</td>
</tr>
<tr>
<td>Ethosuximide</td>
<td>112</td>
</tr>
<tr>
<td>Ethyl chloride</td>
<td>106</td>
</tr>
<tr>
<td>Etopimide</td>
<td>104</td>
</tr>
<tr>
<td>Etopophos</td>
<td>133</td>
</tr>
<tr>
<td>Etoposide</td>
<td>133</td>
</tr>
<tr>
<td>Etoposide (as phosphate)</td>
<td>133</td>
</tr>
<tr>
<td>Etoricoxib</td>
<td>101</td>
</tr>
</tbody>
</table>
## INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etravirine</td>
<td>85</td>
</tr>
<tr>
<td>Everet</td>
<td>113</td>
</tr>
<tr>
<td>Everolimus</td>
<td>200</td>
</tr>
<tr>
<td>Evista</td>
<td>97</td>
</tr>
<tr>
<td>Exelon</td>
<td>125</td>
</tr>
<tr>
<td>Exemestane</td>
<td>146</td>
</tr>
<tr>
<td>Exjade</td>
<td>217</td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td>224</td>
</tr>
<tr>
<td>Eylea</td>
<td>163</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>45</td>
</tr>
<tr>
<td>Ezetimibe Sandoz</td>
<td>45</td>
</tr>
<tr>
<td>Ezetimibe with simvastatin</td>
<td>46</td>
</tr>
<tr>
<td>Factor eight inhibitor bypassing fraction</td>
<td>28</td>
</tr>
<tr>
<td>Famotidine</td>
<td>8</td>
</tr>
<tr>
<td>Febuxostat</td>
<td>99</td>
</tr>
<tr>
<td>FEIBA NF</td>
<td>28</td>
</tr>
<tr>
<td>Felo 10 ER</td>
<td>42</td>
</tr>
<tr>
<td>Felo 5 ER</td>
<td>42</td>
</tr>
<tr>
<td>Felodipine</td>
<td>42</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>108</td>
</tr>
<tr>
<td>Fentanyl Sandoz</td>
<td>108</td>
</tr>
<tr>
<td>Ferinject</td>
<td>18</td>
</tr>
<tr>
<td>Ferodan</td>
<td>18</td>
</tr>
<tr>
<td>Ferric carboxymaltose</td>
<td>18</td>
</tr>
<tr>
<td>Ferric subsulfate</td>
<td>27</td>
</tr>
<tr>
<td>Ferriprox</td>
<td>217</td>
</tr>
<tr>
<td>Ferro-F-Tabs</td>
<td>18</td>
</tr>
<tr>
<td>Ferro-tab</td>
<td>18</td>
</tr>
<tr>
<td>Ferrograd</td>
<td>18</td>
</tr>
<tr>
<td>Ferrosig</td>
<td>18</td>
</tr>
<tr>
<td>Ferrous fumarate</td>
<td>18</td>
</tr>
<tr>
<td>Ferrous fumarate with folic acid</td>
<td>18</td>
</tr>
<tr>
<td>Ferrous gluconate with ascorbic acid</td>
<td>18</td>
</tr>
<tr>
<td>Ferrous sulfate</td>
<td>18</td>
</tr>
<tr>
<td>Ferrous sulphate</td>
<td>18</td>
</tr>
<tr>
<td>Ferrous sulphate with ascorbic acid</td>
<td>18</td>
</tr>
<tr>
<td>Fexofenadine hydrochloride</td>
<td>202</td>
</tr>
<tr>
<td>Fligrastim</td>
<td>34</td>
</tr>
<tr>
<td>Finasteride</td>
<td>60</td>
</tr>
<tr>
<td>Fingolimod</td>
<td>120</td>
</tr>
<tr>
<td>Firazyr</td>
<td>201</td>
</tr>
<tr>
<td>Flagyl</td>
<td>84</td>
</tr>
<tr>
<td>Flagyl-S</td>
<td>84</td>
</tr>
<tr>
<td>Flamazine</td>
<td>52</td>
</tr>
<tr>
<td>Flacaineide acetate</td>
<td>40</td>
</tr>
<tr>
<td>Flacaineide BNM</td>
<td>40</td>
</tr>
<tr>
<td>Flacaineide Controlled Release Teva</td>
<td>40</td>
</tr>
<tr>
<td>Fleet Phosphate Enema</td>
<td>13</td>
</tr>
<tr>
<td>Flixonase Hayfever &amp; Allergy</td>
<td>202</td>
</tr>
<tr>
<td>Flixtide</td>
<td>206</td>
</tr>
<tr>
<td>Flixtide Accuhaler</td>
<td>206</td>
</tr>
<tr>
<td>Floair</td>
<td>206</td>
</tr>
<tr>
<td>Florinef</td>
<td>64</td>
</tr>
<tr>
<td>Flunixin</td>
<td>118</td>
</tr>
<tr>
<td>Fluclid</td>
<td>76</td>
</tr>
<tr>
<td>Fluoxacin</td>
<td>76</td>
</tr>
<tr>
<td>Fluoxacin HCl</td>
<td>76</td>
</tr>
<tr>
<td>Fluconazone</td>
<td>80</td>
</tr>
<tr>
<td>Fluconazole-Clarus</td>
<td>80</td>
</tr>
<tr>
<td>Flucytosine</td>
<td>82</td>
</tr>
<tr>
<td>Fludara Oral</td>
<td>131</td>
</tr>
<tr>
<td>Fludarabine Ebeew</td>
<td>131</td>
</tr>
<tr>
<td>Fludarabine phosphate</td>
<td>131</td>
</tr>
<tr>
<td>Fludrocortisone acetate</td>
<td>64</td>
</tr>
<tr>
<td>Fluids and Electrolytes</td>
<td>34</td>
</tr>
<tr>
<td>Flumazenil</td>
<td>216</td>
</tr>
<tr>
<td>Flumetason pivalate with cloioquinol</td>
<td>210</td>
</tr>
<tr>
<td>Fluocortolone caproate with fluocortolone pivalate</td>
<td>7</td>
</tr>
<tr>
<td>cinchoacaine</td>
<td></td>
</tr>
<tr>
<td>Fluorescin sodium</td>
<td>211</td>
</tr>
<tr>
<td>Fluorescin sodium with lignocaine hydrochloride</td>
<td>212</td>
</tr>
<tr>
<td>Fluorescine</td>
<td>211</td>
</tr>
<tr>
<td>Fluorometholone</td>
<td>211</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>131</td>
</tr>
<tr>
<td>Fluorouracil Ebeew</td>
<td>131</td>
</tr>
<tr>
<td>Fluorouracil sodium</td>
<td>57</td>
</tr>
<tr>
<td>Fluoxetine hydrochloride</td>
<td>111</td>
</tr>
<tr>
<td>Flupenthixol decanoate</td>
<td>118</td>
</tr>
<tr>
<td>Flutamide</td>
<td>145</td>
</tr>
<tr>
<td>Fluoxime</td>
<td>145</td>
</tr>
<tr>
<td>Flutamide</td>
<td>145</td>
</tr>
<tr>
<td>Flucitason</td>
<td>206</td>
</tr>
<tr>
<td>Flucitason furoate with vianalerol</td>
<td>206</td>
</tr>
<tr>
<td>Flucitason propionate</td>
<td>202</td>
</tr>
<tr>
<td>Flucitason with salmeterol</td>
<td>207</td>
</tr>
<tr>
<td>FML</td>
<td>211</td>
</tr>
<tr>
<td>Foban</td>
<td>52</td>
</tr>
<tr>
<td>Folic acid</td>
<td>25</td>
</tr>
<tr>
<td>Fondaparinux sodium</td>
<td>31</td>
</tr>
<tr>
<td>Food Modules</td>
<td>227</td>
</tr>
<tr>
<td>Food/Fluid Thickeners</td>
<td>229</td>
</tr>
<tr>
<td>Forteo</td>
<td>98</td>
</tr>
<tr>
<td>Fortisip (Vanilla)</td>
<td>241</td>
</tr>
<tr>
<td>Fosamax</td>
<td>94</td>
</tr>
<tr>
<td>Fosamax Pl</td>
<td>94</td>
</tr>
<tr>
<td>Foscarnet sodium</td>
<td>89</td>
</tr>
<tr>
<td>Fosomycin</td>
<td>78</td>
</tr>
<tr>
<td>Fragmin</td>
<td>30</td>
</tr>
<tr>
<td>Framycetin sulphate</td>
<td>209</td>
</tr>
<tr>
<td>Fresenius Kabi</td>
<td></td>
</tr>
<tr>
<td>Blood</td>
<td>35-37</td>
</tr>
<tr>
<td>Various</td>
<td>222</td>
</tr>
<tr>
<td>Fresofol 1% MCT/LCT</td>
<td>104</td>
</tr>
<tr>
<td>Frusemide</td>
<td>44</td>
</tr>
<tr>
<td>Frusemide-Claris</td>
<td>44</td>
</tr>
<tr>
<td>Fucidin</td>
<td>79</td>
</tr>
<tr>
<td>Fucithalmic</td>
<td>209</td>
</tr>
<tr>
<td>Fungilin</td>
<td>19</td>
</tr>
<tr>
<td>Furosemide [Frasemide]</td>
<td>44</td>
</tr>
<tr>
<td>Fusidic acid</td>
<td></td>
</tr>
<tr>
<td>Dermatological</td>
<td>52, 56</td>
</tr>
<tr>
<td>Infections</td>
<td>79</td>
</tr>
<tr>
<td>Sensory</td>
<td>209</td>
</tr>
<tr>
<td>- G -</td>
<td></td>
</tr>
<tr>
<td>Gabapentin</td>
<td>112</td>
</tr>
<tr>
<td>Gacel</td>
<td>108</td>
</tr>
<tr>
<td>Gadobenic acid</td>
<td>220</td>
</tr>
<tr>
<td>Gadobutrol</td>
<td>220</td>
</tr>
<tr>
<td>Gadodiamide</td>
<td>220</td>
</tr>
<tr>
<td>Gadoteric acid</td>
<td>220</td>
</tr>
<tr>
<td>Gadovist 1.0</td>
<td>220</td>
</tr>
<tr>
<td>Gadoxetate disodium</td>
<td>220</td>
</tr>
<tr>
<td>Galsulfase</td>
<td>15</td>
</tr>
<tr>
<td>Galvumet</td>
<td>11</td>
</tr>
<tr>
<td>Galvus</td>
<td>11</td>
</tr>
<tr>
<td>Ganciclovir</td>
<td>89</td>
</tr>
<tr>
<td>Gardasil 9</td>
<td>248</td>
</tr>
<tr>
<td>Gastrodenol</td>
<td>8</td>
</tr>
<tr>
<td>Gastrografin</td>
<td>219</td>
</tr>
<tr>
<td>Gazzya</td>
<td>172</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>139</td>
</tr>
<tr>
<td>Gelatine, succinylated</td>
<td>37</td>
</tr>
<tr>
<td>Gelofusine</td>
<td>37</td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>131</td>
</tr>
<tr>
<td>Gemcitabine Ebeew</td>
<td>131</td>
</tr>
<tr>
<td>Gemfibrozil</td>
<td>45</td>
</tr>
<tr>
<td>Genoptic</td>
<td>209</td>
</tr>
<tr>
<td>Gentamicin sulphate</td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td>72</td>
</tr>
<tr>
<td>Sensory</td>
<td>209</td>
</tr>
<tr>
<td>Gestrinone</td>
<td>65</td>
</tr>
<tr>
<td>Gilenya</td>
<td>120</td>
</tr>
<tr>
<td>Ginet</td>
<td>58</td>
</tr>
<tr>
<td>Glatiramer acetate</td>
<td>121</td>
</tr>
<tr>
<td>Glaucoma Preparations</td>
<td>213</td>
</tr>
<tr>
<td>Glecaprevir with pibrentasvir</td>
<td>88</td>
</tr>
<tr>
<td>Glibenclamide</td>
<td>10</td>
</tr>
<tr>
<td>Glilazide</td>
<td>10</td>
</tr>
<tr>
<td>Glilazide</td>
<td>10</td>
</tr>
<tr>
<td>Glilazide</td>
<td>10</td>
</tr>
<tr>
<td>Glucagen Hypokit</td>
<td>9</td>
</tr>
<tr>
<td>Glucagon hydrochloride</td>
<td>9</td>
</tr>
<tr>
<td>Glucerna Select (Vanilla)</td>
<td>233</td>
</tr>
<tr>
<td>Glucerna Select RTH (Vanilla)</td>
<td>233</td>
</tr>
<tr>
<td>Glucobay</td>
<td>9</td>
</tr>
<tr>
<td>INDEX: Generic Chemicals and Brands</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Glucose [Dextrose]</td>
<td></td>
</tr>
<tr>
<td>Alimentary................................9</td>
<td></td>
</tr>
<tr>
<td>Blood.....................................35</td>
<td></td>
</tr>
<tr>
<td>Extemporaneously Compounded</td>
<td></td>
</tr>
<tr>
<td>Preparations ............................224</td>
<td></td>
</tr>
<tr>
<td>Glucose with potassium chloride</td>
<td></td>
</tr>
<tr>
<td>........................................35</td>
<td></td>
</tr>
<tr>
<td>Glucose with sodium chloride</td>
<td></td>
</tr>
<tr>
<td>........................................35</td>
<td></td>
</tr>
<tr>
<td>Glucose with sucrose and fructose</td>
<td></td>
</tr>
<tr>
<td>......................................9</td>
<td></td>
</tr>
<tr>
<td>Glycerin with sodium saccharin</td>
<td></td>
</tr>
<tr>
<td>.....................................225</td>
<td></td>
</tr>
<tr>
<td>Glycerin with sucrose</td>
<td></td>
</tr>
<tr>
<td>.....................................225</td>
<td></td>
</tr>
<tr>
<td>Glycerol</td>
<td></td>
</tr>
<tr>
<td>Alimentary................................13</td>
<td></td>
</tr>
<tr>
<td>Extemporaneously Compounded</td>
<td></td>
</tr>
<tr>
<td>Preparations ............................225</td>
<td></td>
</tr>
<tr>
<td>Glycerol with paraffin</td>
<td></td>
</tr>
<tr>
<td>.....................................54</td>
<td></td>
</tr>
<tr>
<td>Glyceryl trinitrate</td>
<td></td>
</tr>
<tr>
<td>Alimentary................................7</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular..........................46</td>
<td></td>
</tr>
<tr>
<td>Glycine..................................221</td>
<td></td>
</tr>
<tr>
<td>Glycopyrronium</td>
<td></td>
</tr>
<tr>
<td>.....................................203</td>
<td></td>
</tr>
<tr>
<td>Glycopyrronium bromide</td>
<td></td>
</tr>
<tr>
<td>......................................7</td>
<td></td>
</tr>
<tr>
<td>Glycopyrronium with</td>
<td></td>
</tr>
<tr>
<td>indacaterol.........................203</td>
<td></td>
</tr>
<tr>
<td>Glypressin..........63....................71</td>
<td></td>
</tr>
<tr>
<td>Glytryn.................................46</td>
<td></td>
</tr>
<tr>
<td>Gonadorelin.............................66</td>
<td></td>
</tr>
<tr>
<td>Goserelin..............................66</td>
<td></td>
</tr>
<tr>
<td>Granisetron.............................116</td>
<td></td>
</tr>
<tr>
<td>- H -</td>
<td></td>
</tr>
<tr>
<td>Habitrol................................126</td>
<td></td>
</tr>
<tr>
<td>Habitrol (Fruit)........................126</td>
<td></td>
</tr>
<tr>
<td>Habitrol (Mint)........................126</td>
<td></td>
</tr>
<tr>
<td>Haem arginate...........................15</td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenza type B</td>
<td></td>
</tr>
<tr>
<td>vaccine ................................243</td>
<td></td>
</tr>
<tr>
<td>Haldol....................................119</td>
<td></td>
</tr>
<tr>
<td>Haldol Concentrate....................119</td>
<td></td>
</tr>
<tr>
<td>Haloperidol..............................117</td>
<td></td>
</tr>
<tr>
<td>Haloperidol decanoate...............119</td>
<td></td>
</tr>
<tr>
<td>Hartmann's solution...................35</td>
<td></td>
</tr>
<tr>
<td>Harvoni...................................88</td>
<td></td>
</tr>
<tr>
<td>Havrix....................................246</td>
<td></td>
</tr>
<tr>
<td>Havrix Junior............................246</td>
<td></td>
</tr>
<tr>
<td>HBVaxPRO................................246-247</td>
<td></td>
</tr>
<tr>
<td>Healon....................................212</td>
<td></td>
</tr>
<tr>
<td>Healon 5..................................212</td>
<td></td>
</tr>
<tr>
<td>Healon GV................................212</td>
<td></td>
</tr>
<tr>
<td>healthE Calamine Aqueous Cream BP</td>
<td></td>
</tr>
<tr>
<td>.......................................53</td>
<td></td>
</tr>
<tr>
<td>healthE Dimethicone 10%.............53</td>
<td></td>
</tr>
<tr>
<td>healthE Dimethicone 4% Lotion........52</td>
<td></td>
</tr>
<tr>
<td>healthE Dimethicone 5% ................53</td>
<td></td>
</tr>
<tr>
<td>healthE Fatty Cream...................54</td>
<td></td>
</tr>
<tr>
<td>healthE Glycerol BP Liquid...........225</td>
<td></td>
</tr>
<tr>
<td>healthE Urea Cream...................55</td>
<td></td>
</tr>
<tr>
<td>Heparin sodium........................31</td>
<td></td>
</tr>
<tr>
<td>Heparinised saline....................31</td>
<td></td>
</tr>
<tr>
<td>Heparon Junior..........................234</td>
<td></td>
</tr>
<tr>
<td>Hepatitis A vaccine....................246</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B recombinant vaccine ...246</td>
<td></td>
</tr>
<tr>
<td>Hepsera...................................88</td>
<td></td>
</tr>
<tr>
<td>Herceptin................................195</td>
<td></td>
</tr>
<tr>
<td>Hiberix...................................243</td>
<td></td>
</tr>
<tr>
<td>Hiperx....................................79</td>
<td></td>
</tr>
<tr>
<td>Histaclear..............................202</td>
<td></td>
</tr>
<tr>
<td>Histamine acid phosphate.............221</td>
<td></td>
</tr>
<tr>
<td>Holoxan...................................129</td>
<td></td>
</tr>
<tr>
<td>Hormone Replacement Therapy .........64</td>
<td></td>
</tr>
<tr>
<td>HPV........................................248</td>
<td></td>
</tr>
<tr>
<td>Humalog Mix 25........................10</td>
<td></td>
</tr>
<tr>
<td>Humalog Mix 50........................10</td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (6, 11, 16, 18,</td>
<td></td>
</tr>
<tr>
<td>31, 33, 45, 52 and 58) vaccine</td>
<td></td>
</tr>
<tr>
<td>[HPV]......................................248</td>
<td></td>
</tr>
<tr>
<td>Humatin...................................72</td>
<td></td>
</tr>
<tr>
<td>Humira.....................................154</td>
<td></td>
</tr>
<tr>
<td>HumiraPen................................154</td>
<td></td>
</tr>
<tr>
<td>Hyaluronic acid with lidocaine</td>
<td></td>
</tr>
<tr>
<td>Alimentary................................20</td>
<td></td>
</tr>
<tr>
<td>Sensory...................................212, 215</td>
<td></td>
</tr>
<tr>
<td>Hyaluronic acid with lidocaine</td>
<td></td>
</tr>
<tr>
<td>[lignocaine].........................20</td>
<td></td>
</tr>
<tr>
<td>Hyaluronidase.........................98</td>
<td></td>
</tr>
<tr>
<td>Hydralazine hydrochloride............47</td>
<td></td>
</tr>
<tr>
<td>Hydrea.....................................133</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td></td>
</tr>
<tr>
<td>Dermatological......................55</td>
<td></td>
</tr>
<tr>
<td>Extemporaneously Compounded</td>
<td></td>
</tr>
<tr>
<td>Preparations ............................225</td>
<td></td>
</tr>
<tr>
<td>Hormone Preparations..................64</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone acetate</td>
<td></td>
</tr>
<tr>
<td>Alimentary................................6</td>
<td></td>
</tr>
<tr>
<td>Dermatological......................55</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone acetate with</td>
<td></td>
</tr>
<tr>
<td>promoxine hydrochloride .............6</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone and paraffin liquid</td>
<td></td>
</tr>
<tr>
<td>and lanolin............................55</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone butryate..............55, 57</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone with miconazole......56</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone with natamycin and</td>
<td></td>
</tr>
<tr>
<td>neomycin...............................56</td>
<td></td>
</tr>
<tr>
<td>Hydrogen peroxide.....................52</td>
<td></td>
</tr>
<tr>
<td>Hydroxocobalamin</td>
<td></td>
</tr>
<tr>
<td>Alimentary..............................21</td>
<td></td>
</tr>
<tr>
<td>Various..................................216</td>
<td></td>
</tr>
<tr>
<td>Hydroxychloroquine...................94</td>
<td></td>
</tr>
<tr>
<td>Hydroxyurea.............................133</td>
<td></td>
</tr>
<tr>
<td>Hygroton..................................44</td>
<td></td>
</tr>
<tr>
<td>Hylo-Fresh................................215</td>
<td></td>
</tr>
<tr>
<td>Hyoscine butylbromide................7</td>
<td></td>
</tr>
<tr>
<td>Hyoscine hydrobromide...............116</td>
<td></td>
</tr>
<tr>
<td>Hyperuricaemia and Antigout.........98</td>
<td></td>
</tr>
<tr>
<td>Hypermellose............................212, 214</td>
<td></td>
</tr>
<tr>
<td>Hypermellose with dextran...........215</td>
<td></td>
</tr>
<tr>
<td>- I -</td>
<td></td>
</tr>
<tr>
<td>Ibiamox...................................76</td>
<td></td>
</tr>
<tr>
<td>Ibuprofen................................102</td>
<td></td>
</tr>
<tr>
<td>Ibuprofen SR BNM......................102</td>
<td></td>
</tr>
<tr>
<td>Icatibant...............................201</td>
<td></td>
</tr>
<tr>
<td>Idarubicin hydrochloride............130</td>
<td></td>
</tr>
<tr>
<td>Idarucizumab............................28</td>
<td></td>
</tr>
<tr>
<td>Idu sulfate..............................15</td>
<td></td>
</tr>
<tr>
<td>Ifosfamide..............................129</td>
<td></td>
</tr>
<tr>
<td>Ikore......................................48</td>
<td></td>
</tr>
<tr>
<td>Iloprost..................................51</td>
<td></td>
</tr>
<tr>
<td>Imaging Agents..........................146</td>
<td></td>
</tr>
<tr>
<td>Imatinib mesilate......................139</td>
<td></td>
</tr>
<tr>
<td>Imatinib-AFT.............................139</td>
<td></td>
</tr>
<tr>
<td>Imipenem with cilastatin............72</td>
<td></td>
</tr>
<tr>
<td>Imipenem+Cilastatin RBX.............72</td>
<td></td>
</tr>
<tr>
<td>Imiprimine hydrochloride............110</td>
<td></td>
</tr>
<tr>
<td>Imiquimod................................57</td>
<td></td>
</tr>
<tr>
<td>Immune Modulators.....................92</td>
<td></td>
</tr>
<tr>
<td>Immunosuppressants...................147</td>
<td></td>
</tr>
<tr>
<td>Impact Advanced Recovery............239</td>
<td></td>
</tr>
<tr>
<td>Imuran....................................199</td>
<td></td>
</tr>
<tr>
<td>Incruse Ellipta.........................203</td>
<td></td>
</tr>
<tr>
<td>Indacaterol.............................206</td>
<td></td>
</tr>
<tr>
<td>Indapamide...............................44</td>
<td></td>
</tr>
<tr>
<td>Indigo carmine..........................221</td>
<td></td>
</tr>
<tr>
<td>Indinavir..................................87</td>
<td></td>
</tr>
<tr>
<td>Indocyanine green.....................221</td>
<td></td>
</tr>
<tr>
<td>Indomethacin............................102</td>
<td></td>
</tr>
<tr>
<td>Infanrix IPV.............................242</td>
<td></td>
</tr>
<tr>
<td>Infanrix-hexa...........................242</td>
<td></td>
</tr>
<tr>
<td>Ifatrin.....................................237</td>
<td></td>
</tr>
<tr>
<td>Infliximab...............................165</td>
<td></td>
</tr>
<tr>
<td>Influenza vaccine.....................248</td>
<td></td>
</tr>
<tr>
<td>Inhaled Corticosteroids..............205</td>
<td></td>
</tr>
<tr>
<td>Inspra.....................................44</td>
<td></td>
</tr>
<tr>
<td>Instillagel Lido.........................106</td>
<td></td>
</tr>
<tr>
<td>Insulin aspart.........................10</td>
<td></td>
</tr>
<tr>
<td>Insulin aspart with insulin aspart</td>
<td></td>
</tr>
<tr>
<td>protamine...............................9</td>
<td></td>
</tr>
<tr>
<td>Insulin glargine.......................10</td>
<td></td>
</tr>
<tr>
<td>Insulin glulisine......................10</td>
<td></td>
</tr>
<tr>
<td>Insulin isophane.......................9</td>
<td></td>
</tr>
<tr>
<td>Insulin lispro.........................10</td>
<td></td>
</tr>
<tr>
<td>Insulin lispro with insulin lispro</td>
<td></td>
</tr>
<tr>
<td>protamine...............................10</td>
<td></td>
</tr>
<tr>
<td>Insulin neutral.........................10</td>
<td></td>
</tr>
<tr>
<td>Insulin neutral with insulin</td>
<td></td>
</tr>
<tr>
<td>isophane..................................10</td>
<td></td>
</tr>
<tr>
<td>Integrin...................................32</td>
<td></td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

Hangover..............................146
Irrigation Solutions............221
Isetress...............................88
Isetress HD..........................88
Ismo 40 Retard......................46
Ismo-20..............................46
Isolflurane..........................104
Isoniazid..............................82
Isoniazid with rifampicin......82
Isoprenaline [Isoproterenol]..47
Isopropyl alcohol.................218
Isopropenol.........................47
Isotin.................................43
Isoptin SR...........................43
Isoto Carpine.......................213
Isosorbide mononitrate........46
Isotretinoin..........................53
Ispaghula (psyllium) husk...12
Irsadipine...........................42
Itch-Soothe..........................53
Itraconazole........................80
Itrazole...............................80
Ivabradine...........................40
Ivermectin...........................83

- J -
Jadelle.................................59
Jakavi.................................141
Jaydess.................................59
Jevity HiCal RTH.................240
Jevity RTH............................240
Juno Pemetrexed...............131

- K -
Kadcyla.................................196
Kaletra.................................87
Kenacomb.............................210
Kenacort-A 10.....................210
Kenacort-A 40......................210
Ketalar...............................104
Ketamine..............................104
Ketamine-Claris...............104
Ketocal 3:1 (Unflavoured..237
Ketocal 4:1 (Unflavoured..237
Ketocal 4:1 (Vanilla).....237
Ketoconazole......................102
Ketoprofen..........................102
KetoSens.............................252
Kevix.................198
Keytruda..............................198
Kivexa.................................86
Klean Prep............................12
Kogenate FS.........................29
Konakion MM.........................29
Konsyl-D.............................12
Kuvar.................................16

- L -
L-asparaginase....................132
L-ornithine L-aspartate........9
Labetalol............................41
Lacosamide.........................112
Lactose...............................225
Lactulose............................13
Laevolac..............................13
Lamictal..............................113
Lamivudine.........................86,88
Lamotrigine.........................113
Lanoxin...............................40
Lanoxin PG.........................40
Lansoprazole.........................8
Lanthanum.........................10
Lanthus.................10
LantuS SoloStar.................10
Lanzol Relief.......................8
Lapatinib............................139
Largactil............................117
Laridol..................16
Lasix.................................44
Latanoprost.........................214
Lax-Suppositories...............13
Lax-Tabs..............................13
Laxatives.............................12
Laxsol.................................12
Ledipasvir with sofosbuvir..88
Leflunomide.........................94
Lenalidomide.......................133
Lentol..................146
Letrozole............................146
Leukotriene Receptor......206
Antagonists.................206
Leunase...............................132
Leuprolin acetate..............66
Leustatin............................130
Levetiracetam.....................113
Levetiracetam-AFT.............113
Levlen ED............................58
Levocarbamazepine...........16
Levocarnitine......................16
Levodopa with benserazide....104
Levodopa with carbidopa....104
Levomepromazine..............117
Levomepromazine..............118
Levonorgestrel...............59
Levosimendan....................46
Levothyroxine.....................71
Lidocaine [Lignocaine].....106
Lidocaine [Lignocaine]....106
Lidocaine [Lignocaine] hydrochloride with adrenaline........106
Lidocaine [Lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride........106
Lidocaine [Lignocaine] hydrochloride with chlorhexidine........106
Lidocaine [Lignocaine] hydrochloride with phenylephrine hydrochloride........106
Lidocaicne [Lignocaine] with prilocaine........106
Lidocaine-Claris...............106
Lignocaine..........................106

Antagonists.................206
Leunase...............................132
Leuprolin acetate..............66
Leustatin............................130
Levetiracetam.....................113
Levetiracetam-AFT.............113
Levlen ED............................58
Levocarbamazepine...........16
Levocarnitine......................16
Levodopa with benserazide....104
Levodopa with carbidopa....104
Levomepromazine..............117
Levomepromazine..............118
Levonorgestrel...............59
Levosimendan....................46
Levothyroxine.....................71
Lidocaine [Lignocaine].....106
Lidocaine [Lignocaine]....106
Lidocaine [Lignocaine] hydrochloride with adrenaline........106
Lidocaine [Lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride........106
Lidocaine [Lignocaine] hydrochloride with chlorhexidine........106
Lidocaine [Lignocaine] hydrochloride with phenylephrine hydrochloride........106
Lidocaine [Lignocaine] with prilocaine........106
Lidocaine-Claris...............106
Lignocaine..........................106

Alimentary.........................20
Nervous.............................106
Lincomycin........................79
Linezolid.............................79
Linezolid Kabi.....................79
Lioresal Intrathecal.............100
Liothyronine sodium...........71
Lipazil.................................45
Lipid-Modifying Agents........45
Lipidol Ultra Fluid.............219
Liquibar.............................219
Lisinopril...........................38
Lissamine green.................212
Lithicarb FC.......................118
Lithium carbonate.............118
LMX4.................................106
Local Preparations for Anal and Rectal Disorders.................7
Locoid...............................55,57
Locoid Crelo.........................55
Locoid Lipocrem..................55
INDEX: Generic Chemicals and Brands

Lodoxamide ........................................ 211
Logem .................................................. 113
Lomiride.................................................... 211
Lomustine............................................... 129
Long-Acting Beta-Adrenoceptor Agonists.................. 206
Loniten................................................... 48
Loperamide hydrochloride.................. 5
Lopinavir with ritonavir .................... 87
Lorafix .................................................... 202
Loratadine............................................... 202
Lorazepam.............................................. 112, 120
Lorfast................................................... 202
Lormetazepam....................................... 121
Lorstat ................................................... 45
Losartan Actavis.................................. 39
Losartan potassium.............................. 39
Losartan potassium with hydrochlorothiazide .... 39
Lovir ..................................................... 89
Loxamine ............................................. 111
Lucrin Depot 1-month ......................... 66
Lucrin Depot 3-month ......................... 66
Lyderm .................................................. 53
Lynparza .............................................. 133
Lysine acetylsalicylate [Lysine aspin] ........ 32
Lysine aspin ......................................... 32
M -
m-Amoxiclav ......................................... 76
m-Esion ............................................... 109
Matbera ................................................. 175
MacroDol 3350 with ascorbic acid, potassium chloride and sodium chloride .................. 12
MacroDol 3500 with potassium chloride, sodium bicarbonate and sodium chloride .......... 13
MacroDol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate ........................................... 12
MacroDol 400 and propylene glycol ............ 215
Madopar 125 ........................................... 104
Madopar 250 ........................................... 104
Madopar 62.5 ........................................... 104
Madopar HBS .......................................... 104
Madopar Rapid .................................... 104
Mafenide acetate ..................................... 52
Magnesium amino acid chelate .......... 18
Magnesium chloride ......................... 18
Magnesium hydroxide
Alimentary ........................................... 18
Extemporaneously Compounded Preparations ........ 225
Magnesium oxide ................................... 18
Magnesium oxide with magnesium aspartate, magnesium amino acid chelate and magnesium citrate ........................................ 19
Magnesium sulphate ................................ 19
Magnesivist.......................................... 220
Malarone ............................................... 84
Malarone Junior .................................... 84
Maltahion [Maldison] ......................... 53
Maldison ............................................... 53
Mannitol ................................................ 221
Cardiovascular ...................................... 44
Various ............................................. 221
Mantoux ............................................... 251
Maropid ................................................ 111
Marcain .............................................. 105
Marcain Isobaric .................................... 105
Marcain with Adrenaline ..................... 105
Marevan ............................................... 31
Marine Blue Lotion SPF 50+ ............. 57
Mask for spacer device ....................... 252
Mast Cell Stabilisers ......................... 207
Mavirex ............................................... 88
Maxidex .............................................. 210
Maxitrol .............................................. 209
Measles, mumps and rubella vaccine ...... 250
Mebendazole ........................................ 83
Mebeverine hydrochloride ............ 7
Medrol .................................................. 64
Medroxyprogesterone ....................... 66
Medroxyprogesterone acetate Genito-Urinary .............. 59
Hormone Preparations .................... 65
Mefenamic acid ..................................... 102
Mefloquine .......................................... 84
Megestrol acetate ...................... 145
Meglimine gadopentetate ................. 220
Meglimine iotroxate ......................... 220
Melatonin ............................................ 122
Melphalan .......................................... 129
Menacra ............................................. 244
Meningococcal (A, C, Y and W-135) conjugate vaccine ............ 244
Meningococcal C conjugate vaccine .......... 244
Menthol .............................................. 225
Mepivacaine hydrochloride ........... 106
Mercaptopurine ................................... 131
Meropenem .......................................... 73
Meropenem Ranbaxy ......................... 73
Mesalazine .......................................... 6
Mesna ................................................. 144
Mestinon ............................................. 94
Metabolic Disorder Agents ............ 13
Metabolic Products ......................... 229
Metaraminol ....................................... 47
Meterol ............................................. 206
Metformin hydrochloride ............ 11
Methacholine chloride ............ 221
Methadone hydrochloride
Extemporaneously Compounded Preparations .... 225
Nervous ............................................ 108
Methatabs ........................................... 108
Methenamine (Hexamine) hippocurate .......... 79
Methohexital sodium ........... 104
Methopt ............................................. 214
Methotrexate .................................... 131
Methotrexate Ebewe ....................... 131
Methotrexate Sandoz ..................... 131
Methoxasalen [8-methoxysoralen] .... 56
Methoxyflurane .................................. 107
Methyl aminolevulinate hydrochloride .......... 57
Methyl hydroxybenzoate ............ 225
Methylcellulose .................................. 225
Methylcellulose with glycerin and sodium saccharin 225
Methylcellulose with glycerin and sucrose ........ 225
Methyldopa ........................................ 43
Methyldopa Mylan ....................... 43
Methylene blue ................................. 221
Methyalnatrexone bromide .......... 12
Methylphenidate ER - Teva ............. 124
Methylphenidate hydrochloride .... 124
Methylprednisolone (as sodium succinate) .......... 64
Methylprednisolone acepionate ..... 55
Methylprednisolone acetate .......... 64
Methylthioninum chloride [Methylene blue] .................. 221
Methylxanthines ....................... 207
Metoclopramide Actavis 10 ........... 116
Metoclopramide hydrochloride .......... 116
Metoclopramide hydrochloride with paracetamol .......... 115
Metolazone ....................................... 45
Metoprolol succinate .................... 41
Metoprolol tartrate .................... 42
Metronidazole ................................. 52
Infections .................................... 84
Metroplorol IV Mylan .................. 42
Metrypomone .................................... 65
Mexiletilne hydrochloride .......... 41
Mexiletine Hydrochloride USP .... 41

262
INDEX: Generic Chemicals and Brands

Miacalcic........................................62
Mianserin hydrochloride........................111
Micolette........................................13
Miconazole.........................................19
Miconazole nitrate
Dermatological......................................52
Genito-Urinary......................................58
Micreme.............................................58
Micreme H...........................................56
Microgynon 20 ED..................................58
Microgynon 50 ED..................................58
Microlut.............................................59
Midazolam..........................................122
Midodrine............................................41
Mifepristone........................................59
Mifrinone............................................48
Minerals.............................................17
Mini-Wright AFS Low Range......................252
Mini-Wright Standard.............................252
Minididi.............................................10
Minims Prednisolone..............................211
Minirin................................................71
Minocycline..........................................78
Minoxidil.............................................48
Mirena...............................................59
Mirtazapine.........................................111
Misoprostol.......................................... 7
Mitomycin C.........................................130
Mitoxantrone........................................130
Mitoxantrone Ebewe.................................130
Mivacron............................................100
Mivacurium chloride...............................100
Mixed salt solution for eye irrigation...........212
Moclobemide........................................111
Modafinil............................................124
Modavigil............................................124
Moloxole.............................................13
Mometasone furoate...............................55
Monosodium glutamate with sodium aspartate..223
Monosodium l-aspartate............................223
Montelukast.........................................206
Montelukast Mylan..................................206
Morocctocog alfa [Recombinant factor VIII]....28
Morpheine hydrochloride..........................109
Morpheine sulphate................................109
Morpheine tartrate................................109
Motetis...............................................103
Mouth and Throat.................................19
Movapo.............................................103
Moxifloxacine.......................................77
Moxifloxacine Kabli.................................77
Mozobil...............................................33
Mucolytics and Expectorants......................207
Mucosoothe.........................................106
Multithance.........................................220
Multiple Sclerosis Treatments.....................120
Multivitamin and mineral supplement................20
Multivitamin renal..................................20
Multivitamins.......................................21
Mupirocin............................................52
Muscle Relaxants and Related Agents...............100
Mvit...................................................21
Myambutol.......................................... 82
Mycolin..............................................52
MycoNail.............................................200
Mydriacyl............................................214
Mydriatics and Cycloplegics.......................214
Mylan Atenolol......................................41
Mylan Clomiphen.................................. 65
Mylan Midazolam....................................122
Myleran..............................................129
Myozyme.............................................13
N -
Nadolol...............................................42
Naglazyme.......................................... 15
Naloxone hydrochloride............................216
Naltraccord..........................................126
Naltrexone hydrochloride.........................126
Naphazoline hydrochloride.......................211
Naphcon Forte.......................................211
Naprosyn SR 1000.................................102
Naprosyn SR 750....................................102
Naproxen............................................102
Naropin.............................................107
Natalizumab.........................................121
Natamycin..........................................209
Natalan...............................................134
Nausafyx............................................116
Nausicalm..........................................116
Navelbine..........................................144
Nedocromil..........................................207
Nefopam hydrochloride............................107
Neisvuc-C..........................................244
Neo-B12............................................. 21
Neocate Gold (Unflavoured).......................235
Neocate Junior Vanilla.............................235
Neoral...............................................147
Neostigmine metilsulfate..........................94
Neostigmine metilsulfate with glycopyrronium bromide..94
Neosynephrine HCL..................................47
Nepro HP (Strawberry).............................239
Nepro HP (Vanilla)................................239
Nepro HP RTH......................................238
Neulastim.......................................... 34
Neupogen.......................................... 34
NeuroTabs.......................................... 18
Nevirapine.......................................... 85
Nevirapine Alphapharm............................85
Nicardipine hydrochloride....................... 42
Nicerandil.......................................... 48
Nicotine.............................................126
Nicotinic acid...................................... 46
Nifedipine.......................................... 43
Nifuran............................................... 79
Nilotinib.............................................140
Nilstat................................................128
Alimentary.......................................... 19
Genito-Urinary......................................58
Infections.......................................... 80
Nimodipine..........................................43
Nimotop............................................. 43
Nintedanib.........................................203
Nitazoxanide........................................84
Nitrates.............................................. 46
Nitrazepam.........................................122
Nitroderm TTS 10..................................46
Nitroderm TTS 5....................................46
Nitrofurantoin....................................... 79
Nitrolingual Pump Spray......................... 46
Nivestim............................................. 34
Nivolumab..........................................197
Nodia................................................. 5
Nolfam 250..........................................102
Nolfam 500..........................................102
Non-Steroidal Anti-Inflammatory Drugs..........101
Noracog gamma, [Recombinant factor IX]....129
Noradrenaline...................................... 47
Noradrenaline BNM.................................47
Norethisterone......................................59
Genito-Urinary......................................59
Hormone Preparations............................66
Norethisterone with mestranol....................58
Norflex.............................................100
Norfloxacin..........................................77
Norday 28.......................................... 59
Normison............................................122
Norpress............................................111
Nortriptyline hydrochloride.....................111
Norvir............................................... 87
Novasource Renal (Vanilla).......................239
Novatretin.......................................... 56
NovoMix 30 FlexPen............................... 9
NovoRapid FlexPen.................................10
NovoSeven RT.....................................28
Noxafil.............................................. 80
Nozinan...........................................117-118
Nuelin...............................................207
Nuelin-SR...........................................207
# INDEX: Generic Chemicals and Brands

| Nutrisol Energy Multi Fibre | 238 |
| Nutrisol Low Energy Multifibre RTH | 238 |
| Nutrison 800 Complete Multi Fibre | 240 |
| Nutrison Concentrated | 234 |
| Nutrison Energy | 240 |
| Nylexi Retard | 43 |
| Nystatin | 80 |
| O / W Fatty Emulsion Cream | 54 |
| Obinutuzumab | 172 |
| Obstetric Preparations | 59 |
| Ocrelizumab | 121 |
| Ocrevus | 121 |
| Octocog alfa [Recombinant factor VIII] (Advate) | 29 |
| Octocog alfa [Recombinant factor VIII] (Kogenate FS) | 29 |
| Octreotide | 145 |
| Ocular Lubricants | 214 |
| Oestradiol | 64, 66 |
| Oestradiol valerate | 65 |
| Oestradiol with norethisterone acetate | 65 |
| Oestradiol Genito-Urinary Hormone Preparations | 60 |
| Oestrogens | 60 |
| Oestrogens (conjugated equine) | 65 |
| Oestrogens with medroxyprogesterone acetate | 65 |
| Olf | 203 |
| Oil in water emulsion | 54 |
| Oily phenol [Phenol oily] | 7 |
| Olanzapine | 118–119 |
| Olaparib | 133 |
| Olive oil | 225 |
| Olopatadine | 211 |
| Olsalazine | 7 |
| Omalizumab | 173 |
| Omeprazole | 8 |
| Omeprazole actavis 10 | 8 |
| Omeprazole actavis 20 | 8 |
| Omeprazole actavis 40 | 8 |
| Omeprazol IV | 8 |
| Omnipaque | 219 |
| Omiscan | 220 |
| Omnitrope | 67 |
| Ondasol Breezhaler | 206 |
| Oncaspar | 134 |
| Oncaspar LYO | 134 |
| OncoTICE | 199 |
| Ondansetron | 116 |
| Ondansetron Kabi | 116 |
| Ondansetron ODT-DRLA | 116 |
| Ondansetron Claris | 116 |
| One Alpha | 22 |
| Onex | 116 |
| Opdivo | 197 |
| Optional Pharmaceuticals | 252 |
| Ora-Blend | 225 |
| Ora-Blend SF | 225 |
| Ora-Plus | 225 |
| Ora-Sweet | 225 |
| Ora-Sweet SF | 225 |
| Orafrin | 53 |
| Orion Temozolomide | 135 |
| Ornidazole | 84 |
| Orphenadrine citrate | 100 |
| Oruvail SR | 102 |
| Oseltamivir | 91 |
| Osmolite RTH | 240 |
| Other Cardiac Agents | 46 |
| Other Endocrine Agents | 65 |
| Other Oestrogen Preparations | 66 |
| Other Otolological Preparations | 215 |
| Other Progestogen Preparations | 66 |
| Other Skin Preparations | 57 |
| Ovestin | 60 |
| Ox-Pam | 120 |
| Oxaliplatin | 137 |
| Oxaliplatin Accord | 137 |
| Oxandrolone | 62 |
| Oxazepam | 120 |
| Oxefitline | 48 |
| Oxibuprocaine hydrochloride | 212 |
| Oxybutynin | 61 |
| Oxycodone hydrochloride | 109 |
| Oxycodone Sandoz | 109 |
| Oxyemetazoline hydrochloride | 205 |
| OxyNorm | 109 |
| Oxytocin | 59 |
| Oxytocin BNM | 59 |
| Oxytocin with ergometrine maleate | 59 |
| Ozurdex | 210 |
| Pacifen | 100 |
| Paclitaxel | 143 |
| Paclitaxel Ebewe | 143 |
| Paliperidone | 119 |
| Pamidronate disodium | 94 |
| Pamisol | 94 |
| Pan-Penicillin G Sodium | 76 |
| Pancreatic enzyme | 11 |
| Pancuronium bromide | 100 |
| Pantoprazole | 8 |
| Panzop Relief | 8 |
| Papaverine hydrochloride | 48 |
| Paper wasp venom | 201 |
| Para-aminosalicylic Acid | 83 |
| Paracare | 108 |
| Paracare Double Strength | 108 |
| Paracetamol | 108 |
| Paracetamol Kabi | 108 |
| Paracetamol with codeine | 110 |
| Paraflex | 12 |
| Dermatological | 54 |
| Extemporaneously Compounded Preparations | 225 |
| Parafolin | 215 |
| Paraffin | 215 |
| Parafolin with wool fat | 215 |
| Parafolin with wool fat | 54 |
| Paraldehyde | 112 |
| Parecoxib | 102 |
| Paromomycin | 72 |
| Paroxetine | 111 |
| Paser | 83 |
| Patanol | 211 |
| Patent blue V | 221 |
| Paxami | 120 |
| Pazopanib | 140 |
| Peak flow meter | 252 |
| Peanut oil | 224 |
| Pedialyte - Bubblegum | 37 |
| Pediasure (Chocolate) | 238 |
| Pediasure (Strawberry) | 238 |
| Pediasure (Vanilla) | 238 |
| Pediasure RTH | 238 |
| Pegaspargase | 134 |
| Pegasis | 92 |
| Pegasyn | 34 |
| Pegylated interferon alfa-2a | 92 |
| Pembrolizumab | 198 |
| Pemetrexed | 131 |
| Penicillamine | 94 |
| Penicillan G | 76 |
| Penicillin V | 76 |
| Pentacarnat | 84 |
| Pentagastin | 65 |
| Pentamidine isethionate | 84 |
| Pentasa | 6 |
| Pentostatin [Deoxycoformycin] | 134 |
| Pentoxifylline [Oxpentifylline] | 48 |
| Peptamenes OS 1.0 (Vanilla) | 234 |
| Peptsoother | 8 |
| Perflutren | 220 |
| Pherexvaline maleate | 43 |
| Percyclazine | 118 |
INDEX: Generic Chemicals and Brands

Perindopril ........................................ 38
Perjeta ............................................. 174
Pernitrol ........................................... 53
Perrigo ............................................. 57
Pertuzumab ....................................... 174
Peteha ............................................. 83
Pethidine hydrochloride ....................... 110
Pexsg ................................................ 43
Pizer Exemestane ............................... 146
Pharmacy Health SLS-free .................... 54
Phurburea ......................................... 17
Phenasen ......................................... 132
Phenelzine sulphate ............................ 111
Phenindione ...................................... 31
Phenobarbitone .................................. 113, 122
Phenobarbitone sodium ........................ 225
Phenol
Extemoraneously Compounded
Preparations ..................................... 225
Various .......................................... 222
Phenol oily ........................................ 7
Phenol with ioxaglic acid ...................... 222
Phenothin .......................................... 53
Phenoxybenzamine
hydrochloride .................................... 39
Phenoxymethylpenicillin [Penicillin
V] ...................................................... 76
Phentolamine mesylate ......................... 40
Phenylephrine hydrochloride
Cardiovascular ................................... 47
Sensory .......................................... 214
Phenytoin ......................................... 113
Phenytoin sodium ................................ 112–113
Pholcodine ........................................ 205
Phosphorous ...................................... 37
Phytomenadione .................................. 29
Picibanil .......................................... 200
Pilocarpine hydrochloride .................... 213
Pilocarpine nitrate ............................... 225
Pimafucort ........................................ 56
Pindolol ............................................ 42
Pine tar with trolamine laurilsulfate
and fluorescin .................................... 56
Pinetasol .......................................... 56
Pioglitazone ...................................... 11
Piperacillin with tazobactam ................. 76
Pipethazinoic acid ............................... 119
PipTaz Sandoz .................................... 76
Pirfenidone ....................................... 204
Pituitary and Hypothalamic
Hormones and Analogues .................... 66
Pivmecillinam .................................... 79
Pizotifen .......................................... 115
PKU Anamix Junior LQ
(Orange) .......................................... 231
PKU Anamix Junior LQ
(Unflavoured) .................................... 231
Pka................................................... 14
Placenil ............................................. 94
Plasma-Lyte 148 .................................. 34
Plasma-Lyte 148 & 5% Glucose ............. 35
Plendi ER .......................................... 42
Plerixafor ......................................... 33
Pneumococcal (PCV10) conjugate
vaccine ............................................. 244
Pneumococcal (PCV13) conjugate
vaccine ............................................. 245
Pneumococcal (PPV23)
 polysaccharide vaccine ..................... 245
Pneumovax 23 .................................... 245
Podophyllotoxin ................................ 57
Polidocanol ....................................... 27
Polimyelitis vaccine ............................ 250
Poloxamer ......................................... 12
Poly Gel .......................................... 214
Poly-Tears ......................................... 215
Poly-Visc .......................................... 215
Polyhexamethylene biguanide .............. 225
Polyvinyl alcohol with povidone .......... 215
Poractant alfa .................................... 208
Posaonazole ...................................... 80
Postinor-1 ......................................... 59
Potassium chloride .............................. 35, 37
Potassium chloride with sodium
chloride ............................................ 36
Potassium citrate ................................ 61
Potassium dihydrogen
phosphate ......................................... 36
Potassium iodate ................................. 18
Hormone Preparations ......................... 71
Potassium iodate with iodine ............... 18
Potassium perchlorate ......................... 71
Potassium permanganate ................. 56
Povidone .......................................... 225
Povidone-iodine ................................. 218
Povidone-iodine with ethanol ............. 218
Pradaxa ............................................ 30
Pralidoxime iodide .............................. 216
Pramipexole hydrochloride .................. 104
Prasugrel ......................................... 32
Pravastatin ...................................... 45
Praxbind .......................................... 28
Praziquantel ..................................... 83
Prazosin .......................................... 40
Precedex .......................................... 104
Pred Forte ......................................... 211
Prednisolone ..................................... 64
Prednisolone acetate .......................... 211
Prednisolone sodium
phosphate ........................................ 211
Prednisolone- AFT ................................ 211
Prednisone ....................................... 64
Pregabalin ....................................... 113
Pregabalin Pfizer ............................... 113
Preparation test - hCG urine ............... 252
preOp ............................................... 239
Presol .............................................. 41
Prevenar 13 ...................................... 245
Prezista .......................................... 87
Prolactin hydrochloride ....................... 107
Prolactin hydrochloride with
felypressin ...................................... 107
Primacor ......................................... 100
Primaquine phosphate ......................... 84
Primidone ........................................ 113
Primolut N ......................................... 66
Primovist ......................................... 220
Priorix ............................................. 250
Probemecid ....................................... 66
Procarbazine hydrochloride .............. 134
Prochlorperazine .............................. 116
Proctosyd ......................................... 7
Procyclidine hydrochloride ............... 103
Proctoxy .......................................... 129
Progesterone .................................... 59
Protocid .......................................... 9
Proglycem ........................................ 9
Progynova ....................................... 65
Prolia ............................................. 96
Promethazine hydrochloride ............ 202
Propafenone hydrochloride ............... 41
Propamidine isethionate ................. 209
Propofol .......................................... 104
Propanol .......................................... 42
Propylthiouracil ................................ 71
Prostin E2 ......................................... 59
Prostil VR ......................................... 47
Protamine sulphate ............................. 31
Protionamide .................................. 83
Protirelix ......................................... 71
Proveblue ........................................ 221
Provera .......................................... 65
Provera HD ........................................ 66
Proximetacaine hydrochloride ......... 212
Pseudoephedrine
hydrochloride ................................... 205
PSM Citalopram ................................. 111
Psoriasis and Eczema
Preparations ..................................... 56
PTU .................................................. 71
Pulmocare (Vanilla) ......................... 239
Pulmonary Surfactants ....................... 208
Pulmozyme ...................................... 207
Puri-nethol ....................................... 131
Purina .............................................. 22
Pyrazinamide ................................... 83
INDEX: Generic Chemicals and Brands

- Pyridostigmine bromide ........................................ 94
  Pyridoxal-5-phosphate ........................................ 16
  Pyridoxine hydrochloride ...................................... 22
  Pyrimethamine .................................................. 84
  Pytazen SR ....................................................... 32

  Riboflavin 5-phosphate ......................................... 213
  Riboflavin 5-phosphate ......................................... 207
  Riboflavin 5-phosphate ......................................... 207
  Riboflavin 5-phosphate ......................................... 207

  - Q -
  Q 300 ............................................................. 85
  Quetaiapine .................................................... 118
  Quettapril ....................................................... 118
  Quinapril ......................................................... 38
  Quinapril with hydrochlorothiazide ............................ 38
  Quinidine ......................................................... 8
  Quinidine Relief ................................................ 8
  Rapamune ......................................................... 200
  Rasburicase ..................................................... 100
  Readi-CAT 2 .................................................... 219
  Reandron 1000 ................................................... 62
  Recombinant factor IX ........................................... 28–29
  Recombinant factor VIIa ........................................ 28
  Recombinant factor VIII ......................................... 28–29
  Retacrit ............................................................ 12
  Retinol ............................................................ 21
  Retinol Palmitate ................................................. 215
  Retitrate .......................................................... 53
  Retrovir ............................................................ 86
  Retrovir IV ........................................................ 86
  Revlimid .......................................................... 133
  Revolade .......................................................... 26
  Rexacrom .......................................................... 211
  RexAir ............................................................. 207
  Salicylic acid ...................................................... 225
  Salmeterol ......................................................... 206
  Salmonella typhi vaccine ....................................... 246
  Sandimmun ........................................................ 147
  Sandimungran ..................................................... 115
  Sandostatin LAR ................................................... 145
  Sapropterin Dihydrochloride .................................... 16
  Scalp Preparations ............................................... 56
  Scandosen 3% ..................................................... 106
  Sclerosing Agents ............................................... 208
  Scopolerm TTS .................................................... 116
  Sebizeole .......................................................... 52
  Secretin pentahydrochloride .................................... 221
  Secukinumab ...................................................... 190
  Sedatives and Hypnotics ........................................ 121
  Seebri Breezhaler ............................................... 203
  Selegiline hydrochloride ......................................... 104
  Sennosides ........................................................ 13
  Sensipar ............................................................ 62
  Senerace ........................................................... 117
  Seretide ............................................................ 207
  Seretide Accuhaler ............................................... 207
  Serevent ........................................................... 206
  Serevent Accuhaler ............................................... 206
  Sertraline .......................................................... 111
  Setrona ............................................................ 111
  Sevoflurane ........................................................ 105
  Sevredol ........................................................... 109
  Shingles vaccine .................................................. 251
  Sildeanafil ........................................................ 49
  Siltuximab ........................................................ 191
  Silver nitrate ....................................................... 7
  Dermatological .................................................... 57
  Extemporaneously Compounded Preparations ............... 225
  Simeticone ........................................................ 5
  Simulect ........................................................... 164
  Simvastatin ....................................................... 45
  Simvastatin Mylan ............................................... 45
  Sincalide ........................................................... 221
  Sinemet ............................................................ 104
  Sinemet CR ........................................................ 104
  Sirolimus .......................................................... 200
  Siterone ............................................................ 62
  Slow-Lopresor ..................................................... 42
  Smith BioMed Rapid Pregnancy Test ......................... 252
  Snake antivenom .................................................. 217
  Sodiobic ........................................................... 37
  Sodium acetate ..................................................... 36
  Sodium acid phosphate .......................................... 36
  Sodium alginic acid ............................................... 5
  Sodium alginic acid with calcium bicarbonate and calcium carbonate .................................................. 5
<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium aurothiomalate</td>
<td>94</td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td>17</td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
<td>36–37</td>
</tr>
<tr>
<td>Blood</td>
<td>225</td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td></td>
</tr>
<tr>
<td>Sodium calcium edetate</td>
<td>218</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>36–37</td>
</tr>
<tr>
<td>Blood</td>
<td>205</td>
</tr>
<tr>
<td>Respiratory</td>
<td>207</td>
</tr>
<tr>
<td>Various</td>
<td>222</td>
</tr>
<tr>
<td>Sodium chloride with sodium bicarbonate</td>
<td>205</td>
</tr>
<tr>
<td>Sodium citrate</td>
<td>5</td>
</tr>
<tr>
<td>Alimentary</td>
<td></td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td>226</td>
</tr>
<tr>
<td>Sodium citrate with sodium chloride and potassium chloride</td>
<td>31</td>
</tr>
<tr>
<td>Sodium citrate with sodium lauryl sulphocetate</td>
<td>13</td>
</tr>
<tr>
<td>Sodium citro-tartrate</td>
<td>61</td>
</tr>
<tr>
<td>Sodium cromoglicate</td>
<td>7</td>
</tr>
<tr>
<td>Alimentary</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>202</td>
</tr>
<tr>
<td>Sensory</td>
<td>211</td>
</tr>
<tr>
<td>Sodium dihydrogen phosphate [Sodium acid phosphate]</td>
<td>36</td>
</tr>
<tr>
<td>Sodium fluoride</td>
<td>18</td>
</tr>
<tr>
<td>Sodium fusidate [Fusidic acid]</td>
<td>52</td>
</tr>
<tr>
<td>Dermatological</td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td>79</td>
</tr>
<tr>
<td>Sensory</td>
<td>209</td>
</tr>
<tr>
<td>Sodium hyaluronate [Hyaluronic acid]</td>
<td>20</td>
</tr>
<tr>
<td>Alimentary</td>
<td></td>
</tr>
<tr>
<td>Sensory</td>
<td>212</td>
</tr>
<tr>
<td>Sodium hyaluronate [Hyaluronic acid]</td>
<td>215</td>
</tr>
<tr>
<td>with chondroitin sulphate</td>
<td>212</td>
</tr>
<tr>
<td>Sodium hypochlorite</td>
<td>219</td>
</tr>
<tr>
<td>Sodium metabisulphite</td>
<td>226</td>
</tr>
<tr>
<td>Sodium nitrite</td>
<td>216</td>
</tr>
<tr>
<td>Sodium nitroprusside</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>48</td>
</tr>
<tr>
<td>Optional Pharmaceuticals</td>
<td>252</td>
</tr>
<tr>
<td>Sodium phenylbutyrate</td>
<td>17</td>
</tr>
<tr>
<td>Sodium phosphate with phosphoric acid</td>
<td>13</td>
</tr>
<tr>
<td>Sodium poly styrene sulphonate</td>
<td>37</td>
</tr>
<tr>
<td>Sodium stilbogluconate</td>
<td>85</td>
</tr>
<tr>
<td>Sodium tetracetyl sulphate</td>
<td>27</td>
</tr>
<tr>
<td>Sodium thiosulphate</td>
<td>216</td>
</tr>
<tr>
<td>Sodium valproate</td>
<td>114</td>
</tr>
<tr>
<td>Sodium with potassium</td>
<td>223</td>
</tr>
<tr>
<td>Solian</td>
<td>117</td>
</tr>
<tr>
<td>Solifenacin Mylan</td>
<td>61</td>
</tr>
<tr>
<td>Solifenacin succinate</td>
<td>61</td>
</tr>
<tr>
<td>Solifenacin........................................</td>
<td></td>
</tr>
<tr>
<td>Sol-Cortef</td>
<td>64</td>
</tr>
<tr>
<td>Solu-Medrol</td>
<td>64</td>
</tr>
<tr>
<td>Solu-Medrol Act-O-Vial</td>
<td>64</td>
</tr>
<tr>
<td>Somatropin</td>
<td>67</td>
</tr>
<tr>
<td>Sotalol</td>
<td>42</td>
</tr>
<tr>
<td>Soya oil</td>
<td>216</td>
</tr>
<tr>
<td>Spacer device</td>
<td>252</td>
</tr>
<tr>
<td>Span-K</td>
<td>37</td>
</tr>
<tr>
<td>Specialised Formulas</td>
<td>232</td>
</tr>
<tr>
<td>Spiolto Respimat</td>
<td>203</td>
</tr>
<tr>
<td>Spiractin</td>
<td>44</td>
</tr>
<tr>
<td>Spiramycin</td>
<td>85</td>
</tr>
<tr>
<td>Spiriva</td>
<td>203</td>
</tr>
<tr>
<td>Spiriva Respimat</td>
<td>203</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>44</td>
</tr>
<tr>
<td>Sprycel</td>
<td>138</td>
</tr>
<tr>
<td>Standard Feeds</td>
<td>240</td>
</tr>
<tr>
<td>Staphex</td>
<td>76</td>
</tr>
<tr>
<td>Starch</td>
<td>226</td>
</tr>
<tr>
<td>Stavudine</td>
<td>86</td>
</tr>
<tr>
<td>Sterculia with frangula</td>
<td>12</td>
</tr>
<tr>
<td>SteroClear</td>
<td>202</td>
</tr>
<tr>
<td>Stesolid</td>
<td>112</td>
</tr>
<tr>
<td>Stimulants / ADHD Treatments</td>
<td>123</td>
</tr>
<tr>
<td>Stiripentol</td>
<td>114</td>
</tr>
<tr>
<td>Stocin</td>
<td>85</td>
</tr>
<tr>
<td>Strattera</td>
<td>123</td>
</tr>
<tr>
<td>Streptomycin sulphate</td>
<td>72</td>
</tr>
<tr>
<td>Stromectol</td>
<td>83</td>
</tr>
<tr>
<td>Suboxone</td>
<td>125</td>
</tr>
<tr>
<td>Sucralfate</td>
<td>8</td>
</tr>
<tr>
<td>Sucrose</td>
<td>108</td>
</tr>
<tr>
<td>Sugammadex</td>
<td>101</td>
</tr>
<tr>
<td>Sulfadiazine silver</td>
<td>52</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>7</td>
</tr>
<tr>
<td>Sulindac</td>
<td>102</td>
</tr>
<tr>
<td>Sulphacetamide sodium</td>
<td>209</td>
</tr>
<tr>
<td>Sulphadiazine</td>
<td>79</td>
</tr>
<tr>
<td>Sulphur</td>
<td>226</td>
</tr>
<tr>
<td>Sulprixc</td>
<td>117</td>
</tr>
<tr>
<td>Sumatriptan</td>
<td>115</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>142</td>
</tr>
<tr>
<td>Sunscreen, proprietary</td>
<td>57</td>
</tr>
<tr>
<td>Suprane</td>
<td>104</td>
</tr>
<tr>
<td>Surgical Preparations</td>
<td>222</td>
</tr>
<tr>
<td>Sustagen Diabetic (Vanilla)</td>
<td>233</td>
</tr>
<tr>
<td>Sustagen Hospital Formula Active (Choc.)</td>
<td>241</td>
</tr>
<tr>
<td>Sustagen Hospital Formula Active (Van)</td>
<td>241</td>
</tr>
<tr>
<td>Sutent</td>
<td>142</td>
</tr>
<tr>
<td>Suxamethonium chloride</td>
<td>100</td>
</tr>
<tr>
<td>Sylvant</td>
<td>191</td>
</tr>
<tr>
<td>Symmetrel</td>
<td>103</td>
</tr>
<tr>
<td>Sympathomimetics</td>
<td>47</td>
</tr>
<tr>
<td>Synacthen</td>
<td>66</td>
</tr>
<tr>
<td>Synacthen Depot</td>
<td>66</td>
</tr>
<tr>
<td>Tenecteplase</td>
<td>33</td>
</tr>
<tr>
<td>Temazepam</td>
<td>122</td>
</tr>
<tr>
<td>Temazepam</td>
<td>122</td>
</tr>
<tr>
<td>Temazepam</td>
<td>123</td>
</tr>
<tr>
<td>Temazolamide</td>
<td>135</td>
</tr>
<tr>
<td>Temgommolide</td>
<td>135</td>
</tr>
<tr>
<td>Tenecteplase</td>
<td>33</td>
</tr>
<tr>
<td>Tenofovir disoproxil</td>
<td>88</td>
</tr>
<tr>
<td>Tenofovir Disoproxil Teva</td>
<td>88</td>
</tr>
<tr>
<td>Tenoxicam</td>
<td>102</td>
</tr>
<tr>
<td>Terbinafine</td>
<td>82</td>
</tr>
<tr>
<td>Terbutaline</td>
<td>60</td>
</tr>
<tr>
<td>Terbutaline sulphate</td>
<td>205</td>
</tr>
<tr>
<td>Terbutaline sulphate</td>
<td>205</td>
</tr>
<tr>
<td>Terfuzinimid</td>
<td>121</td>
</tr>
<tr>
<td>Teriparadate</td>
<td>98</td>
</tr>
<tr>
<td>Terlipressin</td>
<td>71</td>
</tr>
<tr>
<td>Testosterone</td>
<td>62</td>
</tr>
<tr>
<td>Testosterone cipionate</td>
<td>62</td>
</tr>
<tr>
<td>Testosterone esters</td>
<td>62</td>
</tr>
<tr>
<td>Testosterone undecanoate</td>
<td>62</td>
</tr>
<tr>
<td>Tetra benzine</td>
<td>103</td>
</tr>
<tr>
<td>Tetracaine [Amethocaine] hydrochloride</td>
<td></td>
</tr>
<tr>
<td>Nervous</td>
<td>107</td>
</tr>
<tr>
<td>Sensory</td>
<td>212</td>
</tr>
<tr>
<td>Tetracosactide [Tetracosactrin]</td>
<td>66</td>
</tr>
<tr>
<td>Tetracosactrin</td>
<td>66</td>
</tr>
<tr>
<td>Tetracyclin Wolf</td>
<td>78</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>78</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>136</td>
</tr>
<tr>
<td>Thalomid</td>
<td>136</td>
</tr>
<tr>
<td>Theobroma oil</td>
<td>226</td>
</tr>
<tr>
<td>Theophylline</td>
<td>207</td>
</tr>
<tr>
<td>Thiameine hydrochloride</td>
<td>22</td>
</tr>
<tr>
<td>Thiouaquine</td>
<td>132</td>
</tr>
<tr>
<td>Thiopental [Thiopentone]</td>
<td></td>
</tr>
</tbody>
</table>

**INDEX: Generic Chemicals and Brands**

- T -

- Tacrolimus ........................................ 147
- Tacrilmus Sandoz .................................. 147
- Tagtit V ........................................... 219
- Talc .................................................. 208
- Taliglucerase alfa .................................. 17
- Tambocor ............................................ 40
- Tamoxifen citrate .................................... 146
- Tamoxifen Sandoz .................................... 146
- Tamsulosin hydrochloride .................................. 60
- Tamsulosin-Rex ....................................... 60
- Tarceva ............................................... 138
- Tasigna .............................................. 140
- Tasmar ................................................ 104
- Tecidera ............................................ 120
- Tegetrol ............................................. 112
- Tegetrol CR .......................................... 112
- Teicoplanin ........................................... 79
- Temaccord ............................................ 135
- Temazepam ............................................ 122
- Temozolomide ........................................ 135
- Tenecteplase ......................................... 33
- Tenofovir disoproxil ................................ 88
- Tenofovir Disopoxil Teva ................................ 88
- Tenoxicam ............................................ 102
- Terazosin ............................................ 40
- Terbinafine ........................................... 82
- Terbutaline .......................................... 60
- Terbutaline sulphate ................................ 205
- Terflunomide .......................................... 121
- Teriparadate .......................................... 98
- Terlipressin .......................................... 71
- Testosterone ........................................... 62
- Testosterone cipionate ................................ 62
- Testosterone esters ................................... 62
- Testosterone undecanoate ................................ 62
- Tetra benzine ......................................... 103
- Tetracaine [Amethocaine] hydrochloride ..............
- Nervous ................................................. 107
- Sensory ................................................. 212
- Tetracosactide [Tetracosactrin] ......................... 66
- Tetracosactrin .......................................... 66
- Tetracyclin Wolfl ...................................... 78
- Tetracycline ........................................... 78
- Thalidomide ............................................ 136
- Thalomid ................................................. 136
- Theobroma oil ......................................... 226
- Theophylline ............................................ 207
- Thiameine hydrochloride ................................ 22
- Thiouaquine ............................................ 132
- Thiopental [Thiopentone] ................................
<table>
<thead>
<tr>
<th>Chemical/Brand</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium</td>
<td>105</td>
</tr>
<tr>
<td>Thiopental</td>
<td>105</td>
</tr>
<tr>
<td>Thiopentine</td>
<td>129</td>
</tr>
<tr>
<td>Thrombin</td>
<td>27</td>
</tr>
<tr>
<td>Thymol glycerin</td>
<td>20</td>
</tr>
<tr>
<td>Thyroid and Antithyroid</td>
<td></td>
</tr>
<tr>
<td>Preparations</td>
<td>70</td>
</tr>
<tr>
<td>Thyrotropin</td>
<td>66</td>
</tr>
<tr>
<td>Ticagrelol</td>
<td>32</td>
</tr>
<tr>
<td>Ticarcillin with clavulanic acid</td>
<td>76</td>
</tr>
<tr>
<td>Ticlopidine</td>
<td>33</td>
</tr>
<tr>
<td>Tigecycline</td>
<td>78</td>
</tr>
<tr>
<td>Ticlotil</td>
<td>102</td>
</tr>
<tr>
<td>Timolol</td>
<td>213</td>
</tr>
<tr>
<td>Timolol maleate</td>
<td>42</td>
</tr>
<tr>
<td>Timoptol XE</td>
<td>213</td>
</tr>
<tr>
<td>Tiotropium bromide</td>
<td>203</td>
</tr>
<tr>
<td>Tiotropium bromide with olodaterol</td>
<td>203</td>
</tr>
<tr>
<td>Tivicay</td>
<td>88</td>
</tr>
<tr>
<td>TMP</td>
<td>79</td>
</tr>
<tr>
<td>TOBI</td>
<td>72</td>
</tr>
<tr>
<td>Tobradex</td>
<td>210</td>
</tr>
<tr>
<td>Tobramycin Infections</td>
<td>72</td>
</tr>
<tr>
<td>Sensory</td>
<td>209</td>
</tr>
<tr>
<td>Tobramycin Mylan</td>
<td>72</td>
</tr>
<tr>
<td>Tobrex</td>
<td>209</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>191</td>
</tr>
<tr>
<td>Tofranil</td>
<td>110</td>
</tr>
<tr>
<td>Tolcapone</td>
<td>104</td>
</tr>
<tr>
<td>Tolterodine tartrate</td>
<td>61</td>
</tr>
<tr>
<td>Topamax</td>
<td>114</td>
</tr>
<tr>
<td>Topicaine</td>
<td>106</td>
</tr>
<tr>
<td>Topical Products for Joint and Muscular Pain</td>
<td>102</td>
</tr>
<tr>
<td>Topiramate</td>
<td>114</td>
</tr>
<tr>
<td>Topiramate Actavis</td>
<td>114</td>
</tr>
<tr>
<td>Tracrium</td>
<td>100</td>
</tr>
<tr>
<td>Tramadol hydrochloride</td>
<td>110</td>
</tr>
<tr>
<td>Tramal 100</td>
<td>110</td>
</tr>
<tr>
<td>Tramal 50</td>
<td>110</td>
</tr>
<tr>
<td>Tramal SR 100</td>
<td>110</td>
</tr>
<tr>
<td>Tramal SR 150</td>
<td>110</td>
</tr>
<tr>
<td>Tramal SR 200</td>
<td>110</td>
</tr>
<tr>
<td>Tranexamic acid</td>
<td>27</td>
</tr>
<tr>
<td>Tranexamic-AFT</td>
<td>27</td>
</tr>
<tr>
<td>Tranlcypromine sulphate</td>
<td>111</td>
</tr>
<tr>
<td>Trastuzumab</td>
<td>195</td>
</tr>
<tr>
<td>Trastuzumab emtansine</td>
<td>196</td>
</tr>
<tr>
<td>Travoprost</td>
<td>214</td>
</tr>
<tr>
<td>Travopt</td>
<td>214</td>
</tr>
<tr>
<td>Treatments for Dementia Dependence</td>
<td>125</td>
</tr>
<tr>
<td>Treatments for Substance Dependence</td>
<td>125</td>
</tr>
<tr>
<td>Tretinoin</td>
<td>53</td>
</tr>
<tr>
<td>Dermatological</td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td>136</td>
</tr>
<tr>
<td>Trexate</td>
<td>131</td>
</tr>
<tr>
<td>Tri-sodium citrate</td>
<td>226</td>
</tr>
<tr>
<td>Triamcinolone acetonide</td>
<td></td>
</tr>
<tr>
<td>Alimentary</td>
<td>19</td>
</tr>
<tr>
<td>Dermatological</td>
<td>55</td>
</tr>
<tr>
<td>Hormone Preparations</td>
<td>64</td>
</tr>
<tr>
<td>Triamcinolone acetonide with</td>
<td>210</td>
</tr>
<tr>
<td>ganciclovir, neomycin and nystatin</td>
<td></td>
</tr>
<tr>
<td>Triamcinolone acetonide with</td>
<td>56</td>
</tr>
<tr>
<td>neomycin sulphate, ganciclovir and nystatin</td>
<td></td>
</tr>
<tr>
<td>Triamcinolone hexacetonide</td>
<td>64</td>
</tr>
<tr>
<td>Trizolam</td>
<td>122</td>
</tr>
<tr>
<td>Trichloracetic acid</td>
<td>226</td>
</tr>
<tr>
<td>Trichazole</td>
<td>84</td>
</tr>
<tr>
<td>Trientine dihydrochloride</td>
<td>17</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>79</td>
</tr>
<tr>
<td>Trimethoprim with</td>
<td></td>
</tr>
<tr>
<td>sulphamethoxazole [Co-trimoxazole]</td>
<td>79</td>
</tr>
<tr>
<td>Trometamol</td>
<td>222</td>
</tr>
<tr>
<td>Tropicamide</td>
<td>214</td>
</tr>
<tr>
<td>Tropisetron</td>
<td>117</td>
</tr>
<tr>
<td>Tropisetron-AFT</td>
<td>117</td>
</tr>
<tr>
<td>Tuberculin PPD [Mantoux] test</td>
<td>251</td>
</tr>
<tr>
<td>Tubersol</td>
<td>251</td>
</tr>
<tr>
<td>Two Cal HN</td>
<td>234</td>
</tr>
<tr>
<td>TwoCal HN RTH (Vanilla)</td>
<td>234</td>
</tr>
<tr>
<td>Tykerb</td>
<td>139</td>
</tr>
<tr>
<td>Tysabri</td>
<td>121</td>
</tr>
<tr>
<td>- U -</td>
<td></td>
</tr>
<tr>
<td>Ultibro Breezhaler</td>
<td>203</td>
</tr>
<tr>
<td>Ultraproct</td>
<td>7</td>
</tr>
<tr>
<td>Umeclidinium</td>
<td>203</td>
</tr>
<tr>
<td>Umeclidinium with vilanterol</td>
<td>203</td>
</tr>
<tr>
<td>Univent</td>
<td>202</td>
</tr>
<tr>
<td>Ural</td>
<td>61</td>
</tr>
<tr>
<td>Urea</td>
<td>121</td>
</tr>
<tr>
<td>Dermatological</td>
<td>55</td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td>226</td>
</tr>
<tr>
<td>Ure Forte</td>
<td>44</td>
</tr>
<tr>
<td>Urografin</td>
<td>219</td>
</tr>
<tr>
<td>Urokinase</td>
<td>33</td>
</tr>
<tr>
<td>Urologicals</td>
<td>60</td>
</tr>
<tr>
<td>Uromitexan</td>
<td>144</td>
</tr>
<tr>
<td>Ursodeoxycholic acid</td>
<td>11</td>
</tr>
<tr>
<td>Ursosan</td>
<td>11</td>
</tr>
<tr>
<td>Utrogestan</td>
<td>59</td>
</tr>
<tr>
<td>Vaclovir</td>
<td>89</td>
</tr>
<tr>
<td>Valaciclovir</td>
<td>89</td>
</tr>
<tr>
<td>Valganciclovir</td>
<td>89</td>
</tr>
<tr>
<td>Valganciclovir Mylan</td>
<td>89</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>79</td>
</tr>
<tr>
<td>Varenicline</td>
<td>126</td>
</tr>
<tr>
<td>Varenicline Pfizer</td>
<td>126</td>
</tr>
<tr>
<td>Varibar - Honey</td>
<td>219</td>
</tr>
<tr>
<td>Varibar - Nectar</td>
<td>219</td>
</tr>
<tr>
<td>Varibar - Pudding</td>
<td>219</td>
</tr>
<tr>
<td>Varibar - Thin Liquid</td>
<td>219</td>
</tr>
<tr>
<td>Varcillevaccine [Chickenpox vaccine]</td>
<td>251</td>
</tr>
<tr>
<td>Varicella zoster vaccine [Shingles vaccine]</td>
<td>251</td>
</tr>
<tr>
<td>Varilrix</td>
<td>251</td>
</tr>
<tr>
<td>Vasodilators</td>
<td>47</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>71</td>
</tr>
<tr>
<td>Vasopressin Agents</td>
<td>71</td>
</tr>
<tr>
<td>Vecuronium bromide</td>
<td>100</td>
</tr>
<tr>
<td>Vedafil</td>
<td>49</td>
</tr>
<tr>
<td>Velcade</td>
<td>132</td>
</tr>
<tr>
<td>Veltri</td>
<td>51</td>
</tr>
<tr>
<td>Venclexta</td>
<td>136</td>
</tr>
<tr>
<td>Venetoclax</td>
<td>136</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>111</td>
</tr>
<tr>
<td>Venofer</td>
<td>18</td>
</tr>
<tr>
<td>Ventavis</td>
<td>51</td>
</tr>
<tr>
<td>Ventolin</td>
<td>205</td>
</tr>
<tr>
<td>Vepesid</td>
<td>133</td>
</tr>
<tr>
<td>Verapamil hydrochloride</td>
<td>43</td>
</tr>
<tr>
<td>Vergo 16</td>
<td>116</td>
</tr>
<tr>
<td>Verpamyl SR</td>
<td>43</td>
</tr>
<tr>
<td>Vesnoid</td>
<td>136</td>
</tr>
<tr>
<td>Vexazonc</td>
<td>11</td>
</tr>
<tr>
<td>Vfenf</td>
<td>81</td>
</tr>
<tr>
<td>Vigabatrin</td>
<td>114</td>
</tr>
<tr>
<td>Vildaglaptin</td>
<td>11</td>
</tr>
<tr>
<td>Vildaglaptin with metformin hydrochloride</td>
<td>11</td>
</tr>
<tr>
<td>Vimpal</td>
<td>112</td>
</tr>
<tr>
<td>Vinblastine sulphate</td>
<td>144</td>
</tr>
<tr>
<td>Vincristine sulphate</td>
<td>144</td>
</tr>
<tr>
<td>Vinorelbine</td>
<td>144</td>
</tr>
<tr>
<td>Viral Vaccines</td>
<td>246</td>
</tr>
<tr>
<td>Virmune Suspension</td>
<td>85</td>
</tr>
<tr>
<td>ViraPOS</td>
<td>209</td>
</tr>
<tr>
<td>Viscocat</td>
<td>212</td>
</tr>
<tr>
<td>Visipaque</td>
<td>219</td>
</tr>
<tr>
<td>Vit.D3</td>
<td>22</td>
</tr>
<tr>
<td>VITa-POS</td>
<td>215</td>
</tr>
<tr>
<td>Vital</td>
<td>233</td>
</tr>
<tr>
<td>Vitamin A with vitamins D and C</td>
<td>21</td>
</tr>
<tr>
<td>Vitamin B complex</td>
<td>22</td>
</tr>
<tr>
<td>Vitamin B6 25</td>
<td>22</td>
</tr>
<tr>
<td>Vitamins</td>
<td>20</td>
</tr>
<tr>
<td>Vivonex TEN</td>
<td>233</td>
</tr>
<tr>
<td>Chemical/Brand</td>
<td>Page</td>
</tr>
<tr>
<td>----------------</td>
<td>------</td>
</tr>
<tr>
<td>Volibris</td>
<td>48</td>
</tr>
<tr>
<td>Voltaren</td>
<td>101</td>
</tr>
<tr>
<td>Voltaren D.</td>
<td>101</td>
</tr>
<tr>
<td>Voltaren Ophtha</td>
<td>211</td>
</tr>
<tr>
<td>Volumatic</td>
<td>252</td>
</tr>
<tr>
<td>Volumen</td>
<td>219</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>81</td>
</tr>
<tr>
<td>Votrient</td>
<td>140</td>
</tr>
<tr>
<td>Vttack</td>
<td>81</td>
</tr>
<tr>
<td>Warfarin sodium</td>
<td>31</td>
</tr>
<tr>
<td>Wart Preparations</td>
<td>57</td>
</tr>
<tr>
<td>Water Blood</td>
<td>37</td>
</tr>
<tr>
<td>Water Various</td>
<td>222</td>
</tr>
<tr>
<td>Wool fat Dermatological</td>
<td>55</td>
</tr>
<tr>
<td>Wool fat Extemporaneously Compounded Preparations</td>
<td>226</td>
</tr>
<tr>
<td>X-Opaque-HD</td>
<td>219</td>
</tr>
<tr>
<td>Xanthen</td>
<td>226</td>
</tr>
<tr>
<td>Xarelto</td>
<td>31</td>
</tr>
<tr>
<td>Xifaxan</td>
<td>9</td>
</tr>
<tr>
<td>Xolair</td>
<td>173</td>
</tr>
<tr>
<td>Xylocaine</td>
<td>106</td>
</tr>
<tr>
<td>Xylometazoline hydrochloride</td>
<td>205</td>
</tr>
<tr>
<td>Xyntha</td>
<td>28</td>
</tr>
<tr>
<td>Yellow jacket wasp venom</td>
<td>201</td>
</tr>
<tr>
<td>Yellow jacket venom</td>
<td>201</td>
</tr>
<tr>
<td>Zanamivir</td>
<td>91</td>
</tr>
<tr>
<td>Zantac</td>
<td>8</td>
</tr>
<tr>
<td>Zapril</td>
<td>38</td>
</tr>
<tr>
<td>Zarontin</td>
<td>112</td>
</tr>
<tr>
<td>Zavedos</td>
<td>130</td>
</tr>
<tr>
<td>Zeffix</td>
<td>88</td>
</tr>
<tr>
<td>Zetlan</td>
<td>88</td>
</tr>
<tr>
<td>Zagran</td>
<td>86</td>
</tr>
<tr>
<td>Zidovudine [AZT]</td>
<td>86</td>
</tr>
<tr>
<td>Zidovudine [AZT] with lamivudine</td>
<td>86</td>
</tr>
<tr>
<td>Zimybe</td>
<td>46</td>
</tr>
<tr>
<td>Zinc Alimentary</td>
<td>19</td>
</tr>
<tr>
<td>Zinc Dermatological</td>
<td>53</td>
</tr>
<tr>
<td>Zinc and castor oil</td>
<td>54</td>
</tr>
<tr>
<td>Zinc chloride</td>
<td>19</td>
</tr>
<tr>
<td>Zinc oxide</td>
<td>226</td>
</tr>
<tr>
<td>Zinc sulphate</td>
<td>19</td>
</tr>
<tr>
<td>Zinc with wool fat</td>
<td>54</td>
</tr>
<tr>
<td>Zincaps</td>
<td>19</td>
</tr>
<tr>
<td>Zinfordo</td>
<td>74</td>
</tr>
<tr>
<td>Zinnat</td>
<td>73</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>118</td>
</tr>
<tr>
<td>Zista</td>
<td>202</td>
</tr>
<tr>
<td>Zithromax</td>
<td>74</td>
</tr>
<tr>
<td>Zoladex</td>
<td>66</td>
</tr>
<tr>
<td>Zoledronic acid Hormone Preparations</td>
<td>63</td>
</tr>
<tr>
<td>Zoledronic acid Musculoskeletal</td>
<td>94</td>
</tr>
<tr>
<td>Zoledronic acid Mylan</td>
<td>63</td>
</tr>
<tr>
<td>Zopiclone</td>
<td>122</td>
</tr>
<tr>
<td>Zopiclone Actavis</td>
<td>122</td>
</tr>
<tr>
<td>Zostavax</td>
<td>251</td>
</tr>
<tr>
<td>Zostrix</td>
<td>102</td>
</tr>
<tr>
<td>Zostrix HP</td>
<td>107</td>
</tr>
<tr>
<td>Zuclophenthixol acetate</td>
<td>118</td>
</tr>
<tr>
<td>Zuclophenthixol decanoate</td>
<td>120</td>
</tr>
<tr>
<td>Zuclophenthixol hydrochloride</td>
<td>118</td>
</tr>
<tr>
<td>Zuddone</td>
<td>118</td>
</tr>
<tr>
<td>Zyban</td>
<td>126</td>
</tr>
<tr>
<td>Zypine</td>
<td>118</td>
</tr>
<tr>
<td>Zypine ODT</td>
<td>118</td>
</tr>
<tr>
<td>Zyprenx Relprevv</td>
<td>119</td>
</tr>
<tr>
<td>Zytiga</td>
<td>144</td>
</tr>
<tr>
<td>Zyvox</td>
<td>79</td>
</tr>
</tbody>
</table>